{"title": "PDF", "author": "PDF", "url": "https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2023/englisch/AGO_2023E_Gesamtdatei.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "2023              vs1Diagnostik und Therapie \nfr\u00fcher und fortgeschrittener Mammakarzinome\nHerausgegeben von der Kommission Mamma\n(vertreten durch: Wolfgang Janni)\nder Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie e.V.\nin der Deutschen Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e.V.\nsowie der Deutschen Krebsgesellschaft e.V.\n\u00d8Inhaltsverzeichnis\n\u00d8Levels ofEvidence and Grades ofRecommendation\n\u00d8Abbreviations\n\u00d8Members oftheAGO Breast Commission\n\u00d8Conflict ofInterest\n\u00d8How toUse these Slides\n\u00d8Editor & Copyright2023              vs1Inhaltsverzeichnis Diagnostik und Therapie fr\u00fcher und \nfortgeschrittener Mammakarzinome\nEmpfehlungen der AGO Kommission MammaLevels of Evidence and Grades of Recommendation\nAbbreviations\nMembers of the AGO Breast Committee\nConflict of Interest\nHow to Use the Slides\nEditor & Copyright\n1) Optionen der prim\u00e4ren Pr\u00e4vention: Ver\u00e4nderbare Lifestyle -Faktoren\n2) Brustkrebsrisiko, Genetik und Pr\u00e4vention\n3) Fr\u00fcherkennung und Diagnostik\n4) Pathologie\n5) Prognostische und pr\u00e4diktive Faktoren\n6) L\u00e4sionen mit unsicherem Potential (B3) \u2013 ADH, LIN, FEA, Papillom, Radi\u00e4re Narbe\n7) Duktales Carcinoma in situ (DCIS)\n8) Operative Therapie des Mammakarzinoms unter onkologischen Aspekten\n9) Onkoplastische und rekonstruktive Mammachirurgie\n10) Adjuvante endokrin -basierte Therapie bei Pr\u00e4 -und postmenopausalen Patientinnen\n11) Adjuvante zytostatische und zielgerichtete Therapien\n12) Neoadjuvante (Prim\u00e4re) systemische Therapie\n13) Adjuvante Strahlentherapie\n14) Supportive Therapie und Nebenwirkungsmanagement\n15) Brustkrebs: Spezielle Situationen\n16) Brustkrebs Nachsorge\n17) Lokoregion\u00e4res Rezidiv\n18) Endokrin -basierte und zielgerichtete Therapie des metastasierten Mammakarzinoms\n19) Chemotherapie mit oder ohne zielgerichtete Substanzen beim metastasierten Mammakarzinom\n20) Osteoonkologie und Knochengesundheit\n21) Behandlung in Abh\u00e4ngigkeit der Lokalisation der Metastasierung\n22) ZNS-Metastasen beim Mammakarzinom\n23) Komplement\u00e4re Therapie \u201e Survivorship \u201c\n24) Gyn\u00e4kologische Probleme bei Mammakarzinompatientinnen\n25) Gesundheitskompetenz und Kommunikation\n26) TherapiealgorithmenVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Oxford Levels ofEvidence (LoE)\nLoE Therapy/Prevention, Aetiology/Harm Prognosis\n1a Systematic review (with homogeneity) of randomised controlled trials Systematic review (with homogeneity) of inception cohort studies; clinical \ndecision rule validated in different populations \n1b Individual randomised controlled trials (with narrow Confidence \nInterval)Individual inception cohort study with >80% follow -up; clinical decision rule \nvalidated in a single population\n1c All or none All or none case -series\n2a Systematic review (with homogeneity) of cohort studies Systematic review (with homogeneity) of either retrospective cohort studies or \nuntreated control groups in randomised controlled trials\n2b Individual cohort study (including low quality randomised controlled \ntrials; e.g., <80% follow -up)Retrospective cohort study or follow -up of untreated control patients in a \nrandomised controlled trials; Derivation of clinical decision rule or validated on \nsplit-sample only\n2c \"Outcomes\" Research; Ecological studies \"Outcomes\" Research \n3a Systematic review (with homogeneity) of case -control studies\n3b Individual Case -Control Study\n4 Case -series (and poor quality cohort and case -control studies) Case -series (and poor quality prognostic cohort studies)\n5 Expert opinion without explicit critical appraisal, or based on \nphysiology, bench research or \"first principles\"Expert opinion without explicit critical appraisal, or based on physiology, bench \nresearch or \"first principles\"Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Oxford Grades ofRecommendation (GR)\nA consistent level 1 studies \nB consistent level 2 or 3 studies orextrapolations from level 1 \nstudies\nC level 4 studies orextrapolations from level 2 or 3 studies \nD level 5 evidence or troublingly inconsistent or inconclusive \nstudies of any levelVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1AGO Grades ofRecommendation\n++ This investigation or therapeutic intervention is highly beneficial for patients, \ncan be recommended without restriction, and should be performed. \n+ This investigation or therapeutic intervention is of limited benefit for patients \nand can be performed. \n+/- This investigation or therapeutic intervention has not shown benefit for \npatients and may be performed only in individual cases. According to current \nknowledge a general recommendation cannot be given. \n- This investigation or therapeutic intervention can be of disadvantage for \npatients and might not be performed.\n-- This investigation or therapeutic intervention is of clear disadvantage for \npatients and should be avoided or omitted in any case. Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013I\nA Doxorubicin\nACC Adenoid-zystisches Karzinom (adenoid cystic carcinoma) \nADH Atypische duktale Hyperplasie\nADL Aktivit\u00e4ten des t\u00e4glichen Lebens ( activities ofdaily life)\nADM Azellul\u00e4re dermale Matrix\nADP atypische epitheliale Proliferation vom duktalen Typ\nAHT Arterielle Hypertonie \nAI Aromataseinhibitor\nAK Antik\u00f6rper\nALH Atypische lobul\u00e4re Hyperplasie\nAlip Liposomales Doxorubicin\nALND Axill\u00e4re Lymphknotendissektion\nAML akute myeloische Leuk\u00e4mie\nANC Absolute Neutrophilenzahl\nAPBI Akzelerierte Teilbrustbestrahlung\nAPR Aprepitant\nAR Androgenrezeptor\nARDS Acute Respiratory Distress Syndrome\nASS Acetylsalicyls\u00e4ure\nAT Anthrazyklin/ Taxan\nAZ Allgemeinzustand\nBAL Bronchoalveol\u00e4re Lavage\nBC Mammakarzinom (breast cancer)\nBCFI Brustkrebs- freies IntervallVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013II\nBCI Breast Cancer Index\nBCS Brusterhaltende Operation (breast-conserving surgery)\nBCT Brusterhaltende Therapie (breast-conserving therapy)\nBEO Brusterhaltende Operation\nBET Brusterhaltende Therapie\nBev Bevacizumab\nBfARM Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte \nBIA-ALCL Brustimplantat-assoziiertes anaplastisches gro\u00dfzelliges Lymphom \nBMI Body Mass Index\nBP Bisphosphonat\nBR Brustrekonstruktion\nBSE Selbstuntersuchung (breast self-examination ) \nBZ Brustkrebszentrum\nC Cyclophosphamid\nCa. Karzinom\nCAM Komplement\u00e4re und alternative Medizin\nCap Capecitabin\nCBE klinische Brustuntersuchung (clinical breast examination)\nCDK4/6i Cyklin -abh\u00e4ngige Kinase 4/6-Inhibitor\nCESM Kontrastmittel-verst\u00e4rkte spektrale Mammographie (contrast enhanced spectral Mammography)\nCEUS Kontrastmittel-Sonographie (contrast enhanced ultrasound )  \ncfDNA zellfreie DNA   \nCGA Umfassende geriatrische Einsch\u00e4tzung (Comprehensive Geriatric Assessment)\nCHF Kardiomyopathie (congestive heart failure)Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013III\nCHOP Cyclophosphamid, Doxorubicin, Vincristin, Prednison\nCI Konfidenzintervall (Confidence interval)\nCIA Chemotherapie-induzierte Amenorrhoe\nCIPN Chemotherapie-induzierte periphere Neuropathie\nCISH Chromogene in situ-Hybridisierung\nCMF Cyclophosphamid, Methotrexat, 5-Fluorouracil\nCNB Stanzbiopsie (core needle biopsy)\nCOX2 Cyclooxygenase-2\nCPS Combined positive score\nCRA Chemotherapie-induzierte Amenorrhoe (chemotherapy- related amenorrhea ) \nCSL Komplexe sklerosierende L\u00e4sion\nCT Computertomographie\nCTC Zirkulierende Tumorzellen\nCTS Category of tumor marker study \nCTS5 Clinical Treatment Score 5\nCTx Chemotherapie\nCUP Cancer of unknown primary\nD Docetaxel\nDAC Docetaxel, Doxorubicin, Cyclophosphamid\nDBT Digitale Brust-Tomosynthese\nDCIS Duktales Carcinoma in situ\nDDFS Distant disease free survival \nDDT Dichlordiphenyltrichlorethan\nDES DiethylstilbestrolVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013IV\nDEX Dexamethason\nDFS Krankheitsfreies \u00dcberleben\nDHEA Dehydroepiandrosteron\nDIEP Deep Inferior Epigastric Perforator (Lappen)\nDK-FBEK Deutsches Konsortium f\u00fcr Famili\u00e4ren Brust- und Eierstockkrebs\nDM Digitale Mammographie \nDM Fernmetastasierung \nDmab Denosumab\nDMSO Dimethylsulfoxid\nDOP Dopaminrezeptor-Antagonist\nDPD Dihydropyrimidin-Dehydrogenase\nDS-GPA Diagnosis-specific Graded Prognostic Assessment\nDTC Disseminierte Tumorzellen\nDXA Dual-R\u00f6ntgen-Absorptiometrie\nE Epirubicin\nE2 Estradiol\nEAT Erweiterte adjuvante endokrine Therapie\neBC Fr\u00fches Mammakarzinom\nEBUS Endobronchialer Ultraschall\nECS Extrakapsul\u00e4res Tumorwachstum \nEFS Event-freies \u00dcberleben\nEGFR Epidermaler Wachstumsfaktorrezeptor\nEIC Extensive intraduktale Komponente\nEK Einschlusskriterien Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013V\nELEE Gesch\u00e4tzte lebenslange Estrogen -Exposition ( Estimated lifetime estrogen exposure)\nEM Ca Endometriumkarzinom\nEMA European Medicines Agency\nER Estrogenrezeptor\nESF Erythropoese-stimulierender Faktor\nETx Endokrine Therapie\nF 5-Fluorouracil\nF/U Follow up\nFBC Blutbild (full blood count)\nFCI Fasciocutaneous Infragluteal Flap\nFDA Food and Drug Administration\nFDG -PET18F-2-Fluor-2-Desoxyglucose-Positronen-Emissions-Tomographie\nFEA Flache epitheliale Atypie\nFED Funktioneller Eisenmangel\nFFPE Formalin -fixiertes Paraffin -eingebettetes Gewebe\nFISH Fluoreszenz- in-situ-Hybridisierung\nFN Febrile Neutropenie\nFSH Follikelstimulierendes Hormon\nFSRT Fraktionierte stereotaktische Radiotherapie\nFul Fulvestrant\nG-CSF Granulozyten-Kolonie-stimulierender Faktor\nGC-HBOC German Consortium for Hereditary Breast and Ovarian Cancer \nGCP Gute klinische Praxis (Good Clinical Practice)Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013VI\nGEP Gexexpressionsprofil\nGI Gastrointestinal\nGJG Goshajinkigan\nGKP Gute klinische Praxis\nGKV Gesetzliche Krankenversicherung\nGnRH Gonadotropin-Releasing- Hormon\nGnRHa Gonadotropin-Releasing- Hormon -Agonist\nGR Oxford Grade of Recommendation\nHER2 Human epidermal growth factor receptor 2\nHFS Hand-Fu\u00df-Syndrom\nHR Hazard Ratio\nHR Hormonrezeptor\nHRQoL Gesundheitsbezogene Lebensqualit\u00e4t (Health -related quality of life)\nHRT Hormonersatztherapie\nHT Hormontherapie\nIADL The Lawton Instrumental Activities of Daily Living Scale\nIBC Inflammatorisches Mammakarzinom \nIBR Sofortrekonstruktion (immediate breast reconstruction ) \nIBTR Ipsilaterales Brustrezidiv (Ipsilateral Breast Tumor Recurrence)\nIC Immunzellen\nICG Indocyaningr\u00fcn\nICG Infraklavikul\u00e4rgrube\nICPi ImmuncheckpointinhibitorVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013VII\niddETC Epirubicin, Paclitaxel , Cyclophosphamid, dosis-dicht, dosis-intensiviert\niDFS invasives krankheitsfreies \u00dcberleben\nIGAP Inferior gluteal artery perforator\nIHC Immunhistochemie\nILC Invasives lobul\u00e4res Karzinom\nILRR Ipsilaterales lokoregion\u00e4res Rezidiv\nIMC Mammaria interna Region (internal mammary lymph node chain)\nIMRT Intensit\u00e4tsmodulierte Radiotherapie\nIOERT Intraoperative Elektronen-Radiotherapie\nIORT Intraoperative Radiotherapie\nIR Implantat-Rekonstruktion \nirAE Immunbezogenes unerw\u00fcnschtes Ereignis (Immune- related adverse event)\nISH In-situ-Hybridisierung\nITC Isolierte Tumorzellen\nIUD Intrauterine device\nKFU Krebsfr\u00fcherkennungsuntersuchung \nLap Lapatinib\nLCIS Lobul\u00e4res Carcinoma in situ\nLH Luteinisierendes Hormon\nLHRH Luteinisierendes- Hormon -Releasing- Hormon\nLIN Lobul\u00e4re intraepitheliale Neoplasie\nLITT Laser -induzierte Tumortherapie\nLK LymphknotenVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013VIII\nLN Lobul\u00e4re Neoplasie\nLoE Evidenzlevel (level of evidence)\nLR Lokalrezidiv\nLRFI Lokalrezidiv-freies Intervall\nLVEF Links-ventrikul\u00e4re Ejektionsfraktion\nLVI Lymphovaskul\u00e4re Invasion\nMaCa Mammakarzinom\nMAK Mamillen -Areola -Komplex\nmBC metastasierter Brustkrebs\nMBSR Mindfulness-Based Stress Reduction\nMCP Metoclopramid\nMDS Myelodysplastisches Syndrom\nME Mastektomie\nMedDRA Medical Dictionary for Regulatory Activities\nMF Multifokalit\u00e4t\nMG Mammographie\nMMF Mycophenolate mofetil\nMPA Medroxyprogesteronacetat\nMPE Maligner Pleuraerguss\nMRI Magnetresonanztomographie (magnetic resonance imaging)\nMRM Modifiziert radikale Mastektomie\nMRT/MR Magnetresonanztomographie\nMS Mammasonographie\nMSI Mikrosatelliteninstabilit\u00e4tVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013IX\nMTX Methotrexat\nMUGA Multigated acquisition\nMZ Multizentrizit\u00e4t\nn.a. nicht verf\u00fcgbar (not available)\nn.r. nicht berichtet (not reported)\nn.s. Nicht signifikant\nNabPac Nab-Paclitaxel\nNACT Neoadjuvante Chemotherapie\nNEPA Netupitant / Palonosetron\nNET Neoadjuvante endokrine Therapie\nNGS Next -Generation-Sequencing\nNK1 Neurokinin-1\nNNT Number needed to treat\nNSAID Nicht-steroidale Antiphlogistika (non-steroidal anti-inflammatory drug)\nNSM Mamillensparende Mastektomie (nipple-sparing mastectomy)\nNST Kein spezieller Typ(no special type)\nNW Nebenwirkung\nNX Vinorelbin, Capecitabin\nOC Ovarialkarzinom\nOFS Ovarialfunktions-Suppression\nOLZ Olanzapin\nOM Orale Mukositis\nONJ Kieferosteonekrose (osteonecrosis of the jaw)Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013X\nOP Operation\nOPS Onkoplastische brusterhaltende Operation\nOR Odds Ratio\nOS Gesamt\u00fcberleben (overall survival) \nOSNA One Step Nucleic Acid Amplification\nPac Paclitaxel\nPAF Population attributable fractions \nPAI-1 Plasminogen- Aktivator -Inhibitor Typ 1\nPARP Poly -ADP -Ribose- Polymerase\nPARPi PARP -Inhibitor\nPBI Partielle Brustbestrahlung (partial breast irradiation)\nPCO Polycystic Ovarian Syndrome\npCR pathologische Komplettremission\nPD-1 Programmed cell death protein 1\nPD-L1 Programmed cell death 1 ligand 1\nPE Probeentnahme\nPEA Palmitoylethanolamid\nPET-CT Positronen-Emissions-Tomographie-Computertomographie\nPFS Progressionsfreies \u00dcberleben\nPJP Pneumocystis jiroveci -Pneumonie\nPLAC Placebo \nPMMA Polymethylmethacrylat\nPMRT Post -Mastektomie Radiotherapie\nPOI Pr\u00e4mature OvarialinsuffizienzVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013XI\nPPE Palmares und plantares Erythem\nPPV Positiver pr\u00e4diktiver Wert\nPR Progesteronrezeptor\nPROM Patient-reported outcome measures\nPT Phylloides-Tumor\nPTV Zielvolumen (Planning Target Volume)\nPVP Povidon\nPw Paclitaxel weekly\nPz Pertuzumab\nQA Quality assurance \nQoL Lebensqualit\u00e4t (quality of life)\nRFA Radiofrequenzablation\nRFID Radiofrequenz-Identifikation\nRFS Rezidivfreies \u00dcberleben\nRR Relatives Risiko\nRRBM Risiko -reduzierende bilaterale Mastektomie  \nRRCM Risikoreduzierende kontralaterale Mastektomie\nRRSO Risiko -reduzierende bilaterale Salpingo-Oophorektomie\nRS Recurrence Score\nRT Radiotherapie\nRT-PCR Reverse -Transkriptase- Polymerase -Kettenreaktion\nSAE Schwerwiegendes unerw\u00fcnschtes EreignisVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013XII\nSAPV Spezialisierte ambulante Palliativversorgung \nSCC Plattenepithelkarzinom (squamous cellcarcinoma ) \nSCG Supraklavikul\u00e4rgrube\nSD Standardabweichung (Standard deviation)\nSGAP Superior gluteal artery perforator (Lappen)\nSIEA Superficial inferior epigastric artery (Lappen)\nSIR Standardized incidence ratio\nSIRT Selektive interne Radiotherapie\nSLN Sentinel-Lymphknoten\nSLNE Sentinel-Lymphknoten- Exzision\nSM Synthetische Mammographie\nSNP Single Nucleotide Polymorphism\nSNRI Serotonin-Noradrenalin-Wiederaufnahmehemmer\nSPIO Superparamagnetic Iron Oxide\nSRE Skeletal -related events\nSRS Stereotactic radiosurgery \nSRS-VMAT Stereotactic radiosurgery with volumetric modulated arc therapy\nSSE Symptomatic skeletal events\nSSI Wundinfektion (surgical site infection) \nSSM Hautsparende Mastektomie (Skin sparing mastectomy )\nSSRI Selektive Serotonin-Wiederaufnahmehemmer\nTAD Targeted Axillary Dissection\nTam Tamoxifen\nTB TuberkuloseVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013XIII\nTBP Treatment beyond progression\nTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab\nTDLU Terminale duktulolobul\u00e4re Einheit\nTdP Torsade de Pointes\nTENS Transkutane elektrische Nervenstimulation\nTFI Therapiefreies Intervall\nTFT Schilddr\u00fcsenfunktionstest\nTIA Therapie-induzierte Amenorrhoe\nTIL Tumor-infiltrierende Lymphozyten\nTLNE Targeted Lymph Node Excision\nTMG Transverse Musculocutanaeus Gracilis (Lappen)\nTN triple-negativ\nTNBC triple-negatives Mammakarzinom\nTRAM Transverser Rectus abdominus Muskel (Lappen)\nTTR Zeit zum Rezidiv (time to recurrence)\nTxCHP Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab\nTz Trastuzumab\nUCT Unkonventionelle Therapie\nUE Unerw\u00fcnschtes Ereignis\n\u00dcL \u00dcberleben \nuPA Urokinase- TypPlasminogen Aktivator\nuPCR Urin -Protein:Kreatinin- Ratio\nVAB Vakuumbiopsie (vacuum-assisted breast biopsy)Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Abbreviations \u2013XIV\nVAB Vakuumbiopsie (vacuum-assisted breast biopsy)\nVATS Videoassistierte Thorakoskopie\nVUS Variante unklarer Signifikanz (variant of unknown significance)\nWBI Ganzbrustbestrahlung (whole breast irradiation)\nWBRT Ganzhirnradiatio (whole brain radiotherapy)\nZNS Zentrales Nervensystem\nVorspannDiagnosis and Treatment of Patients with early \nand advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Members of the\nAGO Breast Committee\nwww.ago -online.deVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Members ofthe\nBreast Committee 1\n\u00d8Prof. Dr. Ute -Susann Albert, W\u00fcrzburg\n\u00d8PD Dr. M. Banys -Paluchowski, L\u00fcbeck\n\u00d8Dr. Ingo Bauerfeind, Landshut\n\u00d8Prof. Dr. Jens -Uwe Blohmer, Berlin\n\u00d8Prof. Dr. Wilfried Budach, D\u00fcsseldorf\n\u00d8Prof. Dr. Peter Dall, L\u00fcneburg\n\u00d8Prof. Dr. Nina Ditsch, Augsburg\n\u00d8PD Dr. Eva Fallenberg, M\u00fcnchen\n\u00d8Prof. Dr. Peter Fasching, Erlangen\n\u00d8Prof. Dr. Tanja Fehm, D\u00fcsseldorf \n\u00d8Prof. Dr. Michael Friedrich, Krefeld\n\u00d8Prof. Dr. Bernd Gerber, Rostock\u00d8PD Dr. Oleg Gluz, M\u00f6nchengladbach\n\u00d8Prof. Dr. Nadia Harbeck, M\u00fcnchen \n\u00d8Prof. Dr. J\u00f6rg Heil, Heidelberg\n\u00d8Prof. Dr. Jens Huober, St. Gallen\n\u00d8Prof. Dr. Christian Jackisch, Offenbach\n\u00d8Prof. Dr. Wolfgang Janni, Ulm\n\u00d8Prof. Dr. Cornelia Kolberg -Liedtke, Berlin\n\u00d8Prof. Dr. Hans H. Kreipe , Hannover (DGP)\n\u00d8PD Dr. David Krug, Kiel\n\u00d8Prof. Dr. Thorsten K\u00fchn, Esslingen\n\u00d8Prof. Dr. Sherko K\u00fcmmel, EssenVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Members ofthe\nBreast Committee 2\n\u00d8Prof. Dr. Sibylle Loibl, Neu -Isenburg / Frankfurt\n\u00d8Prof. Dr. Diana L\u00fcftner, Berlin\n\u00d8Prof. Dr. Michael Lux, Paderborn\n\u00d8Prof. Dr. Nicolai Maass, Kiel\n\u00d8Prof. Dr. Volkmar M\u00fcller, Hamburg\n\u00d8Prof. Dr. Christoph Mundhenke, Bayreuth\n\u00d8Prof. Dr. Ulrike Nitz, M\u00f6nchengladbach\n\u00d8Prof. Dr. T. -W. Park -Simon, Hannover\n\u00d8Prof. Dr. Toralf Reimer, Rostock\n\u00d8Prof. Dr. Kerstin Rhiem, K\u00f6ln\n\u00d8Prof. Dr. Achim Rody, L\u00fcbeck\u00d8Prof. Dr. Marcus Schmidt, Mainz\n\u00d8Prof. Dr. Andreas Schneeweiss, Heidelberg (AIO)\n\u00d8Prof. Dr. Florian Sch\u00fctz, Speyer\n\u00d8Prof. Dr. H. Peter Sinn, Heidelberg (Pathologie)\n\u00d8Prof. Dr. Christine Solbach, Frankfurt\n\u00d8Prof. Dr. Erich F. Solomayer, Homburg\n\u00d8Prof. Dr. Elmar Stickeler, Aachen\n\u00d8Prof. Dr. Marc Thill, Frankfurt\n\u00d8Prof. Dr. Christoph Thomssen, Halle\n\u00d8Prof. Dr. Michael Untch, Berlin\n\u00d8Prof. Dr. Isabell Witzel, Z\u00fcrich\n\u00d8Prof. Dr. Achim W\u00f6ckel, W\u00fcrzburgVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Previous Members of\nthe Breast Committee 1\n\u00d8Prof. Dr. Werner Audretsch , D\u00fcsseldorf\n\u00d8PD Dr. Joachim Bischoff, Dessau\n\u00d8Dr. Michael B\u00f6hme, Magdeburg\n\u00d8Dr. Klaus E. Brunnert , Osnabr\u00fcck\n\u00d8Prof. Dr. Dr. Serban D. Costa, Magdeburg\n\u00d8Prof. Dr. Ingo J. Diel, Mannheim\n\u00d8PD Dr. Nikos Fersis , Duisburg\n\u00d8PD Dr. Kay Friedrichs, Hamburg\n\u00d8Prof. Dr. Uwe -Jochen G\u00f6hring , Bonn\n\u00d8Prof. Dr. Volker Hanf, F\u00fcrth\n\u00d8Dr. Georg Heinrich, F\u00fcrstenwalde\u00d8Prof. Dr. Walter Jonat , Kiel (DKH)\n\u00d8Dr. Hans Junkermann, Heidelberg\n\u00d8Prof. Dr. Manfred Kaufmann, Frankfurt\n\u00d8Dr. Bj\u00f6rn -Wieland Lisboa, D\u00fcsseldorf\n\u00d8Prof. Dr. Hans -Joachim L\u00fcck, Hannover\n\u00d8Prof. Dr. Gunter von Minckwitz , Neu -Isenburg /\nD\u00fcsseldorf\n\u00d8Prof. Dr. Volker M\u00f6bus, Frankfurt\n\u00d8Prof. Dr. Markus M\u00fcller -Schimpfle , Frankfurt\n\u00d8PD Dr. Carsten Oberhoff , Essen\nVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Previous Members of\nthe Breast Committee 2\n\u00d8Dr. Mahdi Rezai, D\u00fcsseldorf\n\u00d8Prof. Dr. Gerhard Schaller, M\u00fcnchen\n\u00d8Prof. Dr. Anton Scharl, Amberg\n\u00d8Prof. Dr. Rita Schmutzler, K\u00f6ln\n\u00d8Prof. Dr. Ingrid Schreer, Hamburg\n\u00d8Prof. Dr. H. Seegenschmiedt , Essen\n\u00d8Prof. Dr. W. Simon, Stuttgart\n\u00d8Prof. Dr. Rainer Souchon , Berlin\n\u00d8Prof. Dr. Frederik Wenz, Freiburg\nVorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Potential Conflict of Interest (COI)\n\u00d8The members of theediting committee of these guidelines arespecialists in diagnosis , treatment , \nand research in breast cancer . Most of themembers therefore have cooperations with industry . Thus, \npotential conflict of interest cannot beexcluded .\n\u00d8In order tominimize potential bias within thestatements wefollowed thepre-defined rules :\n\u00d8These guidelines arestrictly based on available evidence from thescientific literature .\n\u00d8The chapters of each edition were prepared byannually alternating teams of authors .\n\u00d8Each statement and thecorrespondent AGO -recommendations were thoroughly discussed\nwithin theentire group and accepted bymajority decisions . \n\u00d8Each member of theediting committee isrequired tosubmit a written declaration of his/her \nconflicts of interests toan elected internal COI committee on an annual basis .\n\u00d8Members who do not submit a COI declaration may not participate in theguideline\npreparation .Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Potential Conflicts of Interest (COI) \n2022 -2023\nAllmembers oftheAGO Breast Committee have submitted their COI report for the past year. Members\noftheAGO Breast Committee indicated that they have received support (e.g. research funding, lecture\norconsulting honoraria etc .)from the following commercial entities :\nAgendia ,Amgen ,AstraZeneca, Atheneum ,AZ, Baxter, Becton /Dickinson, Biontech ,Canon, BMS,\nCECOG, Celgene ,Chugai ,ClearCut ,ClinSol ,Clovis Oncology ,coma UroGyn ,Curevac ,Daiichi\nSankyo, Deutsche Akademie f\u00fcrSenologie, Diaceutics ,DIGIMED Verlag, DSI, Eisai ,EliLilly,\nEndomag ,ESO, Exact Sciences, Genentech, Genomic Health, Genzyme Europe, Georg Thieme\nVerlag, German Breast Group, Gilead, GSK, Gr\u00fcnenthal ,Hexal, high5,Hologic ,I -Med-Institute,\nInivata ,Intuitive, iOMEDICO ,Janssen, Lilly, Medizinwelten- services, medac ,med publico,\nMedscape ,med update, Menarini ,Merck Sharp &Dohme, Merck KGaA, Merit Medical, MICE\nService, Molecular Health, MSD, Mylan, Myriad, Neodynamics ,NOGGO, Norgine ,Novartis,\nOlema ,Onkowissen ,OnkoZert ,Organon, Pantarhei Bioscience , Pfizer, pfmmedical ,PharmaMar ,\nPierre Fabre, Relay, Roche, SamanTree Medical, Samsung, Sanofi -Aventis, Seagen ,Seattle\nGenetics ,Servier ,Sirius Pintuition ,Stemline ,Sysmex ,Teva,Viatris ,Vifor,Zuckschwerdt Verlag\nThe Committee did not consider any of thereported support torepresent a conflict ofinterest that would\npreclude participation inAGO Breast Committee discussions orvoting.Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1How toUse these Slides\n\u00d8The AGO Breast Committee encourages everyone tousethese slides forhisorher own\ninformation , improvement ofpatient care, medical education , presentations , and publications .\n\u00d8Forpresentations , theslides should only be used in their original version and layout , e.g. by\nusing a PDF -copy ofeach slide . The AGO -signet (\"logo\") should not be modified orerased .\nExtracting single phrases orparts of theslides may change theguideline content and istherefore\nnot allowed .\n\u00d8The following citation needs tobe used : \"AGO Breast Committee. Diagnosis and Treatment of\nPatients with Primary and Metastatic Breast Cancer. Recommendations 2021. www.ago -\nonline.de \"\n\u00d8Prior toany print media orelectronic publication (except fororal presentations ), the\ncorresponding tables orfigures have tobesubmitted tothechairman of theAGO Breast\nCommittee in order toobtain written permission (currently at direktion.frauenklinik@uniklinik -\nulm.de ).\n\u00d8A summary of theslides isavailabe aspublication in thejournal \u201eBreast Care\u201c.\n\u00d8Speaking of patients implicates that female / male / diverse gender is included .Vorspannwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1Editor & Copyright\nKommission \u201eMamma\u201c der \nArbeitsgemeinschaft f\u00fcr gyn\u00e4kologische\nOnkologie\n(AGO)\nwww.ago -online.de\nAddress for\ncorrespondence : \nEditorial Assistance:Univ. -Prof. Dr. med. Wolfgang Janni\nFrauenklinik, Dpt. Obst&Gyn\nUniversit\u00e4tsklinikum Ulm\nPrittwitzstr . 43 | 89075 Ulm\nP +49 731 500 58500 | F +49 731 500 58502\ndirektion.frauenklinik@uniklinik -ulm.de\nDr. Kristina VeselinovicProf. Dr. Volkmar M\u00fcller\nUniversit\u00e4tsklinikum Hamburg -Eppendorf\nMartinistr. 52 | 20246 Hamburg\nP +49 40 7410 -52510 | F +49 40 7410 -54355\nv.mueller@uke.deVorspann\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EOptions for Primary Prevention: \nModifiable Lifestyle Factors\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention\n\u00a7Versions 2011 \u20132022:\nDall / Diel / Gerber / Hanf / Maass / Mundhenke / Rhiem / Solbach / \nSolomayer / Thomssen / von Minckwitz\n\u00a7Version 2023:\nAlbert / Thomssen\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRisk Factors for Breast Cancer 1\n\u00a7Older age\n\u00a7Genetics\n\u00a7Family history of cancer\n\u00a7Personal history of breast\nlesions\n\u00a7Non -proliferative lesions\n\u00a7Proliferative lesions w/o atypia\n\u00a7High risk lesions (ADH, LIN)\n\u00a7Breast cancer (DCIS, Inv. BC)\n\u00a7Breast density\n\u00a7Chest irradiation\n\u00a7Type II Diabetes mellitus\n\u00a7Hyperthyreoidism\u00a7Lifetime number of\nmenstrual cycles\n\u00a7Early menarche, late menopause\n\u00a7Maternal pregnancy factors (e.g.\npre-eclampsia) (risk reduction), and\nlow physical activity during\npregnancy (risk increase)\nSocial risk factors\n\u00a7Lower number of births or\nno pregnancy\n\u00a7Advanced age at first full\nterm deliveryOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRisk Factors for Breast Cancer 2\n\u00a7Short duration or absence \nof breast feeding\n\u00a7Postmenopausal BMI < 18.5 and \n> 25 and \nespecially > 40 (obesity)\n\u00a7Food content\n\u00a7Steroid hormone therapy\n\u00a7Recent oral contraceptive use\n\u00a7Hormone therapy (estrogen / \ngestagen combination) in \npostmenopausal women\n\u00a7Alcohol intake\n\u00a7Nicotine\u00a7Light exposure at night (night shifts) \ncontradictory\n\u00a7Low physical activity\n\u00a7Endocrine disruptors in fetal and \nearly childhood development\n(e.g. DES, bisphenol -A, DDT)\n\u00a7Effect of carcinogenic substances / \nworking materials\n\u00a7Exposition to ionizing radiation\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nFactors for the Primary Prevention of Breast Cancer: \nA Meta -Analysis of Prospective Cohort Studies \nPoorolajal J et al. J Res Health Sci. 2021 Jul 20;21(3):e00520.Tamimi et al, 2016\nUSA: more than a third of \npostmenopausal breast cancers are \npreventable through changes in \nmodifiable risk factors \nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePregnancy Related Factors\nOxfordPreventionLoE GR\u00a7Any full -term pregnancy 2b B\u00a7High number of pregnancies 2b B\u00a7First full -term pregnancy before age of 30 years 2b B\u00a7Breast feeding (protective if total breast -feeding time exceeds 1.5 -2 years) 3a B\u00a7Lower birth weight of the first born (3000 -3500 vs. > 4500g RR = 1.53) 2b B\u00a7Lower length of pregnancy first born  \n(26-31. WOP vs. 40 -41. WOP; HR = 2.38, p = 0.03)2b BUnfavourable influence possible\u00a7Polycystic Ovarian Syndrome (PCOS) 2b CNoinfluence\u00a7Assisted reproduction 2b B\u00a7Abortion 2b BOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nImpact ofbreastfeeding on breast cancer risk\n\u00a7 Breastfeeding  reduces  the  risk  of  breast  cancer  by  4.3%  for  \nevery  12  months  of  breastfeeding, which  is  in  addition  to  \nthe  7.0%  decrease  in  risk  observed  for  each  birth.\n\u00a7 Breastfeeding has been shown to primarily reduce the risk of \nTriple -Negative Breast Cancer (20%) as well as in carriers of \nBRCA1 mutations (22 \u201350%).\n\u00a7 An estimated 4.7% of breast cancer cases in the UK are caused by \nnot breastfeeding.\nFrom : Stordal B. Cancer Med. 2022 Sep 26. Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMedical Primary Prevention*\nOxfordLoEGR AGO\u00a7ASS 2a B +/-\u00a7COX2 -Inhibitors 2a B +/-\u00a7Bisphosphonates 2b B +/-\u00a7Vitamin D 2b B +/-\u00a7Statins 2b B -\n*Noapproval , consider side effectsOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nMedical Prevention \nKehm RD et al., Regular useofaspirin and other non-steroidal \nanti-inflammatory drugs and breast cancer risk forwomen at familial or\ngenetic risk: a cohort study . Breast Cancer Res. 2019 Apr. 18;21(1):52\nProspective multinational cohort study , n= 5606, healthy women questionaire , \nregular intake ofASS, NSAID, COX2 -inhibitors\nRegular ASS -intake : HR 0.61, CI 0.33 -1.14, breast cancer incidence\nRegular COX2 -inhibitors : HR 0.39, CI 0.15 -0.97, breast cancer incidence other\nNSAIDs: n.s.\n[independent ofBRCA -status]Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Changing Lifestyle Factors: \nBody Mass Index / Diet\nOxfordLoEGRAGO\u00a7Maintaining normal weight \n(BMI at 18.5 -25 kg/m\u00b2)*2a B ++\n\u00a7Premenopausal 3a B +/-\n\u00a7Postmenopausal 2a B ++\u00a7Prevention / screening and treatment of \ndiabetes mellitus type II \n(reduction of breast cancer incidence and mortality)2b B ++\n*Amount of body fat can be increased in people with normal BMI and correlates with breast cancer riskOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Meta -analysis, ofatotal of150,537 patients inthe bariatric surgery arm\nand 1,461,938 women inthecontrol arm.\n\u00a7The risk ofbreast cancer was reduced by49%[RR:0.39(95%CI[0.31to\n0.56];I2=90%;7studies) .\n\u00a7The risk ofovarian cancer was reduced by53%[RR:0.47(95%CI[0.27to\n0.81];I\u00b2=0%;3studies) .\n\u00a7The risk ofendometrial cancer was reduced by67%[RR:0.33(95%CI\n[0.21to0.51];I2=88%;7studies) .The risk of breast, ovarian and endometrial cancer in obese women \nsubmitted to bariatric surgery: a meta -analysis \nB Ishihara, D Farah, M Fonseca and A Naz\u00e1rio, Surg Obes Relat Dis 2020;16(10):1596 -1602\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nAssociation of Body Fat and Risk of Breast Cancer in Postmenopausal Women \nWith Normal Body Mass Index: A Secondary Analysis of a Randomized \nClinical Trial and Observational Study.\nIyengar NM et al.: JAMA Oncol. 2019 Feb 1;5(2):155 -163\n\u00a7WHI substudy\n\u00a7Among the 3460 women included in the analysis (mean [SD] age, 63.6 [7.6] \nyears), multivariable -adjusted hazard ratios for the risk of invasive breast \ncancer were 1.89 (95 % CI, 1.21 -2.95) for the highest quartile of whole -body \nfat and 1.88 (95 % CI, 1.18 -2.98) for the highest quartile of trunk fat mass.\n\u00a7The corresponding adjusted hazard ratios for ER -positive breast cancer were \n2.21 (95 % CI, 1.23 -3.67) and 1.98 (95 % CI, 1.18 -3.31), respectively.\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Changing \nLifestyle Factors: Diet\nOxford\nLoE GR AGO\u00a7Preference of a balanced diet* 2b B +\u00a7Mediterranean Diet 2a B +\u00a7Dietary components\n\u00a7 Olive oil (extra virgin olive oil), as part of  mediterranean diet 2b B +\n\u00a7 Fat reduced food 2a B +\n\u00a7 Reduced consumption of red meat 2b C +\n\u00a7 Nuts / peanuts (> 10g/d) (peanut butter without effect) 2b B +\n\u00a7 Fiber containing food 2a B +\n\u00a7 Vitamin D substitution for prevention ( MaCa HR1,02) 1b B +/-\n\u00a7 Vegetables / fruits **2a B +/-\n\u00a7Phytoestrogens / soy 2a B +/-\n\u00a7Vegetarian / vegan diet (no significant risk reduction) 2b C +/-\n\u00a7 Coffee (no significant reduction) 2a B +/-\n\u00a7 Supplementation of vitamins, minerals, trace elements 2a B -*As recommended by German Society of Nutrition (DGE)\n**Recommended as a part of healthy nutrition\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nVitamin D Supplements and Prevention of Cancer and Cardiovascular \nDisease\nN Engl J Med. 2019 Jan 3;380(1):33 -44. doi: 10.1056/NEJMoa1809944. Epub 2018 Nov 10.\nRandomized, placebo -controlled trial, with a two -by-two factorial design, \nofvitamin D 3 (cholecalciferol) at a dose of 2000 IU per day and marine n -3 \n(also called omega -3) fatty acids at a dose of 1 g per day\nPrimary end points were invasive cancer of any type and major \ncardiovascular events \n25,871 participants\nmedian follow -up of 5.3 years\n124 breast cancers (Vit D group) vs. 122 (placebo group) Hazard Ratio: 1,02\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nOlive oilconsumption and breast cancer risk\n1. Amount ofolive oilconsumption correlates tobreast\ncancer risk (not significant )\n2. The source / quality oftheolive oil(mediterranean vs\nothers ) seems toberelevant ( ortheorigin ofthedata )\n3. Itisdifficult toseparate between useofolive oiland\ngeneral adherence toa mediterranean diet.\nSealy N et al. British Journal of Nutrition (2021), 125, 1148 \u20131156Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Modifying \nLifestyle Risk Factors: Alcohol\nOxford\nLoE GR AGO\u00a7Reduction of alcohol intace reduces risk of breast \ncancer (ideal < 10g/d, class II evidence)2a B +\nParticularly for\n\u00a7ER+ / PR+ tumors 2a B\n\u00a7Invasive lobular tumors 2a B\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nNature, Nurture and cancer risks: Genetic and nutritional contributions to \ncancer \nTheodoratou, E.: Annu Rev Nutr. 2017 August 21; 37: 293 \u2013320. \ndoi:10.1146/annurev -nutr -071715 -051004 \nNo association was classified as convincing (class I). The association between \nalcohol intake and ER+ breast cancer was classified as highly suggestive (Class II) \nbased on a meta -analysis of 20 prospective studies (\u2265 30 g/d of alcohol \nconsumption versus non -drinkers \nRR (95 % CI): 1.35 (1.23, 1.48, p -value = 5.2 x 10-10, I2= 26 %, \nPsmall effect bias = 0.184, Pexcess significance bias = 4 x 10-8)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Modifying \nLifestyle Risk Factors: Smoking\nOxford\nLoE GR AGO\u00a7Never smoking reduces risk of breast cancer\n(\u223c15-24 % reduction of lifetime risk)2a B ++\u00a7Young women smoking have a 60 % increased risk of BC, \nwhen smoking > 10 years before the first childbirth \n(vs. never smokers)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nSmoking and Risk of Breast Cancer in the Generations Study Cohort\nJones, M.E.: Breast Cancer Res. 2017 Nov 22;19(1):118. doi: 10.1186/s13058 -017-0908 -4.\n102,927 women recruited 2003 \u20132013\naverage of 7.7 years of follow -up\nThe HR (reference group was never smokers) was \n1.14 (95 % CI 1.03 \u20131.25; P\u2009=\u20090.010) for ever smokers, \n1.24 (95 % CI 1.08 \u20131.43; P\u2009=\u20090.002) for starting smoking at ages\u2009<\u200917 years\n1.23 (1.07 \u20131.41; P\u2009=\u20090.004) for starting smoking 1 \u20134 years after menarche\nWomen with a family history of breast cancer (ever vs never smokers HR 1.35; \n95 % CI 1.12 \u20131.62; P\u2009=\u20090.002) had a significantly larger HR \u2026 than women \nwithout (ever smoker vs never smoker HR 1.07; 95 % CI 0.96 \u20131.20; P\u2009=\u20090.22).\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Modifying \nLifestyle Risk Factors: Physical Activity \nOxford\nLoE GR AGO\u00a7Physical exercise 2a B ++\n(Metabolic equivalents to 3 \u20135 hrs \nmoderate pace walking per week)\nThese effects also apply to BRCA1/2 mutation carriers and for women \nwith an increased family risk.Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Prospective cohort study\n\u00a7N = 15 550, women with  fam. Hx of breast cancer\n\u00a7multiplicative interactions of physical activity with predicted absolute\nbreast cancer familial risk based on pedigree data and with BRCA1 and\nBRCA2 mutation status\n\u00a7Higher physical activity \u00e020 % reduction of breast cancer incidence\n\u00a7(HR0.80, CI 0.68 -0.93), independent of BRCA -status or pedigree riskRecreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult \nWomen at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and \nGenetic Risk. \nKehm RD et al.: Cancer Res. 2020 Jan 1;80(1):116 -125. doi: 10.1158/0008 -5472.CAN -19-1847. Epub 2019 Oct 2.\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Modifying Lifestyle Risk Factors:\nHormone Therapy in Postmenopausal Women\nOxford\nLoE GR AGO\u00a7Avoiding hormonal therapy in\npostmenopausal women\n\u00a7 Avoiding estrogen / progestin combinations 1b A+\n\u00a7 Avoiding estrogens only\n(no increased, possibly reduced breast cancer risk, but\nincreased risk for endometrial cancer, if not\nhysterectomized)1b A +/-\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nEpigenome -wide association study for lifetime estrogen exposure \nidentifies an epigenetic signature associated with breast cancer risk. \nJohansson A et al.: Clin Epigenetics. 2019 Apr 30;11(1):66.\nEpidemiological data from EPIC -Italy (n\u2009=\u200931,864)\nStudy:  estimated lifetime estrogen exposure \nMethod: epigenome -wide association study, blood DNA samples, N = 216 , \nand 440 healthy controls\nResults: an estimated 5 % increase in breast cancer risk per 1 -year longer ELEE \n(OR\u2009=\u20091.05, 95 % CI 1.04 -1.07, P =\u20093x10-12) in EPIC -Italy.\n694 CpG sites were associated with ELEE (FDR Q <\u20090.05)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nNMC-RR (95%CI)Further informationWHI WHI: JAMA 2002,\nJAMA 2017\u223c27 0001.3 (1,0-1,6)1.3 (1.1 -1,6) coronary events \n1.4 (1,1 -1,9) insults \n2.1 (1,4 -3,3) pulmonary embolism\n2.1 (1,5 -2,9) deep vein thrombosisHERSHulley S: JAMA 2002 I 2763RCT, med. 4.1 yrs.II 2321open -label, 2.7 yrs.1.2(0.95 -1.5) med. age 67 yrs.\nno secondary prevention\nside effects as comp. to WHI + cholcystectomy \u00e4MillionWomen Beral V: Lancet 20031.084 110\u223c50% HRT \n4.1 J. follow -up1.66 (1.6-1.8)EPC > E\nmode of applic. not relevant\nduration > 5 yrs.\nTibolon RR 1.45 (1.2 -1.7) EPICInt J Cancer 2010 1.153 747 person -years 1.4(1.2-1.6)1.8(1.4-2.2)E-Mono\nEPC > EMetaanalyseNelson HD: JAMA 200216 Studies1.21-1.40side effects as compared to WHI +Prevention of Hormones \nin Postmenopausal Patients\nChlebowski et al., Climacteric 2015, 18:336 -8\nChlebowski et al., J Natl Compr Canc Netw 2015, 13:917 -24\nManson JE et al., JAMA 2017; 318: 927 -938Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nPrevention of Hormones (EGC) \nin Postmenopausal Patients NMC-RR (95% CI)Further statementsCLEAR-study (NSW)Case-Control -Study,retrospect.Australia1236 BC cases2.09  (1.57 -2.78)current user1.03(0.82 -1.28)past user2.62(1.56 -4.38)E/P combination1.80(1.21 -2.68)E only\nSalagame et al., Int J Cancer. 2016;138(8):1905 -14 Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention by Modifying \nLifestyle Risk Factors: Oral Contraception (OC)\nOxford\nLoE\u00a7OC does notincrease the risk of mortality \nfrom breast cancer1a\u00a7Risk of breast cancer slightly increased, \nrisk of ovarian, endometrial cancer is decreased1a(-)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRisk Reduction for Ipsi -and \nContralateral Breast Cancer \nOxfordAdditional preventive effect by LoE GR AGO\u00a7Tamoxifen 1a A+\u00a7Aromatase inhibitors 1a A+\u00a7Suppression of ovarian function + Tamoxifen 1b B+Rationale: Women with breast cancer have an\nincreased risk for a second primary\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRisk reduction for ipsi-and contralateral \nsecond breast cancers (\u201csecond primaries\u201d)\nLocali -\nzationHR /\nRR95% CI p-value ref.Tamoxifen (vsnil) ipsilat. 0.47 SE 0.08 0.00001 EBCTCG \n2005contralat. 0.71 SE 0.06< 0.00001Tamoxifen (vsnil)ER+ orunknownipsilat. n.d. n.d. - EBCTCG \n2005contralat .0.61 0.50\u20130.73 -Aromatase inhibitor (vs Tam)ipsilat . 0.74 0.58 -0.95 0.020 EBCTCG \n2015contralat .0.62 0.48 -0.80 0.0003GnRH-agonist + tamoxifen (vs Tam)ipsilat . 11.8 vs16.7% - Cochrane\n2020\ncontralat. 0.56 0.29-1.07 -Options for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nDeodorant -use and risk\nBreast Cancer and Deodorants/Antiperspirants: a Systematic Review. \nAllam MF1: Cent Eur J Public Health. 2016 Sep;24(3):245 -247. doi: 10.21101/cejph.a4475.\nSo far there is no evidence of a correlation between aluminum containing \ndeodorants and breast cancer risk \n\u00a7All observational studies that evaluated the association between breast\ncancer risk and deodorants / antiperspirants use were reviewed. We have only\nidentified two case -control studies, carried out between 2002 and 2006.\n\u00a7There was no risk of antiperspirants use in the pooled risk (odds ratio 0.40,\n95% confidence interval 0.35 -0.46).\n\u00a7Our comprehensive search has identified an insufficient number of studies to\nconduct a quantitative review and obtain reliable results. Further prospective\nstudies are strongly needed.Options for Primary Prevention: Modifiable Lifestyle Factors\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\u0001\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0002\u0004\n\u0005\u001e\u0016\u001c\"#'\u001e'\u0001\u0016\"\u0019\u0001\u0012&\u001a\u0016(!\u001a\"(\u0001#\u001b\u0001\u000e\u0016(\u001e\u001a\"('\u0001\n+\u001e(\u001d\u0001\u001a\u0016& ,\u0001\u0016\"\u0019\u0001\u0016\u0019*\u0016\"\u0018\u001a\u0019\u0001\u0003&\u001a\u0016'(\u0001\u0004\u0016\"\u0018\u001a&\n\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\u0003&\u001a\u0016'(\u0001\u0004\u0016\"\u0018\u001a&\u0001\u0010\u001e'\u001f-\u0001\b\u001a\"\u001a(\u001e\u0018'\u0001\n\u0016\"\u0019\u0001\u000e&\u001a*\u001a\"(\u001e#\"\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0003&\u001a\u0016'(\u0001\u0004\u0016\"\u0018\u001a&\u0001\u0010\u001e'\u001f\u0001\u0016\"\u0019\u0001\u000e&\u001a*\u001a\"(\u001e#\"\n\u0001\u0002\u0003\u0007\b\u0004\u0006\u0005\b\u0001\f\u000b\u000b\r\n\f\u000b\f\f\t\u0001\n\u0002!\u0018\u001b&(\u00014\u0001\u0003\u001f'\u0019\u001e$\u001c\u001c\u00014\u0001\u0003!$\u001e\"\u001b&4\u0001\u0005\u0017!!\u00014\u0001\u0005\u001f('\u0019\u001e\u00014\u0001\u0001\u0007\u0017'\u0019\u001e\u001f#\u001d\u00014\u0001\u0007\u001b\u001e\"\u00014 \u0001\b\u001b&\u0018\u001b&\u00014\u0001\u000b\u001f\u001b\u0019\u001e!\u001b4\u0001\r\u0017\u0017''4\u0001\n\r*!!\u001b&5\u0012\u0019\u001e\u001f\"%\u001c!\u001b4\u0001\r)#\u001a\u001e\u001b# \u001b4\u0001\u0010\u0017& 5\u0012\u001f\"$#\u00014\u0001\u0011\u001e\u001f\u001b\"4\u0001\u0011$\u001a.4\u0001\u0012\u0019\u001e\"\u001f\u001a(\u0001 4\u0001\u0012\u0019\u001e\")(/!\u001b&4\u0001\u0012(\u001f\u0019 \u001b!\u001b&\u0001\n4\u0001\u0013\u001e$\"''\u001b#\u00014\u0001\u0016\u001f(/\u001b!\n\u0001\u0002\u0003\u0007\b\u0004\u0006\u0005\u0001\f\u000b\f\r\t\n\u000f\u0014\u0019%#*\u0001/\u0001\u0010\u0019\u001e\u001c\"\"\u0016\u001d\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u000e&\u001e\"\u0018\u001e$ \u001a'\u0001#\u001b\u0001\u000e&\u001a*\u001a\"(\u001e#\"\n\u0001\u0015#!\u001a\"\u0001\u0016(\u0001\u001e\"\u0018&\u001a\u0016'\u001a\u0019\u0001&\u001e'\u001f\u0001\u001b#&\u0001\u0017&\u001a\u0016'(\u0001\u0018\u0016\"\u0018\u001a&\u0001\u0016&\u001a\u0001\"#(\u0001\u0018#\"'\u001e\u0019\u001a&\u001a\u0019\u0001\n\u001f\u0016\"\u001a\u0018\u001d\"! \u0017)(\u0001\u0019\u0018\u0016\u001b\"\u0019&\u0001%\u001e\u001c\u0018\u001d #&\u0001\u0017\u001e#\u001d!\u0018\u001b\u0018\u0018!(\n\u0001\u0002\u0001\u0018#!$&\u001a\u001d\u001a\"'\u001e*\u001a\u0001\u001e\"\u001b#&!\u001a\u0019\u0001\u0018#\"' \u001a\"(\u0001(\u0016\u001f\u001e\"\u001c\u0001\u001e\"(#\u0001\u0018#\"'\u001e\u0019\u001a&\u0016(\u001e#\"\n\u0016  \u0001$#(\u001a\"(\u001e\u0016 \u0001'\u001e\u0019\u001a\u0001\u001a\u001b\u001b\u001a\u0018('\u0001\u0016\"\u0019\u0001&\u001e'\u001f'\u0001\u001e'\u0001+\u0016&&\u0016\"(\u001a\u0019\u0001$&\u001e#&\u0001(#\u0001#\u001b\u001b\u001a &\u001e\"\u001c\u0001\n$&\u001a*\u001a\"(\u001e*\u001a\u0001!\u001a\u0016')&\u001a'2\n\u0001\t\u001e\u001c\u001d\u001a'(\u0001$&\u001e#&\u001e(-1\u00014\u0007\u001e&'(0\u0001\u0019#\u0001\"#\u0001\u001d\u0016&!/3\u0001\n)\u000e \u001a\u001c#\u001c\u0001\u001d\u001a\u001b\u0001\u001d\u001e\u0017\u0018 \u0018*Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\b\u001b\u0012\u0017\u0011\u000f\u001f\u0017\u001c\u001b\u0001\u0014\u001c\u001d\u0001\u0006\u0013\u001b\u0013\u001f\u0017\u0011\u0001\u000e\u0013\u001e\u001f\u0017\u001b\u0015\u0001\u001c\u0014\u0001 \u0002\u0004\u0003\u0001\u0006\u0005\u0007 \u0006\u0013\u001b\u0013\u001e\n\u000f\u001b\u0012\u0001\u000b\u001c\u001e\u001e\u0017\u0010\u0019#\u0001\u0005 \u001d\u001f\u0016\u0013\u001d\u0001\f\u0017\u001e\u0018\u0001\u0006\u0013\u001b\u0013\u001e$\u0001\n5\u0010\u0014%'\u0001>\u0001\"\u0019\u0001?\u00014'\u0018&'\u001c!\u001a\u0001 \u0014\u0016\u0016\"%\u0017\u001c!\u001a'\"\u0001\u0019\u0014 \u001c\u001f,\u0001\u001b\u001c&'\"%,6\n\u0007\u0012\u001c\u001a\u001b\u001a\u0016\"\u0001'\u001a#\u0019\u00011\u0016\u0012\u0014\u0019\u0001\u0017!\u001e\u001c\u0001\u001e\u001d\u0016\u0001\u0017\u0012\u001c\u001a\u001b)\u0001\u0013!\u0012\u001d\u0014\u00192\u0001\u0012#\u0001\u001b\u0016\u0012\"# 3\n\u0001#\u0019!\u0016\u0016\u0001'\u001e\u001c\u0016\u001d\u0001'\u001a#\u0019\u0001\u0013!\u0016\u0012\"#\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u001a\u001d\u0015\u0016\u001f\u0016\u001d\u0015\u0016\u001d#\u0001\u001e\u0017\u0001\u0012\u0018\u0016\u0001\n\u0001#'\u001e\u0001'\u001e\u001c\u0016\u001d\u0001'\u001a#\u0019\u0001\u0013!\u0016\u0012\"#\u0001\u0014\u0012\u001d\u0014\u0016!,\u0001\u001e\u001d\u0016\u0001\u0015\u001a\u0012\u0018\u001d\u001e\"\u0016\u0015\u0001\u0013\u0016\u0017\u001e!\u0016\u0001#\u0019\u0016\u0001:7 !\u0013\u001a!#\u0019\u0015\u0012)\u0001\n\u0001\u001e\u001d\u0016\u0001'\u001e\u001c\u0012\u001d\u0001\u0012\u0017\u0017\u0016\u0014#\u0016\u0015\u0001\u0013)\u0001\u0013!\u0016\u0012\"#\u0001\u0012\u001d\u0015\u0001\u001e\u001d\u0016\u0001\u0013)\u0001\u001e&\u0012!\u001a\u0012\u001d\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u001e!\n\u0001\u001e\u001d\u0016\u0001'\u001e\u001c\u0012\u001d\u0001\u0012\u0017\u0017\u0016\u0014#\u0016\u0015\u0001\u0013)\u0001\u0013!\u0016\u0012\"#\u0001\u0012\u001d\u0015\u0001\u001e&\u0012!\u001a\u0012\u001d\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u001e!\n\u0001#'\u001e\u0001'\u001e\u001c\u0016\u001d\u0001\u0012\u0017\u0017\u0016\u0014#\u0016\u0015\u0001\u0013)\u0001\u001e&\u0012!\u001a\u0012\u001d\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u001e!\n\u0001\u001e\u001d\u0016\u0001'\u001e\u001c\u0012\u001d\u0001\u0012\u0017\u0017\u0016\u0014#\u0016\u0015\u0001\u0013)\u0001\u0013\u001a\u001b\u0012#\u0016!\u0012\u001b\u0001\u0013!\u0016\u0012\"#\u0001\u0014\u0012\u001d\u0014\u0016!,\u0001\u0017\u001a!\"#\u0001\u0013\u0016\u0017\u001e!\u0016\u0001:7 !\u0013\u001a!#\u0019\u0015\u0012)\n\u0001\u001e\u001d\u0016\u0001'\u001e\u001c\u0012\u001d\u0001\u0012\u0017\u0017\u0016\u0014#\u0016\u0015\u0001\u0013)\u0001\u0013!\u0016\u0012\"#\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u0013\u0016\u0017\u001e!\u0016\u0001#\u0019\u0016\u00019;!\u0016\u0013\u001a!#\u0019\u0015\u0012)\u0001\u001e!\n\u0001\u001e\u001d\u0016\u0001\u001c\u0012\u001d\u0001\u0012\u0017\u0017\u0016\u0014#\u0016\u0015\u0001\u0013)\u0001\u0013!\u0016\u0012\"#\u0001\u0014\u0012\u001d\u0014\u0016!\r(\u0018 \"\u0016\u0001\u000b \u0006*\u0001.\u0014\u0001\u0001\u0001\u0001\u0001\u0001\b\u000f*\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0002\b\r*\u0001//\n/\n!\u0016\u001f(&\u001c\"!\u0001\u0016%\u001c'\u0018%\u001c\u0014\u0001\"\u0019\u0001'\u001b\u0018\u0001\b\u0018% \u0014!\u0001\u0004\"!&\"%'\u001c( \u0001\"\u0019\u0001\t\u0018%\u0018\u0017\u001c'\u0014%,\u0001\u0003%\u0018\u0014& '\u0001\u0014!\u0017\u0001\u000f)\u0014%\u001c\u0014!\u0001\u0004\u0014!\u0016\u0018%\u00015\b\u0004\t\u0003\u000f\u00046\u0001\n\u0015\u0014&\u0018\u0017\u0001\"!\u0001\u0014\u0001\u0002\u0004\u0003\u0001\u0006\u0005\u0007  ('\u0014'\u001c\"!\u0001#%\u0018)\u0014\u001f\u0018!\u0016\u0018I\u0001>=\u0001G\u0001'\u0018&'\u0018\u0017\u001c!\u0001?>.A=>\u0019\u0014 \u001c\u001f\u001c\u0018&1\u0001\u0002\u001f\u001f\u0001 ('\u0014'\u001c\"! \u0001\u0016\u0014%%\u001c\u0018%&\u0001&\u001b\"(\u001f\u0017\u0001\u0015\u0018\u0001%\u0018\u001a\u001c&'\u0018%\u0018\u0017\u0001\u001c!\u0001\n&\u0016\u001c\u0018!'\u001c\u0019\u001c\u0016\u0001\u0017\u0014'\u0014\u0015\u0014&\u0018&.\u0001'\"\u0001)\u0014\u001f\u001c\u0017\u0014'\u0018\u0001'\u001b\u0018\u0001\u001c!\u0016\u001f(&\u001c\"!\u0001\u0014!\u0017\u0001\u0018+\u0016\u001f(&\u001c\"!\u0001\u0016%\u001c'\u0018%\u001c\u0014\u00015\u001c!\u0016\u001f(\u0017\u001c!\u001a\u0001#\"#(\u001f\u0014'\u001c\"!3\u0015\u0014&\u0018\u0017\u0001&'(\u0017\u001c\u0018&61\u0001Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\b\u001b\u0012\u0017\u0011\u000f\u001f\u0017\u001c\u001b\u0001\u0014\u001c\u001d\u0001\u0006\u0013\u001b\u0013\u001f\u0017\u0011\u0001\u000e\u0013\u001e\u001f\u0017\u001b\u0015\u0001\u001c\u0014\u0001 \u0002\u0004\u0003\u0001\u0006\u0005\u0007 \u0006\u0013\u001b\u0013\u001e\n\u000f\u001b\u0012\u0001\u000b\u001c\u001e\u001e\u0017\u0010\u0019#\u0001\u0005 \u001d\u001f\u0016\u0013\u001d\u0001\f\u0017\u001e\u0018\u0001\u0006\u0013\u001b\u0013\u001e$\u0001\n5\u0010\u0014%'\u0001?\u0001\"\u0019\u0001?\u00013'\u0018&'\u001c!\u001a\u0001\u0014\u0016\u0016\"%\u0017\u001c!\u001a\u0001'\"\u0001\u0017\u001c&\u0018\u0014&\u00186\n\u0001\u000e(\u001d\u001a&\u0001&\u001a\u0018#!!\u001a\"\u0019\u001a\u0019\u0001\u0018&\u001e(\u001a&\u001e\u00161\n\u0001\u001e'\u001d\u0001\u0015\u001a\"\u0016\u0012\"\u0016\u0001\u001e\u0017\u0001#!\u001a\u001f\u001b\u0016\u0001\u001d\u0016\u0018\u0012#\u001a&\u0016\u0001\u0013!\u0016\u0012\"#\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u0015\u001a\u0012\u0018\u001d\u001e\"\u0016\u0015\u0013\u0016\u0017\u001e!\u0016;6!\u0016\u0013\u001a!#\u0019\u0015\u0012)\n\u0001\u001e'\u001d\u0001\u0015\u001a\"\u0016\u0012\"\u0016\u0001\u001e\u0017\u0001\u001e&\u0012!\u001a\u0012\u001d\u0001\u0014\u0012\u001d\u0014\u0016!\u0001\u0013\u0016\u0017\u001e!\u0016\u0001<6!\u0016\u0013\u001a!#\u0019\u0015\u0012)\n\u0001\u001a\u0017\u0001#\u0019\u0016!\u0012\u001f\u0016$#\u001a\u0014\u0012\u001b\u001b)\u0001!\u0016\u001b\u0016&\u0012\u001d#\u00011\u0016.\u0018.\u0001\r\u0002\u000e\r\u001a-\u0001\u0003\u000e\u0004\u00027\u0001\u0012\u001d\u0015\u0001\u0003\u000e\u0004\u00028\u0001\u001e\u001d\u001b)-\u0001 \u001f\u001e\"\"\u001a\u0013\u001b)\u0001\n\r\u0002\n\u000382\r(\u0018 \"\u0016\u0001\u000b \u0006*\u0001.\u0014\u0001\u0001\u0001\u0001\u0001\u0001\b\u000f*\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0002\b\r*\u0001//\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0004\u0016\u0013\u0011\u0018\u0019\u0017\u001e\u001f\u0001\u0014\u001c\u001d\u0001\f\u0013\u0011\u001c\u001d\u0012\u0017\u001b\u0015\u0001\u000f\u0001\u000b\u001c\u001e\u001e\u0017\u0010\u0019\u0013\u0001\u0007\u0013\u001d\u0013\u0012\u0017\u001f\u000f\u001d#\u0001\u0003 \u001d\u0012\u0013\u001b\u0001\n\u001c\u0014\u0001\u0003\u001d\u0013\u000f\u001e\u001f\u0001\u000f\u001b\u0012\u0001%\u0001\u001c\u001d\u0001\n!\u000f\u001d\u0017\u000f\u001b\u0001\u0004\u000f\u001b\u0011\u0013\u001d\n\u000f#!\u001f#\u001b\u0001\u0019\u001e\u001b\u0019 !\u001f'(\u001c$&\u001c\u0017\"\u001f!\u001f\u0017!\u0001\u0018&\u001b\u0017'(\u0017#\u001a\u0001\n$+\u0017&\u001f\u0017#\u0019\u0017#\u0019\u001b&2\n\u0012$)&\u0019\u001b2\u0001\u0005\u001b)('\u0019\u001e\u001b\u0001\u000b&\u001b\u0018'\u001d\u001b'\u001b!!'\u0019\u001e\u0017\u001c(\u0001\u001b3\u00153\u0001\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0010\u001e'\u001f\u0001\u001a'(\u001e!\u0016(\u001e#\"\u0001\u001b#&\u0001',\"\u0019&#!\u001a0\u0016''#\u0018\u001e\u0016(\u001a\u0019\u0001\n\u0017&\u001a\u0016'( \u0018\u0016\"\u0018\u001a&\u00011\"#\"0\u0003\u0010\u0004\u00022\n\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\t\u001f'($&.\u0001\u0017#\u001a\u0001\u001c\u0017\"\u001f!.\u001e\u001f'($&.\u0001$+\u001b&\u0001\u0017(\u0001!\u001b\u0017'(\u0001(\u001e&\u001b\u001b\u0001\u001d\u001b#\u001b&\u0017(\u001f$#\u0001\n6\u001f#\u0019!)\u001a\u001f#\u001d\u0001\u0017\u001d\u001b\u0001$\u001c\u0001\u001c\u001f&'(\u0001\u001a\u001f'\u001b\u0017'\u001b7;\u0018 \u0003 @@\n\u0001\u0004\u001e\u0017&\u0017\u0019(\u001b&\u001f'(\u001f\u0019\u0001\u001a\u001f'\u001b\u0017'\u001b\n\u0001\u0003&\u001b\u0017'(\u0001\u0017#\u001a\u0001$+\u0017&\u001f\u0017#\u0001\u0019\u0017#\u0019\u001b&\n\u0001\u0007)&(\u001e\u001b&\u0001\u001a\u001f'\u001b\u0017'\u001b\n\u0001\u0010\u0017#\u0019&\u001b\u0017(\u001f\u00191\u0001(\u001e.&$\u001f\u001a1\u0019$!$&\u001b\u0019(\u0017!1\u0001'($\"\u0017\u0019\u001e\u001b1\u0001\n\u001e\u001b%\u0017($\u0018\u001f!\u001b\u0017&1\u0001)&$\u001d\u001b#\u001f(\u0017!1\u0001!)#\u001d\u0001\u0019\u0017#\u0019\u001b&1\u0001\"\u001b!\u0017#$\"\u00171\u0001\n$'(\u001b$'\u0017&\u0019$\"\u00171\u0001!\u001b) \u001b\"\u001f\u00171\u0001!.\"%\u001e$\"\u0017\n\u0001\u000b\u001f\u001a#\u001b.\u0001\u0019\u0017#\u0019\u001b&\n\u0001\u0013\u001b'(\u001f#\u0017!\u0019\u0017#\u0019\u001b&\n\u0001\u0006#\u001a$\"\u001b(&\u001f\u0017!\u0001\u0019\u0017#\u0019\u001b&\n\u0001\u0010&$'(\u0017(\u001b\u0001\u0019\u0017#\u0019\u001b&Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\t\u001c\u001b\u0001\u0003\f\u0004\u0002&\u0002\u001e\u001e\u001c\u0011\u0017\u000f\u001f\u0013\u0012\u0001\u0007\u0013\u001d\u0013\u0012\u0017\u001f\u000f\u001d#\u0001\u0004\u000f\u001b\u0011\u0013\u001d\u0001\n\r#\u001b\u0012\u001d\u001c\u001a\u0013\u001e\u0001\"\u0017\u001f\u0016\u0001\b\u001b\u0011\u001d\u0013\u000f\u001e\u0013\u0012\u0001\f\u0017\u001e\u0018\u0001\u0014\u001c\u001d\u0001\u0003\u001d\u0013\u000f\u001e\u001f\u0001\u0004\u000f\u001b\u0011\u0013\u001d\u0001\n\n#\u0018\u000f\u001c\u0019\u0017\u0010 \u0007\u0010\u0018\u0010 \t\u0014\u001d\u0015\u0001\u0011\u0019\u001c\u0001\u0017\f\u0016\u0014\u0012\u0018\f\u0018\u000e#\u0001\n\n\u0019\u0001\u0007 \u0010#\u001c\u0015\u001d\u0019 \u0010\r\u0016\u0015 \u0003 \u0015\u0010!\"*\u0001\u0015\u001d\u0014\u001e\u001c\u0015\" \u0019#\u001c*\u0001\u0013\u001e\u001b\u001e \u0015\u0013\"\u0010\u001b*\u0001!\u001c\u0010\u001b\u001b\u0001\u0019\u001d\"\u0015!\"\u0019\u001d\u0015*\u0001!\"\u001e\u001c\u0010\u0013\u0018*\u0001\u0018\u0015\u001f\u0010 \"\u001e\u0001\u0012\u0019\u001b\u0019\u0010 '*\u0001\n!\u001a\u0019\u001d*\u0001\u001e!\"\u0015\u001e!\u0010 \u0013\u001e\u001c\u0010*\u0001!\u001e\u0016\"\u0001\"\u0019!!#\u0015\u0001!\u0010 \u0013\u001e\u001c\u0010*\u0001# \u001e\u0017\u0015\u001d\u0019\"\u0010\u001b*\u0001\u0004\f\u000e*\u0001\u0002\u0004\u0004*\u0001 \u001b\u0015#\u001a\u0015\u001c\u0019\u0010*\u0001\n\u001b'\u001c\u001f\u0018\u001e\u001c\u0010*\u0001\u001b#\u001d\u0017\n\u0004\u001e%\u0014\u0015\u001d \r\u0010\u0006\f \u0003 \u0015\u0010!\"*\u0001\u0015\u001d\u0014\u001e\u001c\u0015\" \u0019#\u001c*\u0001\"\u0018' \u001e\u0019\u0014*\u0001 \u0013\u001e\u001b\u001e \u0015\u0013\"\u0010\u001b*\u0001\u001a\u0019\u0014\u001d\u0015'*\u0001\u001c\u0015\u001b\u0010\u001d\u001e\u001c\u0010\n\b\u0015 \u0015\u0014\u0019\"\u0010 '\u0001\u0014\u0019\u0016\u0016#!\u0015 \u0001\u0017\u0010!\" \u0019\u0013\u0001\u0013\u0010\u001d\u0013\u0015 \u0001\n!'\u001d\u0014 \u001e\u001c\u0015\u0004\u0005\u0007\u0013 \b\u0015 \u0015\u0014\u0019\"\u0010 '\u0001\u0014\u0019\u0016\u0016#!\u0015\u0001\u0017\u0010!\" \u0019\u0013\u0001\u0013\u0010\u001d\u0013\u0015  *\u0001\u001b\u001e\u0012#\u001b\u0010 \u0001\u0019\u001d$\u0010!\u0019$\u0015\u0001\u0012 \u0015\u0010!\"\u0001\u0013\u0010\u001d\u0013 \u0015 \n\r\u0015#\"(+\t\u0015\u0017\u0018\u0015 !\u0001\u000e'\u001d\u0014 \u001e\u001c\u0015 \u000f\u0010\t\u0013\u0013\u0012\u0001\n\t\u0003\u0013 \u0004\u001e\u001b\u001e \u0015\u0013\"\u0010\u001b*\u0001!\u001c\u0010\u001b\u001b\u0001\u0019\u001d\"\u0015!\"\u0019\u001d\u0015*\u0001!\"\u001e\u001c\u0010\u0013\u0018*\u0001\u001f\u0010\u001d\u0013 \u0015\u0010!*\u0001\"\u0015!\"\u0019\u0013\u001b\u0015*\u0001\u0015\u001d\u0014\u001e\u001c \u0015\" \u0019#\u001c\n\n'\u001d\u0013\u0018 \u000b\n\u0007\u0013\u0011\u0001\u000b\u000f\u0007\u0014\u0011\u0001\u000b\u000f\u0007\u0017\u0011\u0001\n\r\u000b\u000f\u0014\u0011\u0001\u0006\r\u0004\u0002\u000b\u0006\u001d\u0014\u001e\u001c\u0015\" \u0019#\u001c*\u0001\u001e$\u0010 '*\u0001\u0013\u001e\u001b\u001e \u0015\u0013\"\u0010\u001b*\u0001!\u001c\u0010\u001b\u001b\u0001\u0019\u001d\"\u0015!\"\u0019\u001d\u0015*\u0001!\"\u001e\u001c\u0010\u0013\u0018*\u0001\u0018\u0015\u001f\u0010\" \u001e\u0001\u0012\u0019\u001b\u0019\u0010 '*\u0001\n\u001f\u0010\u001d\u0013 \u0015\u0010!*\u0001\u001a\u0019\u0014\u001d\u0015'* \u0001# \u001e\u0017\u0015\u001d\u0019\"\u0010\u001b*\u0001\u0004\f\u000e\n\u0002\"\u0010&\u0019\u0010\u0001\"\u0015\u001b\u0010\u001d\u0017\u0019\u0015\u0013\"\u0010!\u0019\u0010\u0001\n,\u0002\u000f+\u000e'\u001d\u0014 \u001e\u001c\u0015-\u0002\u0010\u000b \u0003 \u0015\u0010!\" \u0013\u0010\u001d\u0013\u0015 *\u0001\u001b\u0015#\u001a\u0015\u001c\u0019\u0010*\u0001!\"\u001e\u001c\u0010\u0013\u0018*\u0001\u001c\u0015\u001b\u0010\u001d\u001e\u001c\u0010*\u0001!\u0010 \u0013\u001e\u001c\u0010\n\u0007 \u0010\u001d\u0013\u001e\u001d\u0019\u0001\u0002\u001d\u0011\u001c\u0019\u0015 \u0003\u000e\u0004\u0002\u0014\u0011\u0001\u0003\u000e\b\r\u0013\u0011\u0001\u000e\u0002\u0005\u0016\u0013\u0004\u0011\u0001\n\r\u0002\n\u0003\u0014\u0002\u000b\n*\u0001\u000b\u0005\u000e*\u0001\u000e\u0004\u0004*\u0001\u001c\u0015\u0014#\u001b\u001b\u001e\u0012\u001b\u0010!\"\u001e\u001c\u0010*\u0001 \u001d\u0015\u001f\u0018 \u001e\u0012\u001b\u0010!\"\u001e\u001c\u0010*\u0001\u0012 \u0015\u0010!\"*\u0001\u001f\u0010\u001d\u0013 \u0015\u0010 !*\u0001\u001e$\u0010 'Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\r#\"0\u0005\u001e&\u001a\u0018(\u001e*\u001a\u0001\u0004#)\"'\u001a \u001e\"\u001c\u0001\u0010\u001a\u001c\u0016&\u0019\u001e\"\u001c\u0001\n\u000e&\u001a*\u001a\"(\u001e*\u001a\u0001\f\u001a\u0016')&\u001a'\n\u0002\u0018\u0018#&\u0019\u001e\"\u001c\u0001(#1\u0001\n\u0001\u0012\u001d\u001a\u0001\b\u001a\"\u001a(\u001e\u0018\u0001\u0005\u001e\u0016\u001c\"#'(\u001e\u0018\u0001\u000b\u0016+\n\u0001\u0012\u001d\u001a\u0001\f\u001a\u0019\u001e\u0018\u0016 \u0001\u0005\u001a*\u001e\u0018\u001a'\u0001\u0002\u0018(\u00018\u001a2\u001c2\u0001&\u001e'\u001f\u0001\u0016''\u001a''!\u001a\"(9\n\u0001\u0002$$ \u001e\u0018\u0016(\u001e#\"\u0001#\u001b\u0001'#\u001b(+\u0016&\u001a\u0001\u001b#&\u0001&\u001e'\u001f\u0001\u0018\u0016 \u0018) \u0016(\u001e#\"\u0001&\u001a%)\u001e&\u001a'\u0001$&#\u001b\u001a''\u001e# \"\u0016 \u0001(&\u0016\u001e\"\u001e\"\u001c\u0001\n\u0016\"\u0019\u0001\u001a,$\u001a&\u001e\u001a\"\u0018\u001a\n\u0004#!!)\"\u001e\u0018\u0016(\u001a1\n\u0001\u0002\u0017'# )(\u001a\u0001\u0018\u0016\"\u0018\u001a&\u0001&\u001e'\u001f'\u0001+\u001e(\u001d\u001e\"\u0001\u0016\u0001!\u0016\"\u0016\u001c\u001a\u0016\u0017 \u001a\u0001(\u001e!\u001a\u001b&\u0016!\u001a\n\u0001\u0010\u001e'\u001f\u0001\u0016\"\u0019\u0001\u0017\u001a\"\u001a\u001b\u001e(\u0001#\u001b\u0001\u0016\u0001!) (\u001e!#\u0019\u0016 \u0001\u001e\"(\u001a\"'\u001e*\u001a\u0001')&*\u001a\u001e  \u0016\"\u0018\u001a\u0001$&#\u001c&\u0016! \u0001\n\u0001\u0010\u001e'\u001f\u0001\u0016\"\u0019\u0001\u0017\u001a\"\u001a\u001b\u001e(\u0001#\u001b\u0001$&\u001a*\u001a\"(\u001e*\u001a\u0001\u0018 \u001e\"\u001e\u0018\u0016 \u0001!\u001a(\u001d#\u0019'\u0001\n\u0001\u0004#!$\u001a(\u001e\"\u001c\u0001&\u001e'\u001f'0\u0001\u001a2\u001c2\u0001&\u001e'\u001f\u0001#\u001b\u0001\u0019\u001e'\u001a\u0016'\u001a\u0001$&#\u001c&\u001a''\u001e#\"\u0001\u001e\"\u0001&\u001a \u0016(\u001e#\"\u0001( #\u0001&\u001e'\u001f\u0001#\u001b\u0001\u0016\u0001\n'\u001a\u0018#\"\u0019\u0016&-\u0001$&\u001e!\u0016&-\u0001\u001e\"\u0001\u0018\u0016'\u001a\u0001+#!\u001a\"\u0001\u0016  &\u001a\u0016\u0019-\u0001\u0016\u001b\u001b\u001a\u0018(\u001a\u0019\u0001\u0017-\u0001$&\u001e!\u0016&-\u0001\u0017&\u001a \u0016'(\u0001\n\u0018\u0016\"\u0018\u001a&\n\u0002  #+\u0001\u0016$$&#$&\u001e\u0016(\u001a\u0001(\u001e!\u001a\u0001\u001b#&\u0001\u0018#\"'\u001e\u0019\u001a&\u0016(\u001e#\"\u0002\b\u000e\u0001HH\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0004)&&\u001a\"(\u0001\u0004 \u001e\"\u001e\u0018\u0016 \u0001\n!$\u0016\u0018(\u0001#\u001b\u0001\u0007)&(\u001d\u001a&\u0001\u0010\u001e'\u001f\u0001\b\u001a\"\u001a'\n\u0001\u0002\u001a\u0017\u0019\u000f\f\u0017\u0001\u0013\u0015\u000b\f\u0017\b\u0019\f\u0001\b\u0014\u000b\u0001\u0012\u0015\u001c \u0017\u0010\u0018\u0011\u0001\u000e\f\u0014\f\u0001\u001b\b\u0017\u0010\b\u0014\u0019\u0018\u0001\b\u0017\f\u0001\u0013\u0015\u0018\u0019\u0001\u0012\u0010\u0011\f\u0012\u001d\u0001\u0019\u0017\b \u0014\u0018\u0013\u0010\u0019\u0019\f\u000b\u0001\t\u001d\u0001\b\u0014\u0001\u0015\u0012\u0010\u000e\u0015 \u0015\u0017\u0001\n\u0016\u0015\u0012\u001d\u000e\f\u0014\u0010\n\u0001\u0019\u0017\b\u0010\u0019\u001f\n\u0001\u0007\u000f\f\u0001\u0016\f\u0014\f\u0019\u0017\b\u0014\n\f\u0001\u0015\r\u0001\u0018\u001a\n\u000f\u0001\u000e\f\u0014\f\u0018\u0001\u000b\f\u0016\f\u0014\u000b\u0018\u0001\u0015\u0014\u0001\u0019\u000f\f\u0001\u0015\u001c\u0014\u0001\b\u0014\u000b\u0001\r\b\u0013\u0010\u0012\u001d\u0001\n\b\u0014\n \f\u0017\u0001\u000f\u0010\u0018\u0019\u0015\u0017\u001d\u001f\n\u0001\u0003\u0014\u000b\u0010\u001b\u0010\u000b\u001a\b\u0012\u0001\u0012\u0015\u001c \u0017\u0010\u0018\u0011\u0001\u001b\b\u0017\u0010\b\u0014\u0019\u0018\u0001\u0010\u0014\n\u0017\f\b\u0018\f\u0001\u0019\u000f\f\u0001\u0017\u0010\u0018\u0011\u0001\u0015\r\u0001\u000b\u0010\u0018\f\b\u0018\f\u0001\u0015\u0014\u0012\u001d\u0001 \u0010\u0014\u0018\u0010\u000e\u0014\u0010\r\u0010\n\b\u0014\u0019\u0012\u001d\u001f\u0001\u0007\u000f\f\u001d\u0001\u000f\b\u001b\f\u0001\b\u0001\n\u0013\u001a\u0012\u0019\u0010\u0016\u0012\u0010\n\b\u0019\u0010\u001b\f\u0001\f\r\r\f\n\u0019\u001e\u0001\u0018\u0015\u0001\u0019\u000f\b\u0019\u0001\u0019\u000f\f\u0001\b\u0014\b\u0012\u001d\u0018\u0010\u0018\u0001\u0015\r\u0001\u0013\u001a\u0012\u0019\u0010\u0016\u0012\f\u0001\u000e\f\u0014\f\u0001\u0017\f \u000e\u0010\u0015\u0014\u0018\u0001!\u0016\u0015\u0012\u001d\u000e\f\u0014\u0010\n\u0001\u0017\u0010\u0018\u0011\u0001\u0018\n\u0015\u0017\f\u001e\u0001\u0004\u0005\u0006\"\u0001\n\u001c\u0010\u0012\u0012\u0001\t\f\u0001\u0015\r\u0001\n\u0012\u0010\u0014\u0010\n\b\u0012\u0001\u0017\f\u0012\f\u001b\b\u0014\n\f\u001f\u0001\u0001\n\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\u0001\u0004!\u001f#\u001f\u0019\u0017!\u0001\u001d\u001b#\u001b(\u001f\u0019\u0001(\u001b'(\u001f#\u001d\u0001$\u001c\u0001\"$\u001a\u001b&\u0017(\u001b5&\u001f' \u0001\u001d\u001b#\u001b'1\u0001\n\u001b3\u001d3\u0001\u001d\u001b#\u001b\u0001%\u0017#\u001b!':\u0018 \u0003 @\n\u0001\u0004!\u001f#\u001f\u0019\u0017!\u0001\u001d\u001b#\u001b(\u001f\u0019\u0001(\u001b'(\u001f#\u001d\u0001\u001c$&\u0001!$,5&\u001f' \u0001+\u0017&\u001f\u0017#('\u00016%$!.\u001d\u001b#\u001f\u0019\u0001&\u001f' \u0001 '\u0019$&\u001b1\u0001\n\u0010\u0011\u00127;\u0018 \u0003 @8\n\u0001\u0011\u001b\u001c\u001b&&\u0017!\u0001($\u0001\u0019\u001b#(\u001b&'\u0001$\u001c\u0001(\u001e\u001b\u0001\b\u00045\t\u0003\u000f\u0004\u0001$&\u0001\u0019$$%\u001b&\u0017(\u001f#\u001d\u0001\u0019\u001b#(\u001b&'\u0001 >\u0005 @\n+\u0004\u001f\u001c\u001c\u0010\u0018\u001e\u0016#$\u0001\u0017\u0019\u000f\u0010\u001c\f\u001e\u0010\u0016#\u0001\u001a\u0010\u0018\u0010\u001e\u001c\f\u0018\u001e\u0001\u0012\u0010\u0018\u0010\u001d\u0001\f\u0018\u000f\u0001\u0016\u0019!(\u001c\u0014\u001d\u0015\u0001 \f\u001c\u0014\f\u0018\u001e\u001d\u0001\u001d\u0013\u0019 \u001f\u0016\u000f\u0001\u0019\u0018\u0016#\u0001\r\u0010\u0001\u0010\"\f\u0017\u0014\u0018\u0010\u000f\u0001\u0014\u0018\u0001\u001e\u0013\u0010\u0001\u000e\u0019\u0018\u001e\u0010\"\u001e\u0001\u0019\u0011\u0001\u001a\u001c\u0019\u001d\u001a\u0010\u000e\u001e\u0014 \u0010\u0001\u000e\u0019\u0013\u0019\u001c\u001e\u0001\u001d\u001e\u001f\u000f\u0014 \u0010\u001d$\u0001\u001d\u001f\u000e\u0013\u0001\f\u001d\u0001\n\u001e\u0013\f\u001e\u0001\u0019\u0011\u0001\u001e\u0013\u0010\u0001\u0007\u0010\u001c\u0017\f\u0018\u0001\u000e\u0019\u0018\u001d\u0019\u001c\u001e\u0014\u001f\u0017$\u0001\u0014\u0018\u0001\u0019\u001c\u000f\u0010\u001c\u0001\u001e\u0019\u0001\f\u001d\u001d\u0010\u001d\u001d\u0001\u001e\u0013\u0010\u0001\u000e\u0016\u0014\u0018\u0014\u000e\f\u0016\u0001 \r\u0010\u0018\u0010\u0011\u0014\u001e'Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u000e\u0016(\u001d#\u001c\u001a\"\u001e\u0018\u0001\u0014\u0016&\u001e\u0016\"('\u0001+\u001e(\u001d\u0001\f#\u0019\u001a&\u0016(\u001a\u0001(#\u0001\t\u001e\u001c\u001d\u0001\n\u000b\u001e\u001b\u001a(\u001e!\u001a\u0001\u0010\u001e'\u001f\u0001\u001b#&\u0001\u0003&\u001a\u0016'(\u0001\u0004\u0016\"\u0018\u001a&\n9\u0001\u0001\u0013\u0014\u001e\u0018\u0001\u001c!'\"\u0001\u0014\u0016\u0016\"(!'\u0001'\u001b\u0018\u0001\u0018\u0019\u0019\u0018\u0016'\u001c)\u0018!\u0018&&\u0001\"\u0019\u0001#%\u0018)\u0018!'\u001c)\u0018\u0001 \u0018\u0014&(%\u0018&\u0001\u0014 !\u0017\u0001\u0016\" #\u0018'\u001c!\u001a\u0001%\u001c&\u001e&\u0001*\u001b\u0018!\u0001 \u0014\u001e\u001c!\u001a\u0001\u0016\u001f\u001c!\u001c\u0016\u0014\u001f\u0001\u0017\u0018\u0016\u001c&\u001c\"!&1\n\u0001\u0010\u0014%'\u001c\u0016\u001c#\u0014'\u001c\"!\u001c!\u0001#%\"&#\u0018\u0016'\u001c)\u0018%\u0018\u001a\u001c&'%\u001c\u0018&\"%&'(\u0017\u001c\u0018&\u001c&\u001b\u001c\u001a\u001b\u001f,%\u0018\u0016\"  \u0018!\u0017 \u0018\u00171\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\u0002\u001d\u001b5&\u001b!\u0017(\u001b\u001a\u0001&\u001f' '\u0001 \u001c$&\u0001\u0018&\u001b\u0017'(\u0001\u0019\u0017#\u0019\u001b&\u0001\n\u0001\u001e\u001f\u001d\u001e2\u0003\r\u0004\u0002\u0012\u0010\u0001\u0003\r\u0004\u0002\u0013\u0010\u0001\f\u0002\t\u0003\u0013\n\u0001\u001e\u001f\u001d\u001e2\u0004\u0005\u0007\u0012\u0010\u0001\f\u000f\u0006\u000b\u0010\u0001\u000f\f\u0015\u0014\u0011\u0001\u000e\u000f\b\u0012\u0012\r\n\u0001\"$\u001a\u001b&\u0017(\u001b2\u0001 \u0002\u000f\n\u0010\u0001\u0004\u0007\u0006\b\u0013\n\u0001\"$\u001a\u001b&\u0017(\u001b2\u0001\u0003 \u0002\r\u0005\u0012\u0010\u0001\r\u0002\u0005\u0015\u0012\u0004\u0010\u0001\r\u0002\u0005\u0015\u0012\u0005\n\u0004!\u001f#\u001f\u0019\u0017!\u0001\u0018\u001b#\u001b\u001c\u001f(8\u0001$\u001c\u0001\u0017\u0001\u001d\u001b#\u001b(\u001f\u0019\u0001(\u001b'(\n\u0001\u0003\r\u0004\u0002\u0012\u0010\u0001\u0003\r\u0004\u0002\u0013 :\u0018 \u0002 @@ \u0001\n\u0001\f\u0002\t\u0003\u0013 <\u0017 \u0003 @ \u0001\n\u0001\u0004\u0005\u0007\u0012\u0010\u0001\f\u000f\u0006\u000b\u0010\u0001\u000f\f\u0015\u0014\u0010\u0001\u000e\u000f\b\u0012\u0012 <\u0018 \u0003 @ \u0001\n\u0001\u0002\u000f\n\u0010\u0001\u0003\u0002\r\u0005\u0012\u0010\u0001\u0004\u0007\u0006\b\u0013\u0010\u0001\r\u0002\u0005\u0015\u0012\u0004\u0010\u0001\r\u0002\u0005\u0015\u0012\u0005 <\u0017 \u0003 @45 \u0001Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0011(\u0016(\u001a\u0001#\u001b\u0001&\u001a'\u001a\u0016&\u0018\u001d.\u0001\u0010\u001a \u001a*\u0016\"\u0018\u001a\u0001#\u001b\u0001\b\u001a\"\u001a(\u001e\u0018\u0001\u0016\"\u0019\u0001\n\"#\"0\b\u001a\"\u001a(\u001e\u0018\u0001\u0010\u001e'\u001f\u0001\u0007\u0016\u0018(#&'\n\u0005\u0017\u0015\u0016\u0001\u001f\u0017 \u0018 \u0015\u0013\u001b\u0013 &\u0001\u0014\u001f\u0013\u001e\"\u0013\u001b!\n\b\u001c$\u0001\u001f\u0017 \u0018 \u0015\u0013\u001b\u0013 &\u0001\u0014\u001f\u0013\u001e\"\u0013\u001b!\u0005\u0017\u0015\u0016\u0001\u001f\u0017 \u0018 \u0015\u0013\u001b\u0013 &\u0001\u001f\u000f\u001f\u0013\n\t\u001c\u0012\u0013\u001f\u000f!\u0013\u0001\u001f\u0017 \u0018\n\u0015\u0013\u001b\u0013 &\u0001\u0014\u001f\u0013\u001e\"\u0013\u001b!\b\u0015\r\u001a\u0013\n\u0019\u0011\u0015\u0014\u0001\u0015\u000f \f\n\u0014\f\u000e\u0017 \u0017\u0011\u0018\u0012 \u000b\u001b\n\u0014\u0015\u0014\u0003\u0010\u000e\u0014\u000e\u0019\u0011\f \u0017\u0011\u0018\u0012 \u000f\n\f\u0019\u0015\u0017\u0018\u0002\u0001\u000e\u0004\u0010\u0004\u0005\n\u0001\u0006\u0010\u000e\n\u0001\u0007\u0017\u000e\n\u0018\u0019 \r\u000e\u0014\u0018\u0011\u0019\u001b\n\u0001\u0006\u0010\u000e\u0001\n\u0019\u0001\u000f\u0011\u0017\u0018\u0019 \u0016\u0017\u000e\u0010\u0014\n\u0014\f\u001b\n\u0001\t\n\u0017\u0011\u0019\u001b\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0006'(\u001e!\u0016(\u001a\u0019\u0001\u0004)!) \u0016(\u001e*\u001a\u0001\u0010\u001e'\u001f\u0001#\u001b\u0001\u0003&\u001a\u0016'(\u0001\u0004\u0016\"\u0018\u001a&\u0001\n+\u001e(\u001d\u0001\u000e&#(\u001a\u001e\"0\u0012&)\"\u0018\u0016(\u001e\"\u001c\u0001\u0014\u0016&\u001e\u0016\"('\u0001\u001e\"\u00018\u0001\b\u001a\"\u001a'\n\f\u0016\u001c$\u001b\u0001\u000f\u001f\u0013\u0001\u0011\"\u001a\"\u0019\u000f!\u0017#\u0013\u0001\u001f\u0017 \u0018 \u0001\u001c\u0014\u0001\u0010\u001f \u0013\u000f !\u0001\u0011\u000f\u001b\u0011\u0013\u001f\u0001!\u0016\u001f\u001c\"\u0015\u0016\u00013.\u0001%\u0013\u000f\u001f \u0001\u001c\u0014 \u0001\u000f\u0015\u0013\u0001\u0014\u001c\u001f\u0001\u001d\u001f\u001c!\u0013\u0017\u001b(!\u001f\"\u001b\u0011 \u000f!\u0017\u001b\u0015\u0001#\u000f\u001f\u0017\u000f\u001b! \u0001\u0017\u001b\u00013\u0001\u0015\u0013\u001b\u0013 \u0001!\u0016\u000f!\u0001\u0016\u000f\u0012\u0001 \u0017\u0015\u001b\u0017\u0014 \u0017\u0011\u000f\u001b!\u0001\n\u0013#\u0017\u0012\u0013\u001b\u0011\u0013\u0001\u001c\u0014\u0001\u000f\u001b\u0001\u000f  \u001c\u0011\u0017\u000f! \u0017\u001c\u001b\u0001$\u0017!\u0016\u0001\u0010\u001f\u0013\u000f !\u0001\u0011\u000f\u001b\u0011 \u0013\u001f\u0001\u001c#\u0013\u001f\u000f\u0019\u0019&\u0001\u001c\u001b\u0001!\u0016\u0013\u0001\u0010 \u000f \u0017 \u0001\u001c\u0014\u0001\u0013 !\u0017\u001a\u000f!\u0013\u0012\u0001\u001c\u0012\u0012 \u0001\u001f\u000f!\u0017\u001c \u0001\u0014\u001f\u001c\u001a\u0001 \u001d\u001c\u001d\"\u0019\u000f!\u0017\u001c\u001b(\u0010\u000f \u0013\u0012\u0001 !\"\u0012\u0017\u0013 '\u0001\u0003\u000f \u0013\u0019\u0017\u001b\u0013\u0001\n\u000f\u0010 \u001c\u0019\"!\u0013\u0001\u001f\u0017 \u0018 \u0001$\u0013\u001f\u0013\u0001\u0012\u0013\u001f\u0017#\u0013\u0012\u0001\u0014\u001f\u001c\u001a\u0001\u001d\u001c\u001d\"\u0019\u000f!\u0017\u001c\u001b\u0001\u0017\u001b\u0011\u0017\u0012\u0013\u001b\u0011\u0013 \u0001\u0017\u001b\u0001!\u0016\u0013\u0001\u000e \u001b\u0017!\u0013\u0012\u0001\u0007\u0017\u001b\u0015\u0012\u001c\u001a\u0001\u0017\u001b\u00010./2'\u0001\r\u0016\u0013\u0001\u0006\u0001\u0010\u000f\u001f \u0001\u0017\u001b\u0012\u0017\u0011\u000f!\u0013\u000141 7\u0001\u0011\u001c\u001b\u0014\u0017\u0012\u0013\u001b\u0011\u0013\u0001\u0017\u001b!\u0013\u001f #\u000f\u0019 '\u0001\n\u0005\u001e \u001b\u0019\u001d\u0017\u0001\n&\u0001\u0004\u0013 $\u0013\u001b\u0018\u001e\u0001\u0010&\u0001\u0002\u001b\u001b\u0016\u001d\u0001\t\u0001\u0016\"\u0001\u0013\u001b(\u0001\u0003 \u0016\u0013!\"*\u0004\u0013\u001d\u0014\u0016 \u0001\u000f\u0019!\u001a\u0001\u0007\u0016\u001d\u0016!\u0001 +\u0002 ! ! \u001e \u0014 \u0019 \u0013 \" \u0019 \u001e \u001d \u0001 \u0002 \u001d \u0013 \u001b % ! \u0019 ! \u0001 \u0019 \u001d \u0001 \u000b \u001e  \u0016 \u0001 \" \u0018 \u0013 \u001d \u0001 / / 1 & . . . \u0001 \u0012 \u001e \u001c \u0016 \u001d ( \u0001 \t \u0013 \u001d # \u0013  % \u0001 0 . & \u0001 0 .0/\u0001\u0005\r\b'\u0001/.(/.34)\f\u0006\t\u000b\u001e\u0013/6/1625Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0003\u0017\r\n\u0018\u0019\u0004\n\u0014\u000b\r\u0017\u0001\b\u0010\u0018\u0011\u000e\u0015\u0017\u0006\u0014\f\u0010\u001b\u0010\f\u001a\n\u0012\u0001\u0007\u001a\u0019\n\u0019\u0010\u0015\u0014\u0018\n1\u0016\u0018\u0018#&\u0019\u001e\"\u001c \r\u0004\u0004\r\u000165672\n\b\u0010\r\f\u0001\u0017\u0010\u0012\f\u0001\u0015\u0010\u0016\u0011\n\u0002\n\u000e\f \u0006\u0005\u0001\u0019\u0004\u0003\u0007\u0010\u000e\u000f\u0001\r\u0015\f\u0014\u0018\f\u0013\u000b\u0019 \t\n\u0015\f\u0001\r\u0015\f\u0014\u0018\f\u0013\u000b\u0019\n\t\u001e\u001c\u001d\u0001\u0010\u001e'\u001f\n8L?<G9\u0003\u0010\u0004\u0002,'\u0001\u0003\u0010\u0004\u0002-'\u0001\u000e\u0002\u000b\u0003- \u0004\u0005\b,'\u0001\u000e\u0012\u0006\r'\u0001\u0012\u000e0.'\u0001\u0011\u0012\n,,\n\f#\u0019\u001a&\u0016(\u001a\u0001\u0010\u001e'\u001f\n8=B6>DG9\u0002\u0012\f'\u0001\u0003\u0002\u0010\u0005,'\u0001\u0004\b\u0006\n-'\u0001\n\u0010\u0002\u00050,\u0004'\u0001\u0010\u0002\u00050,\u0005\n\u000b#+\u0001\u0010\u001e'\u001f\u0001\n8I=BG9\f\u0011\b-'\u0001\f\u000b\b,'\u0001\f\u0011\b1'\u0001\n\u000e\f\u0011-'\u0001\u0006\u000e\u0004\u0002\f\n\u0013\u001d\u0017\u001b\u0018\u0016 \u0001\u0017\u001b\u001a\u001d\u001a\u0017\u0016\u001b\u0001 \u0018\u001b\u0018$\u0016\u001d\u0017\u0018 \u0003\u0010\t\u000e,' \u0001\u0004\u0005\n\r-\u0002'\u0001\u0007\u0002\r\u0004\u0004'\u0001\f\u0010\u0006,,'\u0001\f\u0013\u0012\u0015\b'\u0001\r \u0003\r'\u0001\r\u0007,'\u0001\n\u0010\u0002\u00050+'\u0001\u0010\u0006\u0004\u000f\u000b'\u0001\u0010\t\r\u0012,'\u0001\u0011\u000b\u0014/'\u0001\u0011\f\u0002\u0010\u0004\u0002/'\u0001\u0014\u0010\u0004\u0004-Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0003\"\u0017\u0013#$\u0004\u0013\u001f\u0015\u0017\"\u0001\u000f\u001b#\u001c\u0001\u0004\u0013$\u0017\u0019 \")\n\u0005\u0017\u0018\u001b\u001f\u001b$\u001b \u001f\u0001 \u0018\u001e \u0016\u0017\"\u0013$\u0017,\u001a\u001b\u0019\u001a\u0001\"\u001b#\u001c\u0018 \"\u0014\"\u0017\u0013#$\u0015\u0013\u001f\u0015\u0017\"\n\u000e\n\u0004\u0006\u00015\u000e\u0014'\u001c\"!\u0014\u001f\u0001\n!&'\u001c'('\u0018\u0001\u0019\"%\u0001\t\u0018\u0014\u001f'\u001b\u0001\u0014!\u0017\u0001\u0004\u0014%\u0018\u0001\u0006+\u0016\u0018\u001f\u001f\u0018!\u0016\u00186\u0001\u001a(\u001c\u0017\u0014! \u0016\u00180\u0001\u0007\u0014 \u001c\u001f\u001c\u0014\u001f\u0001\u0015%\u0018\u0014&'\u0001\u0016\u0014!\u0016\u0018%0\u0001\u0016\u001f\u0014&&\u001c\u0019\u001c\u0016\u0014'\u001c\"!.\u0001\u0016\u0014%\u0018\u0001\u0014!\u0017\u0001\n \u0014!\u0014\u001a\u001c!\u001a\u0001\u0015%\u0018\u0014&'\u0001\u0016\u0014!\u0016\u0018%\u0001\u0014!\u0017\u0001%\u0018\u001f\u0014'\u0018\u0017\u0001%\u001c&\u001e&\u0001\u001c!\u0001#\u0018\"#\u001f\u0018\u0001*\u001c'\u001b\u0001\u0014\u0001\u0019\u0014 \u001c\u001f ,\u0001\u001b\u001c&'\"%,\u0001\"\u0019\u0001\u0015%\u0018\u0014&'\u0001\u0016\u0014!\u0016\u0018%\n\u0004\u001f\u001c!\u001c\u0016\u0014\u001f\u0001\u001a(\u001c\u0017\u0018\u001f\u001c!\u0018\u00017\u0004\b>CA8\u0001\u0010(\u0015\u001f\u001c&\u001b\u0018\u00170?B\u0001\u000b(!\u0018\u0001?=>@\f\u0014&'\u0001(#\u0017\u0014'\u0018\u00170? =\u0001\u000e\")\u0018 \u0015\u0018%\u0001?=>DBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\n\u0002\u0010\u0004\u00010 \u0018 \u0016''\u001e\u001b\u001e\u0018\u0016(\u001e#\"\u0001#\u001b\u0001'\u001a%)\u001a\"\u0018\u001a\u0001*\u0016&\u001e\u0016\"('\n1\u000e #\" \u001a(\u0001\u0016 /-\u0001\t)!\u0016\"\u0001\f)(\u0016(\u001e#\"-\u000165582\n\r!\u001e\u001f\u001e\"\u0016\u0015\u0001\u0004\u001b\u0012\"\"\u001a\u0017\u001a\u0014\u0012#\u001a\u001e\u001d\u0001\u000f)\"#\u0016\u001c\u0001\u0017\u001e!\u0001\u000f\u0016 $\u0016\u001d\u0014\u0016\u0001\n\u0011\u0012!\u001a\u0012\u001d#\"\u0001\t\u0015\u0016\u001d#\u001a\u0017\u001a\u0016\u0015\u0001\u0013)\u0001\b\u0016\u001d\u0016#\u001a\u0014\u0001\u0010\u0016\"#\u001a\u001d\u0018\n\u0004\u001b\u0012\"\" \u0005\u0016\"\u0014!\u001a\u001f#\u001a\u001e\u001d \r!\u001e\u0013\u0012\u0013\u001a\u001b\u001a#)\u0001\u001e\u0017\u0001\u0013\u0016\u001a\u001d\u0018\u0001\n\u001f\u0012#\u0019\u001e\u0018\u0016\u001d\u001a\u0014\n>\u0005 \u001b \u001c \u001f # \u001f ( \u001b ! . % \u0017 ( \u001e $ \u001d \u001b # \u001f \u0019 B\u000191??\n=\f \u001f  \u001b ! . \u0001 % \u0017 ( \u001e $ \u001d \u001b # \u001f \u0019 91?>591??\n<\u0014 # \u0019 \u001b & ( \u0017 \u001f # 919>591?=?\n;\f \u001f  \u001b ! . \u0001 # $ ( \u0001 % \u0017 ( \u001e $ \u001d \u001b # \u001f \u0019 \u0001 $ & \u0001 $ \u001c \u0001 ! \u001f ( (!\u001b\u0001\u0019!\u001f#\u001f\u0019\u0017!\u0001'\u001f\u001d#\u001f\u001c\u001f\u0019\u0017#\u0019\u001b 9199:5 919=?\n:\u000e $ ( \u0001 % \u0017 ( \u001e $ \u001d \u001b # \u001f \u0019 \u0001 $ & \u0001 # $ \u0001 $ \u001c \u0001 \u0019 ! \u001f # \u001f \u0019 \u0017 ! \u0001 ' \u001f \u001d # \u001f \u001c \u001f \u0019 \u0017 # \u0019 \u001b A\u00019199:\n\u000e\" -\u0001\u0018 \u0016''\u0001@\u0001\u0016\"\u0019\u0001\u0018 \u0016''\u0001A\u0001*\u0016&\u001e\u0016\"('\u0001\u0016&\u001a\u0001\u0018#\"'\u001e\u0019\u001a&\u001a\u0019\u0001\u0018 \u001e\"\u001e\u0018\u0016  -\u0001&\u001a \u001a*\u0016\"(2\n\u0004 \u0016''\u0001?\u0001\u0016&\u001a\u0001\u0018#\"'\u001e\u0019\u001a&\u001a\u0019\u0001\u0016'\u0001\u0014\u0016&\u001e\u0016\" ('\u0001#\u001b\u0001\u0013\"\u001f\"#+\"\u0001\u0011\u001e\u001c\"\u001e\u001b\u001e\u0018\u0016\"\u0018\u001a\u00018\u0014\u0013\u0011 92Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u00014\u0002\u0001\u0014\u0016&\u001e\u0016\"(\u0001#\u001b\u0001\u0013\"\u001f\"#+\"\u0001\u0011\u001e\u001c\"\u001e\u001b\u001e\u0018\u0016\"\u0018\u001a\u00018\u0014\u0013\u0011\u0001\n\u0002\u0010\u0004\u0001\u0018 \u0016''\u0001?9\u0001\u001e'\u0001\u0016\u0001\u001c\u001a\"\u001a (\u001e\u0018\u0001*\u0016&\u001e\u0016\"(\u0001\n+\u001e(\u001d\u0001)\"\u001f\"#+\"\u0001\u0018 \u001e\"\u001e\u0018\u0016 \u0001&\u001a \u001a*\u0016\"\u0018\u001a 23\u0001\u00018\u000f #\"\u0001\u001a(\u0001\u0016 2\u0001\t)!\u0001\f)(\u0016(\u0001><<C9\n\u0001\f#'(\u0001\u0014\u0013\u0011\u0001\u0016&\u001a\u0001\u001a,(&\u001a!\u001a -\u0001&\u0016&\u001a 8K\u0001?\u0001*\u0016&\u001e\u0016\"('\u0001\u001e\"\u0001J\u0001C< G\u0001#\u001b\u0001\u001b\u0016!\u001e \u001e\u001a'9\n\u0001\u0004 \u0016''\u001e\u001b\u001e\u0018\u0016(\u001e#\"\u0001#\u001b\u0001'\u001a%)\u001a\"\u0018\u001a\u0001*\u0016&\u001e\u0016\" ('\u0001'\u001d#) \u0019\u0001\u0017\u001a\u0001$\u001a&\u001b#&!\u001a\u0019\u0001\u0016\u0018\u0018#&\u0019\u001e \"\u001c\u0001(#\u0001(\u001d\u001a\u0001\n\n\u0002\u0010\u0004\u0001\u0018 \u0016''\u001e\u001b\u001e\u0018\u0016(\u001e#\"\u0001'-'(\u001a!\n\u0001\u0007&\u001a%)\u001a\"\u0018-\u0001#\u001b\u0001\u0014\u0013\u0011\u00018\n\u0002\u0010\u0004\u0001\u0018 \u0016''\u0001?9\u0001\u001e\"\u0018&\u001a\u0016'\u001a'\u0001+\u001e(\u001d\u0001\")!\u0017\u001a&'\u0001#\u001b\u0001(\u001a'(\u001a \u0019\u0001\u001c\u001a\"\u001a'\n\u0001\u0004 \u001e\"\u001e\u0018\u0016 \u0001\u001e\"(\u001a&$&\u001a(\u0016(\u001e#\"\u0001\u0016\"\u0019\u0001\u0019\u001a\u0018\u001e'\u001e#\"\u0001!\u0016\u001f\u001e\"\u001c\u0001\u0019\u001a$\u001a\"\u0019\u001e\"\u001c\u0001#\"\u0001(\u001d\u001a\u0001\n\u0002 \u0010\u0004\u0001\n\u0018 \u0016''\u001e\u001b\u001e\u0018\u0016(\u001e#\"\u0001'-'(\u001a!\u0001\u001e'\u0001\"#(\u0001'(\u0016\"\u0019\u0016&\u0019\u001e.\u001a\u0019\u0001-\u001a(\n\u0001\n\"\u0001'\u001e \u001e\u0018#\u0001$&\u001a\u0019\u001e\u0018(\u001e#\"\u0001(## '\u00018\u000f# -\u000f\u001d\u001a\">0\u0001\u0011\n\u0007\u00129\u0001\u0016&\u001a\u0001\"#(\u0001\u0016\u0019\u001a%)\u0016(\u001a\u0001# &\u0001')\u001b\u001b\u001e\u0018\u001e\u001a\"(\u0001\n\u001b#&\u0001\u0018 \u001e\"\u001e\u0018\u0016 \u0001\u0019\u001a\u0018\u001e'\u001e#\"\u0001!\u0016\u001f\u001e\"\u001c\n\u0001\u0002\u0019\u0019\u001e(\u001e#\"\u0016 \u0001\u0016\"\u0016 -'\u001a'\u0001\u0016&\u001a\u0001&\u001a%)\u001e&\u001a\u00190\u0001\u001a2\u001c2\u0001\u001e\"\u0001*\u001e(&#\u0001'$ \u001e\u0018\u001e\"\u001c\u0001\u0016''\u0016-0 \u0001\u001b)\"\u0018(\u001e#\"\u0016 \u0001\n\u0016''\u0016-0\u0001'\u001a\u001c&\u001a\u001c\u0016(\u001e#\"\u0001\u0016\"\u0016 -'\u001e'0\u0001\u0018#6#\u0018\u0018)&\u001a\"\u0018\u001a\u0001\u0016\"\u0016 -'\u001e'0\u0001 \u0016&\u001c\u001a\u0001\u0018\u0016'\u001a\u0001 5\u0001\u0018#\"(&# \u0001\n'()\u0019\u001e\u001a'\u0014\u0016&\u001e\u0016\"(\u0001#\u001b\u0001\u0013\"\u001f\"#+\"\u0001\u0011\u001e\u001c\"\u001e\u001b\u001e\u0018\u0016\"\u0018\u001a\u00011\u0014\u0013\u00112.\u0001\n\u000e&#\u0017 \u001a!'\u0001\u0016\"\u0019\u0001\u000f)\u001a'(\u001e#\"'\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\f) (\u001e!#\u0019\u0016 \u0001\n\"(\u001a\"'\u001e*\u001a\u0001\n\u0011)&*\u001a\u001e  \u0016\"\u0018\u001a \u000e&#\u001c&\u0016!3\n\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\u0001\u0010&$\u001d&\u0017\"\u0001\u001c$&\u0001\u0003\u0011\u0004\u00025\")(\u0017( \u001f$#\u0001\u0019\u0017&&\u001f\u001b&'\u0001,\u001f(\u001e$)(\u0001\u0003\u0004\n\u0001\u0007$&\u0001(\u001e\u001b\u0001\u001a\u001b(\u001b\u0019(\u001f$#\u0001$\u001c \u0001\u001b\u0017&!.\u0001'(\u0017\u001d\u001b\u0001\u0019\u0017#\u0019\u001b&' ;\u0018 \u0003 @@\n\u0001\u0004\u001f\u001c!\u001c\u0016\u0014\u001f\u0001\u0015%\u0018\u0014&'\u0001\u0018+\u0014 I\u0001?B\u0001,\u0018\u0014%& \u0012\u0018 \u001c3\u0014!!(\u0014\u001f\u001f,\n\u0001\u0012\"!\"\u001a%\u0014#\u001b, I\u0001?B\u0001,\u0018\u0014%& \u0012\u0018 \u001c3\u0014!!(\u0014\u001f\u001f,\n\u0001\r\u0014  \"\u001a%\u0014 I\u0001A=\u0001,\u0018\u0014%& \u0006)\u0018%,\u0001>3?\u0001,\u0018\u0014%&99\n\u0001\u0003%\u0018\u0014&'\r\u0011\n I\u0001?B\u0001,\u0018\u0014%& \u0002!!(\u0014\u001f\u001f,\n\u0001\u0007$&\u0001\u001f\"%&$+\u001b\"\u001b#(\u0001$\u001c\u0001\"\u001b(\u0017'(\u0017'\u001f'5\u001c&\u001b\u001b\u0001\u001f#(\u001b&+\u0017! ;\u0018 \u0003 @\n\u0001\u0011\u0017\u001a\u001f$(\u001e\u001b&\u0017%.\u0001$\u001c\u0001(\u001e$&\u0017\u0019\u001f\u0019\u0001,\u0017!!\u0001\u001f# \u0001(\u001e\u001b\u0001\u0019\u001e\u001f!\u001a\u001e$$\u001a6\u001b3\u001d3\u0001\r3\u0001\t$\u001a\u001d \u001f#7 ;\u0017 \u0003 @@\n9\u0013\u001b\u0018\u0001 (\u001f'\u001c \"\u0017\u0014\u001f\u0001\u0018\u0014%\u001f,\u0001\u0017\u0018'\u0018\u0016'\u001c\"!\u0001#%\"\u001a%\u0014 \u0001&\u001b\"(\u001f\u0017\u0001\u0015\u0018\u0001\u0016\u0014%%\u001c\u0018\u0017\u0001\"('\u0001\u0019 \"%\u0001*\" \u0018!\u0001*\u001c'\u001b\u0001\u0014\u0001#\u0014'\u001b\"\u001a\u0018!\u001c\u0016\u0001 ('\u0014'\u001c\"!\u0001\u001c!\u0001%\u001c&\u001e\u0001\u001a\u0018!\u0018&\u0001\u0014!\u0017\u0001\n'\u001b\"&\u0018\u0001*\u001c'\u001b\u0001\u0014!\u0001\u001c!\u0016%\u0018\u0014&\u0018\u0017\u0001\u0016\u0014\u001f\u0016(\u001f\u0014'\u0018\u0017\u0001%\u001c&\u001e\u0001*\u001c'\u001b\"('\u0001\u0014\u0001 ('\u0014'\u001c\"!\u0001*\u001c'\u001b \u001c!\u0001'\u001b\u0018\u0001\u0019%\u0014 \u0018*\"%\u001e\u0001\"\u0019\u0001'%\u0014!&#\u0014%\u0018!'\u0001$(\u0014\u001f\u001c',\u0001\u0014&&(%\u0014!\u0016\u0018\u0001\u0014!\u0017\u0001\n\u0014##%\"#%\u001c\u0014'\u0018\u0001\u0018)\u0014\u001f(\u0014'\u001c\"!/\u0001\n99\u0001\u0002\u0016\u0016\"%\u0017\u001c!\u001a\u0001'\"\u0001'\u001b\u0018\u0001%\u0018\u0016\"  \u0018!\u0017\u0014'\u001c\"!\u0001\"\u0019\u0001'\u001b\u0018\u0001\u0001\b\u0018% \u0014!\u0001\u0004\"!&\"%'\u001c( \u0001?=??0\u0001\u0005\u0018#\u0018!\u0017\u001c!\u001a\u0001\"!\u0001'\u001b\u0018\u0001\u0014&&\u0018&&\u0014\u0015\u001c\u001f\u001c',\"\u0019\u0001'\u001b\u0018\u0001\u0015%\u0018\u0014&'.\u0001'\u001b\u0018\u0001\n\u001a\u001f\u0014!\u0017(\u001f\u0014%\u0001#\u0014%\u0018!\u0016\u001b, \u0014\u0001\u0017\u0018!&\u001c',\u0001\u0014!\u0017\u0001'\u001b\u0018\u0001#%\u0018)\u001c\"(&\u0001 \u0014  \"\u001a%\u0014#\u001b\u001c\u0016\u0001\u0019\u001c!\u0017 \u001c!\u001a&\u0001\u0018)\u0018%,\u0001>3?\u0001,\u0018\u0014%&\u0001\u0019%\" \u0001'\u001b\u0018\u0001A='\u001b3AB'\u001b\u0001\u0002\u001a\u0018.\u0001(!\u0017\u0018%\u0001A=\u0001\n,\u0018\u0014%&\u0001\"!\u001f,\u0001\u0014\u0019'\u0018%\u0001&'%\u001c\u0016'\u0001\u001c!\u0017\u001c)\u001c\u0017(\u0014\u001f\u0001\u001c!\u0017\u001c\u0016\u0014'\u001c\"!1Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\t\u001e\u001c\u001d0\u0010\u001e'\u001f\u0001\u0003&\u001a\u0016'(\u0001\u0004\u0016\"\u0018\u001a&\u0001\u0011)&*\u001a\u001e  \u0016\"\u0018\u001a\u0001+\u001e(\u001d\u0001\f\u0010\n\u0002\u0014\u000e\u0015\u0001\u000b#\u0001\u0004\u0018\u0012\u0010\u0016\u0001\u0003#\u0001\b\u001b\u001e\u0012\u0001\u0002#\u0001\u0010\u001d\u0001\f\u0016&\u0001\u0006\u0014\u0012\u0013(\u001b\u0014\u001c\u0015\u0001\r\u001b\u0010\f\u001c\u001d\u0001\u000e\f\u0018\u000e\u0010\u001b\u0001\u001c\u001e\u001b\u001f\u0010\u0014\u0016 \u0016\f\u0018\u000e\u0010\u0001 \u0014\u001d\u0013\u0001\t\n\u0007%\u0001.-(\"\u0010\f\u001b\u0001\u0010!\u001a\u0010\u001b\u0014\u0010\u0018\u000e\u0010\u0001\u0011\u001b\u0019\u0017\u0001\u001d\u0013\u0010\u0001\u0005\u0010\u001b\u0017\f\u0018\u0001\u000e\u0019\u0018\u001c\u0019\u001b\u001d\u0014\u001e\u0017\u0001\u0011\u0019\u001b\u0013\u0010\u001b\u0010\u000f\u0014\u001d\f\u001b\"\u0001\r\u001b\u0010\f\u001c\u001d\u0001\f\u0018\u000f\u0001\n\u0019\u001f\f\u001b\u0014\f\u0018\u0001\u000e\f\u0018\u000e\u0010\u001b&\u0001 \u0002\n\b\u0006\u000b\f\u0001\u0003\u0006\t\u0007\b\n\u0001\u0004\b\u000b\u0001\u0005\n\b\u0006\f &\u0001/-.4$.21*.+%/.2)//3&\u0001\u000f\u0019\u0014%.-&.--2'\u001c.-104(-.4(-1.1/(4\u000e\u000b\b\u000e\u0014\u0001\u0006\u0003\u0002\u0004\u0005 \u000f\u000b\b\u000f\u0014\u0001\u0006\u0003\u0002\u0004\u0005 \u0015\u0001 \u0010\u000b\u0001\u0006\u0003\u0002\u0004\u0005\n\u0002\n\u0017\n\b\u0017\u000e\u0013\u0012\u0001\n\u0015\u0006\u0017\n\u0001\u001d,\u001e\u0003\u0003\u0005\u0001\u001d+\u001e \u0002\n\u0017\n\b\u0017\u000e\u0013\u0012\u0001\n\u0015\u0006\u0017\n\u0001\u001d,\u001e\u0003\u0003\u0005\u0001\u001d+\u001e \u0002\n\u0017\n\b\u0017\u000e\u0013\u0012\u0001\n\u0015\u0006\u0017\n\u0001\u001d,\u001e\u0003\u0003\u0005\u0001\u001d+\u001e\n\u0003\u0005\u0004\u0002\u0015 \u000f\u000e\u0007\r \r\u0014\u0007\u000f \r\f\u0007\u0013 \r\u0010\u0007\u0010 \u000e\u000b\u0007\u0010 \u000e\u000e\u0007\u000e\n\u0003\u0005\u0004\u0002\u0016 \r\r\u0007\u0012 \r\u000e\u0007\u000e \r\u000f\u0007\u000e \r\u0012\u0007\u0010 \f\u0011\u0007\u000e \r\u000e\u0007\u0010\n\u0003\u0005\u0004\u0002\u0015\u0013\u0016\u0014\r\u000e\r\u0001\n\u0007\u0006\u000f\u000f\u000b\b\u000f\u0010\u0001\u0012\u000b\u0011\n\u0001\n\n\u000b\t\n\u0001\u000f\u000b\u0010\f\r\u0007\u0014 \r\u0007\u0013 \u0012\u0007\u000f \u0011\u0007\u0013 \f\u000b\u0007\u0014 \f\u000e\u0007\u0013\n\u0005\u0018'\u0018\u0016'\u001c\"!\u0001#\u0018%\u0019\"% \u0014!\u0016\u0018\u0001\"\u0019\u0001\u0014!!(\u0014\u001f\u0001 (\u001f'\u001c \"\u0017\u0014\u001f\u001c',\u0001&\u0016%\u0018\u0018!\u001c!\u001a\u0001%\"(!\u0017&\u0001 *\u001c'\u001b\u0001\r\u0011\n\u0001\u0015,\u0001%\u001c&\u001e\u0001\u001a%\"(#\u0001\u0014!\u0017\u0001\u0014\u001a\u00181\u000e\u000e\u0011'\u0001\u000e\u001e!\u0019\"\u0019$\u0016\u0001\u001f \u0016\u0015\u0019\u0014\"\u0019$\u0016\u0001$\u0013\u001b#\u0016\u0001Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0010\u0016(\u001e#\"\u0016 \u001a1\u0001\n\u0001\n\"\u0018&\u001a\u0016'\u001a\u0019\u0001&\u001e'\u001f\u0001#\u001b\u0001\u0017&\u001a\u0016'(\u0001\u0018\u0016\"\u0018\u001a&\u0001\u0016\u001b(\u001a&\u0001\u0018\u001d\u001a'(\u0001\u001e&&\u0016\u0019\u001e\u0016(\u001e#\"\u0001\u0017\u001a\u0018\u0016)'\u001a \u0001\n#\u001b\u0001\t#\u0019\u001c\u001f\u001e\"\u0001 -!$\u001d#!\u0016\u0001\u001e\"\u0001\u0018\u001d\u001e \u0019\u001d##\u0019\u00018D7=C\u0001-\u001a\u0016&'9\n\u0001\n\"\u0018&\u001a\u0016'\u001a\u0019\u0001&\u001e'\u001f\u0001#\u001b\u0001\u0017&\u001a\u0016'(\u0001#&\u0001#*\u0016&\u001e\u0016\"\u0001\u0018\u0016\"\u0018\u001a&\u0001\u001e\"\u0001+#!\u001a\"\u0001\u001b&#!\u0001\u0003\u0010\u0004\u0002=5 >\u0001\n\"\u001a\u001c\u0016(\u001e*\u001a\u0001\u001b\u0016!\u001e \u001e\u001a'\u0001\u0016(\u0001&\u001e'\u001f\u0001(\u001d\u0016(\u0001\u001e'0\u0001\u001d#+\u001a*\u001a&0\u0001 #+\u001a&\u0001(\u001d\u0016\"\u0001\u001e\"\u0001+#!\u001a\" \u0001\u001b&#!\u0001\n\u0003\u0010\u0004\u0002=5>\u0001$#'\u001e(\u001e*\u001a\u0001\u001b\u0016!\u001e \u001e\u001a'\n\u0001\u0010\u001a\u001b\u001a&&\u0016 \u0001(#\u0001\u0018\u001a\"(&\u001a'\u0001#\u001b\u0001(\u001d\u001a\u0001\b\u00046\t\u0003\u000e\u0004\u0001#&\u0001\u0018##$\u001a&\u0016(\u001e\"\u001c\u0001\u0018\u001a\"(&\u001a'\u0001\u001b#&\u0001( \u001d\u001a\u0001\n\u001a*\u0016 )\u0016(\u001e#\"\u0001#\u001b\u0001'(&)\u0018()&\u001a\u0019\u0001')&*\u001a\u001e  \u0016\"\u0018\u001a\u0001\u0016\"\u0019\u0001\u001b#  #+6)$\f \u0016\u001b\u0018\u001b\u0017\u0016\u0001\u0010%\"&\u0017\u001b\u001d\u001d\u0013\u001f\u0015\u0017\u0001\u000e\" \u0019\"\u0013\u001e\u0001\u0018 \"\u0001\n\u0002\u0004\u0003\u0001-\u001f\u0017\u0019+\u0001\u0012 \u001e\u0017\u001f\u0001\u0013$\u0001\f \u0016\u0017\"\u0013$\u0017\u0001$ \u0001\t\u001b\u0019\u001a\u0001\u000f\u001b#\u001c\u0001\n \"\u0001\u0010%\"&\u001b& \"#\u0001 \u0018\u0001\t \u0016\u0019\u001c\u001b\u001f\u0001\u0005\u001b#\u0017\u0013#\u0017\nBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\f%\u001d$\u001b\u001e \u0016\u0013\u001d\u0001\u0010%\"&\u0017\u001b\u001d\u001d\u0013\u001f\u0015\u0017\u0001\u000e\" \u0019\"\u0013\u001e\u0001\n\u0018 \"\u0001\u0007\u0017\u001e\u0013\u001d\u0017\u0001\u0004\u0013\"\"\u001b\u0017\"#\u0001 \u0018\u0001\u000e\u0013$\u001a \u0019\u0017\u001f\u001b\u0015\u0001\u0003\u000f\u0004\u0002\u0001\f%$\u0013$\u001b \u001f#\u0001\n\u0013\u0018$\u0017\"\u0001\u0011\u001f\u001b\u001d\u0013$\u0017\"\u0013\u001d\u0001\u0003\"\u0017\u0013#$\u0001\u0004\u0013\u001f\u0015\u0017\"\n\u000e,\u001b#&\u0019\n\u000b#\u0006 \b\u0010 \u0002\b\u000e\n\u0001\f) (\u001e!#\u0019\u0016 \u0001\u001e\"(\u001a\"'\u001e*\u001a\u0001')&*\u001a\u001e  \u0016\"\u0018\u001a $&#\u001c&\u0016!:\n\u0001\u0007#&\u0001\u0019\u001a(\u001a\u0018(\u001e#\"\u0001#\u001b\u0001\u001a\u0016& -\u0001'(\u0016\u001c\u001a\u0001\u0017&\u001a\u0016'(\u0001\u0018\u0016\"\u0018\u001a&' >\u0016 \u0003 HH\n\u0001\u0004\u001b\u001a\u001d\u001a\u0014\u0012\u001b\u0001\u0013!\u0016\u0012\"#\u0001\u0016(\u0012\u001c \u000f\u0016\u001c\u001a0\u0012\u001d\u001d$\u0012\u001b\u001b)\n\u0001\u000f\u001e\u001d\u001e\u0018!\u0012\u001f\u0019) \u000f\u0016\u001c\u001a0\u0012\u001d\u001d$\u0012\u001b\u001b)\n\u0001\u000b\u0012\u001c\u001c\u001e\u0018!\u0012\u001c \u0006&\u0016!)\u0001708\u0001)\u0016\u0012!\"33\n\u0001\u0003!\u0016\u0012\"#\u0001\u000b\u000e\t\u00011$\u001d#\u001a\u001b\u0001\u0002\u0004\u000e72 \u0002\u001d\u001d$\u0012\u001b\u001b)\n\u0001\u0007#&\u0001!#&(\u0016 \u001e(-\u0001&\u001a\u0019)\u0018(\u001e#\"\u00018=<6-\u001a\u0016&\u0001')&*\u001e*\u0016 9\u0001 ?\u0016 \u0004H 5 6\n)\u0001\u0002\u0011\u001e\u0010\u001c\u000e\f\u001c\u0010\u0001\u001d\u0013\u0019\u001f\u0016\u000f\u0001\r\u0010\u0001\u000e\f\u001c\u001c\u0014\u0010\u000f\u0001\u0019\u001f\u001e \u0001!\u0014\u001e\u0013\u0014\u0018\u0001\u001e\u0013\u0010\u0001\u0011\u001c\f\u0017\u0010!\u0019\u001c\u0015\u0001\u0019\u0011\u0001\u001e\u001c\f\u0018\u001d \u001a\f\u001c\u0010\u0018\u001e\u0001\u001b\u001f\f\u0016\u0014\u001e#\u0001\f\u001d\u001d\u001f\u001c\f\u0018\u000e\u0010\u0001\f\u0018\u000f\u0001\u000e\u0019\u001c\u001c\u0010\u001d\u001a\u0019\u0018\u000f\u0014\u0018\u0012\u0001\u0010 \f\u0016\u001f\f\u001e\u0014\u0019\u0018'\n))\u0001\u0002\u000e\u000e\u0019\u001c\u000f\u0014\u0018\u0012\u0001\u001e\u0019\u0001\u001e\u0013\u0010\u0001\u001c\u0010\u000e\u0019\u0017\u0017\u0010\u0018\u000f\f\u001e\u0014\u0019\u0018\u0001\u0019\u0011\u0001\u001e\u0013\u0010\u0001\u0001\u0007\u0010\u001c\u0017\f\u0018\u0001\u0004\u0019\u0018\u001d\u0019\u001c\u001e\u0014\u001f\u0017\u0001,* ,,&\u0001\u0005\u0010\u001a\u0010\u0018\u000f\u0014\u0018\u0012\u0001\u0019\u0018\u0001\u001e\u0013\u0010\u0001\f\u001d\u001d\u0010\u001d\u001d\f\r\u0014\u0016\u0014\u001e#\u0019\u0011\u0001\u001e\u0013\u0010\u0001\r\u001c\u0010\f\u001d\u001e$\u0001\u001e\u0013\u0010\u0001\u0012\u0016\f\u0018\u000f\u001f\u0016\f\u001c\u0001\n\u001a\f\u001c\u0010\u0018\u000e\u0013#\u0017\f\u0001\u000f\u0010\u0018\u001d\u0014\u001e#\u0001\f\u0018\u000f\u0001\u001e\u0013\u0010\u0001\u001a\u001c\u0010 \u0014\u0019 \u001f\u001d\u0001\u0017\f\u0017\u0017\u0019\u0012\u001c\f\u001a\u0013\u0014\u000e\u0001\u0011\u0014\u0018\u000f\u0014\u0018\u0012\u001d\u0001\u0010 \u0010\u001c#\u0001+(,\u0001#\u0010\f\u001c\u001d\u0001\u0011\u001c\u0019\u0017\u0001\u001e\u0013\u0010\u0001-*\u001e\u0013(-.\u001e\u0013\u0001\u0002\u0012 \u0010$\u0001\u001f\u0018\u000f\u0010\u001c\u0001-*\u0001#\u0010\f\u001c\u001d\u0001\u0019\u0018\u0016#\u0001\f\u0011\u001e\u0010\u001c\u0001\u001d\u001e \u001c\u0014\u000e\u001e\u0001\n\u0014\u0018\u000f\u0014 \u0014\u000f\u001f\f\u0016\u0001\u0014\u0018\u000f\u0014\u000e\f\u001e\u0014\u0019\u0018'Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0011)&*\u001a\u001e  \u0016\"\u0018\u001a\u0001\u001b#&\u0001\f\u0016 \u001a\u0001\u0004\u0016&&\u001e\u001a&'\u0001#\u001b\u0001\u000e\u0016(\u001d#\u001c\u001a\"\u001e\u0018\u0001\n\u0003\u0010\u0004\u0002\u0001\f)(\u0016(\u001e#\"'3\n9\u0007 \" \u001f \u001f \" * 3 ( # \u0001 \u0016 \u0014 % \u0018 \u0001 2 \u0001 & ( % ) \u0018 \u001c \u001f \u001f \u0014 ! \u0016 \u0018 \u0001 & \u001b \" ( \u001f \u0017 \u0001 \u0015 \u0018 \u0001 \u0016 \u0014 % % \u001c \u0018 \u0017 \u0001 \" ( ' \u0001 \u0014 & \u0001 # \u0014 % ' \u0001 \" \u0019 \u0001'%\u0014!&#\u0014%\u0018!'\u0001$(\u0014\u001f\u001c',\u0001\u0014&&(%\u0014!\u0016\u0018\u0001\u0014!\u0017\u0001\n\u0014##%\"#%\u001c\u0014'\u0018\u0001\u0018)\u0014\u001f(\u0014'\u001c\"!1\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\u0004)&&\u001b#(!.1\u0001#$\u0001'%\u001b\u0019\u001f\u001c\u001f\u0019\u0001')&+\u001b\u001f!!\u0017#\u0019\u001b\u0001\u001f'\u0001&\u001b\u0019$\"\"\u001b#\u001a\u001b\u001a\u0001 \u0003\n\u0006\u0017&!.\u0001\u001a\u001b(\u001b\u0019(\u001f$#\u0001$\u001c \u0001\u0019\u0017#\u0019\u001b&\u0001\u0017'\u0001%\u0017&(\u0001$\u001c\u0001'(\u0017#\u001a\u0017&\u001a\u0001\u0019\u0017&\u001b\n\u0001\u0003\u0011\u0004\u0002:4;\u0001\")(\u0017(\u001f$#\u0019\u0017&&\u001f\u001b&2\u0001\u001b-%!\u0017# \u0017(\u001f$#$\u001c&\u001f' '\u001c$&\u0019\u0017#\u0019\u001b&\u001a\u001f'\u001b\u0017'\u001b\n\u001f#\u0019!)\u001a\u001f#\u001d\"\u0017!\u001b\u0001\u001c\u0017\"\u001f!.\"\u001b\"\u0018\u001b&'>\u0005@ @\n\u0001\u0007$&\u0001\u0018&\u001b\u0017'(\u0001\u0019\u0017#\u0019\u001b&2\u0001'\u001b!\u001c\u0001\u001b-\u0017\"\u001f#\u0017(\u001f$# >\u0005 @\n\u0001\u0007$&\u0001%&$'(\u0017(\u001b\u0001\u0019\u0017#\u0019\u001b&2\u0001\u0004$\"%\u0017&\u001b \u0001\b\u001b&\"\u0017#\u0001\b)\u001f\u001a\u001b!\u001f#\u001b\u0001%&$\u001d&\u0017\" >\u0005 @\n\u0004\r\n\u0001\u0010\u000e\u000b\n\u0017\u000e\u0011\n\u0001\u0015\u000e\u0016\u000f\u0001\u0013\u000b\u0001\u0007\u0015\n\u0006\u0016\u0017\u0001\b\u0006\u0012\b\n\u0015\u0001\u000e\u0012\u0001\u0017\r\n\u0001\f\n\u0012\n\u0015\u0006\u0010\u0001\u0011\u0006\u0010\n\u0001\u0014\u0013\u0014\u0018\u0010\u0006\u0017\u000e \u0013\u0012\u0001\u000e\u0016\u0001!\u001b\"\u0001+\u001b\u0001 \u0003\u0005\u0004\u0002\u0006\u0011\u0018\u0017\u0006\u0017\u000e\u0013\u0012\u0001\b\u0006\u0015\u0015\u000e\n\u0015\u0016\u0001\r\u0006\u0019\n\u0001\u0006\u0001\n\u0015\u000e\u0016\u000f\u0001\u0013\u000b\u0001\u0007\u0015\n\u0006\u0016\u0017\u0001\b\u0006\u0012\b\n\u0015\u0001\u0013\u000b\u0001\u0006\u0007\u0013\u0018\u0017\u0001\"\u0001+\u0001\u0006\u0012\t\u0001\u0006\u0012\u0001\u0018\u0014\u0001\u0017\u0013\u0001\"\u001b(\u0001\u0017\u0013\u0001$\u001b'%\u0001\u0017\u000e\u0011 \n\u0016\u0001\r\u000e\f\r\n\u0015\u0001\u0015\u000e\u0016\u000f\u0001\u000b\u0013\u0015\u0001\u0014\u0015\u0013\u0016\u0017\u0006\u0017\u000e\b\u0001\b\u0006\u0012\b\n\u0015\u0001-&%\u001a\u001b\n\u0003\u0005\u0004\u0002\u0001\u0007\u0001\u0011\u0018\u0017\u0006\u0017\u000e\u0013\u0012\u0001\b\u0006\u0015\u0015\u000e\n\u0015\u0016\u0001\r\u0006\u0019\n\u0001\u0006\u0012\u0001\u0018\u0014\u0001\u0017\u0013\u0001% \u001c'\u0001+\u0001\u0010\u000e\u000b\n\u0017\u000e\u0011\n\u0001\u0015\u000e\u0016\u000f\u0001\u000b\u0013\u0015\u0001\u0007\u0015\n\u0006\u0016\u0017\u0001 \b\u0006\u0012\b\n\u0015\u0001\u0006\u0012\t\u0001\u0006\u0012\u0001\u0018\u0014\u0001\u0017\u0013 \u0001#\u001b%\u0001\u0017\u0013\u0001(\u001b&\u0001\u0017\u000e\u0011\n\u0016\u0001\n\r\u000e\f\r\n\u0015\u0001\u0015\u000e\u0016\u000f\u0001\u000b\u0013\u0015\u0001\u0014\u0015\u0013\u0016\u0017\u0006\u0017\u000e\b\u0001\b\u0006\u0012\b\n\u0015\u0001-\u0001&%\u001a\u001bBreast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0011)&\u001c\u001e\u0018\u0016 \u0001\u000e&\u001a*\u001a\"(\u001e#\"\n\u000e,\u001b#&\u0019\n\u000b#\u0006 \b\u0010 \u0002\b\u000e\n\u0001\u0010\u001e'\u001f6&\u001a\u0019)\u0018\u001e\"\u001c\u0001 )\"\u001e \u0016(\u001a&\u0016 \u0001#&\u0001\u0017\u001e \u0016(\u001a&\u0016 \u0001!\u0016'(\u001a\u0018(#!-\u0001\n8\u0010\u0010\f\u00069\u0001+\u001e(\u001d#)(\u0001(\u001d\u001a\u0001$&\u001a'\u001a\"\u0018\u001a\u0001 #\u001b\u0001\u0018 \u001a\u0016& -\u0001\u0019\u001a\u001b\u001e\"\u001a\u0019\u0001\n\u001c\u001a\"\u001a(\u001e\u0018\u0001&\u001e'\u001f\u0001\u001b\u0016\u0018(#&'>\u0016 \u0003 6:\n\u0001\u0002,\u001e  \u0016&- \u0019\u001e''\u001a\u0018(\u001e#\" #& \u0011\u001a\"(\u001e\"\u001a \u0001 -!$\u001d \"#\u0019\u001a \u001a,\u0018\u001e'\u001e#\"\n\u0019)&\u001e\"\u001c \u0010\u0010\f\u0006>\u0016 \u0003 66\n9& ' ( \u0017 , # \u0014 % ' \u001c \u0016 \u001c # \u0014 ' \u001c \" ! % \u0018 \u0016 \"   \u0018 ! \u0017 \u0018 \u0017Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0011)&\u001c\u001e\u0018\u0016 \u0001\u000e&\u001a*\u001a\"(\u001e#\"\u0001\u001b#&\u0001\t\u001a\u0016 (\u001d,\n\u0007\u001a!\u0016 \u001a\u0001 \u0002\u0004\u0003\u0001\u0006\u0005\u0007 \f)(\u0016(\u001e#\"\u0001\u0004\u0016&&\u001e\u001a&'\n\u000e,\u001b#&\u0019\n\u000b#\u0006 \b\u0010 \u0002\b\u000e\n\u0001\u0010\u001e'\u001f6&\u001a\u0019)\u0018\u001e\"\u001c\u0001\u0017\u001e \u0016(\u001a&\u0016 \u0001'\u0016 $\u001e\"\u001c#6##$\u001d#&\u001a\u0018(#!-\u0001\n8\u0010\u00106\u0003\u0011\u000e9::>\u0016 \u0003\n\u0001\u000e\u0016\u0015$\u0014\u0016\"\u0001\f&\u0004\u0012\u001a\u001d\u0014\u001a\u0015\u0016\u001d\u0014\u0016\u0001\u0012\u001d\u0015\u0001\u001c\u001e!#\u0012\u001b\u001a#) ==3\n\u0001\u000e\u0016\u0015$\u0014\u0016\"\u0001\u001e&\u0016!\u0012\u001b\u001b\u0001\u001c\u001e!#\u0012\u001b\u001a#) ==3\n\u0001\u0010\u001e'\u001f6&\u001a\u0019)\u0018\u001e\"\u001c \u0017\u001e \u0016(\u001a&\u0016 \u0001!\u0016'(\u001a\u0018(#!-\u0001 8\u0010\u00106\u0003\f9\n\u0001\u0011\u001b\u001a)\u0019\u001b'\u0001\u0003\u0004\u0001\u001f#\u0019\u001f\u001a\u001b#\u0019\u001b >\u0017 \u0003 H:\n\u0001\u0011\u001b\u001a)\u0019\u001b'\u0001\u0003\u0004\u0001\"$&(\u0017!\u001f(.\u0001\u001f#\u0001 \u0003\r\u0004\u0002\u0012\")(\u0017(\u001f$#\u0001\u0019\u0017&&\u001f\u001b&'888 >\u0017 \u0003 H:\n9\u0012 ' ( \u0017 , \u0001 # \u0014 % ' \u001c \u0016 \u001c # \u0014 ' \u001c \" ! % \u0018 \u0016 \"   \u0018 ! \u0017 \u0018 \u0017\n99 \u0013\u001b\u0018\u0001\u0011\u00113\u0003\u0012\u000f\u0001\u001c&\u0001%\u0018\u0016\"  \u0018!\u0017\u0018\u0017\u0001\u0019%\" \u0001\u0014\u0015\"('\u0001@B\u0001,\u0018\u0014%&\u0001\u0019\"%\u0001 \u0003\u0007\u0004\u0002\n\u0014!\u0017\u0001\u0019%\" \u0001\u0014\u0015\"('\u0001A=\u0001,\u0018\u0014%&\u0001\u0019\"%\u0001 \u0003\u0007\u0004\u0002\u000b ('\u0014'\u001c\"!\u0001\u0016\u0014%%\u001c\u0018%&.\u0001\n'\u0014\u001e\u001c!\u001a\u0001\u001c!'\"\u0001\u0014\u0016\u0016\"(!'\u0001'\u001b\u0018\u0001\u0014\u001a\u0018\u0001\"\u0019\u0001\")\u0014%\u001c\u0014!\u0001\u0016\u0014!\u0016\u0018%\u0001\u0017\u001c\u0014\u001a!\"&\u001c&\u0001\u001c!\u0001'\u001b\u0018\u0001\u0019\u0014 \u001c\u001f,\u0001\u0014!\u0017\u0001'\u001b\u0018\u0001\u0019\u0014 \u001c\u001f,\u0001#\u001f\u0014!!\u001c!\u001a\u0001&'\u0014'(&1\n999 \u000e\"\u0001%\u0018\u0017(\u0016'\u001c\"!\u0001\u001c!\u0001 \"%'\u0014\u001f\u001c',\u0001\u0016\"(\u001f\u0017\u0001\u0015\u0018\u0001&\u001b\"*!\u0001\u0019\"%\u0001\u0003\u0011\u0004\u0002?\u0001 ('\u0014'\u001c\"!\u0001 \u0016\u0014%%\u001c\u0018%&1\u0001\u0011\u0011\u0003\r\u0001\u0016\"(!&\u0018\u001f\u001f\u001c!\u001a\u0001&\u001b\"(\u001f\u0017\u0001\u0015\u0018\u0001\u001c!\u0017\u001c)\u001c\u0017(\u0014\u001f\u001c&\u0018\u00171Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\b\u0010\u0017\u0011\u001d\u0016\r\f\u0019\u000b\u0010\u0014\u000f\u0001\u0006\u0014\u0018\r\u0016\u001a\r\u0014\u0018\u0010\u0015\u0014\u0017\u0001 \u000e\u0015\u0016\u0001\u0003\b\u0004\u0002\u001e\u001c\u001f\u0001\u0005\r\u0013\t\u0012\r\u0001\n\u0007\u0019\u0018\t\u0018\u0010\u0015\u0014\u0001\u0004\t\u0016\u0016\u0010\r\u0016\u0017\u0001\u0002\u000e\u000e\r\u000b\u0018\r\f \n\u001b\u0001\u0003\u0016\r\t\u0017\u0018\u0001\u0004\t\u0014\u000b\r\u0016\n\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\u0001\u0011\u001f' 5&\u001b\u001a)\u0019\u001f#\u001d\u0001\u0018\u001f!\u0017(\u001b&\u0017!\u0001'\u0017!%\u001f#\u001d$5$$%\u001e$&\u001b\u0019($\".\u0001\u00016\u0011\u00115\u0003\u0012\u000f7 ;\u0018 \u0003 @8\n\u0001\u000b\u0013\u0012\"\u0011\u0013 \u0001\n#\u0004\u000f \u0017\u001b\u0011\u0017\u0012\u0013\u001b\u0011\u0013\u0001\u000f\u001b\u0012\u0001\u001a\u001c\u001f!\u000f\u0019\u0017!%\n\u0001\u000b\u0013\u0012\"\u0011\u0013 \u001c#\u0013\u001f\u000f\u0019\u0019 \u001a\u001c\u001f!\u000f\u0019\u0017!%\n)\u0011\u001c\u001b!\u001f\u000f\u0012\u0017\u0011!\u001c\u001f% \u001f\u0013 \"\u0019! \u0014\u001c\u001f \u001f\u0013\u0012\"\u0011!\u0017\u001c\u001b \u001c\u0014 \u0011\u0019\u0001\u0003\u0004\u0001\u0017\u001b\u0011\u0017\u0012\u0013\u001b\u0011\u0013*\n\u0001\u0010&$%\u001e.!\u0017\u0019(\u001f\u0019\u0001\u0019$#(&\u0017!\u0017(\u001b&\u0017 !\u0001\"\u0017'(\u001b\u0019($\".\u00016\u0011\u00115\u0004\r78 ;\u0018 \u0003 @8\n\u0001\u000b\u0013\u0012\"\u0011\u0013 \u0001\u0003\u0004\u0001\u0017\u001b\u0011\u0017\u0012\u0013\u001b\u0011\u0013\u0001\u000f\u001b\u0012\u0001\u001a\u001c\u001f!\u000f\u0019\u0017!%\n\u0001\u0013\u0017\"$-\u001f\u001c\u001b#\u00016&\u001b\u001a)\u0019\u001b'\u0019$#( &\u0017!\u0017(\u001b&\u0017!\u0003\u0004\u0001\u001f#\u0019\u001f\u001a\u001b#\u0019\u001b7 ;\u0018 \u0003 @458\n\u0001\n#\u001a\u001f\u0019\u0017(\u001f$#\u001c$&\u0011\u00115\u0004\r\u0001'\u001e$)!\u001a\u0019$#'\u001f \u001a\u001b&\u0017\u001d\u001b\u0017(\u0001$#'\u001b($\u001c\u001c\u001f&'(\u0018&\u001b\u0017'(\n\u0019\u0017#\u0019\u001b&\u001f#\u0001\u0017\u001c\u001c\u001b\u0019(\u001b\u001a\u001d\u001b#\u001b;\u0017 \u0003 @@8\n\u0001\u0011\u00115\u0003\r\u0001\u0017\u001c(\u001b&\u0001$+\u0017&\u001f\u0017#\u0019\u0017#\u0019\u001b& =\u0004 @ 4 5 8 8\n9\u0012 ' ( \u0017 , \u0001 # \u0014 % ' \u001c \u0016 \u001c # \u0014 ' \u001c \" ! % \u0018 \u0016 \"   \u0018 ! \u0017 \u0018 \u0017\n99\u0001\u0005\u0018#\u0018!\u0017&\u0001\"!\u0001'( \"%\u0001&'\u0014\u001a\u0018\u00015\u0007\n\b\u000f\u0001 \n2\n\n6.\u0001%\u0018\u0016(%%\u0018!\u0016\u0018\u0001\u0019%\u0018\u0018\u0001\u001c!'\u0018%)\u0014\u001f \u00015I\u0001B\u0001,%&16.\u0001\u0014\u001a\u0018Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\n\u001e!\" &\u0017\u0016\u0001\r&\u0017\"\u0013\u001d\u001d\u0001\u0010%\"&\u001b&\u0013\u001d\u0001\u0002\u0018$\u0017\"\u0001\u0004 \u001f$\"\u0013\u001d\u0013$\u0017\"\u0013\u001d\u0001\n\u000f\u001b#\u001c-\"\u0017\u0016%\u0015\u001b\u001f\u0019\u0001\f\u0013#$\u0017\u0015$ \u001e)\u0001\u001b\u001f\u0001 \u0002\u0004\u0003\u0001\u0006\u0005\u0007 \f%$\u0013$\u001b \u001f\u0001\u0004\u0013\"\"\u001b\u0017\"#\u0001'\u001b$\u001a\u0001\n\u0013\u0001\t\u001b#$ \")\u0001 \u0018\u0001\u0011\u001f\u001b\u001d\u0013$\u0017\"\u0013\u001d\u0001\u0003\"\u0017\u0013#$\u0001\u0004 \u0013\u001f\u0015\u0017\"*\u0001\u0002\u0001\u000e\" #!\u0017\u0015$\u001b&\u0017\u0001\u0002\u001f\u0013\u001d)#\u001b#\u0001\u0001\n\u0002\u0014\f\u0013\u001c\u0018\u0012\u0018\u0001 \u0005\u0017\u0015\u001a\u0016 \t\u000f\u0017\u0018\u0015\u0014\u0001\u001c\u000f\f\u0017\u0018\u0001\u0015\u0010\u0001\n\u0015\r\u0018\u000f\u0017\u001b\f\u0019\u0012\u0015\u0014\u0004\u000f\f\u0019\u0011\u0018 \b\u0015\u0017\u0019\f\u0013\u0012\u0019\u001c\u0002\u001f,(\u0001/\u0001\u0003\u0007 \u0006\n\u0001\u001f,(\u0001/\u0001\u0003\u0007 \n\u001f\f \u000b\u001a\u0017\u001b\u000f\u0012\u0013\u0013\f\u0014\u000e\u000f &##* )( %$\u001d)\u0001\u001f$)\u001d,\u001e%*\u001d) \n\u000f\u0010\n\u0003\n\n\b $,*( $, ,\u001d)\u0001\u001f)\u001d$\u001e$(\u001d$ #\u001d'&\u0001\u001f#\u001d%)\u001e#\u001d*% \u0003\n#\u001d',\u0001\u001f#\u001d%,\u001e#\u001d+% \u0004\n\u001f\r \u000b\u001a\u0017\u001b\u000f\u0012\u0013\u0013\f\u0014\u000e\u000f %)*& () %$\u001d#\u0001\u001f$)\u001d$\u001e%*\u001d% \n\u000f\u0010\u001d\n\u0003\n\n\b $+&* $+ ,\u001d+\u0001\u001f)\u001d%\u001e$(\u001d( #\u001d')\u0001\u001f#\u001d%*\u001e#\u001d*, \u0003\n#\u001d((\u0001\u001f#\u001d&%\u001e#\u001d,( \u0004\n\u0001\u0002\u001c\u000f\u001a& \u0017 \u0001-\u000f.\u0001\u0017 \u0001!\u0016\u0013\u0001\u001b\u000f\u0017\u001c\u0001\u000f\u001c\u000f\u001a& \u0017 \u0001$\u0017!\u0016\u0001 !\u000f\u001f!\u0001\u001d\u0014\u0001\u001d\u0010 \u0013\u001f#\u000f!\u0017\u001d\u001c\u0001\u0010\u0013\u0017 \u001c\u0015\u0001\u0013\u0017!\u0016\u0013\u001f\u0001!\u0016\u0013\u0001\u0012\u000f!\u0013\u0001\u001d\u0014\u0001\u001e\u001f\u0017\u001b\u000f\u001f&\u0001\u0010\u001f\u0013\u000f !\u0001\u0011\u000f\u001c\u0011\u0013\u001f\u0001-\u000b\u0003\u0004.\u0001\u0012\u0017\u000f\u0015\u001c\u001d \u0017 \u0001\u001d\u001f ! \u0016\u0013\u0001\u0012\u000f!\u0013\u0001\u001d\u0014\u0001\u0005\n\u0002\u0001\u0012\u0017\u000f\u0015\u001c\u001d \u0017 (\u0001$\u0016\u0017\u0011\u0016\u0013#\u0013\u001f\u0001\u0011\u000f\u001b\u0013\u0001\u0014\u0017\u001f !+\u0001\b\u001c\u0001!\u0016\u0013\u0001\n\u000f\u0012\u0012\u0017!\u0017\u001d\u001c\u000f\u001a\u0001\u000f\u001c\u000f\u001a& \u0017 \u0001-\u0010.(\u0001!\u0016\u0013\u0001\u001d\u0010 \u0013\u001f#\u000f!\u0017\u001d\u001c\u0001 !\u000f\u001f! \u0001\u0013\u0017!\u0016\u0013\u001f\u00012\u0001&\u0013\u000f\u001f \u0001\u000f\u0014!\u0013\u001f\u0001\u000b\u0003\u0004\u0001\u001d\u001f\u0001\u000f!\u0001!\u0016\u0013\u0001\u0012\u000f!\u0013\u0001\u001d\u0014\u0001\u0005\n\u0002\u0001\u0012\u0017\u000f\u0015\u001c\u001d \u0017 (\u0001$\u0016\u0017\u0011\u0016\u0013#\u0013\u001f\u0001\u0011\u000f\u001b\u0013\u0001\u0014\u0017\u001f ! (\u0001!\u001d\u0001\u0013%\u0011\u001a\"\u0012\u0013\u0001\u001e\u000f!\u0017\u0013\u001c! \u0001$\u0016\u001d\u0001\u001e\u001f\u0013 \u0013\u001c!\u0013\u0012\u0001$\u0017!\u0016\u0001\u0012\u0017 !\u000f\u001c!\u0001\n\u001b\u0013!\u000f !\u000f \u0013 \u0001\u001d\u001f\u0001\u0012\u0017\u0013\u0012\u0001$\u0017!\u0016\u0017\u001c\u00012\u0001&\u0013\u000f\u001f \u0001\u000f\u0014!\u0013\u001f\u0001\u000b\u0003\u0004\u0001\u0012\u0017\u000f\u0015\u001c\u001d \u0017 \u0001- \u000154513.+\u0001\n\u0002\u000b\u0013\u001f\u00011000\u0001\u001e\u0013\u001f \u001d\u001c\u0001&\u0013\u000f\u001f \u0001\u001d\u0014\u0001\u001d\u0010 \u0013\u001f#\u000f!\u0017\u001d\u001c+\u0001\n\u0003\u000e\u001c\u0017#\u000f\u001f\u0017\u000f!\u0013\u0001\u000f\u001c\u000f\u001a& \u0017 +\u0001\n\u0004\t\"\u001a!\u0017#\u000f\u001f\u0017\u000f!\u0013\u0001\u000f\u001c\u000f\u001a& \u0017 (\u0001\u000f\u0012\u0018\" !\u0013\u0012\u0001\u0014\u001d\u001f\u0001\u001f\u0017 \u0019,\u001f\u0013\u0012\"\u0011\u0017\u001c\u0015\u0001 \u000f\u001a\u001e\u0017\u001c\u0015\u001d,\u001d\u001d\u001e\u0016 \u001d\u001f\u0013\u0011!\u001d\u001b&+\u0001\r\u0016\u0013\u0001\u0014\u001d\u001a\u001a\u001d$\u0017\u001c\u0015\u0001#\u000f\u001f\u0017\u000f\u0010\u001a\u0013 \u0001\u0012\u0017\u0012\u0001\u001c\u001d!\u0001\u001b\u0013\u0013!\u0001!\u0016\u0013\u0001\u0011\u001f\u0017!\u0013\u001f\u0017\u000f\u0001\u0014\u001d\u001f \u0001\u0017\u001c\u0011\u001d\u001f\u001e\u001d\u001f\u000f!\u0017\u001d\u001c\u0001\u0017\u001c\u0001!\u0016\u0013\u0001\u001b\"\u001a!\u0017#\u000f\u001f\u0017\u000f!\u0013\u0001\u0004\u001d%\u0001\u001b\u001d\u0012\u0013\u001a\u0001\u000f \u0001\n\u0012\u0013 \u0011\u001f\u0017\u0010\u0013\u0012\u0001\u0017\u001c\u0001!\u0016\u0013\u0001\t\u0013!\u0016\u001d\u0012 \u0001 \u0013\u0011!\u0017\u001d\u001c(\u0001\u000f\u001c\u0012\u0001$\u0013\u001f\u0013\u0001!\u0016\u0013\u001f\u0013\u0014\u001d\u001f\u0013\u0001\u001c\u001d!\u0001\u0017\u001c\u0011\u001a\"\u0012 \u0013\u0012\u0001\u0017\u001c\u0001!\u0016\u0013\u0001\u001b\"\u001a!\u0017#\u000f\u001f\u0017\u000f!\u0013\u0001\u000f\u001c\u000f\u001a& \u0017 *\u0001!&\u001e\u0013\u0001\u001d\u0014\u0001\u001b\"!\u000f!\u0017\u001d\u001c(\u0001&\u0013\u000f\u001f\u0001\u001d\u0014\u0001\u0010\u0017\u001f! \u0016( \u000f\u0015\u0013\u0001\u000f!\u0001\u0005\n\u0002\u0001\u0012\u0017\u000f\u0015\u001c\u001d \u0017 (\u0001\u000f\u0015\u0013\u0001\u000f!\u0001\u000b\u0003\u0004\u0001\u0012\u0017\u000f\u0015\u001c\u001d \u0017 (\u0001\r, !\u000f!\" (\u0001\n\u001e\u001f\u0013 \u0013\u001c\u0011\u0013\u0001\u001d\u0014\u0001\u001e\u001d \u0017!\u0017#\u0013\u0001\u001a&\u001b\u001e\u0016\u0001\u001c\u001d\u0012\u0013 (\u0001\u0012\u0017\u0014\u0014\u0013\u001f\u0013\u001c!\u0017\u000f!\u0017\u001d\u001c\u0001\u0015\u001f\u000f\u0012\u0013(\u0001\u0016\u001d\u001f\u001b\u001d\u001c \u0013\u0001\u001f\u0013\u0011\u0013\u001e!\u001d\u001f\u0001 !\u000f!\" (\u0001\u0007\u0006\f2\u0001 !\u000f!\" \u0001\u000f\u001c\u0012\u0001!\u001f\u0013\u000f!\u001b\u0013\u001c! \u0001\u000f\u0012\u001b\u0017\u001c\u0017 !\u0013\u001f\u0013\u0012\u0001\u0014\u001d\u001f \u000b \u0003\u0004+\u0001\n\u0002\u0010\u0010\u001f\u0013#\u0017\u000f!\u0017\u001d\u001c *\u0001\u0004\f\f\t(\u0001\u0011\u001d\u001c!\u001f\u000f\u001a\u000f!\u0013\u001f\u000f\u001a\u0001\u001f\u0017 \u0019,\u001f\u0013\u0012\"\u0011\u0017\u001c\u0015\u0001\u001b\u000f !\u0013\u0011!\u001d\u001b&)\u0001\u0007\f (\u0001\u0007\u000f'\u000f\u001f\u0012\u0001\u001f\u000f!\u0017\u001d)\u0001\u0004\b(\u0001\u0011\u001d\u001c\u0014\u0017\u0012\u0013\u001c\u0011\u0013\u0001\u0017\u001c!\u0013\u001f#\u000f\u001a+\u0001Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\t\u000f\r\u0017\n\u0016\u001c\u0001\u0015\u000e\u0001\u0005\r\u0017\u0013\u0012\u0010\u0014\r\u0001\u0007\u001a\u0019\n\u0019\u0010\u0015\u0014\u001d\u0002\u0018\u0018\u0015\u000b\u0010\n\u0019\r\f\n\u0003\u0017\r\n\u0018\u0019\u0001\u0004\n\u0014\u000b\r\u0017\n\u000f-\u001c$&\u001a\n\f$\u0006 \b\u0011 \u0002\b\u000f\n\u0001\u0003%\u0018\u0014&'\u0001\u0016\"!&\u0018%)\u001c!\u001a\u0001&(%\u001a\u0018%,\u0014\u0016\u0016\"%\u0017\u001c!\u001a\u0016\"  \"!\u0001&'\u0014!\u0017\u0014%\u0017\u00015\u0014\u0017\u0018$(\u0014'\u0018\u0001\u001f\"\u0016 \u0014\u001f\u0001'( \"%\u0001\u0016\"!'%\"\u001f\u0001\u001c!\u0001\n\u001f\"!\u001a\u0001'\u001c \u0018\u0001\u0019\"\u001f\u001f\"*\u0001(#.\u0001:>=\u0001,\u0018\u0014%&\u0001\"\u0015&\u0018%)\u0014'\u001c\"!6?\u0014 \u0003 H\n\u0001\u0012,&'\u0018 \u001c\u0016\u0001'\u001b\u0018%\u0014#,\u0001\u0014\u0016\u0016\"%\u0017\u001c!\u001a\u0001'\"\u0016\"  \"!\u0001&'\u0014!\u0017\u0014%\u0017\u0001 @\u0014 \u0003 H\n\u0001\u001a\u0003\u0011\u0004\u0002 ('\u0014'\u001c\"!\u0001&'\u0014'(&\u0001\u001c&\u0001#%\u0018\u0017\u001c\u0016'\u001c)\u0018\u0001\u0019\"%\u0001!\u0018\"\u0014\u0017\u001d()\u0014!'\u0016\u001b\u0018 \"'\u001b\u0018%\u0014#,\u0001 \u001c!\u0001\u0018\u0014%\u001f,\u0001\u0013\u000e\u0003\u0004 ?\u0015 \u0003\n\u0001\u001a\u0003\u0011\u0004\u0002 ('\u0014'\u001c\"!\u0001&'\u0014'(&\u0001\u001c&\u0001#%\u0018\u0017\u001c\u0016'\u001c)\u0018\u0001\u0019\"%\u0001\u0004\u0014%\u0015\"#\u001f\u0014'\u001c!\u00015)&1\u0001\u0005\"\u0016\u0018'\u0014+ \u0018\u001f6\u0001\u001c!\u0001 \u0018'\u0014&'\u0014'\u001c\u0016\u0001\u0015%\u0018\u0014&'\u0001\n\u0016\u0014!\u0016\u0018%>\u0015 \u0003\n\u0010\u0002\u0011\u0010\u0001\u001f#\u001e\u001f\u0018\u001f($& 6\t\u001b&;5# \u001b\u001d\u0017(\u001f+\u001b\u0001\u0019\u0017&\u0019\u001f#$\"\u001772\n\u0001\u0018\u0003\u0004\u001b\u001c\u001a\u001b\u0001%\u001c&\u001e0\n\u0001\u000f\u001f\u0014#\u0014%\u001c\u00155\u001c!\u0001\u0016\u0014&\u0018\u0001\"\u0019 \b\u0003\u0007\u0004\u0002\n\t\u000b  ('\u0014'\u001c\"!69 >\u0015 \u0002 HH\n\u0001\r\u0003\u00040\n\u0001\u000f\u001f\u0014#\u0014%\u001c\u0015.\u0001\u0013\u0014\u001f\u0014-\"#\u0014%\u001c\u0015\u001c!\u0001 \b\u0003\u0007\u0004\u0002\n\t\u000b\u0001  ('\u0014'\u001c\"! /\u0010 \u0002 88\n\u0001\u000f\u001f\u0014#\u0014%\u001c\u0015\u001c!\u0001&\u0003\u0007\u0004\u0002\n\t\u000b\u0001  ('\u0014'\u001c\"!5&\" \u0014'\u001c\u0016 ('\u0014'\u001c\"!6 ?\u0015 \u0003 H23\n\u0001\u000f\u001f\u0014#\u0014%\u001c\u0015\u001c!\u0001\u0006\u0002\u0005\u0003\u000b\u001a\u0018% \u001f\u001c!\u0018 ('\u0014'\u001c\"! ?\u0015 \u0003 H23\n\u0006\u0003\u0004&\u0001\u0006\f\u001c\u0016#\u0001\u0003\u001c\u0010\f\u001d\u001e\u0004\f\u0018\u000e\u0010\u001c%\u0001\b\u0003\u0004&\u0001\b\u0010\u001e\f\u001d\u001e\f\u001e\u0014\u000e\u0003\u001c\u0010\f\u001d\u001e\u0004\f\u0018\u000e\u0010\u001c%\u0001)\u0001\u000b\u001d\u0010\u0001\f\u000e\u000e \u0019\u001c\u000f\u0014\u0018\u0012\u0001\u001e\u0019\u0001\u001d\u001e\u001f\u000f#\u0001\u0014\u0018\u000e\u0016\u001f\u001d\u0014\u0019\u0018\u0001\u000e\u001c\u0014\u001e\u0010\u001c\u0014\f\u0001\f\u0018\u000f\u0001\f\u001a\u001a\u001c\u0019 \f\u0016Breast Cancer Risk, Genetics and Prevention\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\f\u001a\u0019\u001e\u0018\u0016 \u0001\u000e&\u001a*\u001a\"(\u001e#\"\u0001\u001b#&\u0001\n\u0015#!\u001a\"\u0001\u0016(\u0001\n\"\u0018&\u001a\u0016'\u001a\u0019\u0001\u0010\u001e'\u001f\n\u000e,\u001b#&\u0019\n\u000b#\u0006 \b\u0010 \u0002\b\u000e\n\u0001\u0012\u0016!#,\u001e\u001b\u001a\"\u0001\u001b#&\u0001+# !\u001a\"\u0001J\u0001?A\u0001-\u001a\u0016&'1\u0001\n\u0010\u001e'\u001f\u0001&\u001a\u0019)\u0018(\u001e#\"\u0001#\u001b\u0001\u001e\"*\u0016'\u001e*\u001a\u0001\u0003\u00040\u0001\u0005\u0004\n\u0011\u0001\u0016\"\u0019\u0001\u000b\r =\u0016 \u0002 H:\n\u0001\u0010\u0016 #,\u001e\u001b\u001a\" \u001b#&\u0001$#'(!\u001a\"#$\u0016)'\u0016 \u0001+#!\u001a\"1\u0001\n\u0010\u001e'\u001f\u0001&\u001a\u0019)\u0018(\u001e#\"\u0001\u0001#\u001b\u0001\u001e\"*\u0016'\u001e*\u001a\u0001\u0003\u0004\u0001#\" - =\u0017 \u0002 H:\n\u0001\u0002\n\u0001\u001b#&\u0001$#'(!\u001a\"#$\u0016)'\u0016 \u0001+#!\u001a\" =\u0017 \u0002 H99\n9\u0001\u0011\u001c&\u001e\u0001&\u001c'(\u0014'\u001c\"!\u0014&\u0017\u0018\u0019\u001c!\u0018\u0017\u001c!\u0001\u000e\u0012\u0002\u0003\u0010\u0001\u0010>3'%\u001c\u0014\u001f\u00015>1CCG\u0001\u001c!\u0001B\u0001,\u0018\u0014%&6\u0001\" %\u0014\u0016\u0016\"%\u0017\u001c!\u001a'\";\u0013,%\u0018%3\u0004(-\u001c\u0016\u001e \"\u0017\u0018\u001f5\n\u0003\n\u00123\n\n6\n99\u0001\u0012\u001c\u001a!\u001c\u0019\u001c\u0016\u0014!'\u0001%\u001c&\u001e\u0001%\u0018\u0017(\u0016'\u001c\"!\u0001*\u0014&\u0001&\u0018\u0018!\u0001\u0019\"%\u0001\u0014!\u0014&'%\"-\"\u001f\u0018\u0001\u0019\"%\u0001\")\u0014% \u001c\u0014!\u0001\u0014!\u0017\u0001\u0018!\u0017\" \u0018'%\u001c\u0014\u001f\u0001\u0016\u0014!\u0016\u0018%.\u0001\n\u0014&\u0001*\u0018\u001f\u001f\u0001\u0014&\u0001&\u001e\u001c!.\u0001\u0016\"\u001f\"%\u0018\u0016'\u0014\u001f.\u0001\u001b\u0018 \u0014'\"\u001f\"\u001a\u001c\u0016.\u0001'\u001b,%\"\u001c\u0017\u0001\u0014!\u0017\u0001(%\u001c!\u0014%,\u0001' %\u0014\u0016'\u0001\u0016\u0014!\u0016\u0018%&1\u0001\u0004\u001b\u0018 \"#%\u0018)\u0018!'\u001c)\u0018\n%\u0018\u001a\u001c \u0018&\u0001&\u001b\"(\u001f\u0017\u0001\"!\u001f,\u0001\u0015\u0018\u0001\"\u0019\u0019\u0018%\u0018\u0017\u0001\u0014\u0019'\u0018%\u0001\u001c!\u0017\u001c)\u001c\u0017(\u0014\u001f\u0001\u0014!\u0017\u0001\u0016\" #%\u0018\u001b\u0018!&\u001c )\u0018\u0001\u0016\"(!&\u0018\u001f\u001c!\u001a1\u0001\u0013\u001b\u0018\u0001!\u0018'\u0001\u0015\u0018!\u0018\u0019\u001c'\u0001\n&'%\"!\u001a\u001f,\u0001\u0017\u0018#\u0018!\u0017&\u0001\"!\u0001%\u001c&\u001e\u0001&'\u0014'(&.\u0001\u0014\u001a\u0018\u0001\u0014!\u0017\u0001#%\u00183\u0018+\u001c&'\u001c!\u001a\u0001%\u001c&\u001e\u0001\u0019\u0014\u0016' \"%&\u0001\u0019\"%\u0001&\u001c\u0017\u0018\u0001\u0018\u0019\u0019\u0018\u0016'&1\u0001Breast Cancer Risk, Genetics and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2021.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EEarly Detection and Diagnosis\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deEarly Detection and Diagnosis\n\u00a7Versions 2005 \u20132022:\nAlbert / Blohmer / Fallenberg / Fersis / Gerber / Junkermann / \nMaass / M\u00fcller- Schimpfle / Scharl / Schreer / W\u00f6ckel\n\u00a7Version 2023:\nFallenberg / K\u00fchn\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deEarly Detection with Mammography\nOxford\nAge Interval LOE GR AGO\n< 40 na - - --\n40-44 na 1b B -\n45\u201349 24-36 1a B +#\n50\u201369* 24 1a A ++\n70\u201374 24 1a A +#\n> 75** 24 4 C +/-#\n*National Mammography -Screening -Program\n**health status + life expectancy more than 10 years\n#clear indication necessary, or indicated if screening age is adaptedEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deEarly Detection in Asymptomatic Women\nDigital Breast Tomosynthesis\nOxford\nLOE GR AGODigital Breast Tomosynthesis (DBT \u00b1SM)* 1a A +ReplacingFFDM bysynthetic MG in addition toDBT 1a A ++\n*Sign. higher sensitivity , heterogeneous specificity , and higher costs [machine , evaluation , archiving ] ofDBT in \ncomparison toFull-Field Digital Mammography (FFDM) \nDose reduction due tocalculated synthetic 2D mammography (SM) instead ofFFDMThe complete DBT dataset ofimages hastobeavailable forjudgment / reporting , thesynthetic\nmammography only isnot sufficient . \nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nMetaanalysesRR 95% CIIndependent UK Panel, 201213-year metaanalysis0.80 (0.73\u20130.89)Cochrane Review, 2011Fixed-effect metaanalysis of 9 RCT -trials0.81 (0.74\u20130.87)As above, but excluding women <50 years 0.77 (0.69\u20130.86)Canadian Task Force, 2011Women aged 50\u201369 years0.79 (0.68\u20130.90)Duffy et al, 2012Review of all trials and age groups0.79 (0.73\u20130.86)Duffy et al, 2020Review of 549,091 Women (30% eligible Swedish screening population)0.59 (0.51-0.68) mortality0.75 (0.66-0.84) advanced BCBreast cancer mortality reduction\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nMetaanalysesRR 95% CICase-Control StudiesBroeders et alScreening MxCorr. for  self selectionInvited for screening0.46  (0.4 \u20130.54)0.52  (0.42\u20130.65)0.69  (0.57\u20130.83)Incidence-based Mortality StudiesBroeders et alScreening MxInvited to screening0.62   (0.56\u20130.69)0.75   (0.69\u20130.81)Randomized Clinical TrialsGotsche and JorgensonScreening Mx0.81   (0.74\u20130.87)ECIBCScreening MX45-490.88 (0.76 -1.02)50-690.77 (0.66 -0.90)70-750.77 (0.54 -1.09)Breast cancer mortality reduction\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\n\u00a7Annual incidence of breast cancer and mortality in the EU (GLOBOCAN \n2012)Breastcancer: incidence and mortality\nFrom: http://gco.iarc.fr/Age Incidence / 1000 Mortality / 1000\n40 to 44 1.2 0.1\n45 to 49 1.7 0.2\n50 to 69 2.7 0.5\n70 to 74 3.0 0.8\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nMammography -Screening \nBenefit and Harm\nSiu Al  on behalf of the USPSTF 2016, 164:279 \u2013296Age40-4950-5960-6970-74Breast cancer death  avoided (CI 95%)3 (0-9)8 (2-17)21 (11-32)13 (0-32)False-positive   (n)1212932808696Breast biopsies (n)164159165175False-negative (n)10111213Data background: Breast Cancer Surveillance Consortium Registry Data\nper 10.000 Women screened over 10 years\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deEarly Detection (normal risk) \nSonography / MRI\nOxford\nLoE GR AGO\u00a7Screening -Breast sonography allone 5 D --\n\u00a7Automated 3D-sonography 3a C -\u00a7Breast sonography asan adjunct :\n\u00a7Dense mammogram\n(heterogeneously dense , extremely dense )2a B ++\n\u00a7Elevated risk 1b C ++\n\u00a7Mammographic lesion 2b B ++\n\u00a7Second -look US (MRI -only detected lesions) 2b C ++\u00a7MRI ifscreening MG isnegative and breast\ncomposition : extremely dense * 45\u201375 LJ1b B +\n*Definition ofextremely dense corresponds toBIRADS -density category D,  heterogeneously dense toBIRADS -category\nC according toACR BI -RADS -Atlas  5th ed. 2013Early Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deEarly Detection (normal risk)\nClinical Breast Examination (CBE)\nOxford\nLoE GR AGOAs stand alone procedure\u00a7Self-examination 1a A -*\u00a7Clinical breast examination (CBE) by health \nprofessionals outside checkup for cancer 1a C -*\u00a7Clinical breast examination (CBE) by health \nprofessionals during checkup for cancer 1a B ++\u00a7Medical palpation by blind / visually impaired \npersons3b C -CBE because of mammographic / sonographic lesion5 D ++CBE in combination with imaging1a A ++\n*May increase breast awarenessEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deAssessment of Breast Symptoms or Lesions\nOxford\nLoE GR AGO\u00a7Clinical examination 3b B ++\u00a7Mammography 1b A ++\n\u00a7Tomosynthesis *** 2a B +\n\u00a7Contrast -enhanced mammography (alone or as \nadjunct)2a B +\u00a7Sonography 2b B ++\n\u00a7Elastography (shear -wave) * 2b B +\n\u00a7Automated 3D -sonography 3b B +/-\u00a7MRI** 2b B +\u00a7Minimally invasive biopsy 1b A ++\n* Adjunct assessment\n** If clinical examination, mammography and sonography incl. needle biopsy do not allow a clear assesment\n*** Replacement of FFDM with SMEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.dePre-therapeutic Assessment \nof Breast and Axilla Oxford\nLoE GR AGO\n\u00a7Clinical examination 5D ++\n\u00a7Mammography (completion oftheimaging ) 2b B ++\n\u00a7 + Tomosynthesis (DBT)*** 2b B+\n\u00a7 Contrast -enhanced mammography (alone) adjusted with regards of\nradiation sensitivity of patient and availability2a B+\n\u00a7Sonography (breast /axilla#) 2b/2a# B ++\n\u00a7MRI* 1b A+\n\u00a7Minimally invasive biopsy ** 1b A ++\n\u00a7CNB axilla , if lymph node (LN) issuspect , LN-marking ifTAD is\nplanned /\u22643 susp . LN2b B ++\n\u00a7Breast -CT 4D -\n\u00a7Axillary PET (PET -CT, PET -MR) 2b B-\n* MRI-guided vacuum biopsy is mandatory in case of MRI-detected additional lesions (in house or with cooperations ).\nIndividual decision for patients at high familiar risk, with dense breast (density C / D), lobular invasive tumors, suspicion ofmultilocular disease.\n** Histopathology of additional lesions if relevant for treatment\n***   Replacement of FFDM with SMEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.deSensitivities CEM (contrast enhanced \nMammography)\n* Recall from Screening CESM is comparable to MRI regarding index, a bit inferior for additional lesions Author N MG CESM MRI US Analyse\nDromain 2011 110 78 92 Per patient\nFallenberg 2014 118 77.9 94.7 Per patient\nMokhtar 2014 60 93.2 97.7 Per patient\nLobbes 2014* 113 96.9 100 Per patient\nPerez 2015 ECR 98 78 66 Per lesion\nLuczinska 2014 152 91 100\nJochelson 2012 52 81\n5996\n8396\n93Per patient\nPer lesion\nFallenberg 2013 80 81 100 97 Per patient\nFallenberg  2016 155 81\n5594\n7295\n76Index\nPer Lesion\nLalji 2016* 199 93 96,9 Per patient \n10 reader \nTennant 2016 100 84 95\nLuczynska 2016 116 90 100 92\nXing 2019 235 91,5 91,5 Per lesionEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.dePre-therapeutic Staging\n*Contrast enhanced ultrasound\n**especially in patients with high tumor stage (III) if availableOxford\nLoE GR AGO\u00a7History and clinical examination 5D ++Onlyin case ofhigh metastatic potential and/orsymptoms and/orindication for(neo -) adjuvantchemotherapy and/orantibody -therapy :\u00a7CT scan of thorax / abdomen 2a B+\u00a7Bone scan 2b B+\u00a7Chest X -ray 5C +/-\u00a7Liver ultrasound 5D +/-\u00a7Further investigation in case of additonal suspicious lesions\n(e.g. liver -MRI, CEUS*, biopsy etc.)2a B+\u00a7FDG -PET orFDG -PET-CT** FDG -PET-MRI** 2b B +/-\u00a7Whole body MRI 4C +/-Early Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nPathology\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePathology\n\u00a7Versions 2004 \u20132022:\nBlohmer / Costa / Fehm / Friedrichs / Harbeck / Huober /         \nKreipe / L\u00fcck / Maass /Schneeweiss/ Sinn / Thomssen / Schmidt\n\u00a7Version 2023:\nKreipe / Schmidt / Sinn\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePreanalytics: Fixation\nOxford\nLoE GR AGO\u00a7Minimize time to fixation (cold ischemia time) 5 D ++\u00a7Minimal fixation time of 6 hours for\noptimal antigen preservation5 D ++\u00a7Optimal fixation time 6 -72 h for core biopsies 5 D ++\u00a7Optimal fixation time for resection specimens:\n12 -72 h5 D ++\u00a7Use of neutral buffered formalin 5 D ++Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deUse of Breast Cytology*\nOxford\nLoE GR AGO\u00a7Nipple secretion 5 D +\u00a7Tumor 5 D -\u00a7Cyst 5 D +/-\u00a7Lymph node 5 D +/-\n*Ultrasound -guided core biopsy recommendedPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deWorkup: Core Needle Biopsies \n(US-guided or stereotactic)\nOxford\nLoE GR AGO\u00a7Routine workup in step sections\n(14G: 1\u20133 step sections / 11G, 8G: 6 \u20138 step\nsections)5 D ++\u00a7Correlation with imaging (density, calcifications), \nuse of B -classification1b B ++\u00a7Frozen section diagnosis on core biopsies 5 D --\u00a7Routine evaluation of ER/PR and HER2 status 3b C ++\u00a7Turn -around time < 24 h (histology) 5 D +Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deWorkup: Breast -Conserving Specimens\nOxford\nLoE GR AGO\u00a7Slicing perpendicular to the longitudinal axis\n(or perpendicular to the nipple -peripheral axis\nin case of spherical specimens)5 D ++\u00a7Systematic sampling, at least 1 tissue block \nevery 1 cm5 D ++\u00a7Inking of resection margins. Sampling of resection \nmargins5 D ++\u00a7Documentation after slicing using specimen \nradiography, photo documentation or diagram5 D +Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deWorkup: Mastectomy Specimens\nOxford\nLoE GR AGO\u00a7Margins always to be sampled 5 D ++\n\u00a7Skin close to tumor\n\u00a7Deep margin\n\u00a7Other margins, if close (< 1 cm)\u00a7Attention to soft tissue margins in skin \nsparing mastectomy5 D ++\u00a7Routine sampling of uninvolved quadrants,\nskin above tumor, and retroareolar region5 D ++\u00a7Systematic sampling in prophylactic \nmastectomies ( patients with BRCA -1/2 mutation ) 5 D ++Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deWorkup: Sentinel Node Biopsy\nOxford\nLoE GR AGO\u00a7Full workup using step sections of \u2264 500 \u00b5m on paraffin embedded tissue 5D ++\u00a7Cytokeratin immunohistochemistry\n\u00a7 If suspicious, to detect micrometastases 2b B+\n\u00a7 For micrometastasis detection after NACT 2b B+\n\u00a7 As a routine procedure 5D +/-\u00a7Frozen section (compromises paraffin histomorphology )\n\u00a7 If clinical consequences 5D +\n\u00a7 If no clinical consequences from frozen section\n(e.g. cT1 or cT2 and cN0 and BCT)5D -\u00a7Imprint cytology instead of, or in addition to frozen section 3b C +/-\u00a7RT-PCR for epithelial genes 4D -\n\u00a7 OSNA 3b B-Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deWorkup: Intraoperative pathological evaluation\nand frozen sections\nOxford\nLoE GR AGO\u00a7Sentinel node biopsy for invasive cancer\n(compromises final paraffin histomorphology)\n\u00a7If clinical consequences 5 D +\n\u00a7No clinical consequences 5 D -\u00a7Closest margin of resection\n\u00a7If macroscopically < 1 cm 5 D +\n\u00a7If macroscopically > 1 cm 5 D -\u00a7Lesions \u2265 1 cm, without core biopsy 5 D +\u00a7Non -palpable lesions or lesions < 1 cm 5 D --\u00a7Conservation of fresh tissue (tumor banking) 5 D +Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Histologic Tumor Type\nOxford\nLoE GR AGO\u00a7Histologic tumor typing according to \nWHO -Classification, ( 5th ed., 2019 )3b C ++\n\u00a7Partial special differentiation: \n> 50% NST component\nand < 50% special tumor type (minor component)\n\u00a7Mixed differentiation: \n> 50% special tumor type \nand < 50% NST component\nExample: mucinous breast cancer, mixed type\n\u00a7Pure types: \n> 90% special tumor type \nExamples: tubular or cribriform Ca.Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDuctal TNBC: Comparable survival rates and similar response \nrates to chemotherapy for ER = 0% compared to ER 1% -<10%ReferencePatientsResultsVillegas, S. L. Eur J Cancer148, 159 \u2013170 (2021)DOI: 10.1016/j.ejca.2021.02.020Neoadjuvant clinical trial cohorts (n = 2765) comparing neg. ER/PR  (<1%) vs. ER/PR low pos. (ER and/or PR <9%) vs. strong-pos. (ER or PR >= 10%) HR expression.Low HR-positive, HER2 -negative tumours had a similar clinical behavior compared to TNBC, showing high pCR rates and poor survival and also a basal -like gene expression signature. Patients with low HR-positive tumours should be regarded as candidates for therapy strategies targeting TNBC.Dieci, M. V. et al. Npj Breast Cancer 7, 101 (2021)DOI: 10.1038/s41523 -021-00308 -7406 patients with ER < 10% HER2-negative BC. Pat. Were categorized in ER-negative (ER < 1%; N = 364) and ER-low positive (1 \u20139%, N = 42).No difference was observed in overall survival (OS) according to ER expression levels (5-years OAS 82.3% vs. 76.7% for ER-negative and ER -low positive BC, respectively, p = 0.8). Our results suggest the use of a 10% cut-off, rather than <1%, to define triple -negative BC (TNBC).Reddy, S. M. et al.British Journal of Cancer118, 17\u201323 (2018)\nDOI: 10.1038/bjc.2017.379Stage I-III TNBC pat. (n=873) who were disease free at 5 years from diagnosis. Recurrence-free interval (RFI), r.f. survival (RFS), and distant r.f. survival (DRFS) rates were calculated.After a disease-free interval of 5 years, patients with low hormone receptor-pos. cancers had a higher risk of late events as measured by RFS, and similar risk by RFI or DRFS, compared to TNBCsurvivors.Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRare histological TNBC subtypes show divergent \ntumor differentiation patterns and clinical behavior\nApocrine TNBC\n\u2022 Luminal phenotype (no basal markers)\n\u2022 High expression of the androgen receptor\n\u2022 Low tumor proliferation\n\u2022 Poor response to chemotherapy\n\u2022 Better prognosis than ductal TNBC\nMetaplastic TNBC\n\u2022 See chapter 15 Special Situations\nRare and salivary -type TNBC\n\u2022 Tumors with divergent clinical behavior and specific genetic alterations\n\u2022 Mostly low tumor proliferation\n\u2022 Poor response to conventional chemotherapy\n\u2022 Experimental treatment according to the molecular pathology ( e.g. NTREK for \nsecretory ca.)Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deApocrine TNBC: More favorable survival and poor response to \nadjuvant chemotherapy ReferencePatientsResultsSaridakis, A. et al.Ann Surg Oncol28, 5610 \u20135616 (2021). DOI: 10.1245/s10434 -021-10518 -9Women with invasive apocrine cancer were retrospectively identified from the Surveillance, Epidemiology, and End Results (SEER) database. N= 533 triple-negative apocrine cancers were identified.Half of apocrine tumors are triple negative, but these have more favorable features and much better survival than non-apocrine triple -negative cancers. Compared with non-apocrine triple -negative, apocrine triple-negative patients were much older, with smaller, lower-grade tumors and much better survival (86% vs. 74%). Montagna, E. et al. Breast53, 138 \u2013142 (2020).\nDOI: 10.1038/s41523 -021-00308 -7406 patients with ER < 10% HER2-negative BC. Pat. Were categorized in ER-negative (ER < 1%; N = 364) and ER-low positive (1\u20139%, N = 42).The outcome of selected apocrine triple negative breast cancer patients who did not received adjuvant chemotherapy is excellent and supports a treatment de-escalation.Mills, A. M., et al.Am J Surg Pathol40, 1109 \u20131116 (2016). DOI: 10.1097/pas.0000000000000671All pure apocrine carcinomas diagnosed during a 10-year period were reviewed, and clinicopathologiccharacteristics were compared with a control group of 26 non-apocrine TNBC cases. Twenty apocrine carcinomas were identified (\u223c0.8% of all breast cancers). Apocrine TNBC had a favorable clinical prognosis, with 80% of patients showing no evidence of disease-related morbidity or mortality (mean follow-up: 45.2 mo). Pure apocrine carcinomas represent a clinicopathologicallydistinct subgroup of triple-negative breast cancer characterized by AR positivity. Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRare and salivary -type TNBC: Tumors with divergent clinical \nbehavior and specific genetic alterations\nSecretory carcinoma\nETV6 -NTRK3\ngene fusions\nPolymorphous carcinoma\nPRKD1 E710D\nPRKD1/PRKOZ/PRKD3\nrearrangements \nAdenoid -cystic\ncarcinoma\nMYB -NFIB \nMYBL1 rearrangements\nMYB gene amplificationTall cell carcinoma with \nreversed polarity \nIDH2 hotspot mutations\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Grade of Malignancy\nOxford\nLoE GR AGO\u00a7Use of Nottingham grading system ( Elston & Ellis\n1991) for all types of invasive breast cancer (incl.\nstatus post neoadjuvant systemic therapy)5D ++\u00a7In case of very little tumor tissue, pure nuclear\ngrading or additional criteria, such as Ki -67\nproliferation fraction, may be used5D ++\u00a7Grading of DCIS, e.g. according to WHO -\nClassification, ( 5th ed., 2019 )5D ++\u00a7Reporting of tumor grade in numeric form\n(e.g. G3)5D ++Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Tumor Size \nand Total Extent of Tumor\nOxford\nLoE GR AGO\u00a7Reporting of invasive tumor size taking into \naccount macroscopic and histologic findings \nand clinical imaging results5 D ++\u00a7Additional reporting of total extent of invasive\ncarcinoma in case of satellite nodules or \nmultifocality5 D ++\u00a7Reporting of size of non -invasive component \n(DCIS or LCIS) when DCIS or LCIS component is \nextensive  (more than 2x invasive Ca ) 5 D ++\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: pTNM\nOxford\nLoE GR AGO\u00a7Use of current UICC classification ( 8th ed.) 5 D ++\npT 1 -3:   Invasive tumor size (largest focus in \ncase of multifocality or multicentricity )\npT4:       Invasion of dermis alone does not qualify \nas pT4. Criteria for pT4a/b/c/d must be met.\npT4d:     Negative skin biopsy does not rule out pT4d\n(inflammatory carcinoma).\npM:        pM1 indicates any non -regional disease, except \n2ndprimary contralateral. \nUse of MX is not recommended.Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Margins of Resection \nand R -Classification\nOxford\nLoE GR AGO\u00a7Evaluation of distance to all resection margins \nmacroscopically and close margins histologically \n(< 1 cm)5 D ++\u00a7Reporting of minimal distance to resection margin and itstopography5 D ++\u00a7R-Classification 5 D ++\nR0: No residual tumor\nR1: Microscopic invasive or noninvasive \ncarcinoma involving resection margin\nRX: Presence of residual tumor cannot be \nassessed (e.g. tumor in multiple specimens)Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Lymphovascular Invasion\nOxford\nLoE GR AGO\u00a7L1: Lymphovascular invasion\nL0: No lymphovascular invasion5 D ++\u00a7IHC for evaluation of lymphovascular invasion 3b C -\u00a7Differentiation of peritumoral and extensive \nlymphovascular invasion3b C ++\u00a7Reporting of venous invasion (V0/V1) optional, \nprognostic significance not established5 D +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Evaluation of \nTumor -Infiltrating Lymphocytes (TIL)\nOxford\nLoE GR AGO\u00a7Identification of tumors with predominant \nlymphocytic infiltrate (> 50%) in tumor stroma \n(according to Salgado et al.*)5 D +/-\nConsider only lymphocytic infiltrate in tumor stroma and \nnot at the invasion front\nDo not consider central fibrosis and necrotic areas\nReport average of lymphocytic infiltrate as percentage\n*Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., et al. \n(2014). The evaluation of tumor -infiltrating lymphocytes (TILs) in breast cancer: \nrecommendations by an International TILs Working Group 2014. Annals of OncologyPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deReporting: Evaluation after \nNeoadjuvant Chemotherapy\nOxford\nLoE GR AGO\u00a7Identification of tumor bed, otherwise ypTX 4 D ++\u00a7Reporting of tumor size as total extent of tumor bed area involved by infiltrates of residual vital invasive carcinoma4 D ++\u00a7pCR when absence of invasive Ca. and absence of \nangioinvasion or LN metastases.\nPresence of ypTis should be recorded2b D +\u00a7Use of IHC to identify tumor residues (lymphnodes) 2b B +/-\u00a7Reporting of ypTN after neoadjuvant systemic therapy 5 D ++\u00a7Repeat IHC forER, PR, and HER2 5 D +/-\u00a7Intraoperative frozen section (reduced sensitivity ) 5 D -\u00a7Tumorregression -Scores : RCB -Score orSataloff -Score 4 D +/-Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSpecial Studies:\nER-Testing by IHC\nOxford\nLoE GR AGO\u00a7Immunohistochemical detection on paraffin\nembedded (FFPE) tissue1a A ++\u00a7Reporting percentage of pos. tumor nuclei\n(pos. if \u2265 10%, low pos. if \u2265 1% \u201310%)1a A ++\u00a7Staining intensity 4 D +\u00a7Only Allred Score (0 \u20138) or Remmele Score (0 \u201312) 4 D -\u00a7Re-evaluation on excision specimen if uncertain or\ntriple -negative on core biopsy5 D +Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLow ER+ (1 \u201310%)ReferencePatientsResultsSanford, R. A. et al.Cancer121, 3422 \u20133427 (2015). DOI: 10.1002/cncr.29572314 Pat. 1\u20139% ER, Anteil BRCA mutierter F\u00e4lle wie bei ER -High Incidence of Germline BRCA Mutation in Patients with ERLow-Positive/PR Low -Positive/HER -2 neu Negative TumorsDeyarmin, B. et al.Ann Surg Oncol20, 87\u201393 (2013).DOI: 10.1245/s10434-012-2588 -826 Pat. 1\u201310% ER, Genexpression  eher wie TN oder HER2 enrEffect of ASCO/CAP Guidelines for Determining ER Status on Molecular SubtypePrabhu, J. S. et al.J Cancer5, 156 \u2013165 (2014)DOI: 10.7150/jca.766821 Pat. 1\u201310% ER, Genexpression wie ER-, \u00dcberleben < ER+A Majority of Low (1\u201310%) ER Positive Breast CancersBehave Like Hormone Receptor Negative TumorsYi, M. et al.AnnalsofOncology 25, 1004 \u20131011 (2014).DOI: 10.1093/annonc /mdu053251 Pat. 1\u20139% ER\u00dcberleben = ER-Which threshold for ER positivity? a retrospective study based on 9639 patientsPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSpecial Studies:\nPR-Testing by IHC\nOxford\nLoE GR AGO\u00a7Immunohistochemical detection on paraffin\nembedded (FFPE) tissue1a A ++\u00a7Reporting percentage of pos. tumor nuclei\n(pos. if \u2265 10%)1a A ++\u00a7Only Allred Score (0 -8) orRemmele Score (0 -12) 4 D -\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdditional Special Studies:\nMolecular Analysis of ER/PR Status\nOxford\nLoE GR AGO\u00a7Evaluation of hormone receptors using\nvalidated gene expression test kits3b A +/-\u00a7Exclusive evaluation of hormone receptor by\nRNA -quantification5D -\u00a7Use of molecular receptor analysis for subtyping 3b A +/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHER2 -Analysis by IHC\nOxford\nLoE GR AGO\n\u00a73+ staining pattern: HER2+ if strong complete circular \nmembrane staining of > 10% invasive cells1a A ++\n\u00a72+ staining pattern: If > 10% circular but moderate/weak \nmembrane staining or \u2264 10% strong staining, U -shaped \nstaining in micropapillary carcinoma :ISH required (CISH, \nSISH, FISH)1a A ++\n\u00a71+ staining pattern: with >10 % incomplete membrane \nstaining that is weak or barely perceptible (caveat: \nreproducibility).1a A +\n\u00a70 grade staining : tobeconfirmed bysecond determinationin case that Trastuzumab -Deruxtecan treatment *isconsidered5 D ++\n\u00a7HER2 -low: 1+ oder 2+ /ISH negativ 1b A ++\n* Due toheterogeneity and therapeutic relevancePathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHER2 -Analysis by ISH when IHC 2+\nOxford\nLoE GR AGO\u00a7Single -Color In-Situ-Hybridisation (ISH): 3a C ++\n\u00a7HER2+ if signal counts \u2265 6 in at least 20 cohesive cells\n\u00a7negative if signal counts < 4 signals/nucleus\n\u00a72-Color ISH recommended for \u2265 4 and < 6 signals/nucleus\u00a7Two -Color In-Situ-Hybridisation (ISH): 3a D ++\n\u00a7Group 1: Ratio \u2265 2.0 and signals/nucleus \u22654.0 -> HER2+\n\u00a7Group 2: Ratio \u2265 2.0 and signals/nucleus <4.0\n-> HER2 -(no benefit of anti -HER2 therapy)\n\u00a7Group 3: Ratio < 2.0 and signals/nucleus \u22656.0 \n-> HER2+ (but benefit of anti -HER2 therapy not certain)\n\u00a7Group 4: Ratio < 2.0 and signals/nucleus \u22654.0 und < 6\n-> HER2 -(no benefit of anti -HER2 therapy)\n\u00a7Group 5: Ratio < 2.0 und signals/nucleus <4.0 -> HER2 -Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nBatch controls and on -slide controls show appropriate hybridization\nHER2/CEP17 ratio \u2265 2.0HER2/CEP17 ratio < 2.0\nGroup 1\nAverage HER2 \ncopy number \u2265 4.0 \nsignals/cellGroup 2\nAverage HER2 \ncopy number < 4.0 \nsignals/cellGroup 3\nAverage HER2 \ncopy number \u2265 6.0 \nsignals/cellGroup 4\nAverage HER2 \ncopy number \u2265 4.0  \n-< 6.0 signals/cellGroup 5\nAverage HER2 \ncopy number <4.0 \nsignals/cell\nHER2\nnegativemostly mostly mostly\nHER2\npositive\nHER2\nnegative\nHER2\npositive\nHER2\nnegativeHER2 testing by validated dual -probe ISH assay\nwhen IHC = 2+\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nFalse positive immunohistochemical labeling may occur in core biopsies. \nTherefore, methods of individual laboratories should be validated by comparison of \ncore biopsies and resection specimens. Background staining should be evaluated by \ncomparison with normal duct epithelium.\nAlternatively, all G1 and G2 cases with HER2 3+ in core biopsies may be analyzed by \nISH or may be re -evaluated in the resection specimen.\nFalse positivity is likely when HER+ was reported in G1 tumors of the following types:\nInfiltrating ductal or lobular carcinoma, ER and PR positive, Tubular (at least 90% \npure), Mucinous (at least 90% pure) Cribriform (at least 90% pure), Adenoid cystic \ncarcinoma (90% pure).\nIn case of discrepancy between core biopsy and specimen, the HER2 overexpressing \nsample should be re -evaluated by a different method. If still discrepancy \u2013anti-HER2 -\ntreatment if amplified in one of both samples. Expected rate of HER2 -overexpression: \n15% HER2 positiveHER2 Testing on Core Biopsies\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdditional Special Studies:\nMolecular Analysis of HER2 Status\nOxford\nLoE GR AGO\u00a7Therapy decisions should onlybe based on IHC and ISH1a A ++\u00a7Evaluation of HER2 using validated gene \nexpression test kits3b B -\u00a7Evaluation of HER2 -amplification by RNA -\nsequencing5 D -\u00a7Use of molecular HER2 -testing for subtyping 3b B +/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSpecial Studies:\nEvaluation of Ki -67 Score\nOxford\nLoE GR AGO\u00a7Counting of tumor nuclei at the invasion front 5 D ++\u00a7Semiquantitative eyeballing or counting of labelled \ncells in core needle biopsies2 A ++\u00a7Consideration of weakly stained tumor nuclei 5 D ++\u00a7Reporting of Ki -67 positive nuclei as percentage 5 D ++\u00a7Establishing of laboratory standards and cut -off values 5 D ++\u00a7Use of image analysis for objective Ki -67 evaluation 5 D +\u00a7Determination of Ki -67 dynamics after short term (2 -4 \nweeks) endocrine therapy*1b B +\n* See chapter Neoadjuvant Systemic Therapy Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePredictive PD -L1 AssayOxfordImmunohistochemical assayLoEGRAGOImmune Score (IC): Cytoplasmic staining of at least 1% of the leucocyte stromal infiltrate (lymphocytes, macrophages, plasma cells, granulocytes outside of abscesses) for prediction of atezolizumab efficacy in triple-negative metastatic breast cancer2A++Metastatic or primary tumor tissue2A++Detection with antibodies equivalent to Impassion 130 study reagents3B+Combined positive score (CPS): positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells multiplied by 100; \u226510 = positive) for prediction of pembrolizumab efficacy in metastatic triple-negative breast cancer (FDA approval, EMA pending)3B+/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMutational studies in mBC:\n\u201ePrecision medicine\u201c for targeted therapiesGeneTherapeuticRelevanceGene regionSourceOxford\nLoE GR AGOBRCA1, BRCA2PARP Inhibitorall exonsGerm line: blood cellsSomatic: tissue1b\n2bA\nB++\n+/-PIK3CAAlpelisibexons 7,9 and 20Primary tumor, metastases, plasma1b A ++HER2-mutation (irrespective of HER2-status)Neratinib, Lapatinibkinase and extracellular domain; S310, L755, V777, Y772_A775dup Primary tumor, metastases, plasma4 C +/-ESR1Resistance vs aromatase inhibit.exons 4,7 und 8metastases, plasma2b B +/-NTRK gene fusionLarotrectinib, EntrectinibGene fusions and splice variantsTumor tissue, in particular secretory breast caner2a B +MSIPembrolizumabMikrosatellite instabilitytissue2a B +Pathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EPrognostic and\nPredictive Factors\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrognostic and\nPredictive Factors\n\u00a7Versions 2002 \u20132022:\nCosta / Fasching / Fersis / Friedrichs / Gerber / G\u00f6hring / Harbeck / \nJackisch / Janni / Kolberg-Liedtke / Kreipe / Loibl / L\u00fcck / Mundhenke / \nNitz / Rody / Schaller / Schmidt / Schmutzler / Schneeweiss / Simon / \nSolomayer / Thill / Thomssen / Untch / Witzel / W\u00f6ckel\n\u00a7Version 2023:\nGluz / Witzel\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDefinition\nA Prognostic Factors is associated with the probability of the course of the disease (e.g. \ndisease -free or progression -free survival, overall survival). The probability can be influenced \nby therapy. \nA Predictive Factor is associated with the probability of the effect of a given therapy.\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u201cLow absolute risk implies \nlow absolute benefit\u201d\nEarly Breast Cancer Trialists' Collaborative Group (EBCTCG), Lancet 379: 432 -444, 2012Prognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Biological hypothesis\n\u00a7Simple and standardized assessment method, quality assurance (QA) of\nthe test\n\u00a7Prospectively planned statistical evaluation (primary goal)\n\u00a7Validation of clinical significance according to\n\u00a7\u201eOxford Level of Evidence (LoEOx2001)\u201c criteria and \u201eGrades of\nRecommendation (GR)\u201c\n\u00a7\u201eGrades of Recommendation (GR)\u201c as well as modified LoE criteria for the use\nin archived specimen (LoE2009) and category of tumor marker study (CTS)\n\u00a7Clinical relevance for treatment decisionsQuality Criteria\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEarly Breast Cancer (M0) \u2013eBC\nPrognostic Factors I\nOxfordFactorLoEOx2001 GR AGO\u00a7Tumor size -pT 1a A ++\u00a7Axillary lymph node status -pN 1a A ++\u00a7Histological tumor type (mucinous, tubular etc.) 2b B ++\u00a7Grade (Elston & Ellis) -G 2a B ++\u00a7Age 2a B ++\u00a7Histologically proven peritumoral lymphatic vessel \nand vascular invasion (L1 V1) 1b B ++\u00a7pCR after NACT* in (luminal -B-like, HER2+, TN) 1a A ++\n\u00a7Increased risk of recurrence in invasive -\nlobular BC, cT3/4, N+2a B +/-\u00a7Obesity (BMI > 30 kg/m\u00b2) 1b B +\u00a7Margins (resection status) -R0 / R1 1a A +\n*NACT = Neoadjuvant ChemotherapyPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors II\nOxfordFactorLoE GR AGO\u00a7ER / PR 1a A ++\u00a7HER2 (IHC, ISH) 1a A ++\u00a7ER / PR / HER2/ Ki -67 to assess the intrinsic type with regards to tumor \nhistology and biology2b B ++\u00a7Proliferation markers\n\u00a7Ki-67 before, during, or after treatment1a B +\n\u00a7Ki-67 Re -Evaluation after short term \npreoperative endocrine therapy (2 -4 weeks) (ypT and ypN)*1a B +\n*Biomarker and Multi Gene Expression test should be evaluated on core needle biopsy prior endocrine therapyPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7ER / PR: concordance  central vs local is high (97%; Plan B, SABCS 2014)\n\u00a7Grade: concordance central vs local is 68% (PlanB, JCO 2016)\n\u00a7HER2: frequency of false -positive test results 6% (ASCO /CAP JCO 2013)\n\u00a7Impact of routine pathologic review in N0 BC: 20% changes: grade 40%, LVI  26%, N \n15%, margin 12% (JCO 2012)\n\u00a7pN0 from MIRROR study: pN0 was upstaged in 22%, in central pathology review \n(Ann Oncol 2012)\n\u00a7Ki67: \n\u00a7Inter -and intraobserver variability in measurement of Ki -67 is high (J Nat. \nCancer Institute 2011)\n\u00a7High reproducibility for low and high Ki67 levels (J Pathol 2002)\n\u00a7Standardized methodology improves analytical validity (JNCI 2020)Reproducibility \u2013Quality Assurance is Key for \nClinical Decision Making\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors IIIFactorLoE GR AGO\u00a7Gene expression profiles (GEP, multigene assays, gene signatures)\n\u00a7 MammaPrint \u00ae (N0 -1) 1b A +*\n\u00a7 Oncotype DX\u00ae  (N0 -1, HR+ HER2 -) 1b A +*\n\u00a7 EndoPredict\u00ae (N0-1, HR+, HER2 -) 2b B +*\n\u00a7 Prosigna\u00ae (N0-1, HR+, HER2 -) 2b B +*\n\u00a7 Breast Cancer IndexSM(N0-1, HR+ HER2 -)** 2b B +/-*\u00a7IHC4 (ER / PR / HER2 / Ki -67) (validated forcentral testing ) 2b B +/-\u00a7PREDICT\u00ae algorithm (https://breast.predict.nhs.uk/) 1b A +\u00a7Clinical -pathological score for lobular breast cancer (nodal status, tumor size, \nlymphovascular invasion LVI)2b B +/-\u00a7CTS5 Clinical Treatment Score** 2b B +\u00a7CPS-EG Score 2b B +\n*Should only be used in the context of clinical -pathological criteria (tumor size, nodal involvement, grade, Ki -67, ER, PR, HER2)\n**Estimation of late recurrenceOxford\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors IVFactorLoEGRAGO\u00a7Disseminated tumor cells (DTC, in bone marrow) 1a A +/-\u00a7Circulating tumor cells (CTC, in blood, Cell Search \u00ae)* 1b A +/-\u00a7CTC before NACT (regarding OS, DDFS, LRFI) 1b B +/-\u00a7Therapy decisions based on CTC phenotypes 3a C -\u00a7Cell-free DNA (cfDNA, in blood, for DFS, PFS, OS) 2a B +/-\n*Validated clinical data only available for this assayOxford\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nCommercially Available Molecular Tests\n70 gene signature\n(MammaPrint\u00ae) $21 gene Recurrence score\n(Oncotype DX\u00ae) $8 gene signature\n(Endopredict\u00ae)$PAM 50\n(Prosigna\u00ae)$Breast Cancer \nIndex\u00ae (BCI)$\nProvider Agendia Genomic Health Sividon (Myrirads) NanoString Biotheranostics\nType of assay 70-gene assay 21-gene recurrence score 11-gene assay 50-gene assay 5 + 2  (MGI+H/I)\nType of tissue fresh frozen\n(technical validation for FFPE available)FFPE FFPE FFPE FFPE\nTechnique Microarrays for RNA qRT-PCR q-RT-PCRDirect hybridization (nCounter\u00ae)q-RT-PCR\nCentral lab yes yes no no yes\nIndication and population studiedprognostic\nN-/+, < 70 Jahreprognostic\nN-/+, ER+ \nendocrine treatedprognostic \n(pre-) postmenopausal \nN-/+, ER+ HER2 -\nendocrine treatedprognostic \npostmenopausal \nN-/+, ER+ HER2 -\nendocrine treatedPrognostic\npT1-3pNo \u2013pN1\nER+ / HER2 \u2013\nEndocrine treated\nRisk classes Low \u2013high RS (Low \u2013intermediate \u2013high) Low \u2013high ROR (Low \u2013inter -mediate \u2013high), molecular typesLow -high\nClinical ValidationYes yes yes yes Yes\nRegistration FDA clearance as \u201c In Vitro Diagnostic Multivariate Index Assay (IVDMIA)\u00ab\nCE-Mark\n(fresh tissue and FFPE)Clinical Laboratory Improvement Amendments  (CLIA) + College of American Pathologists  (CAP) -accredited ref labCE-Mark CE-Mark\nFDA 510(k) Clearance Service Mark (SM)\n$Validated clinical data only available for this assayPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n$Validated clinical data only available forthis assayCommercially Available Molecular Tests\n70 gene signature\n(MammaPrint\u00ae) $21 gene Recurrence score\n(Oncotype DX\u00ae) $8 gene signature\n(Endopredict\u00ae)$PAM 50\n(Prosigna\u00ae)$Breast Cancer \nIndex\u00ae (BCI)\nPrognosis after 5 \nyrs (late \nrecurrences) not separately \nshownyes yes yes yes\nPredictive impact\n(chemotherapy \nbenefit)poorly validated yes not shown not shown EAT after 5 yrs\nProspective -\nretrospective \nevidence\n(% of recruited \npatients)Multicenter\nvalidationNSABP B -14   (14%)\nNSABP B -20   (28%)\nECOG 9127\nSWOG 8814    (40%)\nATAC (30%)ABCSG 6    (19%)\nABCSG 8    (36%)\nGEICAM -9906  (45%)\nATAC                  (10%)MA.12        (59%)\nMA.5          (66%)\nABCSG 8    (44%)\nATAC          (16%)TransATTOM (11%)\nProspective \nevidenceMINDACT (N0, N1)  (8y DFS, OS)TAILORx (12 yDFS, OS), N0, RS \u2264 25 vs. \u2265 26  PlanB (N0 highrisk /N+) (5 yDFS, OS)\nRxPONDER (5 yDFS, OS), N1, RS \u2264 25 vs. \n\u226526)   \nADAPT (5 yDFS, OS), N0 -1, RS 0 -11; RS 12 -\n25/Ki67 response\u2013 \u2013 --\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nProspective Clinical Trials (Oncotype DX\u00ae [TAILORx, PlanB, \nRxPONDER, ADAPT], MammaPrint\u00ae [MINDACT])\nTailorX RxPONDER PlanB ADAPT MINDACT\nFollow -up median  7.5 years median 5.1 years 5-year -DFS median 60 months median 8.7 years \nTrial design ( biomarker\nquestion )pN0; Randomization RS \n11-25 (+/ -CTX)pN1; Randomization \nRS0-25 (+/ -CTX)Prospective ODX \ntesting: ET alone in \nRS 0 -11 pN0 -1Non -inferiority (iDFS) ET alone: \nRS 0 -11 vs  RS12 -25/ET \nresponseProspectively defined 5y -DMFS \nthreshold for ET alone\nPercentage  clinically \ndefined low -risk group6615/9427 (70.2%, adj -\nonline)all 1-3 involved \nlymph nodesall clincial CTX \nindication (pN0 -1)all clincial chemotherapy (CTX)  \nindication (c/pN0 -1)3336/ 6693 (49.8%, adj -online)\nPercentage high clinical risk \nand low genomic risk \n(clinical CTX  indication)16.7% (RS 0 \u201310) 42.8% (RS 0 -13) 15.3% (RS 0 \u201311) ET-trial (pN0 -1): all RS 0 -25, i.e. \nlow genomic risk with ET alone23.2% \n(high clinical/low genomic risk)\nTest failure rate n.r. n.r. 2.9% n.r. 26% (fresh frozen)\nPercentage genomically \nintermediate -risk group \n(only for Oncotype DX, ODX)69.1% (RS 11 \u201325) 57.2% (RS 14 -24) 60.4% (RS 12 \u201325) Included only RS 0 -11 (37.9%) \nor\nRS 12 -25/ET response (62.1%)n.a.\nPercentage genomically \nhigh -risk group (only for \nOncotype DX)14.3% (RS \u2265 26) n.a. 24.3% (RS \u2265 26) n.a. 27.0% (high clinical and high \ngenomic risk)\n12-year follow -up reported n.r. n.r. n.r. n.r.Prognosis in low -risk groups excellent for both tests: ~ 94% 5 J. DFS with only adjuvant endocrine therapy (ET)\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant Endocrine Therapy\nPredictive Factors for DFS\nOxford\nTherapy Factor LoE GR AGO\n\u00a7 Endocrine therapy \u00a7 ER / PR status [%] 1a A ++\n\u00a7 IHC staining intensity (ER/PR) 1a A-\n\u00a7 Ki-67 Re -Evaluation after short preoperative\nendocrine therapy (2 -4 weeks) ( ypT and ypN)*1b A+\n\u00a7 Extended endocrine therapy\n(EAT)\u00a7 Breast Cancer Index\u00ae\nMammaPrint2b B +/-\n\u00a7 Tamoxifen \u00a7 CYP2D6 -polymorphism 2b B-\n\u00a7 Ovarian ablation or\nsuppression\u00a7 Menopausal status 1c A ++\n\u00a7 Aromatase inhibitors vs.\ntamoxifen\u00a7 Menopausal status 1c A ++\n\u00a7 ER / PR / HER2 as single factors 1c A-\n\u00a7 Invasiv -lobular breast cancer 2b B+\n\u00a7 Ki-67 high 2b B +/-\n\u00a7 Obesity (BMI > 30 kg/m\u00b2) 2b B +/-Prognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant Chemotherapy and Targeted Therapy \nPredictive Factors for DFS\n*Consider decision according toage/menopausal status , prospective evidence available forMammaprint and OncotypeDX\nonly (seenext slide )Therapy FactorOxford\nLoE GR AGO\n\u00a7Adjuvant\nChemotherapy70-Gene -signature ( Mammaprint \u00ae) 1b A+\n21-Gene -signature ( Oncotype DX RS\u00ae) 1b A+\nEPclin (Endopredict \u00ae) 2b B+\nPAM -50 (Prosigna \u00ae) 2b B+\nHistological type ( lobular vs. NST) 2b B-\nTIL\u00b4sin TNBC 2b B +/-\n\u00a7Anti -HER2 -Therapy HER2 (IHC, ISH) 1a A ++\n\u00a7PARP -Inhibitors gBRCA1/Mutation (HER2 neg.) 1a A+Prognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nbiomarker /\nsignaturePopulation (HR+/HER2 -patients) therapy options\nMammaprint\n(MINDACT \nn=2140)Clinically high/genomic low risk (n=1550)\nN0-1, age >50 yrs\nN0-1, age <50 yrs (patients with OFS in the ET arm: 26%)ET, noadjuvant CT\nadjuvant CT \u00e0ET*: 2.6% CT -benefit in 5-y DDFS (93.6 vs. 96.2%)\nOncotype DX \n(TAILORx \nn=6711)\nRxPonder \n(n=5018)TailorX (T1b -T2, N0, 74% clinically lowrisk, 13% OFS in \npremenopausal women ))\nN0, RS 0 -25 age>50 yrs. \nN0 RS 0 -15 age<50 yrs\nN0 RS 16 -25 age<50 yrs\nRxPonder : N1\nRS 0 -25: postmenopausal \nRS 0 -25: premenopausal (patients with OFS in theET arm: \n19%)ET, no adjuvant CHT \nET, no adjuvant CHT \nadjuvant CT \u00e0ET*: (3.2 -3.4% CT -benefit  in 5 -y DRFI (93 \u00e095-96% 5 y DRFI, in RS \n16-20 if clinical high risk only, 16 -20: HR=1.4 (n.s. ), 21 -25: HR=2.19 (sign) for ET \nvs. CT \u00e0ET\nET, no adjuvant CT\n(neo)adjuvant CT \u00e0ET* 2.4% CT benefit in 5 -y DRFI (5 -y DRFI 93.9 vs. 96.3%, \nHR=0.062, p=0.02)\nexplorative analysis: no effect of CT age 50 and older (p interaction 0.06) \nRS + KI -67post (ADAPT, n=2290 endocrine \ntreated)clinically intermediate/high risk , RS 0 -25 (RS 12, \n25+Ki67 post<10% ) \nN0-1, age>50 yrs\nN0, RS 0 -11 and age <50 yrs\nN0, RS 12 -25 with Ki67 post<10% and age <50 yrs\nN1: RS 0 -25 (+ Ki -67post<10% in RS 12 -25) and age <50 yrs\nN1: RS 0 -25 and ki -67post>10%ET, noadjuvant CT\nadjuvant ET, noadjuvant CT\nadjuvant ET+/ -OFS, ifRS >16 orclinically high risk+/-CT: 5 -yr-DDFS: 97% with ET \nalone , nosignificant difference between RS 0 -15 and 16 -25\nadjuvant ET+OFS orCT\u00e0ET  5 -yrs. DDFS 97% with ET alone\n(neo)adjuvant CT \u00e0ETResults for prospectively evaluated biomarkers (LOE1a) \nin early HR+/HER2 -breast cancer\n* IfCT isrefused : alternative ET+OFS\nDDFS= distant -disease -free-survival , DRFI= distant recurrence free interval , ET= endocrine treatment , CT= chemotherapy , OFS= ovarian function suppression , RS= Recurrence Score Prognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFactorpCR* ProbabilityLoE GR AGO\u00a7Young age \u00ad 1a A +\u00a7Obesity \u00af 2a B +\u00a7cT1 / cT2 tumors o. N0 o. G3 \u00ad\u00ad 1a A ++\u00a7Negative hormone receptor status \u00ad\u00ad 1a A ++\u00a7Triple negative breast cancer \u00ad\u00ad 1a A ++\u00a7Positive HER2 -status \u00ad\u00ad 1a A ++\u00a7Early clinical response \u00ad 1b A +\u00a7Lobular tumor type \u00af 1a A +\u00a7Metaplastic tumor type \u00af\u00af 4 C +Oxford\n* High ( \u00ad) or very high ( \u00ad\u00ad) probability to reach pCR, low ( \u00af) or very low ( \u00af\u00af) probability to reach pCR\nSee aso chapter  \u201ePrognostic and predictive factors\u201cNeoadjuvant Systemic Chemotherapy  (NACT) \nPredictive Factors for pCR I\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Chemotherapy  (NACT) \nPredictive Factors for pCR II\nOxfordFactorpCR*\nProbabilityLoEGR AGO\u00a7Gene expression profiles (gene signatures) \n(Mammaprint\u00ae, Endopredict\u00ae  Oncotype DX\u00ae, \nProsigna\u00ae, Breast Cancer IndexSM)\u00ad 2b B +/-\u00a7Ki-67 \u00ad 2b B +\u00a7Tumor infiltrating lymphocytes** \u00ad 2a B +\u00a7PIK3CA mutation (for HER2 -positive BC) \u00ad 2a B +/-\u00a7gBRCA -mutation (for the effect of chemotherapy) \u00ad 2b B +\u00a7gBRCA -mutation (for the effect of platinum) \u2194 2b B +/-\n** Defined as dense lymphocytic infiltration of inner peritumoral stroma outside of the invasion front (lymphocytes make up \n>50% of  stroma area)* High ( \u00ad) or very high ( \u00ad\u00ad) probabililty of pCR, low ( \u00af) or very low ( \u00af\u00af) probabililty of pCRPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetastatic Breast Cancer (mBC)\nPrognostic FactorsFactorOxford\nLoEGRAGO\u00a7Circulating tumor cells (CTC in blood, Cell Search\u00ae)\n\u00a7Prognosis 1a A +\n\u00a7Early response assessment (3w) 1b B +\u00a7Therapy decision solely based on dynamics\nof CTC numbers over time or CTC phenotype1b A -*\u00a7Cell-free DNA (cfDNA in blood) 2a A +/-\n*Study participation recommendedPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTreatment of Metastatic Breast Cancer\nPredictive Factors for response\nOxford\nTherapy Factor LoE GR AGO\n\u00a7 Endocrine therapy ER / PR (prim. tumor , better : metastasis ) 1a A ++\nResponse toprior therapy 2b B ++\nAutocrine receptor mutation (ESR1 ) 2b B +\n\u00a7 Alpelisib PIK3CA mutation (prim. tumor , metastases , \nplasma )1b A ++\n\u00a7 Trastuzumab Deruxtecan HER2 -low orHER2 -positive 1b A ++\n\u00a7 Chemotherapy Response to prior therapy 1b A ++\n\u00a7 Anti -HER2 -therapy HER2 (prim. tumor, better: metastasis) 1a A ++\n\u00a7 Checkpoint -Inhibitors PD-L1 positivity#(PD-L1ic, CPS) in TNBC \n(primary tumor or metastasis)1b B ++\n\u00a7 PARP -Inhibitors gBRCA1/2 -mutation 1a A ++\n\u00a7 Bone modifying drugs Bone metastasis 1a A ++\n# seechapter \u201epathology \u201cPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMutation Diagnostics* in mBC:\n\u201ePrecision Medicine\u201c for Targeted TherapiesAltered genesTherapeutic relevanceGene regionMaterialOxford\nLOE GR AGOBRCA1, BRCA2Olaparib, TalazoparibOlaparibAll exonsGermline: Blood cells Somatic: Tissue1b\n2bA\nB++\n+/-PALB2OlaparibGermline: Blood cells2b B +PIK3CAAlpelisibExons 7, 9 and 20Primary tumor, metastases, plasma1b A ++HER2-mutation (independent of HER2-status)Neratinib, lapatinibKinase-and extracellulardomains; S310, L755, V777, Y772_A775dup Primary tumor, metastases, plasmaparticul. lobular BC4 C +/-ESR1Resistance against AIResponse oral SERDsExons 4, 7 and 8Metastases, plasmaMetastases, plasma2b\n1bB\nB+/-\n+/-NTRK gene fusionLarotrectinib, entrectinibFusion-and splice variantsTumor tissue, particul. secretory breast cancer2a B +MSIPembrolizumabMicrosatellite-instabilityTissue2a B +\n*Ideally panel diagnosticsPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nBiomarker /Signature-therapy optionSubtyp /PopulationTherapy optionPDL-L1 \u2265 1%TNBCFirtst line Atezolizumab + nab PaclitaxelCPS > 10TNBCFirst line Pembro + chemotherapyPIK3CA mutation HR+ / HER2-Fulvestrant+ Alplisib after failure offirst line ETBRCA1/2 mutation (OlympiAD, EMBRACA)HER2 \u2013 Olaparib, TalazoparibDecision guidance prosepectively evaluated \nbiomarkers (LOE1a) and therapy options (mBC)\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTherapy -Relevant Mutational Analysis for \n\u201eActionable\u201c Genomic Alterations in BCDiagnostic Tool*OutcomeLoEGRAGOEvidence from studies with other cancer patients (\u201etumor-agnostic testing\u201c)\u00a7Companion Diagnostics for therapies of other\ntumor entities (e.g. BRAF, FGFR1, \u2026)Efficacy of diverse therapies4 D +/-**\u00a7Large Panel Gene Analysis (e.g. FoundationOne,GPS Cancer, NeoSelect, Molecular Health Guide,local \u201ehand -selected\u201e panels)Efficacy of diverse therapies, prognosis3a C +/-**\u00a7Next Generation Sequencing (NGS)\n(recommended only in Tier 1 + 2)Efficacy of evaluateddrugs1b B +/-**\n*A s s e s s m e n t  method forsomatic mutations (tumor tissue , cf-DNA) isnot taken into consideration forLoE\n**Participation in clinical trials orstructured registries recommendedOxford\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nJoint Consensus Recommendations of AMP , ACMG, ASCO and \nCAP for Reporting Genetic Variants in Cancer\nTier\nTier 1LoE Explanation\nBiomarkers that predict response orresistance toFDA-approved therapies fora\nspecific type ofcancerA.1 Variants of strong clinical\nsignificance\nBiomarkers included in professional guidelines that predict response totherapies\nfora specific type oftumorA.2\nBiomarkers that predict response or resistance to therapies for a specific type of \ntumor based on well -powered studies with consensus from experts in the fieldB\nTier 2 Biomarkers that predict response or resistance to  therapies approved by the FDA\nor professional societies for a different type of tumorC.1 Variants of potential clinical\nsignificance\nBiomarkers  that serve as inclusion criteria for clinical trials C.2\nBiomarkers that show plausible therapeutic significance based on preclinical studiesD\nTier 3 Not observed at a significant allele frequency in the general or specific subpopu -\nlation databases, or pan -cancer or tumor -specific variant databasis. No convincing\npublised evidence or cancer associationVariants of unknown clinical\nsignificance\nTier 4 Observed at significant allele frequency in the general or specific subpopulation\nDatabases. No existing published evidence of cancer associationBenign or likely benign variants Prognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELesions of Uncertain \nMalignant Potential (B3)\n(ADH, LIN, FEA, Papilloma, Radial Scar /Complex Sclerosing \nLesion) \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deLesions of Uncertain Malignant Potential (B3)\n\u25aaVersionen 2005 \u20132022:\nAlbert / Audretsch / Bauerfeind / Brunnert / Ditsch / Fallenberg / Fersis / \nFriedrich /  Friedrichs / Gerber / Huober / Kreipe / Maass / Nitz / Rody / \nSchmidt / Schreer / Sinn / Thomssen\n\u25aaVersion 2023:\nKolberg -Liedtke / Reimer / Sinn\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePathology Reporting for Minimal \nInvasive Biopsies\nB-Classification* \nB1 = Unsatisfactory or normal tissue only\nB2 = Benign lesion\nB3 = Lesion of uncertain malignant potential\nB4 = Suspicion of malignancy\nB5 = Malignant\nB5a = Non -invasive\nB5b = Invasive\nB5c = In situ / invasion not assessable\nB5d = Non epithelial, metastatic\n*AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V. (Hrsg.). Interdisziplin\u00e4re S3 -Leitlinie f\u00fcr \ndie Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 4.4, Juni 2021Lesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deB3-Lesions\n1. Lesions with increased risk of associated DCIS or invasive carcinoma  \n\u00a7Atypical ductal hyperplasia (ADH) or atypical epithelial proliferation of ductal type (classification \npossibly as B4, depending on extent of lesion)\n\u00a7Flat epithelial atypia (FEA)\n\u00a7Lobular neoplasia (LIN; LN; now subdivided into ALH and LCIS, no differentiation according to \nolder nomenclature) classical and non -classical type \n\u00a7Atypical apocrine adenosis\n2. Potentially heterogeneous lesions with risk of incomplete sampling\n\u00a7Cellular fibroepithelial lesion or phyllodes tumour without evidence of malignancy\n\u00a7Intraductal papilloma with / without atypia (possibly also B4, depending on the extent of the \nlesion)\n\u00a7Radial scar or complex sclerosing lesion (unless the radial scar only microscopically, not \nradiologically detected: B2)\n\u00a7Hemangioma\n3. Rare Lesions\n\u00a7Adenomyoepithelioma , nipple adenoma, microglandular adenosis, mucocele -like lesion, nodular \nfasciitis, desmoid -type fibromatosis, spindle cell lesion of unknown significanceLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deManagement after \nMinimally Invasive Biopsy\nOxford\nLoE GR AGO\u00a7Interdisciplinary conference: \nConcordant findings in pathology and imaging? \n\u00a7yes: proceed according to histologic type and \ndimension of lesion3a C ++\n\u00a7no: open biopsy 3a C ++\nVacuum -assisted biopsy (after core biopsy) 5 D +\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deStrategy after Diagnosis of ADH\nin Biopsy Sypecimen\nOxford\nLoE GR AGOADH in core-/ vacuum -assisted biopsy:\u00a7Open excisional biopsy 3a C ++\u00a7Open excisional biopsy may be omitted, if all following \nrequirements apply:5 C +/-\na) No mass -lesion radiologically, and\nb) a small lesion (\u2264 2 TDLU*) in vacuum biopsy, and\nc) complete removal of imaging abnormality ADH at margins in open biopsy specimen:\u00a7No further surgery, if incidental finding \naccompanies invasive or intraductal \ncarcinoma3a C +\n*Terminal ductal -lobular unitLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Includes:\n\u00a7Atypical lobular hyperplasia\n\u00a7Classical lobular carcinoma in situ (LIN, classical variant)\n\u00a7Non -Classical lobular carcinoma in situ (LIN, classical variant)\n\u00a7LIN 1 \u20133 classification is not sufficiently validated prognostically\n\u00a7Non -Classical LIN (pleomorphic LIN, florid LIN) are classified as lesions with \nelevated risk \u2192 potentially B5a\n\u00a7Indicator / precursor lesion:\nIpsi-and contralaterally increased breast cancer risk: \n7x after 10 yearsLobular Intraepithelial Neoplasia (LIN) \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nUpgrade rates * forB3 lesions\n* i.e., upgrade tomalignant diagnosis when excised\nRisk lesion Upgrade rate to in situ or invasive Ca References\nAtypical lobular hyperplasia (ALH) 5% [1]\nClassical lobular neoplasia (C -LCIS) 4 -16% [1-3]\nNon-classical lobular neoplasia (pleomorphic , florid\nLCIS, NC -LCIS)33 -39% [3, 4]\nAtypical ductal hyperplasia (ADH) 23% [1]\nFlat epithelial atypia (FEA) 0 -14% [5, 6]\nPapilloma 12% [7]\n-noatypia 6 -10% [7, 8]\n-atypia 21 -29% [8, 9]\nRadial scar or complex sclerosing lesion 7 -11% [10-12]\n-no atypia 5% [12]\n-atypia 25% [13]Lesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRisk ofmalignant disease during follow -up*\n* i.e. ipsilateral orcontralateral disease irrespective oflocalization ofprior lesion\nRisk lesion Upgrade rate to in situ or invasive Ca\nLIN 7x / 10 yrs (ipsi -/contralateral)\nAtypical ductal hyperplasia (ADH) 3-5x / 10 years (ipsi -/contralateral)\nPapilloma\n\u2022no atypia 4.6% (ipsilateral)\n\u2022atypia 13% ( ipsilateral )\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLIN with elevated risk\n\u00a7Non -classical LCIS:\n\u00a7Pleomorphic LCIS: high -grade cellular atypia, common involvement of ducts with\ncomedo necrosis and microcalcifications\n\u00a7Florid LCIS: involvement of multiple lobuli with a maximum extension until confluence\nand involvement of ductuli and neighboring TDLU\n\u00a7Microinvasion in classical and non -classical LCIS*:\n\u00a7classical LCIS: n = 11\n\u00a7florid LCIS: n = 4\n\u00a7pleomorphic LCIS: n = 1\n*Ross DS & Hoda SA. Am J Surg Pathol 2011; 35: 750 \u20136.Microinvasion in 0.37% of all LCIS (n = 4310) and in 0 .43% among all invasive lobular breast \ncancers (n = 3740) .\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deStrategy after Diagnosis of LIN\nOxford\nLoE GR AGO\u00a7LIN in core -/ vacuum -assisted biopsy:\n\u00a7 No further measures if LIN (LCIS, classical variant)\nwith involvement of \u2264 3 TDLU (terminal ductulo -lobular unit) in\nvacuum biopsy and concordant with imaging.2b C ++\n\u00a7 Open excisional biopsy, with pleomorphic LIN,\nflorid LIN (LIN 3), or LIN with comedo type necrosis\nor if not concordant with imaging findings.2b C ++\u00a7LIN at margins of resection specimen (BCT):\n\u00a7 No further surgery. 2a C ++\nExceptions:\na) Pleomorphic LIN, florid LIN, or LIN with necrosis\nb) Imaging abnormality is not removedLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deStrategy after Diagnosis of FEA\nOxford\nLoE GR AGO\u00a7FEA in core biopsy / vacuum -assisted biopsy:\n\u00a7 Open excisional biopsy 2b B+\n\u00a7 Open excisional biopsy may be omitted under the following\ncircumstances:2b B+\na. a small lesion (\u2264 2 TDLU* in vacuum biopsy)\nand\nb. Complete or near complete removal of imaging abnormality\u00a7FEA at margins in resection specimen:\n\u00a7 No further surgery, unless calcifications have not been completely\nremoved3b C ++\n*TDLU = Terminal ductal -lobular unitLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Includes: Central and peripheral papilloma > 2 mm,\natypical intraductal papilloma (B3)\n\u00a7To be distinguished from peripheral micropapilloma arising in the TDLU,\nsize \u2264 2 mm, may be multiple\n\u00a7To be distinguished from papilloma with DCIS, from intraductal papillary\ncarcinoma, and from encapsulated papillary carcinoma\n\u00a7Precursor lesion:\nMay be associated with in -situ or invasive cancer (up to 6% without atypia\nif concordant imaging, up to 30% with atypia), increased ipsilateral risk for\ncancer (up to 4.6% and up to 13% in case of atypical papilloma) .Papilloma \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deStrategy after Diagnosis of \nPapilloma\nOxford\nLoE GR AGO\u00a7Papilloma without atypia in core needle or\nvacuum biopsy:\n\u2192no further therapy , if biopsy sufficiently representative\n(100mm3) and concordant with imaging2b C+\u00a7Multiple papillomas (>2 mm)\n\u2192open biopsy 3a C ++\u00a7Papilloma with atypia in core needle or\nvacuum biopsies:\n\u2192open biopsy 3a C ++\u00a7Papilloma at resection margin:\n\u2192no published data availableLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Benign pseudoinfiltrative lesion with central fibroelastic core and \nradial configuration . \n\u00a7Includes:\n\u00a7radial scar (usually \u2264 1 cm)\n\u00a7complex sclerosing lesion (> 1 cm)\n\u00a7Additional risk factor in patients with benign epithelial \nhyperplasia (proliferating breast disease)\n\u00a7Risk for upgrade in open biopsy after diagnosis of a radial \nsclerosing lesion, depending on the size of the needle (CNB) or \nmethod (VAB) and additional atypia: 1 \u201318%Radially Sclerosing Lesion\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deStrategy after Diagnosis of Radial Scar, \nComplex Sclerosing Lesion (CSL)\nOxford\nLoE GR AGO\u00a7Radial scar / CSL in core -/ vacuum -assisted\nbiopsy:\n\u00a7Open excisional biopsy 3a C +\n\u00a7Without atypia 3a C +\n\u00a7With atypia 3a C ++\n\u2192Omission of open excisional biopsy if small (< 5mm) lesion or (near) complete removal of imaging \nabnormality 5 C +\u00a7Radial scar / CSL at margins in resection specimen:\n\u2192No further surgery 3b C ++Lesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer Early Detection: Follow -up Imaging for Women \nAge 50\u201369 Years with B3 -Lesions\nOxford\nLoE GR AGO\u00a7FEA, non -atypical papilloma , radial sclerosing\nlesion\n\u00a7Screening mammography 5 C ++\u00a7LIN\n\u00a7Mammography (12 months) 3a C ++\u00a7ADH\n\u00a7Mammography (12 months) 3a C ++\n\u00a7Women with LIN and ADH should be \ninformed about their elevated risk of breast cancer 3a C ++Lesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMedical Prevention for B3 -Lesions With Increased \nRisk of Associated DCIS or Invasive Carcinoma  \nOxford\nLoE GR AGO\u00a7Tamoxifen 20 mg/d (5 yrs) for women > 35 years 1a A +/-\u00a7Low -dose Tamoxifen 5 mg/d* (3 years ) independent of\nmenopausal status2b B +/-\u00a7Aromatase inhibitors (Exemestan e, Anastrozole)for postmenopausal women1b A +/-\u00a7Raloxifen for postmenopausal women :Risk reduction of\ninvasive BConly1b A +/-**\nMedical prevention should only be offered after individual and \ncomprehensive counseling; overall benefit depends on classification, age, \nand pre -existing conditions that may influence occurrence of side effects.\n*5 mg Tablet not available ; alternatively 10 mg p.o. q2d\n** Risk situation as defined in NSABP P1 -trial (1.66% in 5 years)Lesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nDuctal Carcinoma in Situ\n(DCIS) \nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDuctal Carcinoma In Situ\n(DCIS)\n\u25aaVersions 2002 \u20132022: \nAudre tsch / Bauerfeind / Blohmer / Brunnert / Budach / Costa/ Ditsch / \nFersis / Friedrich / Gerber / Hanf / Junkermann / K\u00fchn / Lux / Maass /  \nM\u00f6bus / Mundhenke / Nitz / Oberhoff / Scharl / Sch\u00fctz / Solbach / \nSolomayer / Souchon / Thill / Thomssen / Wenz \n\u25aaVersion 2023: \nBlohmer / Mundhenke\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDCIS -Pretherapeutic Assessment\nOxford\nLoE GR AGO\u25aaMammography 1b B ++\n\u25aa Magnification view of microcalcifications 4C ++\n\u25aa Increased detection rate of G1 / G2 DCIS by full -field digital\nmammography (versus screen -film)2b B+\u25aaUltrasound (to rule out an accompanying invasive component)4C ++\n\u25aaFor tumors with a solid part 4C ++MRI to determine the extension and planning of surgery1a B +/-\u25aaClinical examination 5D ++\u25aaStereotactic core needle / vacuum biopsy (VAB) 2b B ++\n\u25aa Specimen radiography 2b B ++\n\u25aa Marker (clip) left at biopsy site for localization if lesion is completely\nremoved5D ++\u25aaInterdisciplinary board presentation 5D ++DCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nDCIS \u2013Upstaging, ipsi -/ Contralateral Events \nund MortalityUpstaging to BC%Ipsilateral events (cum. incidence)%Contralateral events (cum. incidence)%BC-specific mortality %(95% CI)5-25.910 years:BCS: 24.6BCS and radiotherapy:9.620 years:BCS: 30.6BCS and radiotherapy:18.210 years:4.8-6.415 years:6.4-~1110 years: 0.9 (0.7-1.1) (BCS)0.8 (0.7-1.0) (BCS and radiotherapy)1.3 (1.1-1.5) (unilateral mastectomy)~ 50% of all ipsilateral events are invasive.\nBreast cancer specific mortality is 3,3%. \nWomen with DCIS have a 1.8 -3-fold increased risk of death  compared to normal \npopulation/women without DCIS. Risk is greater for young and black women.DCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u25aa144,524 women treated for DCIS, 1,540 women died of breast cancer,\n\u25aacohort study included data for women who had first primary DCIS diagnosed\nbetween 1995 and 2014 from the SEER registries database (use of ET is not\nreported),\n\u25aaretrospective analysis,\n\u25aaresults:\n\u25aa standardized mortality ratio for death from breast cancer among women with\nDCIS was 3.36 (95% CI, 3.20 -3.53),\n\u25aa risk is greater for young and black women,\n\u25aa 4,502 (3.1%) ipsilateral invasive recurrences, resulting in a 20 -year actuarial\nrisk of 13.9%,\n\u25aa 5,527 (3.8%) contralateral invasive breast cancers, resulting in a 20 -year\nactuarial risk of 11.3%,\n\u25aa women with DCIS had a 3 -fold increased risk of death from breast\ncancer compared to women without DCIS.Association of a Diagnosis of Ductal Carcinoma In Situ With \nDeath From Breast Cancer\nGiannakeas V, Sopik V, Narod SA. JAMA Netw Open. 2020 Sep 1;3(9):e2017124\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRisk Factors for Upstaging from DCIS to \nInvasive Cancer in Final Surgical Specimen\nOxford\nLoE\nHigher risk\n\u00a7 DCIS without microcalcification in core needle or vaccum biopsy 3b\n\u00a7 Microcalcification  \u2265 11,5 mm 3b\n\u00a7 Presentation as tumor in MRI 3b\n\u00a7 Increased Ki -67 (\u2265 20%) 3b\n\u00a7 PR negative 3b\n\u00a7 High peak contrast enhancement on MRI 3b\n\u00a7 Irregularly shaped, non -circumscribed, heterogeneous or margin -enhancing tumors with \nintratumoral high signal intensity or peritumoral edema on MRI3b\n\u00a7 Biopsy technique: diagnosis by core needle biopsy versus vacuum biopsy (smaler sampling volume) 3b\n\u00a7 High platelet -lymphocyte ratio 3b\nLower risk\n\u00a7 Removal \u2265 90% of the microcalcifications by vacuum biopsy 3bDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGood Clinical Practice (GCP)\nSurgical excision (BCS or mastectomy) is the standard\ntreatment for DCIS.\nAdjuvant treatment (radiotherapy, endocrine treatment)\nmust be discussed with the patient individually. Adverse \neffects should be weighted against risk reduction.\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSurgical Treatment for \nHistologically Proven DCIS I \nOxford\nLoE GR AGO\u25aaExcisional biopsy (wire guided) 2b B ++\n\u25aa Localization with wire -free procedure 3b C +/-\u25aaBracketing wire localization in large lesions 3a C+\u25aaSpecimen radiography 2b B ++\u25aaIntraoperative ultrasound (pre -op visible lesion) 3a C +/-\u25aaImmediate re-excision in case of incomplete resection\n(specimen radiography)1c B ++\u25aaIntraoperative frozen section (in individual cases for\nmargin assessment)3a D +/-\u25aaInterdisciplinary board presentation 2b C ++\nOpen biopsy in suspicious lesions (mammographic microcalcifications, suspicious US, MRI etc.)\nwithout preoperative needle biopsy should be avoidedDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSurgical Treatment for \nHistologically Proven DCIS II\nOxford\nLoE GR AGO\u25aaHistologically clear margins (Ris0) 1a A ++\u25aaMultifocal DCIS: BCS if feasible 2b B +\u25aaRe-excision required for close margin in case of BCS and radiotherapy (\u2264 2 mm in paraffin section)*2b C +\u25aaMastectomy ** \n\u25aa Large lesions confirmed by multiple biopsies; no clear margins after re -excision 2a B ++\u25aaSLNE\n\u25aa Mastectomy 3b B +\n\u25aa BCS 3b B --\n\u25aa In case of DCIS in the male breast 5 D +/-\u25aaALND 2b B --\n*      Individual approach taking into account age, tumor size, grading and implementation ofradiation , especially in case ofnosubsequent radiation\n** Patients who present with a palpable mass have a significantly higher potential foroccult invasion (26%), multicentricity and local recurrenceDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrognostic Factors for an \nIpsilateral Recurrence after DCIS  ILoE\u25aaResection margins 1a\u25aaAge 1a\u25aaSize 1a\u25aaGrade 1a\u25aaComedo necrosis 1a\u25aaMethod of diagnosis 1a\u25aaFocality 1a\u25aaHER2 -overexpression 1a\u25aaER / PR (positive vs. negative) 1aDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nPrognostic Factors foran \nIpsilateral Recurrence after DCIS II\nLoE\n\u25aaHereditary breast cancer risk 2a\n\u25aaPremenopausal at time ofDCIS diagnosis 2a\n\u25aaHigh BMI 2a\n\u25aaHigh breast density 2a\n\u25aaGrowth pattern (cribriform / solid versus \u201e clinging \u201c / micro -papillary ) 2b\n\u25aaResidual tumor -associated microcalcifications 2b\n\u25aaArchitecture 2b\n\u25aa(modified ) Van Nuys Prognostic Index/ mitotic rate 2b\n\u25aaPalpable DCIS 2b\n\u25aaER-, HER2+, Ki -67+ 2b\n\u25aaScores : DCIS, Oncotype DX Breast DCIS Score (12 genes); CCP (23 genes) 2b\n\u25aaMSKCC Nomogram 2b\n\u00a7DCISionRT 2b\n\u25aaIntrinsic subtypes (luminal A, B, HER2+, triple negative) 2b\n\u25aaDCIS compared toinvasive carcinoma with higher risk ofcontralateral BC 2b\n\u25aaHigh number ofTILs                                                                                                                         2bDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDCIS Radiotherapy \nStatements\u25aaRadiotherapy has no impact on survival LoE 1a\u25aaRadiotherapy reduces the risk of ipsilateral  (invasive and non \ninvasive) recurrences by 50 %LoE 1a\u25aaThe number needed to treat (for ipsilateral breast recurrence)is 9 (over all risk groups).\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDCIS \nAdjuvant Radiotherapy\nSide effects and disadvantages must beweighed against riskreduction . Omitting radiotherapy implies elevated risk forlocal recurrence without\neffect foroverall survival even in thesubset of\u201egood risk\u201d patients . Lack oflevel -1 evidence supporting theomission ofadjuvant radiotherapy in \nselected low-riskcases : < 2.5 cm, low and intermediate nuclear grade, mammographically detected .\n* < 50 years or\u2265 50 years and diagnosis based on symptoms , \u2265 15 mm, multifocality , palpable tumor , resection margins < 10 mm, G2 / 3,  central\nnecrosis , comedo typeOxford\nLoE GR AGORadiotherapyafter:\u25aaBreast conserving surgery (BCS) 1a A ++\u25aaMastectomy 2b B --Radiotherapyprocedure :\u25aaConventionally fractionated radiotherapy (50 Gy in 25 fract.) 1a A +\u25aaHypofractionated radiotherapy (40 -42,5 Gy in 15 -16 fract.) 1a A +\u25aaRadiotherapy boost of the tumor bed 1b B +/-\n\u25aa in case of risk factors* (absolute benefit 5 -y-RFS 4 %, rate of fibrosis significant \nincreased)1b B +/-\n\u25aa without risk factors 2b B -\u25aaPartial breast irradiation [age\u2265 50y, DCIS \u2264 3 cm, G1 -2, R0 (\u2265 5 mm), \nunifocal / unicentric ]1b B +\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDCIS \u2013\nAdjuvant Systemic Treatment\u25aaAdjuvant endocrine treatment has no impact on survival LoE 1a\u25aaEndocrine treatment may have a small effect on ipsilateral \ninvasive and DCIS recurrencesLoE 1a\u25aaEndocrine treatment for DCIS has an effect on contralateral \ninvasive and non -invasive cancerLoE 1a\u25aaThe number needed to treat for any ipsilateral breast event is 15LoE 1a\u25aaThe number needed to treat to prevent invasive breast cancer is 29 for anastrozole vs. 59 for tamoxifen*LoE 1b\n* within 12 years; according to IBIS II -trialDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDCIS \u2013\nAdjuvant Systemic Treatment\nOxford\nLoE GR AGO\u25aaTamoxifen (only ER+) 20 mg 1a A +/-*\u25aaTamoxifen (only ER+) 5 mg (long -term data missing)2ba B +/-*\u25aaAromatase inhibitor (only ER+) in postmenopausal\nwomen only1b A+/-*#\u25aaTrastuzumab (only H ER2+) 5D --\n*Indication for treatment depends on risk factors, side effects and patient preference\n# Anastrozole versus Tamoxifen: Anastrozole higher fracture rate (OR 1.34), Tamoxifen higher rate of stroke\n(OR 3.10) and TIA (OR 3.10)DCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u25aa N = 3,864 postmenopausal women at inceased risk for breast cancer,\n\u25aa median follow -up of 131 months,\n\u25aa results:\n\u25aa 49% reduction of all breast cancers with anastrozole (HR 0.51, 95% CI 0.39 \u20130.66,\np<0.0001),\n\u25aa significant reduction in incidence for anastrozole for ductal carcinoma in situ (HR 0.41,\n0.22 \u20130.79, p = 0.0081), especially for oestrogen -positive (HR 0.22, 0.07 \u20130.65, p =0.0062),\n\u25aa 5-year adherence anastrozole 74.6% vs. 77.0% for placebo,\n\u25aa no difference in major side effects (fractures, mycardial infarctions, deep vein thrombosis,\npulmonary embolism),\n\u25aa NNT to prevent one breast cancer during 12 years: 29 (anastrozole) vs. 59 (tamoxifen).3864 postmenopausal \nwomenRUse of Anastrozole for Breast Cancer Prevention (IBIS -II):\nLong -Term Results of a Randomised Controlled Trial\nCuzick J et al, Lancet 2020\nN = 1,944 placeboN = 1,920 anastrozole 1 mg, 5 y\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLow Dose Tamoxifen (5 mg) in Premalignant Lesions\nLazzeroni M et al: Breast 2019\n\u25aaN = 500,\n\u25aafollow -up 5.69 years,\n\u25aaresults:\n\u25aaEFS: Tam 5.5% (14/253) vs. Pacebo 11.3% (28/247),\n\u25aasevere adverse event with same incidence (endometrial cancer \nTam 1 vs. PLAC 0, thrombo -embolic event Tam 1 vs. PLAC 1)\n\u25aaadherence Tam 65% vs. PLAC 61%. DCIS (69%), LCIS (11%), \nADH (20%)RTamoxifen 5 mg 3 y\nPlacebo\nDCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2022.1E\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTherapy of Local DCIS Recurrence \nafter Tumorectomy\nOxford\nLoE GR AGOAfter Radiation:\u25aaSimple Mastectomy 3a C++ SLNE5D +\u25aaSecondary breast conserving surgery 4C +/-Without radiation after first tumorectomy\u25aaTreatment like primary disease 3C ++DCIS\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E \nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nIn collaboration\nwith: Breast Cancer Surgery\nOncological Aspects\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Breast Cancer Surgery\nOncological Aspects\n\u00a7Versions 2002 \u20132022:\nBanys -Paluchowski / Bauerfeind / Blohmer / B\u00f6hme / Brunnert / Costa / \nDitsch / Fallenberg / Fersis / Friedrich / Gerber / Hanf / Janni / \nJunkermann / Kaufmann / K\u00fchn / K\u00fcmmel / M\u00f6bus/ Nitz / Rezai / Simon \n/ Solomayer / Thomssen / Thill / Untch / W\u00f6ckel\n\u00a7Version 2023\nBauerfeind / Thill\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Breast Cancer Surgery\nOncological Aspects\nAGO: ++\nSurgery is one sub -step out of multiple steps in breast cancer\ntreatment. Thus, both diagnostic and oncological\nexpertise are an essential requirement for every breast surgeon.\nAGO: +\nAvoidance of a significant delay in cancer treatmentBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Pre-therapeutic Assessment \nof Breast and Axilla Oxford\nLoE GR AGO\n\u00a7Clinical examination 5 D ++\n\u00a7Mammography (completion oftheimaging ) 2b B ++\n\u00a7 + Tomosynthesis (DBT)*** 2b B +\n\u00a7 Contrast -enhanced mammography (alone) adjusted with regards of \nradiation sensitivity of patient and availability2a B +\n\u00a7Sonography (breast /axilla *)2b/2a*B ++\n\u00a7MRI* 1b A +\n\u00a7Minimally invasive biopsy ** 1b A ++\n\u00a7CNB axilla , iflymph node (LN) issuspect , LN-marking ifTAD is\nplanned /\u22643 susp . LN2b B ++\n\u00a7Breast -CT 4 D -\n\u00a7Axillary PET (PET -CT, PET -MR) 2b B -\n* MRI -guided vacuum biopsy is mandatory in case of MRI -detected additional lesions (in house or with cooperations ). \nIndividual decision for patients at high familiar risk, with dense breast (density C / D), lobular invasive tumors, suspicion ofmultilocular disease. \n** Histopathology of additional lesions if relevant for treatment\n***   Replacement of FFDM with SMBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Pre-therapeutic Staging\n*Contrast enhanced ultrasound\n**especially in patients with high tumor stage (III) if availableOxford\nLoE GR AGO\u00a7History and clinical examination 5 D ++Onlyin case ofhigh metastatic potential and/orsymptoms and/orindication for(neo -) adjuvantchemotherapy and/orantibody -therapy :\u00a7CT scan of thorax / abdomen 2a B +\u00a7Bone scan 2b B +\u00a7Chest X -ray 5 C +/-\u00a7Liver ultrasound 5 D +/-\u00a7Further investigation in case of additonal suspicious lesions \n(e.g. liver -MRI, CEUS*, biopsy etc.)2a B +\u00a7FDG -PET orFDG -PET-CT** FDG -PET-MRT** 2b B +/-\u00a7Whole body MRI 4 C +/-Breast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Evidence of Surgical Procedure\nOxford\nLoE GR\n\u00a7Survival rates after lumpectomy + RT are at least \nequivalent to those after (modified) radical \nmastectomy1a A\n\u00a7Local recurrence rates after skin sparing \nmastectomy are equivalent to those after \nmastectomy 2b B\n\u00a7Conservation of the NAC (nipple areola complex) is \nan adequate surgical procedure, if R0 resection is \nachieved2b C\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Breast -Conserving Surgery (BCS):\nOptions toLocalize Non -Palpable Lesions\n* The lesion must be sonographically visualized by the same examiner pre -and intraoperatively in its whole extension.\nAdequate equipment and training of the surgeon are mandatory.\n** according to approval\n*** not suitable for MRI -based response assessment under NACT\n**** not approved in GermanyOxford\nLoE GR AGO\n\u00a7Wire -guided localization 1a A ++\n\u00a7Wireless intraoperative ultrasound -guided localization* 1a A ++\n\u00a7Other procedures:**\nRadar reflectors 2b B +/-\nMagnetic Seeds*** 2b B +/-\nRadiofrequency -based markers (RFID) 2b B +/-\nRadionuclide -guided localization (ROLL) 1a A +/-\nRadioactive seeds****1a A +/-\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Localization Methods for non -Palpable Breast \nCancer: a Meta -Analysis\nAthanasiou et al. EurJ Surg Onc 2021:\n\u2022 Meta -analysis of RCTs\n\u2022 18 studies with 3112 patients\n\u2022 Pairwise and network meta -analysis\nUltrasound -guided surgery vs. wire -guided surgery:\n\u2022 decreased positive margin both in the pairwise [OR = 0.19 (0.11, 0.35); P < 0.01] and network \nmeta -analysis [OR = 0.19 (0.11, 0.60)]\n\u2022 a statistically significant reduction in re -operation rate [OR = 0.19 (0.11, 0.36); P < 0.01] and \noperative time [MD = -4.24 ( -7.85, -0.63); P = 0.02] \nUltrasound -guided surgery vs. ROLL / RSL: \n\u2022 a statistically significant reduction in positive margin compared to ROLL [OR = 0.19 (0.11,0.6)] \nand RSL [OR = 0.26 (0.13, 0.52)]\n\u201eUltrasound -guided surgery has potential benefits in reduction of positive \nsurgical margin, the rest of the techniques seem to have equivalent efficacy.\u201dBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Breast -Conserving Surgery (BCS):\nResection Margins\nOxford\nLoE GR AGO\n\u00a7Invasive breast cancer without extensive intraductal\ncomponent (EIC)*\n\u00a7 Aim: tumor -free margins (\u201cno ink on tumor\u201c is sufficient even\nin case of unfavorable tumor biology)2a A ++\n\u00a7 Re-excision for invasive or non -invasive tumor cells reaching\nmargin (final histology)2a B ++\n\u00a7Invasive breast cancer with EIC*\n\u00a7 Re-excision for invasive or non -invasive tumor cells reaching\nmargin (final histology)2a B ++\n\u00a7 Re-excision in case of a close margin of the intraductal\ncomponent (< 2 mm on final histology)**2a B-\n* No clear definition of EIC in the literature. Increased risk of local recurrence in case of EIC with at least twice the great est\ndimension of the invasive tumor component (definition according to the German S3 guideline).\n** Individual approach with consideration of patient\u2018s age and tumor extentBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Breast -Conserving Surgery (BCS):\nSurgical and Technical Aspects\nOxford\nLoE GR AGO\n\u00a7Specimen radiography and / or -sonography in non -palpable\nlesions and / or tumor -associated microcalcifications*2b B ++\n\u00a7Intraoperative ultrasound to increase negative margin rates in\nnon-palpable lesions1a A+\n\u00a7Intraoperative ultrasound to increase negative margins rates in\npalpable lesions (with smaller resection volumes)1b B+\n\u00a7Surgical clip marking of the tumor bed if boost or partial breast\nirradiation is indicated2b B+\n\u00a7Intraoperative margin evaluation (with Margin Probe\u00ae) 1b A +/-\n\u00a7Therapeutic stereotactic excision alone 4D --\n*Mandatory also for probe -guided detection systems (magnetic seeds, radar reflectors, RFID, radioactive seeds, ROLL)Breast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Breast -Conserving Surgery (BCS) \nwithout Neoadjuvant Therapy\nOxford\nLoE GR AGO\n\u00a7Multifocality / Multicentricity\n(R0 resection of all lesions required)2b B+\n\u00a7Positive microscopic margins after repeated\nexcision2b B --\n\u00a7Inflammatory breast cancer 2b B --\nFor surgery after neoadjuvant chemotherapy see chapter \n\u201eNeoadjuvant chemotherapy\u201cBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Axillary Lymph Node Dissection\n(ALND) without Neoadjuvant Chemotherapy\nOxford\nLoE GR AGO\n\u00a7 Endpoint: Survival (if patient receives adequate multimodal therapy) 3 D -\n\u00a7 Endpoint: Staging 3 A -\n\u00a7 Endpoint: Locoregional control 2a A +/-\n\u00a7 pN+ (histologically confirmed pre -surgery) 2a B +\n\u00a7 cN0 pN0 ( i+) (sn) 1b A --\n\u00a7 cN0 pN1mi ( sn) 2b B --\n\u00a7 cN0 pN1 ( sn) (T1/2 , < 3 SN+*, BCS + RT + adequate systemic therapy) 1b A -\n\u00a7 cN0 pN1 (sn) and mastectomy (no chestwall radiotherapy) 1b B +**\n\u00a7 cN0 pN1 (sn) and mastectomy (T1/2, < 3 SN+, chestwall radiotherapy) 5 D +/-**\n\u00a7 ALND indicated, but not feasible\n\u00a7 Radiotherapy according to AMAROS trial (validated for cN0 pN1sn) 1b B +\n*ACOSOG Z0011 trial protocol without clear definition ofgross extra nodal disease; **Study participation recommendedBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Axillary Surgery and NACT Oxford\nLoE GR AGO\ncNstatus\n(before\nNACT)pNstatus\n(before\nNACT)ycN status\n(after NACT)Axillary surgery\n(after NACT)AGO ypN status (after NACT \nand surgery )Surgical consequence \nbased on histopathology\ncN0* Nosurgery\nbefore NACTycN0 SLNE ++ ypN0 ( sn) none 2b B ++\nypN0 (i+) ( sn) ALND 2b C +/-\nypN1mi (sn) ALND 2b C +\nypN1 (sn) ALND 2b C ++\n*  Study participation in EUBREAST -01 recommendedBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:\n* Study participation in AXSANA recommended, **Cave: In 30.3% false -positive findings , consider CNB ifnecessaryAxillary Surgery and NACT ( cN+)Oxford\nLoE GR AGO\ncNstatus\n(before\nNACT)pNstatus\n(before\nNACT)ycN status\n(after NACT)Axillary surgery\n(after NACT)AGO ypN status (after NACT \nand surgery )Surgical consequence\nbased on histopathology\ncN+* pN+ CNB ycN0 ALND + ypN0 / ypN+ none 2b B ++\nTAD + ypN0 none 2b B +\nypN0 (i+) ALND 2b B +/-\nypN+ inkl. ypN1mi ALND 2b B +\nSLNE +/- ypN0 none 2b B +/-\nypN0 (i+) ALND 2b B +/-\nypN+ inkl. ypN1mi ALND 2b B +\nTLNE +/- ypN0 none 2b B +/-\nypN0 (i+) ALND 3b B +/-\nypN+ inkl. ypN1mi ALND 3b B +\nycN+** ALND ++ ypN0 / ypN+ none 2b B ++Breast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Targeted Axillary Dissection (TAD)\n= TLNE + SLNE\n*Study participation in AXSANA recommendedOxford\nLoE GR AGO\n\u00a7 Core needle biopsy and marking of suspicious lymph nodes (LN) 2b B ++\n\u00a7 Marking of multiple LN if more than one LN is suspicious 2b B +/-\n\u00a7 Evidence for comparison of different markers (clip / coil, carbon, magnetic seed, \nradar reflector, radiofrequency -based marker etc.) is insufficient *2b B\n\u00a7 TAD in case of 1 -3 suspicious LN before NACT 2b B +\n\u00a7 TAD in case of \u2265 4 suspicious LN before NACT 5 D +/-\n\u00a7 Full workup using step sections of \u2264 500 \u00b5m on paraffin embedded tissue 5 D ++\n\u00a7 Immunohistochemistry for ITC detection 5 D +/-\n\u00a7 ALND in case of pre -or intraoperatively undetectable marker 5 D +\n\u00a7 Further intervention to retrieve lost marker (incl. after ALND) 5 D -\n\u00a7 TLNE only without SLNE 2B B +/-Breast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Oxford\nLoE GR AGO\n\u00a7Clinically / sonographically negative axilla (cN0) 1b A ++\n\u00a7cT 1\u20132 2b A ++\n\u00a7cT 3\u20134c 3b B +\n\u00a7Multifocal / multicentric breast cancer 2b B +\n\u00a7DCIS\n\u00a7 Mastectomy 3b B +\n\u00a7 BCT 3b B -\n\u00a7 DCIS in male 5 D +/-\n\u00a7Male breast cancer 2b B +\n\u00a7Omission of axillary intervention in elderly patients (\u2265 70 yrs., co -\nmorbidities, pT1, HR+)3b B +/-Sentinel Lymph Node Excision (SLNE)\nIndications I\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Sentinel Lymph Node Excision (SLNE)\nIndications II\nOxford\nLoE GR AGO\n\u00a7During pregnancy and / or breast feeding \n(only99mTc-colloid, no patent or methylene blue dye, no \ndata to SPIO or ICG )3 C ++\n\u00a7After prior tumor excision 2b B +\n\u00a7After prior major breast surgery \n(e.g. reduction mammoplasty)3b C +/-\n\u00a7Ipsilateral breast recurrence after prior BCS \nand prior SLNE4 D -\n\u00a7SLNE in the mammary internal chain 2b B -\n\u00a7After axillary surgery 3b B +/-\n\u00a7Prophylactic bilateral / contralateral mastectomy 3b B --\n\u00a7Inflammatory breast cancer 3b C -Breast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Sentinel Lymph Node Excision (SLNE)\nMarking\nOxford\nLoE GR AGO\n\u00a799mTc Kolloid 1a A ++\n\u00a7Preoperative lymphoscintigraphy (added infomation\nlimited, but mandatory by legal regulations)*1b A+\n\u00a7Patent blue dye 1a A +/-\n\u00a7Indocyanin green (ICG) \u00b0 2a B+\n\u00a7SPIO#2a B+\n\u00a7Methylene blue 2a B +/-\n*In Germany required for quality assurance of nuclear medicine\n#  SPIO: Superparamagnetic Iron Oxide (Caveat: impaired MRI -sensitivity during follow -up)\n\u00b0no approval for LN marking in the axilla, off -labelBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Surgical Approach in the Neoadjuvant Setting\nOxford\nLoE GR AGO\n\u00a7Early marking of tumor (incl. detailed topographic \ndocumentation)5 D ++\n\u00a7Surgical removal of tumor / representative excicion of \npost -therapeutic, marked tumor area2b C ++\n\u00a7Tumor resection in new margins 2b C ++\n\u00a7Microscopically clear margins 2a B ++\nFor \u201eSurgery after neoadjuvant chemotherapy\u201c see chapter \n\u201eNeoadjuvant chemotherapy\u201cBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nIn collaboration\nwith:Begin of Adjuvant Therapy after Primary \nSurgery\nOxford\nLoE GR AGO\n\u00a7Start adjuvant systemic therapy and radiotherapy (RT) as\nsoon as possible (asap) after surgery1b A ++\n\u00a7Start of adjuvant chemotherapy +/ -HER2 therapy  asap\nafter surgery, prior to RT1b A ++\n\u00a7Without cytotoxic therapy +/ -anti-HER2 therapy:\n\u00a7Start adjuvant RT within 6 \u20138 weeks after surgery 2b B ++\n\u00a7Start endocrine therapy after surgery asap 5D ++\n\u00a7Endocrine therapy concurrent with RT 2b B+\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EOncoplastic and\nReconstructive Surgery\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EPlastic -Reconstructive Aspects after \nMastectomy\n\u25aaVersions 2002 \u20132022:\nAudretsch / Bauerfeind / Blohmer / Brunnert / Dall / Ditsch / Fersis / \nFriedrich/ Gerber / Hanf/ Heil / K\u00fchn / K\u00fcmmel / Lux / Nitz / Rezai / \nRody / Scharl / Solbach / Thill / Thomssen / W\u00f6ckel\n\u25aaVersion 2023:\nDall / Ditsch\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EUse ofplastic surgical techniques at thetime oftumor\nremoval toenable safe resection margins and topreserve\naesthetic breast contour .\nFocus on favorable scar placement , adequate soft tissue\nformation , choice ofproper reconstruction procedure\n(including in thecontext ofradiation ) and presentation of\nthepossibilities ofthealigning operation ofthe\ncontralateral side toachieve symmetric results . Definition of Oncoplastic Surgical Procedures\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EClassifications\n1.B y  H o f f m a n n  /  W a l l w i e n e r :\nClassification byreconstructive surgery complexity with respect tobreast\nconservation and mastectomy : PubMed Central, Figure 1: BMC Cancer. \n2009; 9: 108. Published online 2009 Apr 8. doi:10.1186/1471 -2407 -9-108 \n(nih.gov)\n2. By Clough:\nOncoplastic classification forbreast conservation according torelative \nresection volume : Level 1: < 20 % ofbreast volume resection (\u201esimple \noncoplastic surgery \u201c) and Level 2 > 20 % ofbreast volume resection with\nquadrant per quadrant techniques of mastopexy . \nHoffmann D et al., BMC 2009; Clough KB et al., Ann Surg Oncol 2010Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EOncoplastic Breast Conserving Surgery (OPS) \nOxford\nLoE GR AGO\n\u25aaOPS may replace mastectomy in selected patients\n\u25aa also in case ofmulticentric / multifocal tumors2b\n2b(a)B\nB+\n+ \n\u25aaOPS and BCS areoncologically similiar 2a B ++\n\u25aaComplication rates ofOPS and BCS aresimiliar 2a B +/-\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EAlgorithm of Breast Reconstruction\nPatient wishes toundergo breast reconstruction\nN.B.: Habitus, breast volume , wishes , previous surgery , individual riskfactors\nSSM / NSM and implantation\nor\nMRM + tissue expander \u00e0Implant\nor\nnot suitable for alloplastic\nreconstruction or wish of patient \n\u00e0autologous reconstructionPostmastectomy radiotherapy indicated\nMastectomy\n\u00e0 Radiotherapy \n\u00e0 Delayed autologous\nreconstructionNot suitable for autologous\nreconstruction\nE.g. too little subcutaneous fat,\nwishes of patient \nDirect prosthesis reconstruction or \ntwo-staged implant -based \nreconstruction: \nMRM \u00e0Tissue expander \u00e0\nImplant + Radiotherapy\nN.B.: Increased complication rate, \nparticularly capsular fibrosisTo be discussed in individual cases:\nImmediate autologous reconstruction\nN.B.: Increased fibrosis rate\nDelayed prothesis reconstruction\nN.B.: Increased complication rateNo postmastectomy radiotherapy\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\u00a7Planning ofreconstructive procedure byinterdisciplinary tumor board before mastectomy\n\u00a7Counseling regarding all surgical techniques , including advantages and disadvantages\n\u00a7Preference forautologous reconstruction after radiotherapy orifradiotherapy isplanned\n\u00a7Offer second opinion\n\u00a7Discussion ofneoadjuvant treatment (iftumorbiologically indicated ) in case ofunfavorable tumor -\nbreast -relation\n\u00a7Consideration ofcontralateral breast ; \n\u00a7discuss possible alignment / sequencing surgical procedures toproduce symmetry ; \nusually after at least 3 -6 months (Caveat : need forpost -resections , consider effects\nofradiotherapy foraffected side)\n\u00a7Preference forless stressful surgical technique with stable long -term esthetic result\n(prefer BCS / OPS over mastectomy )\n\u00a7Avoid delay ofadjuvant therapy due toreconstruction\n\u00a7Assessment ofoutcome , e.g. Patient Reported Outcome (PRO)\n\u00a7Oncologic safety isnot impairedAGO: ++ Breast Reconstruction Principles\nGood Clinical Practice\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EMastectomy and Reconstruction Options\nOxford\nLoE GR AGO\n\u00a7Use ofsilicone gel filled breast implants * \none step ortwo steps after expander2a B +\n\u00a7Autologous tissue reconstruction 2a B +\n\u00a7Pedicled tissue reconstruction 2a B +\n\u00a7Free tissue reconstruction \n(including vascular anastomoses)2a B +\n\u00a7Autologous tissue procedure plus implants 3a C +/-\nCaveat : BMI > 30, smoking status , diabetes , radiotherapy , age, bilateral mastectomy\n* Documentation in implant registryOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ETiming of Reconstruction\nOxford\nLoE GR AGO\n\u25aaImmediate breast reconstruction 3b B ++\n\u25aa Mandatory : SSM / NSM\n\u25aa Avoidance of a postmastectomy syndrome\n\u25aaDelayed breast reconstruction (2 -step) 3b B ++\n\u25aa No interference with adjuvant procedures (CHT, RT) \n\u25aa Disadvantage: loss of skin envelope\n\u25aa\u201eDelayed -immediate\u201c breast reconstruction \n(placeholder before definitive reconstruction)3b B +\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ETiming of implant Based Reconstruction \nand Radiotherapy\nOxford\nLoE GR AGO\n\u00a7Implant reconstruction (IR) 2a B +\n\u00a7IR without radiotherapy 2a B ++\n\u00a7IR prior to radiotherapy 2a B +\n\u00a7IR following radiotherapy 2b B +/-\n\u00a7IR following secondary mastectomy \n(after BCS* with radiotherapy)2a B +/-\n\u00a7Perioperative antibiotic prophylaxis (max. 24 hours) 2a B +\n*BCS: Breast Conserving SurgeryOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\u25aa11 studies (15,966 mastectomy procedures) \n\u25aaThree studies comparing topical antibiotics with no topical antibiotics \ndemonstrated statistical significance (RR = 0.26, 95% CI: 0.12 \u20130.60, \nP=0.001)\n\u25aa8 studies comparing extended systemic antibiotics with standard of care \nfound no statistical significance (RR = 0.80, 95% CI: 0.60 \u20131.08, P = 0.13).\nLoE2a B\nIn the setting of immediate breast reconstruction (IBR) following mastectomy, there is insufficient evidence for \nthe use of extended prophylactic antibiotics to reduce surgical site infection (SSI) rates. Welldesigned\nrandomized controlled trials in patients undergoing IBR should be conducted to determine the appropriate \nregimen and/or duration of prophylactic antibiotics on SSI outcomes .\nHai Y et al. Plast Reconstr Surg Glob Open 2020;8:e2613; doi: 10.1097/GOX.0000000000002613 , Metaanalysis ofProphylactic Antibiotics > 24 h in \nImplant -based Immediate Breast Reconstruction (IBR)\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\u00a7US FDA Breast Implant Postapproval Studies (LPAS)\nLong -term Outcomes in 99,993 Patients\n(Primary Augmentation: N = 71.937 / Primary Reconstruction: N = 9942)\n-56% of implants were silicone implants\n\u00a7Possible Associations:\n-Sjogren syndrome: (SIR* 8.14)\n-scleroderma: (SIR 7.00)\n-rheumatoid arthritis: (SIR 5.96)\n-stillbirth: (SIR 4.50)\n-melanoma: (SIR 3.71)\n\u00a7At 7 years, reoperation rate is 11.7% for primary augmentation, and 25% for primary /\nrevision reconstruction.\n\u00a7One case of BIA -ALCLPossible Associations between Implants \nand Rare Diseases\n* Standardized incidence ratioAssociations need to be further analyzed with \npatient -level data to provide conclusive evidence!Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ERare Systemic Harms Compared With the General Population:\nAllergan follow -up2 years\nMentor follow -up7yearsPossible Associations between Implants\nand Rare Diseases\nManufacturerStudy \nEventsStudy Event Rate \n(Per 10,000 Person Yr)General Population Event \nRate\n(Per 10,000 Person Yr) SIRSIR 95% CIP Value\nFibromyalgia Allergan 9 1.8 112.8 0.02 0.01 \u20130.03 < 0.001\nMentor 307 28.4 112.8 0.25 0.22 \u20130.28 < 0.001\nRheumatoid arthritis Allergan 4 0.8 5.4 0.15 0.04 \u20130.38 < 0.001\nMentor 349 32.2 5.4 5.96 5.35 \u20136.62 < 0.001\nScleroderma Mentor 46 4.2 0.6 7.00 5.12 \u20139.34 < 0.001\nSjogren syndrome Mentor 62 5.7 0.7 8.14 6.24 \u201310.44 < 0.001\nSystemic lupus erythematosus Allergan 3 0.6 5.4 0.11 0.02 \u20130.32 < 0.001\nMentor 66 6.0 5.4 1.11 0.86 \u20131.41 0.398\nCancer Allergan 80 16.0 41.3 0.39 0.31 \u20130.48 < 0.001\nMentor 532 63.8 41.3 1.54 1.42 \u20131.68 < 0.001\nBreast cancer Mentor 116 13.9 12.5 1.11 0.92 \u20131.33 0.26\nLung cancer Mentor 5 0.6 5.2 0.12 0.04 \u20130.27 < 0.001\nBrain cancer Mentor 3 0.4 0.6 0.67 0.14 \u20131.95 0.639\nMelanoma Mentor 65 7.8 2.1 3.71 2.87 \u20134.73 < 0.001\nNeurological disorder Allergan 18 3.6 22.5 0.16 0.09 \u20130.25 < 0.001\nMentor 394 35.8 22.5 1.59 1.44 \u20131.76 < 0.001\nMultiple sclerosis Mentor 47 4.3 2.5 1.72 1.26 \u20132.29 0.001\nMyositis Mentor 17 1.5 0.8 1.88 1.09 \u20133.00 0.018Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Implant Associated Anaplastic Large Cell \nLymphoma (BIA -ALCL)\n\u00a7Approximately 10.000.000 implant carrier\n\u00a7Rare disease, 3% of Non -Hodgkin Lymphomas, 0.04 -0.5% of all malignant breast \ndiseases\n\u00a71:3.000 \u201330.000 in women with textured implants (caveat: underreporting!)\n\u00a7Estimated incidence 0.6 -1.2 / 100.000 women with implants (median age: 54 y)\n\u00a7Mainly associated with textured implants\n\u00a7Interval to diagnosis: 8 years (median)\n\u00a7Clinical symptoms\n\u00a7Swelling and seroma. (60%)\n\u00a7Solid tumor (17%)\n\u00a7Seroma and solid tumor (20%)\n\u00a7Histology: CD30+ / ALK -T-Cell Lymphoma\n\u00a7Compulsory registration as SAE ( \u00a73 MPSV to BfArM)Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\u00a7The cause of BIA -ALCL is not established; however, it has been proposed that lymphomagenesis may \nbe driven by a chronic in\ufb02ammatory reaction induced by capsule contents or surface. The risk for \nBIA-ALCL has been shown to be significantly higher for implants with grade 3 and 4 surfaces.BIA-ALCL -Surfaces of Breast Implants\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBIA-ALCL \u2013Diagnosis \nOxford\nLoE GR AGO\n\u00a7Breast US ( assessment ofnew seromas > 1 year after implant\ninsert , solid lesion (sensitivity : 84%, specificity : 75%)3a D ++\n\u00a7Mamma -MRT in confirmed cases 3a D ++\n\u00a7Staging (Imaging, e.g. CT, PET -CT) 3a D ++\n\u00a7Cytology oflate seromas\n\u00a7> 50 ml \n\u00a7Complete assessment\n\u00a7flow -cytology (T-cellclone )\n\u00a7BIA-ALCL specific cytologic diagnostic (CD 30+)3a D ++\n\u00a7Core needle biopsy in solid lesions\n\u00a7Lymphoma assessment of resected tissue and histologic staging3a D ++\n\u00a7Documentation of the implant (manufacturer, size, volume, surface, \nBatch -number) and enter in registry 5 D ++Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBIA-ALCL \u2013Therapy\nOxford\nLoE GR AGO\n\u00a7Implant resection and complete capsulectomy including\ntumorectomy3a C ++\n\u00a7Resection of suspicious lymph nodes, no routine use of \nsentinel -node -biopsy, no axillary dissection4 D ++\n\u00a7Polychemotherapy ( e.g. CHOP) in cases of extra capsular \nextension4 D +\n\u00a7Radiotherapy in unresectable tumors 5 D +/-\n\u00a7Case discussion in an interdisciplinary tumor board in the \npresence of a specialist for lymphomas5 D ++Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EDiagnostic Pathways and Assessment\nLate Seroma\n> 12 months since \n1stimplant\nUltrasound\nBreast + Axilla\nMass\nCore biopsy\n(any solid mass)\nHistology\nImmunohistology\nCapsule -related \nsolid tumor mass\n+/-\nMammogram\n(not useful if age < 40 yrs)\nEffusion\nFNA fluid\n(take > 50 ml)\nCytology\nimmune -cytology \nfor CD30\nPathological\nskin lesion\nPathological\nlymph nodes\nLymphomata\nB-SymptomsSuspicion Imaging\nSkin biopsy\nPET CT\n(r/o systemic disease)\nMRI Breast\n(if diagnosis is \nindeterminate)\nFindings Samples Assessment\nFlow -Cytometry\nClonality studies\n(for T -cell rearragenemnts)\nIndeterminate?\nSuspicious?\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBIA-ALCL Treatment Pathways\nBIA-ALCL\nconfirmed\nReferral to\nexperienced\nbreast cancer \ncenter\nEn-bloc \ncapsulectomy and \ncomplete excision \n(mass)\nStage I : No further \ntreatment\nClinical follow -up \n(ultrasound / CT \nscan) 3 \u20136 m for 2 y, \nafterwards for 5 y\nIndeterminate\nPET-CT & \nbreast MRI\n+/-other breast\n+/-axilla biopsy \n(SNB not recommended)\nStage II -IV:\nConsider adjuvant \ntreatment\nPET-CT if\nsymptomatic\nNegative for \nBIA-ALCLOutcome Workup\nClinical suspicion \nremains\nChemo -\nimmunotherapySurgery Adjuvant Therapy Follow -up\nTreatment of infection / \nbenign seroma (serial \naspiration, implant \nexchange with \ncapsulectomy)Options: Further imaging \nUS/MRI /Repeat FNAC , \nTertiary referral\nRoutine bloods\n(+/- bone marrow bx)\nMTD Discussion\nConsider diagnostic \ncapsulectomy\nRadiotherapy for \npositive margins / \nirresectable thoracic \nwall infiltration but \nN0/M0Histological Staging \n(Clemens et al. 2016)\nMTD \nDiscussion\nReports to BfArM , \nmanufacturer, DGPR\u00c4C, \nPROFILE database (FDA)\nTreatment as per \nsystemic ALCL regimes\n24-36 Gyin 15\nfractionsOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ETNM Staging of BIA -ALCL\nTNM -\nKategorieDefinition\nTumor extent\n(cT/pT)T1Confined to seroma or a layer on \nluminal side of capsule\nT2 Early capsule infiltration\nT3Cell aggregates or sheets infiltrating \nthe capsule\nT4Lymphoma infiltrates beyond the \ncapsule\nRegional lymph \nnodes (cN/pN)N0 No lymph node involvement\nN1 One regional lymph node positive\nN2Multiple regional lymph nodes \npositive\nMetastasis\n(cM/pM)M0 No distant spread\nM1Spread to other organs or distant \nsitesStage Definition\nIA T1 N0 M0\nTB T2 N0 M0\nTC T3 N0 M0\nIIA T4 N0 M0\nIIB T1-3 N1 M0\nIII T4 N1 -2 M0\nIV T any N any M1\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\u00a7Despite an increase of BIA -ALCL in association with texture implants\nthe use of textured implants is still permitted!\n\u201eFor the moment, textured implants can safely continue to be used with patient's fully informed \nconsent, and that women that have these type of implants already in place don't need to remove \nor substitute them, which would undoubtedly cause harm to many tens of thousands of women, \nto prevent an exceptionally rare, largely curable and currently poorly understood disease.\"BIA-ALCL \u2013EUSOMA -Recommendation\nOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn Zusammen -\narbeit mit:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Implant Capsule -Associated\nSquamous Cell Carcinoma\n\u00a7Squamous cell carcinomas associated with breast implant augmentation are\nexceedingly rare (11 cases reported).\n\u00a7Breast implant capsule -associated squamous cell carcinoma occurs in patients\nwith long standing breast implant augmentations (>11 years).\n\u00a7Presentation with breast enlargement/swelling and pain, skin changes\n\u00a73/11 pts. developed metastatic disease within 1 year.\nThe reported metastatic sites include axilla, soft tissue (arm and leg), liver, lung,\nmediastinum, retroperitoneum, and leptomeninges.\n\u00a74/5 patients with follow -up data showed a correlation between extracapsular\nextension and development of metastases (1- 8 months; mean 4.25 months).\n\u00a7In this limited cohort it is difficult to ascribe prognostic factors, but extracapsular\nextension does appear to be a concerning finding.Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EImplant Lodge, Tissue Replacement Techniques and \nMeshes (Details ofImplant Reconstruction)\nOxford\nLoE GR AGO\n\u00a7The prepectoral lodge is superior to the subpectoral\nlodge3a C +/-\n\u00a7Acellular dermal matrix (ADM)\n\u00a7subpectoral 1b A +/-\n\u00a7prepectoral 2b B +/-\n\u00a7Synthetic meshes\n\u00a7subpectoral 2b B +/-\n\u00a7prepectoral 2b B +/-Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ELipotransfer \nOxford\nLoE GR AGO\n\u00a7Lipotransfer following mastectomy and \nreconstruction2a B +\n\u00a7Lipotransfer after BCS* 2a B +\n\u00a7Autologous adipose derived stem cells (ASCs) -\nenriched fat grafting vs. without stem cells 2a B +/-\n*BCS: Breast Conserving SurgeryOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EPostmastectomy Pedicled Reconstruction\nOxford\nLoE GR AGO\nBreast reconstruction (BR) with autologous tissue\n\u00a7TRAM, latissimus -dorsi -flap (both can be \nperformed as a muscle -sparing technique)2a C +\n\u00a7Delayed TRAM in patients at high -risk 3a B +\n\u00a7Ipsilateral pedicled TRAM 2a B +\n\u00a7Omentum Flap 4 C +/-\n\u00a7Radiotherapy :\n\u00a7BR following radiotherapy 2a B +\n\u00a7BR prior to radiotherapy 2a B +/-\n\u00a7(higher rates offibrosis , wound healing problems , \nliponec rosisand reduced aesthetic outcome )Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EFree Flaps for Reconstruction\n*ICG: indocyanin greenOxford\nLoE GR AGO\nType offree flap\n\u00a7DIEP 2a B +\n\u00a7Free TRAM 2a B +\n\u00a7SIEA 3a C +/-\n\u00a7Glutealis flaps (SGAP -/ IGAP, FCI) 4 C +/-\n\u00a7Free gracilis flap (TMG) 4 C +/-\n\u00a7Omentum Flap 4 C +/-\n\u00a7 Use ofICG* toassess flap perfusion 2a B +\nAdvantages\n\u00a7DIEP and free TRAM are potentially muscle -sparing procedures. DIEP has a lower rate of \nabdominal hernias, especially in obesity\nDisadvantages\n\u00a7Time -and personnel consuming microsurgical procedure s\n\u00a7Intensified postoperative monitoringOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EPedicled versus Free Tissue Transfer\nOxford\nLoE GR AGO\n\u00a7Muscle -sparing techniques and accuracy\nofabdominal wall closure lead tolow rates oflate\ndonor site complications independent ofmethod\nused3a A ++\n\u00a7Autologous abdominal -based reconstructions have \nhighest satisfaction rates (PROM)\n\u00a7Donor site morbidity (e.g. impaired muscle \nfunction) has to be taken into consideration with\nall flap technique sOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ESkin -/ Nipple -Sparing Mastectomy (SSM / NSM)\nand Reconstruction\n*ICG = Indocyanine GreenOxford\nLoE GR AGO\n\u00a7Skin -/nipple -sparing Maste ctomy (SSM / NSM)\n\u00a7Safe (same recurrence rate assimple mastectomy ) 2b B ++\n\u00a7Higher QoL for patients 2b B ++\n\u00a7NAC can be preserved under special conditions 2b B ++\n\u00a7Feasible after mastopexy / reduction mammoplasty 4 C ++\n\u00a7Use of ICG* to predict necrosis of the skin 1b B +\n\u00a7Skin incisions -different possibilities:\n\u00a7Periareolar \n\u00a7Hemi -periareolar with / without medial / lateral extension\n\u00a7Reduction pattern: \u201einverted -T\u201c or vertical\n\u00a7Inferior lateral approach, inframammary fold\n\u00a7Lowest incidence of complications 2b B +Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn Zusammen -\narbeit mit:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EMastectomy + Reconstruction \nRisk ofcomplications with theaddition ofradiotherapy\nAutologous reconstruction Implant -based reconstruction\nEndpoint Risk Ratio with\naddition of\nradiotherapy\n(95% -CI)Endpoint Risk Ratio with\naddition of\nradiotherapy\n(95% -CI)\nWound infection 1.14 (NA) Wound infection 2.49 (1.43,4.35)\nSecondary surgery 1.62 (1.06, 2.48) Secondary surgery 1.64 (1.17 -2.31)\nReconstructive failure 0.80 (NA) Reconstructive failure 2.89 (1.30,6.39)\nVolume loss 8.16 (4.26,15.63)\nFat necrosis 1.91 (1.45, 2.52)\nCapsular contracture 5.17 (1.93,13.80)\nME skin flap nekrosis 1.62 (1.27, 2.08)\nImplant extrusion 3.44 (2.18, 5.43)\nFurther risks ofautologous reconstruction :\nDistorsion ofbreast shape , fibrosis , vascular complications\nAutologous reconstruction isfavored in terms ofpatient satisfaction and and assessment ofthe\naesthetic outcome . \nNA: not availableOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EPrevention and Therapy of Capsular Contracture\nOxford\nLoE GR AGO\n\u25aa Prevention\n\u25aaTextured implantats (Caveat: BIA -ALCL) 1a A+\n\u25aaAcellular Dermal Matrix (ADM) vs. nil 2a B+\n\u25aaSynthetic mesh vs. nil 3a C+\n\u25aaTopical antibiotics / antiseptics 2a B+\n\u25aaPVP (Povidone -Iodine) 2a B +/-\n\u25aaLeukotriene -antagonists 2a B +/-\n\u25aaBreast massage 3a C-\n\u25aa Surgical interventions\n\u25aaCapsulectomy 3b C+\n\u25aaCapsulotomy (Caveat: exclusion of BIA -ALCL) 3b C+Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ESeroma after Implant -Based Reconstruction I\nOxford\nLoE GR\n\u00a7Incidence : approx . 5-10 % (2 -50 %) 2a B\nInfluencing factors :\n\u00a7History ofradiation increases risk (RR approx . 3) 2a B\n\u00a7Obesity increases risk (e.g. BMI > 30 vs. < 30; RR approx . 3) 2a B\n\u00a7Use ofADM increases risk (RR approx . 3) 2a B\n\u00a7Use ofexpander with smooth surface increases risk (RR\napprox . 5)3b C\n\u00a7History ofneoadj . Chemotherapy doesn \u00b4tseem toincrease\nrisk2a B\n\u00a7Prepectoral lodge doesn \u00b4tseem toincrease risk 2b BOncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ESeroma after Implant -Based Reconstruction II\nOxford\nLoE GR AGO\nPrevention \n\u00a7Drain 3b C +\n\u00a7Drain removal at < 30ml per 24 hours 2b B +\nTherapy \n\u00a7Evacuation of serma by FNA or re -insertion of drain 4 C +\n\u00a7Dressings 5 D +/-\n\u00a7Revision surgery with capsulectcomy (ultima ratio) 5 D +\n\u00a7Revision surgery with implant removal (ultima ratio) 5 D +Oncoplastic and Reconstructive Surgerywww.ago -online.de\nIn collaboration\nwith:\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ESurgical Prevention\nOxford\nLoE GR AGO\u00a7Risk-reducing unilateral or bilateral mastectomy \n(RRME) without the presence of clearly defined \ngenetic risk factors2a B -*\u00a7Axillary dissection orSentinel lymph node biopsy\nduring RRME2a B --\n*study participation recommendedOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSurgical Prevention for Healthy\nFemale BRCA1/2 Mutation Carriers\nOxfordLoEGR AGO\u00a7Risk-reducing bilateral salpingo -oophorectomy \n(RR-BSO)**2a B\n\u00a7Reduces OvCa incidence and mortality ++*\n\u00a7Reduces overall mortality ++*\u00a7Risk-reducing bilateral mastectomy (RR -BM)\n\u00a7Reduces BC incidence 2b B +*\n\u00a7Reduces BC mortality in BRCA1 mutation carriers*** 2b B +*\n* Study participation recommended\n** The RR -BSO is recommended from about 35 years for BRCA1 and from about 40 years for BRCA2 mutation carriers, \ntaking into account the age of ovarian cancer diagnosis in the family and the family planning status.\n*** No reduction in mortality could be shown for BRCA2 mutation carriers. RRBM counselling should be individualised .Oncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRisk-reducing Interventions forBRCA1/2 Female\nMutation Carriers Affected byBreast Cancer\nOxford\nLoE GR AGO\u00a7Risk-reducing bilateral salpingo -oophorectomy  (RR -BSO) 2b B +*\n\u00a7 Reduces OvCa incidence and mortality\n\u00a7 Reduces overall mortality\n(contradictory results forreduction ofcl BC incidence )\u00a7Prophylactic contralateral mastectomy (RR -CM)* 2b B +*\n\u00a7 Reduces BC incidence and mortality\u00a7Tamoxifen ( reduces contralateral BC incidence ) 2b B +/-*\u00a7Indication forRR-CM should consider age, age at onset offirst breast\ncancer in affected gene2a B ++*\u00a7RR-BM after ovarian cancer 4 C +/-**\n*Study participation recommended\n** Depends on tumor stage (FIGO I/II), recurrence free interval (\u2265 5 yrs.), ageOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2021.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1EAdjuvant Endocrine- based Therapy in pre -\nand postmenopausal Patients\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deAdjuvant Endocrine Therapy in \nPre-and Postmenopausal Patients \n\u00a7Versions 2002 \u20132022:\nBauerfeind / Dall / Diel / Fasching / Fersis / Fehm / Friedrich / Friedrichs / \nGerber / G\u00f6ring / Hanf / Harbeck / Huober / Jackisch / Lisboa / Loibl / L\u00fcck\n/ Lux / Maass / von Minckwitz / M\u00f6bus / M\u00fcller / Nitz / Oberhoff / \nSchaller / Scharl / Schneeweiss / Sch\u00fctz / Solomeyer / Stickeler / \nThomssen / Untch\n\u00a7Version 2023:\nGerber / JackischAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deAssessment of\nSteroid Hormone Receptor Status\nOxford LoE: 1 GR: A AGO: ++\nEndocrine responsive \u2013hormone receptor positive\nImmunhistology (ER and/or PgR)0%pos. cells:endocrine resistant1\u201310%pos. cells:possibly endocrine sensitive> 10%pos. cells:endocrine sensitiveUnknown hormone receptor status:endocrine sensitiveIf ER negative / PR positive (> 10% positive cells): reassess IHC statusAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deAdjuvant Endocrine Therapy\nAssessment of Menopausal Status\nOxford\nLoE GR AGOAssessment of menopausal status:\u00a7Menstruation history ++\u00a7FSH, E2 ++\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deAdjuvant Endocrine Therapy\nOxford\nLoE GR AGO\u00a7Endocrine responsive 1a A ++\u00a7Endocrine doubtful responsiveness 3b D+\u00a7Endocrine therapy \nsequentially after CT2a B +\u00a7Endocrine therapy simultaneous to anti -HER2 \ntherapy (w/o chemotherapy)2b B +\u00a7Not sensitiv toendocrine therapy 1a A --Adjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deGeneral Principles in \nAdjuvant Endocrine Therapy AGO ++\n\u00a7Adjuvant endocrine therapy is divided into initial therapy (years 1 -5) and \nextended adjuvant therapy (EAT, years 6 -10+).\n\u00a7Standard treatment duration is 5 years.\n\u00a7Extended therapy should be considered based on individual risks and \nbenefits.\n\u00a7Duration, choice & sequence of AI or Tam mainly depend on menopausal \nstatus, tolerability, and risk of recurrence.\n\u00a7Switch to another better tolerated endocrine treatment (Tam or AI) is \nbetter than stopping endocrine therapy altogether. \n\u00a7AI should be used as first treatment in patients, in case of lobular cancers \nand / or high risk of recurrence.\n\u00a7To date, there is no sufficiently validated biomarker for identification of \npatients at risk for early versus late recurrence.Adjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nTEXT / SOFT Joint Analysis\nTamoxifen 20 mg/day\n+ OFS* (n = 1328)Premenopausal\nPatients with HR+ BC\n\u2264 12 wks after \nsurgery\n(N = 2672)\n*OFS\n\u25aaTEXT: triptorelin 3.75 \nmg IM every 28 days for \n6 mos, then optional \nbilateral oophorectomy \nor irradiation\n\u25aaSOFT: choice of methodTEXT\nExemestane 25 mg/day\n+OFS* (n = 1014)\nTamoxifen 20 mg/dayPremenopausal\npatients with HR+ \nBC\n\u2264 12 wks after \nsurgery\n(if no chemo) or\n\u2264 8 mos after chemo\n(N = 3066)SOFTTamoxifen + OFS*\n(n = 2344)\nTamoxifen 20 mg/day\n+ OFS* (n = 1016)Exemestane + OFS*\n(n = 2346)Exemestane 25 mg/day\n+OFS* (n = 1332)Joint Analysis\n5 yrs\nNach Pagani O, et al. N Eng J Med, 371(2) 2014Median follow -up: 5.7 yrsAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.dePremenopausal Patients\nInitial Adjuvant Endocrine Therapy (Year 1- 5)\nOFS: ovarian function suppression; \n*aslong astolerated and thepatient isclearly premenopausal after chemotherapy if ovarian function resumes\nwithin 24 months . The application of chemotherapy in the trials served as surrogate for high recurrence risk\n# in premopausal women AI only in combination with OFS Oxford\nLoE GR AGO\u00a7Low recurrence risk:\n\u00a7Tamoxifen for 5 years 1a A ++\u00a7Increased recurrence risk:\n\u00a7OFS 2 -5 years *+ tamoxifen for 5 years 1a A ++\n\u00a7OFS# +AI for 5 years 1a A ++\u00a7GnRHa monotherapie\n(If severe contraindications for Tam exist, compared to no therapy)1a B+\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nAdjuvant endocrine therapy in \npremenopausal patients (OFS + TAM / AI) \nEBCTCG: Lancet Oncol.  2022;23:382 -392 Adjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nEBCTCG: Lancet Oncol . 2022;23:382 -392 Adjuvant endocrine therapy in \npremenopausal patients (OFS + TAM / AI) \nAny recurrence Distant recurrence\nBreast cancer\nmortalityAll-case mortality\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.dePostmenopausal Patients\nInitial Adjuvant Endocrine Therapy (Years 1- 5)\nOxford\nLoE GR AGO\u00a7Aromatase inhibitor (AI) for first 5 years 1a A ++\n\u00a7Non steroidal -AI in lobular cancer 2b B+\n\u00a7High risk of recurrence 2b B+\u00a7Sequential therapy for first 5 years * 1a A ++\n\u00a7Tam (2 -3 yrs.) followed by AI to complete 5 years     1a A ++\n\u00a7AI (2 -3 yrs.) followed by tamoxifen to complete 5 years 1b C ++\u00a7Tamoxifen 20 mg/d for 5 years** 1a A+\n* in postmenopausal patients, AI should be integrated in the first five years \n** Tamoxifen may be offered to individual patients with very low risk of recurrence or if contraindications for AI are \npresentAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nAromatase Inhibitor vs. Tamoxifen vs. \nSequential Therapy -5 years up-front Therapy\nAromatase inhibitors versus tamoxifen in early breast cancer: patient -level meta -analysis of the randomised trials. \nEarly Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2015 Oct 3;386(10001):1341 -52.\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deAdjuvante Endocrine -Based Therapy with CDK4/6 \nInhibitors and PARP Inhibitors\nOxford\nLoE GR AGOIn patients with increased risk of recurrence and characteristics corresponding to study criteria\u00a7Abemaciclib for 2 years* 1b B+\u00a7Olaparib for1 year in patients with gBRCA1/2 \nmutations **1b B ++\n* corresponding to MonarchE -Study\n** corresponding to OlympiA -StudyAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nMittendorf EA, J Clin Oncol 2011;29:1956 -1962 \nMarm\u00e9 F, et al. EurJ Cancer 2021;153:203 -212Clinical Stage\nI0 T1N0; T0N1mi, T1N1mi\nIIA 0 T0N1; T1N1; T2N0\nIIB 1 T2N1; T3N0\nIIIA 1 T0-2N2\nIIIB 2 T4N0 -2\nIIIC 2 Any T N3Pathologic Stage\n00 T0/isN0\nI0 T1N0; T0N1mi, T1N1mi\nIIA 1 T0N1; T1N1; T2N0\nIIB 1 T2N1; T3N0\nIIIA 1 T0-2 N2\nIIIB 1 T4 N0 -N2\nIIIC 2 Any T N3 Tumor Biologic Factors\nER negative 1\nNuclear grade 3 1Point assignment for CPS+EG score\nGBG / AGO B meta -database\n(N = 2454 HR+ / HER2 -)\n25%How to calculate CPS+EG Score?\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.dePremenopausal Patients \nExtended Adjuvant Endocrine Therapy (EAT) (Years 6 \u201310)\nOxford\nLoE GR AGOIn case of high risk of recurrence\u00a75 years tamoxifen after 5 years tamoxifen 1a A ++\u00a72,5\u20135 years AI after 5 years tamoxifen in initially \npremenopausal patients who obtain validated \npostmenopausal status during course of therapy1b B+\u00a75 years tamoxifen after 5 years of endocrine therapy + OFS 5D +\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.dePostmenopausal Patients\nExtended Adjuvant Endocrine Therapy (EAT) (Years 6 \u201310)\nOxford\nLoE GR AGOIn case of high risk of recurrence\u00a75 years tamoxifen after 5 years tamoxifen 1a A+\u00a72\u20135 years AI after 5 years tamoxifen 1a A ++\u00a7After initial AI -containing therapy (upfront or switch),\nprolongation of endocrine therapy with AI in total for 7 -8 years*\n\u00a7 High -risk of recurrence and good tolerability of AI, good bone health 1a A+\n\u00a7 Low -risk, poor tolerabilty of AI 1a A-\u00a7Interruption of endocrine treatment up to 3 months during EAT \nwith AI1b B +/-\n*Up to date, no impact on OSAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nExtended Aromatase Inhibitor Treatment following 5 or more Years of \nEndocrine Therapy: A Metaanalysis of 22192 Women in 11 Randomised \nTrials (EBCTCG)\n1 (new primary breast cancer, local and distant recurrence)Adjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nExtended Adjuvant Treatment, Overiew\nBraun: Tamoxifen\nGr\u00fcn: Tamoxifen \noder AI\nBlau: AI\nGestreift: Zeit der\nrandomisierten \nIntervention vs \nkeine \nTherapie od. \nPlazebo\n*: Rando -\nmisierungs-\nzeitpunkt\n\u00a7: MA17R nach 5\nJahren AI mit\n/ohne Tam zuvorStudie Therapien De-facto -\nVergleich\ne (Jahre)HR f\u00fcr \nDFSAI-\nTherapie \nJahre 0 -\n5 (%)\nJahre nach \nDiagnose12 345 6 7 8 9 10 15\nStudien mit Tamoxifen nach 5 Jahren Tamoxifen\nATLAS * 5 vs 10 0,75 \u20130,99 \n\u01970\nATTOM * 5 vs 10 0,75 \u20130,99 \n\u01970\nStudien mit AI nach 5 Jahren Tamoxifen\nMA. 17 * 5 vs 10 0,57 0\nNSAPB B -33 * 5 vs 10 0,68 0\nABCSG 6a * 5 vs 8 0,62 0\nStudien mit erweiterter AI -Th. Nach 5 Jahren endokrin inkl. AI\nDATA * 6 vs 9 0,79 100\nNSABP B -42 * 5 vs 10 0,85 100\nGIM 4 5 vs 7 0,78 100\nMA. 17R \u00a7 10 vs 15 0,66 100\nStudien bzgl. optimaler Dauer in Jahr 5 -10\nBOOG 2006 -\n05 IDEAL* 7,5 vs 10 0,92 88\nABCSG 16 * 7 vs 10 1,007 49\nSOLE Cont vs \nunterbr1,08 81Adjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nFactors indicating a clinical benefit from EAT:\n\u00a7Adjuvant tamoxifen therapy only\n\u00a7Condition after chemotherapy (indicating high risk)\n\u00a7Positive lymph node status and / or T2 / T3 tumors\n\u00a7Elevated risk of recurrence based on immunohistochemical criteria or based on\nmulti -gene expression assays\n\u00a7High CTS5 -score\n\u00a7BCI (H/I) (Breast Cancer Index)\nFurther decision criteria:\n\u00a7Wish of patient\n\u00a7up to now well tolerated AI therapy,\n\u00a7good bone health\n\u00a7younger age\n\u00a7adherenceDecision Criteria for Extended Adjuvant \nTherapy\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.deOvarian Protection with GnRHa and Fertility Preservation in \nPremenopausal Patients Receiving (Neo) -Adjuvant \nChemotherapy (CT) \nOxford\nLoE GR AGO\u00a7CTx + GnRHa\n(preservation of ovarian function)\n(GnRHa application > 2 weeks prior to chemo -\ntherapy, independent of hormone receptor\nstatus)1a A+\u00a7CTx + GnRHa\n(preservation of fertility)2a B +/-\u00a7Fertility preservation counselling including\nreferral ofall potential patients to appropriate\nreproductive specialists (ART; further informationhttps://fertiprotekt.com/english ; S2k guideline\nFertility protection in patients with malignancies)++\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7Pretreatment approaches topreserve fertility\nGnRHa 1a A ++\nCryopreservation of ovarian tissue with\nsubsequent transplantation24D +\nCryopreservation of oocytes (unfertilized / \nfertilized ) after ovarian stimulation2a C+\u00a7ART after (neo -)adjuvant systemic treatment 4C +\n1 Evidence is limited due tostudies with poor quality e.g. (prospective randomized trials arenot feasible)\n2Risk ofrelapse caused bytransplantation of ovarian tissue containing tumor cells from theoriginal malignancy ; removal oftransplanted\novarian tissue isnecessary in patients with BRCA1/2 mutations due toincreased risk of ovarian cancerFertility Preservation and Assisted Reproductive Therapy (ART)\n-Oncologic safety1 -\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant endocrine therapy in premenopausal\npatients with thedesire togetpregnant\nTemporary interruption of adjuvant endocrine treatment (ET) after 18 -30 \nmonth of ET, allowing a wash out period of 3 months, the attempt to get \npregnant in a period of up to 2 years for those women with the desire to get \npregnant does not impact short -term breast cancer  outcome.\nAGO +\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant endocrine therapy in premenopausal\npatients with thedesire togetpregnant\nN=516\nMedian 41 mo\n\u2022Premenopausal women (\u226442 years at study entry) wishing to get pregnant\n\u2022At least 18 months and no more than 30 months of prior adjuvant ET\nforstage I-III HR+ BC\n\u2022Up to 2 years to attempt pregnancy, conceive, deliver, and breastfeed, including\n\u20223 - months washout period\n\u2022If no pregnancy by 1 y., fertility assessment recommended\n\u2022ET resumption strongly recommended after pregnancy to complete planned 5 -10 yrs.Study designAGO +\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2023.1E\nwww.ago -online.de\nAdjuvant endocrine therapy in premenopausal\npatients with thedesire togetpregnant\nBREAST CANCER OUTCOMES \u2013 POSITIVE & SOFT/TEXTPregnancies outcome : 317 (64% of all women) had at least one live birth, 62% \nreported breast feeding, 2% showed birth defects\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n3-YEAR BCFI CUMULATIVE INCIDENCE \u2013POSITIVE onlyAdjuvant endocrine therapy in premenopausal\npatients with thedesire togetpregnant\nAdjuvant Endocrine-based Therapy in pre- and postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1 \nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E Adjuvant Cytotoxic and \nTargeted Therapy\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant Cytotoxic and Targeted Therapy\n\u00a7Versions 2002 \u20132022:\nAlbert / Dall / Fasching / Fehm / Harbeck / Jackisch /Janni / K\u00fcmmel / \nLoibl / Lux / von Minckwitz / M\u00f6bus / M\u00fcller / Nitz / Rody / Schmidt / \nSchneeweiss / Simon / Sch\u00fctz / Solomayer / Stickeler / Thill / Thomssen / \nUntch\n\u00a7Version 202 3:\nGluz / Thill\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deStrategies forDifferentiated\nSystemic Treatment in theCurative Situation\nAGO\nIf chemotherapy is indicated systemic treatment before surgery (neoadjuvant) should be preferred; \nstudy participation recommended\n\u00a7HR+ / HER2 -and \u201elow recurrence -risk\u201d\n\u00a7Endocrine therapy without chemotherapy ++\n\u00a7HR+ / HER2 -and \u201ehigh recurrence -risk\u201d\n\u00a7Endocrine / endocrine -based therapy (abemaciclib) ++\n\u00a7Patients with indication for chemo -endocrine therapy*\n\u00a7Conventionally dosed AT-based chemotherapy (q3w) +\n\u00a7Dose dense chemotherapy (including weekly schedule) ++\n\u00a7Triple -negative (TNBC)\n\u00a7Conventional dosed AT -based chemotherapy (q3w) +\n\u00a7Sequential AT-based chemotherapy (incl. weekly schedule ) ++\n\u00a7Neoadjuvant platinum -containing chemotherapy +\n\u00a7Neoadjuvant platinum -containing chemotherapy with ICPI (Pembrolizumab) +\n\u00a7gBRCA1/2mut (HR+/HER -orTNBC respectively1)\n\u00a7Olaparib1postneoadjuvant ++\n\u00a7HER2+\n\u00a7Trastuzumab (plus Pertuzumab in N+ or NACT) ++\n\u00a7Sequential AT -based chemotherapy with concurrent T + anti -HER2 therapy ++\n\u00a7Anthracycline -free, chemotherapy + anti -HER2 therapy ++\n1according to approval or study population (if not approved), *see prognosis chapterAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLee Index\n\u2022This index was developed in 11,701 community -dwelling adults from theeastern , western and central United States who were\ninterviewed in theHealth Retirement Survey in 1998 ( mean age67, 57% female , 81% white , 12% 4 -year mortality ).\n\u2022The index was internally validated in 8009 Health Retirement Survey interviewees from thesouthern United States ( mean age67, 57% \nfemale , 71% white , 13% 4 -year mortality ) and externally validated in 7042 English Longitudinal Study on Ageing interviewees .\n\u2022Discrimination : This riskcalculator sorts patients who died from patients who lived correctly 82% ofthetime (c -statistic ). The life\nexpectancy calculator sorts patients who lived longer from patients who lived shorter correctly 78-80% ofthetime in thevalidation\nstudies\n\u2022Calibration : The model was well calibrated across all risklevels with less than 3% difference between estimated and actual mortality\nrates .\nSchonberg Index 50%                             60%                                70%                             80%                       90%\n\u2022This index was developed in 16,077 community dwelling older adults who responded tothe1997 -2000 National Health Interview \n(NHIS) (27% >80 years old, 60% female , 85% white , 17% 5 -year mortality )\n\u2022The index was internally validated in a random sample of8038 from respondents from thesame data source from 2001 -2004 and\nfollowed through 2006 (27% >80 years old, 60% female , 85% white , 17% 5 -year mortality ). The index was internally validated in 16,063 \nrespondents from theoriginal development cohort and 8,027 respondents from theoriginal validation cohort from 1997 -2000 and\nfollowed through 2011 (10 and 14-year mortality ).\n\u2022Discrimination : This riskcalculator sorts patients who died within 5 years from patients who lived correctly 75% ofthetime (c -\nstatistic ). The discrimination was thesame in theindependent validation study . For10 year and 14 year mortality thecalculator sorts\npatients correctly 73% and 72% ofthetime.\n\u2022Calibration : The model was well calibrated across all risklevels with less than 10% difference between estimated and actual mortality .\n50% 60%                           70%                           80%                          90%Lee-Schonberg Index\nhttps:// eprognosis.ucsf.edu /leeschonberg -result.php\npoor moderate good very good excellent\npoor moderate good very good excellentAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLee-Schonberg Index\nhttps:// eprognosis.ucsf.edu /leeschonberg -result.php\nRisk Calculator questions\n1. How oldisyour patient ?\n2.What isthesexofyour patient ?\n3.What isyour patient's ?\n4.Which best describes your patient's health in general ?\n5.Does your patient have chronic lung disease , such asemphysema orchronic bronchitis ?\n6.Has your patient ever had cancer (excluding minor skin cancers )?\n7.Does your patient have congestive heart failure ?\n8.Does your patient have diabetes orhigh blood sugar ?\n9.Which best describes your patient's cigarette use?\n10.Does your patient have difficulty walking 1/4 mile (several cityblocks ) without help from other people orspecial equipment ?\n11.During thepast 12 months , how many times was your patient hospitalized overnight ?\n12.Because ofa physical , mental oremotional problem , does your patient need thehelp ofothers in handling routine needs such aseveryday\nhousehold chores , doing necessary business , shopping , orgetting around forother purposes ?\n13.Because ofa health ormemory problem , does your patient have difficulty managing money -such aspaying bills and keeping track of\nexpenses ?\n14.Because ofa health ormemory problem , does your patient have difficulty with bathing orshowering ?\n15.Because ofa health problem , does your patient have difficulty pushing orpulling large objects like a living room chair ?Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant Chemotherapy : \nin Small, Node -Negative Tumors (T1)\u00a7Indication for chemotherapy in\n\u00a7TNBC\n\u00a7> 10 mm 2b B ++\n\u00a7> 5\u201310 mm 2b B+\n\u00a7\u2264 5 mm 2b B +/-\n\u00a7HER2+ in combination with trastuzumab\n\u00a7> 10 mm 1a A ++\n\u00a76\u201310 mm 2b B+\n\u00a7\u2264 5 mm 2b B +/-Oxford\nLoE GR AGONew slide !\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant Chemotherapy \nwithout Trastuzumab: Overview\nOxford\nLoE GR AGO\u00a7Dose -dense anthracycline / taxane based (incl. weekly) \nchemotherapy1a A ++\u00a7Conventional anthracycline / taxane based (q3w) 1a A +\u00a7\u201eTailored\u201c anthracycline -/ taxane based 1b B +/-\u00a7If anthracyclines are not a preferred option\n\u00a7Docetaxel plus cyclophosphamide 1b B ++\n\u00a7Paclitaxel mono weekly 1b B +/-\n\u00a7CMF 1a A +/-\u00a7Low -dose maintenance chemo 1b B -Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.de\nGray R et al., Lancet 2019\nEarly Breast Cancer Trialists\u2018 Cooperative Group (EBCTCG)\nIncreasing the dose -density of adjuvant chemotherapy: an EBCTCG meta -analysis\nSame chemotherapy drugs and doses (n = 10,004)\nRecurrence -free survival: 10 -y Gain 4.3% (95% -C.I. 2.2 \u20136.5)\n(RR = 0.83; 95% -C.I. 0.76 \u20130.91; p < 0.0001)\nOverall survival: 10 -y Gain 2.8% (95% -C.I. 0.8 \u20134.8)\n(RR = 0.86; 95% -C.I. 0.77 \u20130.96; p = 0.0054)\nER negative: 10-y Gain 4.7% (95% -C.I. 2.3 \u20137.1)\nER positive:  10-y Gain 3.1% (95% -C.I. 1.5 \u20134.7)Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deRecommended Dose -dense and / or Dose -escalated, \nSequential Adjuvant Chemotherapy \nOxford\nLoE GR AGODose-dense regimen \u00a7A60x 4\u00e0Pac 175 x 4\u00e0C600x 4 q2w 1b A ++\u00a7A60C q2w x 4 \u00e0Pac 175q2w x 4 1b B ++\u00a7E90C q2w x 4 \u00e0Pac 175q2w x 4 1b A ++\u00a7E90C q2w x 4 \u00e0Pac 80q1w x 12 1b B ++\u00a7NabPac 125 x 8-12 \u00e0E90C q2 (3)w x 4 1b B +Dose-dense and dose -escalated regimen  (N \u2265 4+)\u00a7E150\u00e0Pac 225\u00e0C2000 q2w 1b A ++Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deRecommended Conventional Regimens \nfor Adjuvant Chemotherapy\n*Extrapolation from doxorubicin trialsOxford\nLoE GR AGOAnthrazyklin-/ taxan -based regimen\n\u00a7*EC q3w x 4 \u00e0Pac q1w x 12 2b B ++\n\u00a7AC q3w x 4 \u00e0Pac q1w x 12 1b A ++\n\u00a7AC \u00e0Dqw3 A60C q3w x 4 \u00e0D100x 4 1b A +\n\u00a7*EC \u00e0Dqw3 E90C q3w x 4 \u00e0D100x 4 1b B +\n\u00a7DAC D75A50C q3w x 6 1b A +aAnthrazyklin-free regimen\n\u00a76 x DC corresponds to EC \u00e0D or 3 x (F)EC ->  \n3 x DocD75C600 x 6 1b B +\n\u00a74 x DC >> 4 x AC D75C600 x 4 1b B +\n\u00a7Pac mono P80q1w x 12 1b B +/-\n\u00a7CMF 1a A +/-Taxan-free regimen\n\u00a7EC (q3 -2w) x 4 -6 E90C600x 4-6 2b(a)B +Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant Chemotherapy\nOther Drugs\nOxford\nLoE GRAGO   \u00a7Capecitabine -containing regimen in TNBC*                            \n\u00a7adjuvant / neoadjuvant 1a A +/-\n\u00a7postneoadjuvant in non -pCR patients**\n\u00a7With non-pCR after A -T-containing chemotherapy 1a A ++\n\u00a7With non-pCR after platinum +/-pembrolizumab -containing therapy 5 D +/-\n\u00a7Anthracycline -free adjuvant therapy in TNBC ( combinationwithtaxan )1b B +\n\u00a7Anthracycline -based adjuvant therapy in TNBC 5 D +/-\u00a75-fluorouracile added to EC / AC 1b A --\n*DPYD genotyping fortheidentification ofa  DPD Deficiency\n** in stage II-III without platinum /pembrolizumab -based pretreatmentAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nVan Mackelenbergh M et al ., JCancer 2022\nEffects of capecitabine as part of neo -/ adjuvant chemotherapy\nMeta -analysis of individual patient data from 12 randomized trials (n = 15,457) \nHR for DFS overall    0.952 (95% -C.I. 0.895 -1.012, p = 0.115)\nX add.      0.888 (95% -C.I. 0.817 -0.965, p = 0.005)\nX instead 1.035 (95% -C.I. 0.945 -1.134, p = 0.455)\nHR for OS   overall    0.892 (95% -C.I. 0.824 -0.965, p = 0.005)\nX add.      0.837 (95% -C.I. 0.751 -0.933, p = 0.001)\nX instead 0.957 (95% -C.I. 0.853 -1.073, p = 0.450)\nSignificance only for TNBC overall  DFS 0.886 (95% -C.I. 0.789 -0.994, p = 0.040)\nOS  0.828 (95% -C.I. 0.720 -0.952, p = 0.008)\nX add.: DFS 0.818 (95% -C.I. 0.713 -0.938, p = 0.004)\nOS  0.778 (95% -C.I. 0.657 -0.921, p = 0.004 )Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant HER2- directed Treatment\nOxfordLoEGRAGO\u00a7Trastuzumab + Pertuzumab\n\u00a7pN+ 1ba B ++\n\u00a7pN- 1ba B +/-\u00a7Neratinib\n\u00a71 year after 1 year trastuzumab (HR -positive, stage II -III)1b B+\n\u00a71 year after trastuzumab /pertuzumab /T-DM1 at high risk and\nHR-positive5D +/-\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant Treatment\nwith Trastuzumab / Pertuzumab\nOxford\nLoE GR AGOStart of treatment\u00a7Simultaneously with taxanes 1a A ++\u00a7Sequentially up to 3 months after chemotherapy 1b B +Duration\u00a7For 1 year 1a A ++\u00a7For 0.5years (Trastuzumab) 1a A +\u00a7For 2 years 1b A -Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deAdjuvant Treatment with Trastuzumab +/ -\nPertuzumab: Chemotherapy regimen\nOxford\nLoE GR AGOTrastuzumab simultaneously with\u00a7paclitaxel / docetaxel after AC / EC 1a A ++\n\u00a7P q1w 12 x in pT < 2 cm, pN0 2b B +\n\u00a7docetaxel and carboplatin 1b A +Trastuzumab + Pertuzumab simultaneously with\u00a7paclitaxel q1w (or docetaxel q3w) after EC / AC 1b B ++\n\u00a7docetaxel+ carboplatin 1b B ++\n\u00a7taxan esdose-dense 2b B +Radiotherapy concurrently with Trastuzumab / Pertuzumab1a A ++Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deOxford\nLoE GR AGOHR positive (pCR and non-pCR)\u00a7Endocrine therapy according to menopausal state (s. chap. 10) 1a A ++\u00a7Abemaciclib for 2 yrs + endocrine therapy \nif high risk of recurrence11b B +\u00a7Olaparib for1 yr+ endocrine therapy (gBRCA1/2MUT, ifnon-\npCR and CPS-EG Score \u2265 3)21b A ++\u00a7Capecitabine (non -pCR) 1b A +/-Postneoadjuvant Therapy HR+ / HER2 -\n1 According inclusion criteria monarchE -study,\n2 According inclusion criteria OlympiA -studyAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.de\nMittendorf EA, J Clin Oncol 2011; \nMarm\u00e9 F, et al. Eur J Cancer 2016Clinical Stage\nI 0 T1N0; T0N1mi, T1N1mi\nIIA 0 T0N1; T1N1; T2N0\nIIB 1 T2N1; T3N0\nIIIA 1 T0-2N2\nIIIB 2 T4N0 -2\nIIIC 2 Any T N3Pathologic Stage\n0 0 T0/isN0\nI 0 T1N0; T0N1mi, T1N1mi\nIIA 1 T0N1; T1N1; T2N0\nIIB 1 T2N1; T3N0\nIIIA 1 T0-2 N2\nIIIB 1 T4 N0 -N2\nIIIC 2 Any T N3 Tumor Biologic Factors\nER negative 1\nNuclear grade 3 1Point assignment for CPS+EG score\nGBG/ AGO B meta -database\n(N=2454 HR+/HER2 -)\n25%How to calculate CPS+EG Score?\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.de\nAdjuvant / Post -Neoadjuvant Treatment with \nCDK4/6i \nIDFS: invasive disease -free survivalmonarchEPALLASPENELOPEBN5,6375,6001,250CDK4/6iAbemaciclibPalbociclibPalbociclib% of pts. with NACT37%n.r.100%Duration of CDK4/6i treatment24 mths24 mths12 mthsFollow-up42.0 mths24 mths43 mthsDiscontinuation rate28%42%20%Discontinuation rate due to  AECDKi17%27%5%IDFS-HR (95% -CI)0.664 (0.578-0.762)p < 0.00010.96 (0.81-1.14)p = 0.650.93 (0.74-1.16)p = 0.5252-yrs IDFS92.7% vs. 89.9%n.r.88% vs. 78%3-yrs IDFS89.2% vs. 84.4%88% vs. 89%81% vs. 78%4-yrs IDFS85.8% vs. 79.4%84.2% vs. 84.5%73% vs. 72%Adjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deOxford\nLoE GR AGOpCR\u00a7Continuation of pembrolizumab, if started with neoadj. \ntherapy (q3w for 9 courses)1b B +Non-pCR\u00a7Capecitabine (q3w upto8 courses )*\n\u00a7With non-pCR after A -T-containing chemotherapy * 1a A ++\n\u00a7With non -pCR after platinum +/ -pembrolizumab -containing therapy5 D +/-\n\u00a7Platinum salts (carboplatin orcisplatin ) q3w after AT -pretreatment1b B +/-\n\u00a7Olaparib (gBRCAMUT)11b A ++\u00a7Continuation of pembrolizumab , if started with neoadj . \ntherapy (q3w for 9 courses)1b B +Postneoadjuvant Therapy TNBC\n1according inclusion criteria ofOlympiA trial, advantage especially with platinum -free NACT\n*in stage II-III without platinum /pembrolizumab -based pretreatmentAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.dePostneoadjuvant Therapy HER2- positive\nOxford\nLoEGRAGO\npCR\u00a7Low risk: Trastuzumab (to complete 12 mths) 2a C ++\u00a7High risk (cN+): Trastuzumab + Pertuzumab (to complete 12 mths) 2b C+\u00a7Neratinib after 1 year Trastuzumab (HR -positive, high -risk, for example\nstage II -III)*2b B +/-non-pCR\u00a7T-DM1 1b B+\u00a7Trastuzumab + Pertuzumab (to complete 12 mths) 2b C+\u00a7Additional HER2 -directed therapy after 1 yr (extended adjuvant th.)\n\u00a7Neratinib after Trastuzumab (HR-positive , high risk ,forexample\nstage II-III)*2b B+\n\u00a7Neratinib after other HER2 -directed therapies (HR -positive, high risk\n(stage II -III)*)5D +/-\n*I n  c o m b i n a t i o n  w i t h  s t a n d a r d  e n d o c r i n e  t r e a t m e n tAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ENeoadjuvant \n(Primary) Systemic Therapy\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Therapy\n\u00a7Versions 2002 \u20132022:\nBauerfeind / Blohmer / Costa / Dall / Fehm / Fersis / Friedrich / G\u00f6hring / \nHarbeck / Heinrich / Huober / Jackisch / Kaufmann / Liedtke / Loibl /    \nLux / von Minckwitz / M\u00fcller / Mundhenke / Nitz / Schneeweiss /    \nSch\u00fctz / Solomayer / Stickeler / Untch / Thill / Thomssen\n\u00a7Version 2023:\nFasching / Friedrich \nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deStrategies for Differentiated \nSystemic Treatment in the Curative Situation\nAGO\nIf chemotherapy is indicated systemic treatment before surgery (neoadjuvant) should be preferred;\nstudy participation recommended\n\u00a7HR+ / HER2 -and \u201elow recurrence -risk\u201d\n\u00a7 Endocrine therapy without chemotherapy ++\n\u00a7HR+ / HER2 -and \u201ehigh recurrence -risk\u201d\n\u00a7 Endocrine / endocrine -based therapy (abemaciclib ) ++\n\u00a7 Patients with indication forchemo -endocrine therapy *\n\u00a7 Conventionally dosed AT-based chemotherapy (q3w) +\n\u00a7 Dose dense chemotherapy (including weekly schedule) ++\n\u00a7Triple -negative (TNBC)\n\u00a7 Conventional dosed AT-based chemotherapy (q3w) +\n\u00a7 Sequential AT-based chemotherapy (incl. weekly schedule ) ++\n\u00a7 Neoadjuvant platinum -containing chemotherapy +\n\u00a7 Neoadjuvant platinum -containing chemotherapy with ICPI ( Pembrolizumab ) +\n\u00a7gBRCA1/2mut (HR+/HER -orTNBC respectively1)\n\u00a7 Olaparib1 ++\n\u00a7HER2+\n\u00a7 Trastuzumab (plus Pertuzumab in N+ or NACT) ++\n\u00a7Sequential AT -based chemotherapy with concurrent T + anti -HER2 therapy ++\n\u00a7Anthracycline -free, chemotherapy + anti -HER2 therapy ++\n1according to approval or study population (if not approved), *see prognosis chapterNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLee Index\n\u2022This index was developed in 11,701 community -dwelling adults from theeastern , western and central United States who were\ninterviewed in theHealth Retirement Survey in 1998 ( mean age67, 57% female , 81% white , 12% 4 -year mortality ).\n\u2022The index was internally validated in 8009 Health Retirement Survey interviewees from thesouthern United States ( mean age67, 57% \nfemale , 71% white , 13% 4 -year mortality ) and externally validated in 7042 English Longitudinal Study on Ageing interviewees .\n\u2022Discrimination : This riskcalculator sorts patients who died from patients who lived correctly 82% ofthetime (c -statistic ). The life\nexpectancy calculator sorts patients who lived longer from patients who lived shorter correctly 78-80% ofthetime in thevalidation\nstudies\n\u2022Calibration : The model was well calibrated across all risklevels with less than 3% difference between estimated and actual mortality\nrates .\nSchonberg Index 50%                             60%                                70%                             80%                       90%\n\u2022This index was developed in 16,077 community dwelling older adults who responded tothe1997 -2000 National Health Interview \n(NHIS) (27% >80 years old, 60% female , 85% white , 17% 5 -year mortality )\n\u2022The index was internally validated in a random sample of8038 from respondents from thesame data source from 2001 -2004 and\nfollowed through 2006 (27% >80 years old, 60% female , 85% white , 17% 5 -year mortality ). The index was internally validated in 16,063 \nrespondents from theoriginal development cohort and 8,027 respondents from theoriginal validation cohort from 1997 -2000 and\nfollowed through 2011 (10 and 14-year mortality ).\n\u2022Discrimination : This riskcalculator sorts patients who died within 5 years from patients who lived correctly 75% ofthetime (c -\nstatistic ). The discrimination was thesame in theindependent validation study . For10 year and 14 year mortality thecalculator sorts\npatients correctly 73% and 72% ofthetime.\n\u2022Calibration : The model was well calibrated across all risklevels with less than 10% difference between estimated and actual mortality .\n50% 60%                           70%                           80%                          90%Lee-Schonberg Index\nhttps:// eprognosis.ucsf.edu /leeschonberg -result.php\npoor moderate good very good excellent\npoor moderate good very good excellentNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLee-Schonberg Index\nhttps:// eprognosis.ucsf.edu /leeschonberg -result.php\nRisk Calculator questions\n1.How oldisyour patient ?\n2.What isthesexofyour patient ?\n3.What isyour patient's ?\n4.Which best describes your patient's health in general ?\n5.Does your patient have chronic lung disease , such asemphysema orchronic bronchitis ?\n6.Hasyour patient ever hadcancer (excluding minor skincancers )?\n7.Does your patient have congestive heart failure ?\n8.Does your patient have diabetes orhigh blood sugar ?\n9.Which best describes your patient's cigarette use?\n10.Does your patient have difficulty walking 1/4 mile (several cityblocks ) without help from other people orspecial equipment ?\n11.During thepast 12 months , how many times was your patient hospitalized overnight ?\n12.Because ofa physical , mental oremotional problem , does your patient need thehelp ofothers in handling routine needs such as\neveryday household chores , doing necessary business , shopping , orgetting around forother purposes ?\n13.Because ofa health ormemory problem , does your patient have difficulty managing money -such aspaying billsandkeeping\ntrack ofexpenses ?\n14.Because ofa health ormemory problem , does your patient have difficulty withbathing orshowering ?\n15.Because ofa health problem , does your patient have difficulty pushing orpulling large objects like a living room chair ?Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nAnthracycline -free Taxan / Carboplatin \nbased Regimen for HER2+ \nT Docetaxel, Tx Paclitaxel, C Carboplatin, H Trastuzumab, P PertuzumabRegimenPpts. (n)pCR rate (%)OUTCOME6 x TCH (TRIO B07)34 47Not published6 x TCHP (TRYPHAENA)75 643-yr-DFS: 90%6 x TCHP (KRISTINE -TRIO -021)221 563-yr-EFS: 94.24 x TCHP (NSABP-B52; nur HR+)155 41Not published9 x TxCHP (TRAIN-2) 206 683-yr-EFS: 93.5%\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Chemotherapy\nClinical Benefit\nOxford\nLoE GR\u00a7Leads to improvement of prognosis by individualization of neoadjuvant and\npost -neoadjuvant therapy (data most consistent for HER2pos and TNBC)1b A\u00a7Survival is similar after neoadjuvant (preoperative, primary) and adjuvant\nsystemic therapy (with same regimen and number of cycles), if the\npostneoadjuvant therapy is not stratified according to pathologic response1a A\u00a7Pathological complete response is associated with improved survival 1b A\u00a7Can achieve operability in primary inoperable tumors 1b A\u00a7Improved options for breast conserving surgery 1b A\u00a7Decreases rate of axillary lymphadenectomies lymphonodectomies 2b B\u00a7Allows individualization of therapy according to mid -course treatment effect1b BNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic \nChemotherapy -Indications\nOxford\nLoE GR AGO\u00a7If similar postoperative adjuvant chemotherapy is \nindicated1b A ++\u00a7Toallow a risk adapted postoperative therapy(data most consistent for HER2pos and TNBC)1b A ++\u00a7Inflammatory breast cancer 2b B ++\u00a7Inoperable breast cancer 1c A ++\u00a7Large operable breast cancer requiring mastectomy and adjuvant chemotherapy with the goal of breast conservation 1b B ++\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFactorpCR* ProbabilityLoE GR AGO\u00a7Young age \u00ad 1a A +\u00a7Obesity \u00af 2a B +\u00a7cT1 / cT2 tumors o. N0 o. G3 \u00ad\u00ad 1a A ++\u00a7Negative hormone receptor status \u00ad\u00ad 1a A ++\u00a7Triple negative breast cancer \u00ad\u00ad 1a A ++\u00a7Positive HER2 -status \u00ad\u00ad 1a A ++\u00a7Early clinical response \u00ad 1b A +\u00a7Lobular tumor type \u00af 1a A +\u00a7Metaplastic tumor type \u00af\u00af 4 C +Oxford\n* High ( \u00ad) orvery high ( \u00ad\u00ad) probability toreach pCR, low (\u00af) orvery low(\u00af\u00af) probability toreach pCR; See asochapter \u201ePrognostic and predictive factors \u201cNeoadjuvant Systemic Chemotherapy  (NACT) \nPredictive Factors for pCR I\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Chemotherapy  (NACT) \nPredictive Factors for pCR II\npCR*\nProbabilityOxfordFactorLoEGR AGO\u00a7Gene expression profiles (gene signatures) \n(Mammaprint\u00ae, Endopredict\u00ae  Oncotype DX\u00ae, \nProsigna\u00ae, Breast Cancer IndexSM)\u00ad 2b B +/-\u00a7Ki-67 \u00ad 2b B +\u00a7Tumor infiltrating lymphocytes** \u00ad 2a B +\u00a7PIK3CA mutation (for HER2 -positive BC) \u00ad 2a B +/-\u00a7gBRCA -mutation (for the effect of chemotherapy) \u00ad 2b B +\u00a7gBRCA -mutation (for the effect of platinum) \u2194 2b B +/-\n* High ( \u00ad) orvery high ( \u00ad\u00ad) probabililty ofpCR, low (\u00af) orvery low (\u00af\u00af) probabililty ofpCR\n** Defined as dense lymphocytic infiltration of inner peritumoral stroma outside of the invasion front (lymphocytes make up \n> 50 % of  stroma area)Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Chemotherapy\nRecommended Regimens\nOxford\nLoE GR AGO\u00a7Use of adjuvant standard regimens for NACT* 1a A ++\u00a7Taxane mono followed by anthracycline (reverse order) 4 D +/-\u00a7Platinum in TNBC (cT1 / cN+ or cT2) (irrespective of BRCA \nstatus)1b A +\u00a7Platinum in TNBC (from cT1 / cN+ or cT2) (irrespective of \nBRCA status)1a A +\u00a7Nab-paclitaxel weekly instead of paclitaxel qw1 (in TNBC) 1a A +\u00a7Pembrolizumab in combination with carbo / paclitaxel \u00e0\n4x EC q3w (TNBC**)1b B +\n* See chapter Adjuvant Chemotherapy ; \n** >2 cm orcN+, PD -L1 independentNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRecommended Regimen\nin Triple Negative Breast Cancer\nOxford\nLoE GR AGONon-platinum -containing regimen\u00a7ddEC x 4 \u00e0pacli 80 q1w x 12 1b B ++\u00a7NabPac125q1w x 12 \u00e0E90C q(2)3w x 4 1b B +/-Platinum-containing regimen\u00a7NabPac125 / carboAUC 2 q1w x 8 \u00e0ddEC x 4 1b B +\u00a7Pacli80 q1w x 12 / carboAUC 6 q3w x 4 \u00e0ddAC / ddEC x 4 1b B +\u00a7Docetaxel / carbo AUC6 q3w x 6 or paclitaxel/carbo AUC1,5 q1w x18 2b B +\u00a7NabPac 1oo / carbo AUC 6 q4w x 4 2b C +Checkpoint inhibitors\u00a7Pembro200 q3w + Pac80 / carboAUC 1,5 q1w x 12 \u00e0E90C q3w x 4 1b B +\u00a7Pembro200 q3w + Pac80 q1w x 12 / carboAUC 5 q3w \u00e0E90C q3w x 4 1b B +Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nICPi plus Neoadjuvant Chemotherapy for Triple \nNegative Breast Cancer PatientsGeparNuevoIMpassion031Keynote 522neoTRIPPhaseIIIIIIIIIIN174333602 (pCR)1174 (EFS)280Prim. endpointpCRpCRpCR + EFSEFSCPiDurvalumab (24-26 weeks)Atezolizumab (1 y)Pembrolizumab (1 y)Atezolizumab (24 weeks)ChemoNabPac125q1w x12 \u00e0EC q2w x4NabPac125q1w x12 \u00e0EC q2w x4Pac q1w x12 + carbo q3w AUC 5 or q1w AUC 1,5 \u00e0AC/EC q3w x4NabPac125+ carbo AUC 2 q1w d1 and d8Inclusion criteriacT1b-cT4a -dcT2-cT4, cN0 -cN3cT1cN1-2 or cT2 N0 -2cT1cN1; cT2cN1; cT3cN0PD-L1 positive87%46%83%56%pCR ITT53.4% vs. 44.2%D10.8% (n.s.)57.6% vs. 41.2%D16.5% (p < 0.01)64.8% vs. 51.2%D13.6% (p < 0.00055)43.5% vs. 40.8%D2.6% (n.s.) pCR PD-L1 positive58% vs. 50%69% vs. 49%69% vs. 55%52% 48%pCR PD-L1 negative44% vs. 18%48% vs. 34%45% vs. 30%32% vs. 32%Follow up/EFS/iDFS (months)/HR EFS/iDFS43.7 monthsiDFS: 0.48 (p = 0.0389) 20 monthsEFS: 0.76 (n.s.)39.1 monthsEFS: 15.7 vs. 23.8 m0.63 (p = 0.00031)---EFS/iDFS adjusted to pCR/non-pCRpCR 95.5% vs. 86.1%npCR 76.3% vs. 69.7%---pCR 94.4% vs. 92.5%npCR 67.4% vs. 56.8%---Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Therapy\nRecommended Methods of Monitoring of Response\nOxford\nLoE GR AGO\u00a7Breast ultrasound 2b B ++\u00a7Palpation 2b B ++\u00a7Mammography 2b B ++\u00a7MRI 2b B+\u00a7PET( -CT) 2b B +/-\u00a7Pretherapeutical marking of tumor region 5D ++\u00a7Pretherapeutical diagnostic core needle biopsyandmarking in case of of cN+ (CNB) (in case TAD is\nplanned for\u2264 3 suspect lymph nodes )2b B ++*\n(CNB: core needle biopsy; TAD: targeted axillary dissection; \n*study participation recommended (AXSANA /Eubreast 3 Trial)Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7Pertuzumab + trastuzumab in combination with \nchemotherapy  (high -risk defined as cT2 -4 and / or \ncN+)2b B ++\u00a7Trastuzumab in combination with stand \npolychemotherapy (low -risk)*1b A +\u00a7Anti -HER2 agents without chemotherapy 2b B +/-\n*Single agent chemotherapy combined with trastuzumub should preferably be used in the adjuvant \nsettingNeoadjuvant Targeted Therapy \nin HER2 Positive Tumors\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGOIn case of early response\u00a7 Completion of neoadjuvant chemotherapy 1b A ++In case of no change:\u00a7 Completion of neoadjuvant chemotherapy (NACT) followed by surgery 2b C ++\n\u00a7 Continuation of NACT with non cross -resistant regimen 2b B +\n\u00a7 AC or EC x 4 \u2192 D x 4 or Pw x 12 2b B +\n\u00a7 DAC x 2 \u2192NX x 4 1b B +In case of disease progression\u00a7 Re-evaluation of tumorbiological factors 5 D +/-\n\u00a7 Stop NACT and proceed to surgery or radiotherapy 4 D ++\n\u00a7 Additional adjuvant chemotherapy with non cross -resistant regimen 4 D +/-Neoadjuvant Chemotherapy\nTreatment Strategies Based on Clinical Response\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAxillary Surgery and NACT Oxford\nLoE GR AGO\ncNstatus\n(before\nNACT)pNstatus\n(before\nNACT)ycN status\n(after NACT)Axillary surgery\n(after NACT)AGO ypN status (after NACT \nand surgery )Surgical consequence \nbased on histopathology\ncN0* Nosurgery\nbefore NACTycN0 SLNE ++ ypN0 ( sn) none 2b B ++\nypN0 (i+) ( sn) ALND 2b C +/-\nypN1mi (sn) ALND 2b C +\nypN1 (sn) ALND 2b C ++\n*  Study participation in EUBREAST -01 recommendedNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n* Study participation in AXSANA recommended, **Cave: In 30.3% false -positive findings , consider CNB ifnecessaryAxillary Surgery and NACT ( cN+)Oxford\nLoE GR AGO\ncNstatus\n(before\nNACT)pNstatus\n(before\nNACT)ycN status\n(after NACT)Axillary surgery\n(after NACT)AGO ypN status (after NACT \nand surgery )Surgical consequence\nbased on histopathology\ncN+* pN+ CNB ycN0 ALND + ypN0 / ypN+ none 2b B ++\nTAD + ypN0 none 2b B +\nypN0 (i+) ALND 2b B +/-\nypN+ inkl. ypN1mi ALND 2b B +\nSLNE +/- ypN0 none 2b B +/-\nypN0 (i+) ALND 2b B +/-\nypN+ inkl. ypN1mi ALND 2b B +\nTLNE +/- ypN0 none 2b B +/-\nypN0 (i+) ALND 3b B +/-\nypN+ inkl. ypN1mi ALND 3b B +\nycN+** ALND ++ ypN0 / ypN+ none 2b B ++Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Therapy\nLoco -regional Surgery (Breast)\nOxford\nLoE GR AGO\u00a7Pretherapeutic discussion in a multidisciplinary tumor \nboard (e.g. to define the surgical procedure)1a B ++\u00a7Early marking of tumor (incl. detailed topographic \ndocumentation)5 D ++\u00a7Surgical removal of tumor / representative excicion of \nposttherapeutic, marked tumorareal2b C ++\u00a7Tumor resection in new margins 2b C ++\u00a7Microscopically clear margins 2a B ++Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Therapy\nIndications for Mastectomy\nOxford\nLoE GR AGO\u00a7Positive margins after repeated excisions 3b C ++\u00a7Radiotherapy not feasible 5 D ++\u00a7In case of clinical complete response\n\u00a7Inflammatory breast cancer (in case of pCR) 2b C +/-\n\u00a7Multicentric lesions 2b C +/-\n\u00a7cT4a -c breast cancer 2b B +/-\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Systemic Therapy\nTiming of Diagnosis, Surgery and Radiotherapy\nOxford\nLoE GR AGOInitiation of therapyDelay of therapy (> 60 days) associated with worse \nprognosis2b    B +Timing of surgery4-8 weeks after last course of chemotherapy2a B ++Radiotherapy within 2 months after surgery2b B ++Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant endocrine Therapy (NET)\n-Good clinical practice -\n\u00a7Suitable for patients who are\n\u00a7inoperable\n\u00a7not able or willing to undergo chemotherapy\n\u00a7Data for premenopausal in contrast to postmenopausal patients is limited\n\u00a7Optimale duration of NET is at least 4 -6 months or until best repsonse or\nprogression\n\u00a7Choice of endocrine therapy is based on the menopausal status\n\u00a7Ki-67 analysis after preoperative short term endocrine therapy for 2 to 4\nweeks may predict response to endocrine treatment (prognostic / predictive\nevaluation)\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deNeoadjuvant Endocrine Therapy in Patients \nwith Endocrine -responsive Breast Cancer\naOptimal duration ofneoadjuvant endocrine therapy isunknown . Nolong term results forneoadjuvant endocrine therapy (vs. adjuvant\nendocrine therapy )Oxford\nLoE GR AGO\n\u00a7 Postmenopausal patients :\n\u00a7 Optimizes the option for breast conserving  therapy 1b A +\n\u00a7 Aromatase inhibitors (at least 6 months) 1aa B +\n\u00a7 Aromatase inhibitor + lapatinib (HER2+ BC) 2b B +/-\n\u00a7 Premenopausal patients\n\u00a7 Tamoxifen 2b C +\n\u00a7 Aromatase inhibitors + LHRHa 1b C +/-\n\u00a7 Concurrent chemo -endocrine therapy 1b A -\n\u00a7 Ki-67 analysis after preoperative short term endocrine therapy for2 to4 weeks\n(Tam / AI \u00b1GnRha ) (prognostic / predictive evaluation information )1b B +\n\u00a7 Prognostic score: \n\u00a7 PEPI: pTN-Stage, ER expression and Ki -67 expression after     \nneoadjuvant endocrine therapy1b B +Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deOxford\nLoE GR AGOHR positive (pCR and non-pCR)\u00a7Endocrine therapy according to menopausal state (s. chap. 10) 1a A ++\u00a7Abemaciclib for 2 yrs + endocrine therapy \nif high risk of recurrence11b B +\u00a7Olaparib for1 yr+ endocrine therapy (gBRCA1/2MUT, ifnon-\npCR and CPS -EG Score \u2265 3)21b A ++\u00a7Capecitabine (non -pCR) 1b A +/-Postneoadjuvant Therapy HR+ / HER2 -\n1 According inclusion criteria monarchE -study,\n2 According inclusion criteria OlympiA -studyNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.de\nMittendorf EA, J Clin Oncol 2011; \nMarm\u00e9 F, et al. EurJ Cancer 2016Clinical Stage\nI 0 T1N0; T0N1mi, T1N1mi\nIIA 0 T0N1; T1N1; T2N0\nIIB 1 T2N1; T3N0\nIIIA 1 T0-2N2\nIIIB 2 T4N0 -2\nIIIC 2 Any T N3Pathologic Stage\n0 0 T0/isN0\nI 0 T1N0; T0N1mi, T1N1mi\nIIA 1 T0N1; T1N1; T2N0\nIIB 1 T2N1; T3N0\nIIIA 1 T0-2 N2\nIIIB 1 T4 N0 -N2\nIIIC 2 Any T N3 Tumor Biologic Factors\nER negative 1\nNuclear grade 3 1Point assignment for CPS+EG score\nGBG/ AGO B meta -database\n(N=2454 HR+/HER2 -)\n25%How to calculate CPS+EG Score?\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nAdjuvant / Post -Neoadjuvant Treatment with \nCDK4/6i \nIDFS: invasive disease -free survivalmonarchEPALLASPENELOPEBN5,6375,6001,250CDK4/6iAbemaciclibPalbociclibPalbociclib% of pts. with NACT37%n.r.100%Duration of CDK4/6i treatment24 mths24 mths12 mthsFollow-up42.0 mths24 mths43 mthsDiscontinuation rate28%42%20%Discontinuation rate due to  AECDKi17%27%5%IDFS-HR (95% -CI)0.664 (0.578-0.762)p < 0.00010.96 (0.81-1.14)p = 0.650.93 (0.74-1.16)p = 0.5252-yrs IDFS92.7% vs. 89.9%n.r.88% vs. 78%3-yrs IDFS89.2% vs. 84.4%88% vs. 89%81% vs. 78%4-yrs IDFS85.8% vs. 79.4%84.2% vs. 84.5%73% vs. 72%Neoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.deOxford\nLoE GR AGOpCR\u00a7Continuation of pembrolizumab, if started with neoadj. therapy (q3w for 9 courses)1b B +Non-pCR\u00a7Capecitabine (q3w upto8 courses )*\n\u00a7 With non-pCR after A -T-containing chemotherapy * 1a A ++\n\u00a7 With non-pCR after platinum +/-pembrolizumab -containing therapy 5 D +/-\n\u00a7Platinum salts (carboplatin orcisplatin ) q3w after AT -pretreatment 1b B +/-\n\u00a7Olaparib (gBRCAMUT)1 1b A ++\u00a7Continuation of pembrolizumab, if started with neoadj. therapy (q3w for 9 courses)1b B ++Postneoadjuvant Therapy TNBC\n1according inclusion criteria ofOlympiA trial, advantage especially with platinum -free NACT\n* in stage II-III without platinum /pembrolizumab -based pretreatmentNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E \nwww.ago -online.dePostneoadjuvant Therapy HER2- positive\nOxford\nLoE GR AGO\npCR\u00a7Low risk: Trastuzumab (tocomplete 12 mths ) 2a C ++\u00a7High risk (cN+): Trastuzumab + Pertuzumab (to complete 12 mths) 2b C+\u00a7Neratinib after 1 year Trastuzumab (HR-positive, high -risk, forexample\nstage II-III)*2b B +/-non-pCR\u00a7T-DM1 1b B +\u00a7Trastuzumab + Pertuzumab (to complete 12 mths) 2b C +\u00a7Additional HER2 -directed therapy after 1 yr (extended adjuvant th.)\n\u00a7Neratinib after Trastuzumab (HR-positive , high risk,forexample\nstage II-III)*2b B+\n\u00a7Neratinib after other HER2 -directed therapies (HR -positive, high risk\n(stage II -III)*)5D +/-\n*I n  combination with standard endocrine treatmentNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EAdjuvant Radiotherapy \nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant Radiotherapy (RT)\n\u00a7Versions 2002 \u20132022:\nBlohmer / Budach / Friedrich / Friedrichs / G\u00f6hring / Huober / Janni / \nKrug / K\u00fchn / M\u00f6bus / Rody / Scharl / Schmidt / Seegenschmiedt / \nSouchon / Thomssen / Untch / Wenz \n\u00a7Version 2023:\nBudach / Krug / Solbach\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePreliminary Note\n\u00a7The recommendations on adjuvant radiotherapy  for breast \ncancer are based on a consensus discussion between AGO and \nDEGRO experts.\n\u00a7For technical radiotherapy details, we refer to the corresponding \nupdated DEGRO practical guidelines.\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRadiotherapy (RT) after Breast Conserving Surgery \n(Invasive Cancer): Whole Breast Irradiation\nOxford\nLoE GR AGO\u00a7Radiotherapy of the affected breast 1a A ++\u00a7Moderately hypofractionated radiotherapy (total dose approx. 40 Gy in 15 -\n16 fractions within 3 -5 weeks1a A ++\u00a7Ultra -hypofractionated RT (total dose 26 Gy in 5 fractions over one week = \n1 fraction/day or 28.5 Gy in 5 fractions over 5 weeks = 1 fraction/week)1b B +/-\u00a7Conventionally fractionated radiotherapy (total dose about 50 Gyin \napprox. 25 -28 fractions in 5 -6 weeks)1a B +\u00a7Ultra -hypofractionated RT (total dose 26 or 28,5 Gy in 5 fractions in 1 or 5 \nweeks)1b B +/-\u00a7In case of life expectancy < 10 years and pT1, pN0, R0, ER /PR-positive, \nHER2 -negative, endocrine therapy (all criteria), radiotherapy can be \nomitted after individual counseling, resulting in an increased risk for in -\nbreast recurrence.1a B +Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nFAST / FAST -ForwardFASTFAST ForwardTimeframe2004-20072011-2014Sample size9154096Dose / Fractionation50 Gy/ 2 Gy/ 5 weeks30 Gy/ 6 Gy/ 5 weeks28,5 Gy/ 5,7 Gy/ 5 weeks40 Gy / 2,67 Gy / 3 weeks27 Gy / 5,4 Gy / 1 weeks26 Gy / 5,2 Gy / 1 weeksMedian follow-up119.8 months71.5 monthsPrimary endpointchange in photographic breast appearanceIpsilateral breast tumor recurrence (non-inferiority margin 1,6%)Inclusion criteriapT1-2 (< 3 cm) pN0Age \u2265 50 yearsBreast conserving surgeryNo chemotherapypT1-3 pN0 -1Age \u2265 18 yearsBreast-conserving surgery or mastectomyApprox. 25% adj. chemotherapyBoostNoApprox. 25%, 5-8x 2 Gy\nBrunt AM et al. J Clin Oncol . 2020 Oct1;38(28):3261 -3272. Brunt AM et al. Lancet. 2020 May 23;395(10237):1613 -1626.Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nFAST / FAST -ForwardFAST (10 year-data) FAST Forward (5 year-data)DoseFrequencyHazard ratio(95%-CI)DoseFrequencyHazard ratio(95%-CI)Ipsilateral in-breast recurrence50 Gy0.7% -40 Gy2.1% -30 Gy1.4% HR 1.36 (0.3-6.06)27 Gy1.7% HR 0.86 (0.51-1.44)28.5 Gy1.7% HR 1.35(0.3-6.05)26 Gy1.4% HR 0.67 (0.38-1.16)Moderate / marked normal tissue effects breast / chestwall50 Gy33.6%-40 Gy26.8%-30 Gy50.4%HR 1.79 (1.37-2.34)27 Gy35.1%HR 1.41 (1.23-1.61)28.5 Gy47.6%HR 1.45 (1.10-1.91)26 Gy28.5%HR 1.09 (0.95-1.27)\nBrunt AM et al. J Clin Oncol . 2020 Oct1;38(28):3261 -3272. Brunt AM et al. Lancet. 2020 May 23;395(10237):1613 -1626.Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRandomized controlled trials ofradiotherapy omission after \nbreast -conserving surgery in early breast cancer\nTrial N Time -\nframeInclusion criteriaFollow upLocal \nrecurrence\n(no RT)Local recurrence (RT)Hazard \nratio\nToronto -British \nColumbia769 1992 -\n2000\u2265 50 years, T1/2 N0 R0 \n(ink) 80% HR+5 y\n8 y7.7%\n17.6%0.6%\n3.5%8.3\nBASO -II 204 1992 -\n2000< 70 J., T1, G1 L0 5 y 0.8% p.a. 0.2% p.a. 7.34\nCALGB 9343 636 1994 -\n1999\u2265 70 years , T1 (98%) cN0 \nER+ (97%), R0 ( ink)5 y\n10 y4% \n8%1%\n2%5.55\nABCSG -8A 831 1996 -\n2004Postmenopausal\nT \u2264 3 cm N0, G1/2, ER+ \nand/or PR+5 y\n10 y5.1%\n7.5%0.4%\n2.5%10.2\nPRIME II 1326 2003 -\n2009\u2265 65 years, T \u2264 3 cm N0, \nER+ and/or PR+, R0 (\u22651 \nmm)5 y\n10 y4.3%\n9.8%1.3%\n0.9%5.2Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRadiotherapy (RT) after Breast Conserving Surgery \n(Invasive Cancer) \u2013Boost Irradiation \nOxfordLoEGRAGO\u00a7Boost -RT (improves local control, no survival benefit)\n\u00a7Premenopausal 1b B ++\n\u00a7Postmenopausal, if > T1*, G3, HER2 -positive, triple negative, EIC \n(at least 1 factor) 2b B +\u00a7Techniques\n\u00a7Percutaneous boost (photons, electrons) as sequential boost 1a A ++\n\u00a7Multicatheter brachytherapy -boost 1a A ++\n\u00a7Percutaneous boost as simultaneous integrated boost (with \nhypofractionated whole -breast irradiation)1baB +\n\u00a7Percutaneous boost as simultaneous integrated boost (with \nconventionally fractionated whole -breast irradiation)1b B +\n\u00a7Intraoperative boost irradiation (followed by whole -breast irradiation) 2b B +\u00a7Intraoperative clipplacement at thetumor bed ifboost irradiation is\nindicated2b B +\n* continuous parameter with regard to risk of relapseAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nEORTC 22881 -10882: Boost vs no Boost \n(Endpoint: Ipsilateral Breast Recurrence)\n@20 yrs\n(95% C.I.)Boost  \n(n = 2.661)No boost \n(n = 2.657)Hazard Ratio\n(95% C.I.)\nOverall Survival\n(D= -1.4%)59.7%\n(56.3 \u201363.0)61.1%\n(57.6 \u201364.3)HR 1.05\n(0.92 \u20131.19) n.s.\nCumulative Risk of Ipsilateral Breast Tumour Recurrence\nAll patients 12.0%\n(9.8\u201314.4)16.4%\n(14.1 \u201318.8)HR=0.65 \n(0.52 \u20130.81); p < 0.0001\n\u2264 40 years\n(D= 11.6%)24.4%\n(14.9 \u201333.8)36.0%\n(25.8 \u201346.2)HR=0.56 \n(0.34 \u20130.92); p = 0.003\n41\u201350 years\n(D= 5.9%)13.5%\n(9.5\u201317.5)19.4%\n(14.7 \u201324.1%)HR=0.66 \n(0.45 \u20130.98); p = 0.007\n51\u201360 years\n(D= 2.96%)10.3% \n(6.3\u201314.3)13.2% \n(9.8\u201316.7)HR=0.69 \n(0.46 \u20131.04); p = 0.020\n> 60 years\n(D= 3.0%)9.7% \n(5.0\u201314.4)12.7% \n(7.4\u201318.0)HR=0.66 \n(0.42 \u20131.04); p = 0.019\nacc. to: Bartelink et al. Lancet Oncol 2015; 16: 47 \u201356 (Median F/U 17.2 y)Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nEORTC 22881 -10882: Boost vs. no Boost \n(Endpoint: Any First Recurrence)\n@15 yrs/20 yrs\n(95% C.I.)Boost \n(n = 2.661)No boost \n(n = 2.657)Hazard Ratio\n(95% C.I.)\nOverall Survival\n(D= -1.4%)59.7%\n(56.3 \u201363.0)61.1%\n(57.6 \u201364.3)HR 1.05\n(0.92 \u20131.19) n.s.\nCumulative Risk of Any First Recurrence\nAll patients\n(D\u2265 4%)@15y\n@20y28.1%\n32,8%32.1%\n38.7%HR = 0.92\n(0.81 -1.04), n.s.\n\u2264 40 years\n(D> 6%)@15y\n@20y41.5%\n49.5%48.1%\n56.8%HR = 0.80 \n(0.56 -1.15) , n.s.\n41\u201350 years @15y\n@20y34.0%\n38.6%35.6%\n44.2%HR = 0.91 \n(0.71 -1.16) , n.s.\n51\u201360 years @15y\n@20y28.5%\n34.7%28.7%\n36.2%HR = 0.96 \n(0.76 -1.21) , n.s.\n>6 0  y e a r s @15y\n@20y27.4%\n32.1%29.1%\n32.8%HR = 0.94 \n(0.74 -1.19), n.s.\nacc. Bartelink et al. Lancet Oncol 2015; 16: 47 \u201356. Suppl. (Median F/U 17.2 y)Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nModerate hypofractionation with\nsimultaneous -integrated boostRTOG 1005 (ASTRO 2022)IMPORT-HIGH (ESTRO 2021)Patient number22622617Schedule Breast40 Gy in 15 fx36 Gy in 15 fx40 Gy in 15 fxSchedule Boost48 Gy in 15 fx48 Gy in 15 fx vs. 53 Gy in 15 fxIpsilateral in-breast recurrenceat 5 yearsHR 1.32 (0.8-2.1)\u00e0Non -inferiority for SIBHR 1.04 (0.56-1.92) \u00e0Non -inferiority for 48 Gy(absolute diff.)HR 1.76 (1.01-3.04)\u00e0Inferiority for SIB 53 Gy(absolute + relat .)ToxicityToxicity grade \u22653 (ROTG)p = 0.79Any moderate / marked breast AEp = 0.041 for SIB 48 Gyvs. sequential boost (less toxicity with SIB)p = 0.823 for SIB 53 Gyvs. sequential boostAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTechniques for Partial Breast Irradiation (PBI) after \nBreast Conserving Surgery (Invasive Cancer)\nOxford\nLoE GR AGO\u00a7Intraoperative Radiotherapy (low -risk)*\n\u00a7 As sole radiotherapy, during first breast surgery (IORT 50 kV, IOERT)\n\u00a7 > 50 years 1b A +/-\n\u00a7 > 70 years 1b A +\u00a7Postoperative partial breast irradiation (low -risk)*\n\u00a7 Interstitial Multicatheter -Brachytherapy 1b A +\n\u00a7 Intracavitary balloon -technique 2b B -\n\u00a7 Intensity -modulated radiotherapy (IMRT) (5 x 6 Gy in 1.5 weeks ) 1b A +\n\u00a7 3D-conformal radiotherapy (15 x 2.67 Gy in 3 weeks ) 1b A ++\n\u00a7 3D-conformal radiotherapy (10 x 3.8 -4 Gy in 2 weeks ) 2b B +/-\n\u00a7 3D-conformal radiotherapy (10 x 3.85 Gy in 1 week ) 1b A +/-\u00a7Intraoperative clipplacement at thetumor bed ifpartial breasst irradiation\nisindicated2b B +\n* only for pT1 pN0 R0 G1 -2, HR+, non -lobular, > 50 years, no extensive DCISFordefinition oftarget volume and practical conduct seeDEGRO practical guidelinesAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nMeta -analyses on partial -breast irradiationMeta-analysis of13 studies with 15,561 patients comparing partial breast irradiation (PBI) and whole -breastirradiation (WBI), median follow -up8.6 years ; Odds Ratio (95% -confidence interval )OverallEBRTEBRT/BTBTIORTAbsolute diff. Local recurrence (primary site)1.01 (0.65-1.59)0.85 (0.52-1.39)0.84 (0.56-1.27)0.87 (0.25-3.02)3.51 (1.36-9.11)+0.02%Local recurrence (elswhere)2.21(1.53-3.20)2.26(1.12-4.55)2.07 (1.31-3.27)7.88(0.42-146)3.06(0.1-91.59)+0.64%Meta-analysis of11 studies with 15,438 patients comparing partial breast irradiation (PBI) and whole -breastirradiation (WBI); Hazard Ratio (95% -confidence interval )OverallEBRTEBRT/BTBTIORTOverall survival1.02 (0.89-1.16)1.06 (0.83-.37)1.10(0.90-1.35)0.64 (0.36-.12)0.95(0.72-1.24)\nEBRT = external beam RT; BT = brachytherapy , IORT = intraoperative RT; EBRT/BT = both techniques were allowed on trialAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nComparison ofdifferent techniques forpartial breast\nirradiation\nIntraoperative radiotherapy Multicatheter interstitial \nbrachytherapyExternal -beam radiotherapy\nAdvantages \u2022 Shortest possible\ntreatment time\n\u2022 Direct visualization of\nthetumor bed\u2022 High conformality\n\u2022 Longest available\nfollow -up\u2022 Broad availability\n\u2022 Reproducibility\nDisadvantages \u2022 Lack of complete\nknowledge ofriskfactors\n(e.g. margin status,\nlympho -vascular\ninvasion)\n\u2022 Potentially increased risk\nof fibrosis with\nadditional whole -breast\nirradiation\n\u2022 Availability limited to\nspecialized centers\n\u2022 Prolongation of\nanesthesia\u2022 Availability limited to\nspecialized centers with\nhigh expertise\n\u2022 Additional invasive\nprocedure\n\u2022 Additional hospital stay\n\u2022 Risk oftarget miss due\nvisualization of the\ntumor bed\u2022 Risk of target miss due\nvisualization ofthetumor bed\n\u2022 Larger irradiated volume due\ntointra -and interfractional\nmotion\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePostmastectomy Radiotherapy\n(PMRT)* to the Chest Wall \u2013Indication \nOxford\nLoE GR AGO\u00a7> 3 tumor infiltrated lymph nodes (LN) 1a A ++\u00a71\u20133 tumor infiltrated LN (high -risk) 1a A +\u00a71\u20133 tumor infiltrated LN (low -risk*) 5 D +/-\u00a7T3 / T4 1a A ++\n\u00a7pT3 pN0 R0 (and no additional risk factors) 2b B +/-\u00a7If R0 is impossible to reach (for invasive tumor) 1a A ++\u00a7In young pts with high -risk features 2b B ++The indications for PMRT and regional RT are independent of adjuvant systemic treatment1a AInflammatorybreast cancer :PMRT and regional nodal irradiation 2c B ++\n*For definition of low -risk, see next slide Radiotherapy of the Chest Wall After Mastectomy (PMRT)Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePostmastectomy Radiotherapy\n(PMRT)* totheChest Wall* \u2013Fractionation\nOxford\nLoE GR AGO\u00a7Moderately hypofractionated radiotherapy (total dose approx. 40 \nGyin 15 -16 fractions within 3 -5 weeks1a A ++\n\u00a7After breast reconstruction 2b B +\u00a7Ultra -hypofractionated RT (total dose 26 Gy in 5 fractions over one week = 1 fraction/day or 28.5 Gy in 5 fractions over 5 weeks = 1 \nfraction/week)1b B +/-\u00a7Conventionally fractionated radiotherapy (total dose about 50 Gy\nin approx. 25 -28 fractions in 5 -6 weeks)1a B +\n*Regarding fractionation forregional nodal irradiation , refer toslide \u201eFractionation ofRadiotherapy in \nCase ofRegional Nodal Irradiation\u201c.Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRadiotherapy of the Chest Wall After Mastectomy (PMRT) in \nCase of 1 -3 Axillary Lymph Node Metastases\nER pos, G1, HER2 neg, pT1\n(at least 3 criteria present)\u2265 45 y. AND > 25% pos. ax. Lnn  in case of \naxillary dissection  OR\n<45 y. AND (ER neg. OR>25% pos. ax. Lnn in case \nof axillary dissection OR medial tumor location)\n< 40 y. OR\nHER2 pos. OR\nlymphovascular invasion\nG3 OR\nlymphovascular invasion OR\ntriple negativeKyndi et al. 2009\nTruong et al. 2005\nShen H et al. 2015\nDifferent publicationsPMRT \ncan be omitted\nLoE 3b B AGO +PMRT \nrecommended\nLoE 3b B AGO +\nPatients, who \ndon\u2018t fulfill\nthe mentioned \ncriteria for\nhigh or low\nriskPMRT\nto be discussed\nLoE 3b B AGO + /-\nComment: In case of an indication for radiotherapy of regional lymph nodes, \nradiotherapy of the chest wall should also be administeredAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBoost in PMRT\n\u00a7An additional boost irradiation to a part of the chest wall has not \nbeen shown to improve DSS and overall survival\n\u00a7An additional boost irradiation to a part of the chest wall should be \ngiven in case of of R1 / R2 -resection, if secondary resection is not \nfeasible\n\u00a7In case of tumor extention to the pectoral resection margin, but no \nclinical signs of extention beyond the fascia, the resection margin \nshould be regarded as R0 (provided, that the pectoral fascia was \nresected). A boost radiotherapy is not required in this situationOxford\nLoE GR AGO\n2a B\n5 D ++\n5 D ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRadiotherapy of Axillary Lymph Nodes in Patients with \nPositive Sentinel -Lymph Nodes**, Who Did not \nUndergo Axillary Dissection \nOxford\nLoE GR AGOBCS and ACOSOG Z0011-criteria+met\n\u00a7Radiotherapy of the breast including LN level 1 + 2 to 5 mm below\nthe axillary vein (PTV)2b B +*BCS and ACOSOG Z0011-criteria+notmet\u00a7Radiotherapy of the axillary lymph nodes (analog AMAROS)1b B ++*ME and chest wall RT indicated and ACOSOG Z011-criteria+notmet or ME and chest wall RT not planned\u00a7Radiotherapy of the axillary lymph nodes (analog AMAROS) 1b B ++\u2265 3 pos. SLN\u00a7Radiotherapy of the axillary lymph nodes (analog AMAROS) 1b B+\n*Study participation recommended\n** Macrometastases\n+< T3, no palpable LN, R0, 1 -2 positive SN, noNACTAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n1Incidental dose toparts oflevel i/II isinevitable . 2The indication forsupra -/infraclavicular and internal mammary node RT hastobeassessed\nseparately . 3Cranial border 5 mm below theaxillary vein . 4< T3, nopalpable LN, R0, 1 -2 positive SN, noNACT, always in conjunction with supra -\n/infraclavicular RTAdditional RT of the Axilla after Primary Surgery\n(in case of an indication for RT of the breast/chest wall1+/-supra -/infraclavicular \nand internal mammary node RT2)\nExpansion of the PTV (planning target volume) to level I -II3Oxford\nLoE GR AGO\npN-status\npN0(sn) / pN1mic(sn) 1b B --\npN0/+ after ALND 1a A --\npN+(sn) in analogy to ACOSOG Z0011 (no ALND) 2b B +\npN+(sn) not fitting ACOSOG Z0011 -criteria \u00e0RT in analogy to AMAROS4 \n(no ALND)1b B ++\nR2-situation in the axilla 5 D ++Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n1Incidental dose to parts of level i/II is inevitable. 2The indication for supra-/infraclavicular and internal mammary node RT has to be assessed \nseparately. 3Cranial border 5 mm below the axillary vein. 4Study participation recommended. Additional RT oftheAxilla after Neoadjuvant Therapy\n(in case ofan indication forRT ofthebreast /chest wall1+/-supra -/ infraclavicular\nand internal mammary node RT2)\nExpansion ofthePTV ( planning target volume ) tolevel I-II3Oxford\nLoE GR AGO\nN-status\npre/post\nNACTpN-status\ncN0 / ycN0 ypN0(sn) 5D -\ncN0 / ycN0 ypN1mic(sn) / ypN+(sn)\n(no ALND)5D +4\ncN+ CNB/ ycN0 ypN0(sn/TAD) 5D +/-4\ncN+ CNB/\nycN0ypN1mic(sn/TAD) / ypN+(sn/TAD)\n(no ALND)5D +4\ncN0/cN+ ypN0/+ after ALND 2b B-\nR2-situation in theaxilla 5D ++Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nACOSOG Z0011 Trial\n45%  micrometast. in the exp. arm\n2% no RT\nData from 228/856 pat.\u201ehigh tangent\u201csupra -\nclavicularmean         encompassed\nLN level 1 dose *     volume **\nAMAROS           > 95% > 95%\nhigh tangent 86% 79%\nstandard tangent           66%             51% \nIMRT+ 29% 1%\nLN-level 2\nAMAROS        > 95% > 95%   \nhigh tangent 71% 51%\nstandard  tangent           44%            26% \nIMRT+ 7%               0%\n*   in relation to the prescribed dose in the breast\n**  % volume receiving the prescribed dose\n+  Lee et al. Medicine 2016 (3)\u201estandard\ntangent\u201cDose in theAxillary LN-levels I + II Using Different RT -\nTechniques\nAMAROS\nJagsi (2) : \u201cThe results of Z0011 should not be extrapolated to patients who receive RT \nusing partial -breast or prone techniques, in which substantially less of the axilla is \nincluded\u201dIII17%\n53%\n28%axillary veinRT-volume\n% of  patients\nbreast\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRadiotherapy (RT) of Other Locoregional \nLymph Node Areas (SCG / ICG)\nOxford\nLoE GR AGORT to supra-/ infraclavicular lymphatic regions\u00a7\u2265 4 positive axillary lymph nodes (LN) or involved LN in \nlevel III or in supra -/ infraclavicular LN1b A ++\u00a71\u20133 positive axillary lymph nodes1in case of 2a B +\n-central or medial tumor and G2 -3 or HR -negative\n-premenopausal patient and G2 -3 or HR -negative\u00a7pN0 with central or medial tumors, if premenopausal and \nG2-3 and HR -negative2a B +/-\n1not applicable for micrometastasesAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRadiotherapy (RT) of Other Locoregional \nLymph Node Areas  (IMN) \nOxford\nLoE GR AGOInternal mammary lymph node region (IMN)\u00a7pN0 high -risk with central or medial tumor and premenopausal \nand G2 -3 and ER/PR -negative1b B +/-\u00a71\u20133 positive axillary lymph nodes1in case of 2a B +\n-central or medial tumor\n-HR-negative\u00a7\u2265 4 positive axillary lymph nodes 2a B +\u00a7involved internal mammary lymph nodes 2a B +\u00a7In case ofleft-sided breast cancer with elevated cardiac risk orif\nsimultaneous HER2 -targeted therapy isgiven2b A -\n1not applicable for micrometastasesAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRadiotherapy totheinternal mammary nodes\nDBCG -IMN KROG 15 -03\nPatient number 3089 735\nTimeframe 2003 -2007 2008 -2013\nMedian FU 14.8 years 8.3 years\nDesign Prospective cohort study , right -sided\ntreated with IMNI, left-sided without\nIMNI. All received SCV-RT.Randomized controlled trial\nAll received SCV-RT, randomization to+/-\nIMNI.\nInclusion criteria N+, noNACT N+, ALND with \u22658 lymph nodes , noNACT\nStratification All patients Medial/central lateral\nDistant recurrence HR 0.88 (0.78 -0.99) HR 0.44 (0.23 -0.85) HR 1.07 (0.68 -1.68)\nBreast -cancer mortality HR 0.88 (0.78 -1.00) HR 0.41 (0.17 -0.99) 0.91 (0.53 -1.57)\nOverall survival HR 0.86 (.77 -0.96) HR 0.51 (0.24 -1.11) 1.07 (0.64 -1.77)\nSubgroup analysis No benefit in 1 -3 LN+ with lateral tumor, \nlarger benefit with N2 -3Benefit forER/PR -negative tumors (p-\ninteraction = 0.03)Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFractionation of Radiotherapy in Case of \nRegional Nodal Irradiation\nOxford\nLoE GR AGO\u00a7Conventionally fractionated radiotherapy\n(total dose about 50 Gy in approx. 25 -28 fractions\nwithin 5\u20136 weeks)1a A ++\u00a7Moderately hypofractionated radiotherapy\n(total dose approx. 40\u201343.5 Gy in 15 -16 fractions within \n3\u20135 weeks)1baB +\u00a7Ultra -hypofractionated RT (total dose 26 Gy in 5 fractions\nover one week = 1 fraction /day)2b B -\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nHypofractionated regional nodal irradiation\nSTART -P/A/B\nsubgroupsWang et al. DBCG Skagen 1\n(Abstract)FAST -Forward Nodal \nsubstudy (Abstract)\nPatient number 864 820 2963 469\nFractionation 39-42.9 Gy in 13 -15 fx 43.5 Gy in 15 Fx 40 Gy in 15 Fx 26 Gy / 27 Gy in 5 Fx\nMedian FU 10 years 58.5 months 3 years ?\nPrimary endpoint Late normal tissue \neffectsLocoregional \nrecurrenceLymphedema at 3 \nyearsArm/hand swelling at \n5 years\nStatistical design Retrospective analysis Non-inferiority Non -inferiority Non -inferiority\nResults No statistically \nsignificant differences \nfor LRR or late normal \ntissue effectsNon-inferiority for LRR (primary analysis)No increased risk of \nlymphedema or LRR\n(primary analysis) Noincreased riskof\nlate normal tissue\neffects (preliminary\ndata at 2-3 years )Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRadiotherapy following NACT\nPretreatment\nPost- treatmentRT-BCS PMRT RNI* Oxford\nAGO LoE GR\nLocally advanced pCR / no pCR yes yes yes++/++/++ 1a/1a/1a A/A/A\ncT1/2  cN1+* ypT1+ or ypN1\n+( n o  p C R )yes yes yes++/+/+ 1a/2b/2b A/B/B\ncT1/2  cN1+* ypT0/is  ypN0 yes Increased risk of relapse1 +/+/+ 2b/2b/2b B/B/B\ncT1/2  cN0\n(Sonogr . obligatory )ypN+ orypT3/4 yes yes yes+/+/+ 2b/2b/2b B/B/B\ncT1/2  cN0\n(Sonogr. obligatory)ypT0/ isypN0 yes no no+/-/- 2b/2b/2b A/B/B\ncT1/2  cN0\n(Sonogr. obligatory)ypT1-2  ypN0 yes no no+/-/- 2b/2b/2b A/B/B\nLocally advanced : T3-4 orcN2-N3\n1Criteria for increased risk of relapse: \n\u00a7 pN0 premenopausal high risk: central ormedium tumor localization , and (G2-3 and ER/PR -neg.)\n\u00a7 pretreatment pN1a/ cN+* high risk: central ormedium tumor localization and (G2 -3 or ER/PR -neg.) or\npremenopausal, lateral tumor localization and  (G2 -3 or ER/PR -neg.)\n* Regarding coverage ofaxilla level I/II please also see slides \u201eAdditional RT oftheaxilla after primary surgery \u201c and\n\u201eAdditional RT oftheaxilla after neoadjuvant therapy \u201c. ** = confirmed bycore biopsyAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMolecular Predictors and Use of Radiotherapy \nOxford\nLoE GR AGO\u00a7Results of gene expression profiling should not be\nused for indication of radiotherapy2b B ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deUse of Concomitant Systemic Therapy\nwith Adjuvant Locoregional Radiotherapy \nOxford\nLoE GR AGO\u00a7Trastuzumab / Pertuzumab* 1a A ++\u00a7T-DM1 1b A +\u00a7Tamoxifen 2b B +\u00a7Aromatase inhibitors 2b B +\u00a7Checkpoint inhibitors 2b C +\u00a7Capecitabine** 2b B +\u00a7CDK4/6 -inhibitors*** 4 C +/-\u00a7Olaparib**** 2b C +/-\n* Simultaneous parasternal RT should be avoided in patients with HER2 -positive tumors and tumor -localisation on    \nthe left side\n**     With hypofractionated RT approx . 40 Gy, consider dose reduction ofCapecitabine , Pat. with high risk for\nlocoregional recurrence\n***    In currently available phase III-trials ( monarchE , PALLAS, Penelope -B) RT was given before initiation ofCDK4/6 -\ninhibitors . Nodefinitive signs ofsignificantly increased toxicity with concomitant RT in thepalliative setting .\n**** In currently available phase III-trials, RT was given before initiation ofOlaparib .Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nSimultaneous Capecitabine wi th Locoregional \nRadiotherapy\nWoodward et al. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):777 -783\n\u2022 Prospective phase trial, 32 pat. with LABC, sim. def. / neoadj. chemoradiotherapy, median total \ndose 66 Gy\n\u2022 \u201cThe first 9 patients analyzed [\u2026] received CAP 825 mg/m2twice daily continuously beginning \non the first day of RT. Because of observed excess grade 3 toxicity the protocol was amended, \nand subsequent patients received CAP only on RT days (5 days per week).\u201d\n\u2022 \u201cNoncontinuous CAP dosing was much better tolerated than continuous dosing. Thirteen of 26 \npatients (50%) had grade \u2265 3 and higher treatment -related dermatologic toxicity . \u201c\nAlhanafy et al. Menoufia Medical Journal 2015, 28:325 -332 \n\u2022 Randomised phase II -trial, 100 pat., adj. Radiotherapy 40 Gy / 15 fr. +/ -CAP 825 mg/m2 Mo -Fr, \nLABC\n\u2022 \u201c [\u2026] concurrent capecitabine was feasible with a high percent of patients (96%), [\u2026] only two \nout of 50 (4%) patients had capecitabine dose modification \u2026\u201d.\n\u2022 \u201cAll early toxicities were GI/GII. Radiation dermatitis had  a peak incidence in the last few \nfractions of the radiation therapy and the week after radiotherapy; no treatment interruption \nwas needed and the incidence was close in both groups\u201d. \n\u2022 Radiation dermatitis grade I 14% vs. 18%; grade 2 4% vs. 4%Adjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSmoking and Risk\nof Secondary Lung Cancer\nOxford\nLoE GR AGO\u00a7Increased risk of lung cancer secondary to breast\ncancer radiotherapy in smokers1a A\u00a7Inform patients about risk ++\u00a7Recommend smoking cessation ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ESupportive Care and \nManagement of Side Effects\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSupportive Care and \nManagement of Side Effects\n\u00a7Versions 2002 \u20132022:\nAlbert / Bauerfeind / Brunnert / Bischoff / Costa / Dall / Diel / Fersis / \nFriedrich / Friedrichs / Gerber / G\u00f6hring / Hanf / Harbeck / Heinrich / \nHuober / Jackisch / Lisboa / L\u00fcck / L\u00fcftner / von Minckwitz / M\u00f6bus / \nM\u00fcller / Mundhenke / Nitz / Oberhoff / Reimer/ Rody / Schaller / Scharl / \nSchmidt / Schneeweiss /Sch\u00fctz / Solomayer / Souchon / Stickeler / \nThomssen / Untch\n\u00a7Version 2023:\nMaass / Park- Simon\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGuidelines \u2013Evidence\nSpecific national and international guidelines deal with various aspects of \nevidence -based supportive therapy of cancer patients.\nWithout claiming completeness, such guidelines will be quoted, with an \nemphasis on German guidelines.\nAspects concerning breast cancer patients will especially be highlighted.\nThe \u201eArbeitsgemeinschaft Supportive Ma\u00dfnahmen in der Onkologie, \nRehabilitation und Sozialmedizin der DKG\u201c should especially be\nhighlighted (http://www.onkosupport.de).\nMultidisciplinary S 3 guidelines of the AWMF (Reg. -Nr. 032 -054OL): \n\u00a7S3-Leitlinie: Supportive Therapie bei onkologischen Patientinnen \nLangversion 1.3 \u2013Februar 2020 AWMF -Registernummer: 032/054OLSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Acute toxicity (NCI -CTCAE)\n\u00a7Long term toxicity (ICPC, ICD -GM)Toxicity Assessment\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deToxicity Assessment\nAcute Toxicity (according to WHO1or NCI -CTC\u00b2)Acute toxicities should be asked for and documented after every treatment courseLoE 5 D  AGO ++GradeInformation required0 noneorgans involved1 mildtype of toxicity2 moderatetime interval after treatment3 severeeffect on general health status4 life threateningtreatment required5 deathrecovery achievedLong term toxicity (= secondary diseases after tumour therapy)Long term surveillance and documentation in regular intervals (acc. ICPC\u00b3 following symptoms or acc. ICD-10-GM4following  diagnoses)LoE5 D AGO ++Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Grade 1 \nMild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not \nindicated.\n\u00a7Grade 2 \nModerate; minimal, local or noninvasive intervention indicated; limiting age -appropriate \ninstrumental ADL*.\n\u00a7Grade 3 \nSevere or medically significant but not immediately life -threatening; hospitalization or \nprolongation of hospitalization indicated; disabling; limiting self care ADL**.\n\u00a7Grade 4 \nLife-threatening consequences; urgent intervention indicated.\n\u00a7Grade 5 \nDeath related to AE.Acute Toxicity (NCI CTCAE v 5.0, 2017)\nActivities of Daily Living (ADL)\n*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.\n**Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not \nbedridden.Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7According to product information by \nMedDRA* classification\n*MedDRA -Medical Dictionary for Regulatory ActivitiesIncidence of Side Effects\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy \u2013Acute Toxicities I\nListing and grading of side effects was performed according the MedDRA -classification with the following categories of frequency :1. Very rarely (<1/10,000); 2. rarely (\u2265 1/1,000 to < \n1/10,000); 3. occasionally (\u2265 1/1,000 to < 1/100);  4. frequently (\u2265 1/100 to < 1/10); 5. very frequently (\u2265 1/10).  -unknown ( based on available data incidence not assessable)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy \u2013Acute Toxicities II\nListing and grading of side effects was performed according the MedDRA -classification with the following categories of frequency : 1. Very rarely (<1/10,000); \n2. rarely (\u2265 1/1,000 to < 1/10,000); 3. occasionally (\u2265 1/1,000 to < 1/100); 4. frequently (\u2265 1/100 to < 1/10); 5. very frequ ently (\u2265 1/10).\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnostics* before Start of\n5-FU (i.v.) / Capecitabine -Therapy\nOxford\nLoE GR AGO\u25aaDPD (Dihydropyrimidin -Dehydrogenase) -\nDeficiency Testing ( DPYD -Genotype or Phenotype)\nPhenotype determination (e.g. uracil in plasma / urine, determination of DPD -\nactivity) are less standardized assays1a A ++\n* Recommendation according to Medical Alert (Rote -Hand -Brief) 4.6.2020\n** Sharma et al, Oncologist 2021Systematic review (cancer patients under 5 -FU therapy)**:\n\u00a7DPYD -variants (heterozygous or homozygous) 4.1%\n\u00a7Therapy -associated mortality 2.3% (vs. 0.1% w/o DPYD -variants) \u2013risk for therapy -\nassociated death 25.6 -fold increaseSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine Therapy \u2013Toxicities\nListing and grading of side effects was performed according the MedDRA -classification with the following categories of frequency :\n1. Very rarely (< 1/10,000); 2. rarely (\u2265 1/1,000 to < 1/10,000); 3. occasionally (\u2265 1/1,000 to < 1/100); 4. frequently (\u2265 1/ 100 to < 1/10); 5. very frequently (\u2265 1/10). \n-unknown (based on available data incidence not assessable)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deKey-Toxicities \u2013Antibodies\nOxford\nLoE GRTrastuzumab\u00a7 Cardiotoxicity in the adjuvant setting (1.0 \u20132.0%) 1b A\n\u00a7 Troponin I may identify patients at risk for cardiotoxicity 2b BPertuzumab\u00a7 Skin rash, diarrhea, mucositisBevacizumab1b A\n\u00a7 Hypertension, proteinuria , bleeding , leftventricular dysfunction 1a A\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deToxicities of New Compounds: anti-HER2-TKI \n\u2013Neratinib, Lapatinib \u2013AE, %Alle Grade Grad >/=3Diarrhea90 40,1Nausea43 2Abdominal pain36 2Fatigue27 2Emesis26 3Exanthema18 0,6Stomatitis14 0,6Appetite loss12 0,2Dyspepsia10 0,4ALAT elevated9 1,2ASAT elevated7 0,7Nail disorders8 0,3Dry skin6 0Lapatinib NeratinibAE, %All grades Grade >/=3Diarrhea61% 6%Nausea18% 4%Rash60% 6%Fatigue16% 4%Cardiac3% < 1% SAEHepatobiliary8%All AE %92% SAE 6%\nLoE GRAGOPrimary prophylaxis with loperamide 2b B ++Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCommon Toxicities with anti -HER2-TKI: \nTucatinib + Trastuzumab + Capecitabine\nEvent Capecitabine + Tucatinib + Trastuzumab\nAny grade (%)                                    \u2265 3 grade (%)\nAny adverse event 99.3 55.2\nDiarrhea 80.9 12.9\nPPE syndrome 63.4 13.1\nNausea 58.4 3.7\nFatigue 45.0 4.7\nVomiting 35.9 3.0\nStomatitis 25.5 2.5\nReduced appetite 24.8 0.5\nHeadache 21.5 0.5Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deKey-Toxicities \u2013\nAntibody -Drug -Conjugates\nOxford\nLoE GRSacituzumab Govitecan\u00a7 (Febrile) neutropenia, leukopenia, anemia, diarrhea, nausea, alopecia 1b ATrastuzumab-Emtansin (T-DM1) \n\u25aa Thrombozytopenia , elevation liver enzymes, pyrrexia , headache\npneumonitis, neuropathy1b ATrastuzumab-Deruxtecan\n\u25aa Interstitial lung disease, neuropenia, nausea, alopecia , 1b A\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deToxicities of CDK 4/6 Inhibitors \n(Palbociclib / Ribociclib / Abemaciclib)UE, %All Grades Grade 3 Grade 4Neutropenia79,5/ 74,3 /41,3 56,1/ 49,7 /19,6 10,4/ 9,6/1,5Leukopenia39,0/ 32,9 /20,8 24,1/ 19,8 /7,3 0,7/ 1,2/0,3\nAnemia 24,1/ 18,6 /28,4 5,2/ 0,9/5,8 0,2/ 0,3/0\nThrombocytopenia 15,5/ 5,7/10,0 1,4/ 0,6/2,0 0,2/ 0/< 1,0Fatigue37,4/ 36,5 /40,1 1,8/ 2,1/1,8 0/0,3/0Nausea35,1/ 51,5 /38,5 0,2/ 2,4/0,9 0/0/0Vomiting15,5/ 29,3 /28,4 0,5/ 3,6/1,2 0/0/0Diarrhea26,1/ 35,0 /81,3 1,4/ 1,2/9,5 0/0/0Alopecia32,9/ 33,2 /26,6 - -Exantheme17,8/ 17,1 /14,0 0,9/ 0,6/< 1,0 0/0/0ALT elevated 9,9/ 15,6 /15,6 1,7/ 7,5/5,8 0,1/ 1,8/0,3AST elevated 9,7/ 15,0 /15,0 2,5/ 4,8/3,0 0/0,9/0Infections60/50,3 /39,1 6,0/ 3,6/4,0 1/0,6/0,9QT-prolongation N.A./ 7,5/N.A. N.A./ 3,0/N.A. N.A./ 0/N.A.Palbociclib/Ribociclib /AbemaciclibSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nInterstitial Lung Disease (ILD) \nand CDK 4/6 Inhibitors\nPulmonary toxicity of cyclin -dependent kinase (CDK) 4/6 inhibitors from the publicly available \nFDA Adverse Event Reporting System (FAERS):\n\u2022 2.1% of all reports for abemaciclib; 0.3% of all reports palbociclib / ribociclib\n\u2022 Increased reporting found for\n\u2022 CDK4/6 inhibitors vs. other drugs (ROR = 1.50; 95% CI = 1.28 \u20131.74) \n\u2022 Abemaciclib vs other anticancer agents (4.70; 3.62 \u20135.98).\nOverall incidence: \nSystematic review of published data: \nCDK 4/6i: Any grade 1.64% (0.68% control). Pooled RR 2.26, 95% CI: 1.60 -3.19, p < 0.00001\nCDK 4/6i: Grade 3/4 0.28% (0.06% control). Pooled RR 2.35, 95% CI: 0.37 -15.08, p = 0.37\nMonarch -E: \nAbemaciclib any grade 2.9% ( >G3 0.4% -1 G5 event); control 1.2% ( >G3 n = 1; 0%)Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nVenous Thromboembolic Events:\nAdjuvant Abemaciclib (Monarch -E trial)\nAbemaciclib : All grade 2.3% (grade 3/4  1.2%)  \nControl arm:  All grade 0.5%  (grade 3/4  0.1%)\nCharacterization of VTE (DVT or PE)*\n\u2022VTE by first ET = AI\n\u2022Abemaciclib: any grade 1.7% (G3/4  0.9%)\n\u2022Control arm: any grade 0.5% (G3/4  0.2%)\n\u2022VTE by first ET = tamoxifen\n\u2022Abemaciclib: any grade 4.1% (G3/4  2.2%)\n\u2022Control arm: any grade 0.7% (G3/4  0.4%)\n* DVT is a composite term for several forms of venous thrombosis; PE is a composite term including \nembolism and pulmonary embolismSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nQT-Interval -Prolongation: \nRibociclib v s. Placebo\n\u25aaPost -baseline prolongation QT -interval > 480 msec 6,9 % vs. 1,2 %\n\u25aaPost -baseline prolongation QT -interval > 500 msec 1,5 % vs. 0,3 %\n\u25aaDicsontinuation due to  QT -interval prolongation 0,3 % vs. 0,6 %\n\u25aaProlongation of QT -interval is not associated with clinical symptoms , but\nwith an increased risk of the life -threatening arrhythmia torsades de\npointes (TdP)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deToxicities of mTOR -Inhibitor (Everolimus) \nUE, % All grades (%) grade >/=3 (%)\nStomatitis 11,6 1,6\nExanthema 7,4 0,02\nAnemia 3,3 1,3\nFatigue 6,8 0,8\nNausea 5,6 0\nEmesis / Vomiting 2,9 0\nDiarrhea 6,2 0,02\nLoss ofappetite 6,0 0,02\nHeadache 3,9 0\nWeight loss 3,9 0\nDyspnea 3,8 0,08\nArthralgia 3,3 0\nEpistaxis 3,1 0\nEdema 2,9 0\nConstipation 2,6\nPyrexia 2,9 0\nCough 4,5 0\nALT Elevated 2,6 0\nPneumonitis 0,2 0\nAsthenia 2,4 0,04\nDysgeusia 4,3 0Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deToxicities of PI3K Inhibitor Alpelisib in \nCombination with Endocrine Therapy UE, %All Grade Grad >/=3Hypergycemia63,7% 32,7%Diarrhea57,7% 6,7%Nausea44,7% 2,5%Decreased appetite35,6% < 1% SAERush35,5% 9,9%Vomiting27,1% < 1% SAEWeight loss26,8% 3,9%Stomatitis24,6% 2,5%Fatique24,3% 3,5Asthenia20,4% 1,8Alopecia19,7% 0Mucositis18,3% 2,1Alpelisib + Fulvestrant\nRegard recommendations for \nmanagement of side effects (Diabetes \nmellitus, hyperglycemia, Insulin resistance \nund metabolic syndrom)\nAndre F, et al N Engl J Med 2019;380:1929 -1940LoEGRAGO\n2b B ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deToxicities of PARP -Inhibitors\n\u2013Olaparib, TalazoparibAE. %all grades (%) grade >/=3 (%)AE, overall97.1 36.6Neutropenia27.3 9.3Anemia40.0 16.1Fatigue28.8 2.9Nausea58.0 0Emesis29.8 0Diarrhea20.5 0.5Appetite loss16.1 0Headache20.0 1Pyrexia14.1 0Cough17.1 0ALT elevated11.2 1.5AST elevated 9.3 2.4PPE0.5Treatm. discontinuation4.9Olaparib TalazoparibAE. %all grades (%) grade >/=3 (%)AE, overall98,6 31,8neutropenia34,6 20.9Anemia52.8 39,2Fatigue50,3 1,7Nuasea48,6 0,3Emesis24,8 2,4Diarrhea22,0 0,7Appetite loss21,3 0,3Headache32,5 1,7Back pain21,0 2,4Dyspnea17,5 2,4Pleural effusion2,1 1,7PPE1,4 0,3Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deImmune Checkpoint Inhibitors\n\u00a7Therapeutic approaches (antibodies)\n\u00a7PD-1 / PD -L1\nPD-1\n\u00a7Nivolumab\n\u00a7Pembrolizumab\nPD-L1\n\u00a7Atezolizumab\n\u00a7Durvalumab\n\u00a7Avelumab\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nImmune Checkpoint Inhibitors\nTime Course of Adverse Events, e.g. Ipilimumab\nHaanen J et al. Ann Oncol 2017; 28 (suppl 4): 119 -142\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nImmune Checkpoint Inhibitors\n\u2013Side Effects \u2013\n\u00a7Adverse events \u2265 grade 3\n\u00a7diarrhea\n\u00a7fatigue\n\u00a7skin lesions (maculopapular exanthema, vitiligo, epidermolysis)\n\u00a7pneumonitis\n\u00a7colitis\n\u00a7hypophysitis\n\u00a7hepatitis\n\u00a7nephritis\n\u00a7thyreoiditis (hyper -/ hypothyroidism)\n\u00a7Guillain -Barr\u00e9 syndrome\n\u00a7cardiomyopathy\n\u00a7myopathy \u2013myalgia \u2013rhabdomyolysis\n\u00a7uveitisSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deImmune Checkpoint Inhibitors\nToxicities (Total in %)\natezolizumab nivolumab pembrolizumabdiarrhea18.6% 13% 18%colitis1.1% 2% 1% exanthema18.6% 15% < 1%hepatoxicity0.3% 1% 0.5%hypophysitis< 0.1% < 1% 0.5%pneumonitis3.1% 3% 2.9%thyroid dysfunctionhyper -1.7%\nhypo -4.7%hyper -1%\nhypo -4%hyper -1.2%\nhypo -8.3%nephritis< 1% 1% 0.7%neuropathy0.2% < 1% < 1%\nAtezolizumab technical product information 2018; Nivolumab, safety management BMS 2014; Pembrolizumab PI 2014 Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deImmune Checkpoint Inhibitors\nPrinciples of Adverse Event ManagementCTC AE-GradeManagement1\u00a7supportive therapy\u00a7close examination\u00a7exclusion of infective complications\u00a7patient information\n2Like grade 1 but\u00a7intermission of therapy until recovery of all irAE to grades 0 -1\u00a7consider corticosteroids\n3\u00a7supportive therapy\u00a7IV steroids (e.g. 1 -2 mg/kg prednisolone)In case of no improvement within 48 h:\u00a7consider additional immunosuppressive therapy (infliximab, MMF)\u00a7consider further organ specific diagnostics (eg. colonoscopy)\u00a7consider specialists consultations\u00a7exclusion or treatment of infection\u00a7stop of treatment, re -initiation after recovery to CTC AE grades 0, 1\u00a7slow reduction of steroids (3 -6 weeks)\n4Like grade 3 but persistent withdrawal of therapySupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePneumonitis\nCourtesy of Andreas Schneeweiss, NCISupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nCourtesy of Andreas Schneeweiss, NCIRenal toxicity\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHypophysitis\nHaanen et al.: ESMO guideline. Ann Oncol 2017\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nCourtesy of Andreas Schneeweiss, NCIDiarrhea and Colitis\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHepatitis\nCourtesy of Andreas Schneeweiss, NCISupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deThyreoiditis\nCourtesy of Andreas Schneeweiss, NCISupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n1.Infections\n\u00a7General prophylaxis for infections\n\u00a7Hepatitis B virus screening\n\u00a7Covid -19 (see joint guidelines with DGHO)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7Avoidance of highly infection -risking \nbehavior or situations5 D +\u00a7Prophylactic treatment in low -risk patients 1a B -\u00a7Prophylactic treatment in high -risk* patients \n(e.g. according to NCCN Guidelines) with\n\u00a7Antibiotics 1a A ++\n\u00a7Anti -fungal agents (triazole) 1a B +/-\n\u00a7Virostatics in solid tumors 5 D -\n\u00a7Granulocyte colony -stimulating factors 1a A ++\n*High risk: estimated duration of neutropenia < 100/\u00b5l > 7d Prophylaxis of Infections\nrarely Applicable to Patients with Solid Tumors (e.g. BC)\nASCO Practice Guideline \u201eAntimicrobial Prophylaxis...\u201c 2018\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxfordLoEGRAGO\u00a7Hepatitis B virus screening before adjuvant chemotherapy \n(HBsAG, anti -HBC, anti -HBs)2c B +In case of positive serology or reactivation:\u00a7Prophylactic therapy with virustatic drugs if HBV -DNA \ndetected (according AGIHO / DGHO \u2013recommendations)1b A ++\u00a7Hepatitis C virus screening before chemotherapy 5 D +/-Hepatitis B Virus Screening before \nChemotherapy\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAGIHO / DGH O \u2013Recommendations on \nHepatitis B Virus Screening in Oncology\nSandherr M et al. Ann Hematol. 2015 Sep;94(9):1441 -50\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n2.Neoplasms benign, malignant and unspecified \n(incl. cysts and polyps)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSecondary Malignancies I\nOxfordLoEGR\u00a7With regard to solid tumors, chemotherapy induced secondary \nmalignancies are rare events2a\u00a7Alkylating agents increase the risk of leukemia dose -dependently to a total of 0.2 \u20130.4% within 10 \u201315 years2a\u00a7Anthracycline -containing regimens increase the risk of MDS and \nleukemia to 0.2 \u20131.7% within 8 to 10 years2a\u00a7PARP -inhibitors are associated with an increased risk of AML and \nMDS to 0.5 \u20131%2b\u00a7Radiotherapy increases the risk of leukemia by 0.2 \u20130.4% in patients \ntreated with anthracycline -containing chemotherapy2b\u00a7Tamoxifen approximately doubles the risk for developing endometrial cancer (in pts. older than 55 yrs. at start of therapy)2bSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSecondary Malignancies II\n(After Radiotherapy)OxfordLoE\u00a7Radiotherapy (PMRT, BET) may moderately enhance the risk of \nipsilateral lung cancer and angiosarcoma (10 -15/10.000) 5 \u201310 \nyears after treatment1a\n\u00a7Enhanced risk especially among ever smokers 2b\n\u00a7No difference of secondary malignancy between PBI und WBI 2c\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n3.Blood and Lymphatic System Disorders\n\u00a7Anemia\n\u00a7Neutropenia\n\u00a7Febrile Neutropenia (FN)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAnemia \u2013Indications for Therapy with \nErythropoiesis- stimulating Agents (ESAs)\nOxford\nLoE GR AGO\u00a7Indicated in asymptomatic anemia 1a B-\u00a7Therapy and secondary prophylaxis in CTx -induced\nanemia1a A+\n\u00a7 Adjuvant setting 1b A+\n\u00a7 Neoadjuvant / metastatic setting 1a A +/-\n\u00a7 In dose -dense / dose -escalated CTx (iddETC) 1b A+\u00a7Treatment start at Hb -levels < 10 g/dL 1a A+\u00a7Target Hb 11 \u201312 g/dL 1a A+\u00a7Improvement of outcome (DFS, OS) 1a B --\u00a7Risk of thromboembolic events is increased by use of ESAs1a ASupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Epoetin \u03b1 and Darbepoetin are equieffective\n\u00a7Dosage:\n\u00a7Epoetin \u03b1: 150 IU/kg 3 x weekly s.c. or\n40.000 IU 1 x /week s.c. or\n80.000 IU  q2w s.c. or\n120.000 IU q3w s.c.\n\u00a7Epoetin \u00df: 30.000 IE weekly s.c.\n\u00a7Darbepoetin: 2,25 \u00b5g/kg s.c. weekly or  500 \u00b5g s.c. q3w\n\u00a7Weekly hematologic blood controls\n\u00a7Dose reduction if Hb -increase > 1g/dl within 2 weeks\n\u00a7Dose increase if Hb -increase < 1g/dl  within 4 -6 weeks\n\u00a7In case of FID (\u201cfunctional iron deficiency\u201d) iron supplementation,    \npreferably i.v.\n\u00a7Stop ESA -treatment if there is no Hb increase after 9 weeksPractical Use of ESAs\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGranulocyte Colony -Stimulating Factors\nOxford\nLoE GR AGO\u00a7Primary prophylaxis for expected febrile neutropenia (FN)\n\u00a7 If expected risk for FN 10 \u201320% 1b B +/-\n\u00a7 In case of individual risk factors 3b C +\n\u00a7 If expected risk for FN > 20% (e.g. DAC, dose -dense CT) 1a A ++\u00a7Secondary prophylaxis during chemotherapy \n(previous FN or neutropenia grade IV > 7 days)1b A ++\u00a7Therapeutic usefor FN 1a A +/-\u00a7Start related to chemotherapy and duration\n\u00a7 Pegfilgrastim day 2 1b A ++\n\u00a7 Lipegfilgrastim day 2 1b A ++\n\u00a7 Filgrastim / Lenograstim from day 2 \u20133 until ANC > 2 \u20133 x 1091b A ++Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deManagement of Febrile Neutropenia\nc.f. Recommendations by Arbeitsgemeinschaft Infektionen in der H\u00e4matologie und Onkologie \n(AGIHO) der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und Onkologie e.V. (DGHO) www.dgho -\ninfektionen.de\nDefinition (oral temperature of > 38.5 \u2103or two consecutive readings of > 38 \u2103for 2 h in a patient with \nan ANC of < 500 cells/mm3or expected to fall to <500 cells/mm3) Oxford\nLoE GR AGO\u00a7Clinical examination 5 D ++\u00a7Daily evaluation 5 D ++\u00a7Hospitalization of high -risk patients 1b A ++\u00a7Homecare in low -risk patients 1b A +\u00a7Differential blood count 5 D ++\u00a7Blood cultures 5 D ++\u00a7Imaging of lungs 3 C ++\u00a7Immediate initial lyempiric antibiotic therapy 1a A ++\u00a7Empiric antifungal therapy 4 \u20137 d in case of failure of antibiotic therapy 1b A ++\u00a7G-CSF for treatment (not prophylactic) 2b B +/-Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nEORTC and ASCO G -CSF \nGuideline -Based FN Risk Assessment\nStep 1: Assess frequency of FN associated with the planned chemotherapy regimen\nHigh risk: Age > 65 years\nIncreased risk: Advanced disease\n(level I and II evidence) History of prior FN\nNo antibiotic prophylaxis\nOther Factors: Poor performance (ECOG > 1)\n(level III and IV Female gender\nevidence) Haemoglobin < 12 g/dL\nLiver, renal or cardiovascular disease\nNutritional status\nProphylactic G -CSF recommended G-CSF prophylaxis not indicatedFN risk 10 -20% FN risk \u2265 20% FN risk < 10%\nStep 3: Define the patient\u2019s overall FN risk for planned chemotherapy regimen\nOverall FN risk \u2265 20% Overall FN risk < 20%Step 2: Assess factors that may increase the risk of FN:\nReass\ness at \neach \ncycle\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de4. Toxicities / OvariesTherapy-associated amenorrhea (CRA, CIA, TIA) Oxford\nLoE\u00a7CRA may be permanent or temporary (depending on age of the patient \nand type of chemotherapy)2b\u00a7The risk of CRA increases with patient\u2018s age and duration of the \nchemotherapy2b\u00a7CRA is an imperfect surrogate for menopause and fertility 5\u00a7Adjuvant endocrine therapy with GnRHainduces reversible amenorrhea,  but delays conception to a less fertile period5\u00a7Ovarian reserve of women who remain premenopausal \nafter CTX is reduced2b\u00a7CRA is associated with improved outcome (DFS / OS) 1b\nSynonym: Chemotherapy related or induced / Treatment induced Amenorrhea (CRA, CIA, TIA)Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n5. Psychiatric Disorders \n\u00a7Depression\n\u00a7Fatigue\n\u00a7Cognitive impairment \n\u00a7Sleep disturbances\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de(Therapy -associated) \nDepression\nOxford\nLoE GRAGO\u00a7Depression is an often reported adverse event in breast cancerpatients (20 \u201330%)2a B\u00a7Psychological interventions are effective to improve mood, butnot survival in distressed and depressed patients1b A\u00a7Antidepressants have shown to improve depression in breast\ncancer patients1b A\u00a7Regular exercise participation can prevent depression in breastcancer survivors2b B+\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de(Therapy -related) \nFatigue\nOxford\nLoE GR AGO\u00a7Fatigue frequent in breast cancer patients (30 \u201360%) 2a B\u00a7Exclusion of somatic reasons (anemia, tumor burden, \nco-morbidity, medication) for fatigue1a A ++\u00a7Psycho -social interventions specifically addressing \nfatigue efficient in reducing fatigue1a A ++\u00a7Physical exercise can improve fatigue 1b D +\u00a7Yoga can improve fatigue 2b B +\u00a7Methylphenidate or corticosteroids (short -term) can \nimprove fatigue1a D +Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de(Therapy -associated) \nCognitive Impairment\nOxfordLoEGR\u00a7Therapy -related cognitive deficits (\u201cchemobrain\u201d) frequently described (16 \u201375%)2a B\u00a7Cognitive -behavioral therapy beneficial for cognitive function2b B\u00a7Methylphenidate may improve cognitive function in cancer \npatients3a C\u00a7Under therapy with aromatase inhibitors, deterioriation of  cognitive performance was observed (espec. verbal memory) 1a B\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de(Therapy -associated) \nSleep Disturbances\nOxford\nLoEGRAGO\u00a7Sleep disturbances are a common problem in breast \ncancer patients during and after therapy (20 \u201370%)2a B\u00a7Behavioral therapies demonstrated efficacy in treatment of insomnia and improved quality of life1b A ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n6. Nervous system disorders \n\u00a7Chemotherapy -Induced Peripheral Neuropathy \n(CIPN)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy -Induced Peripheral \nNeuropathy (CIPN)\n\u00a7Incidence with taxanes:\n\u00a7Grade 1 \u20132:  20 \u201350%\n\u00a7Grade 3 \u20134: 6\u201320%\n\u00a7Risk factors: type and dose of chemotherapy, BMI, reduced physical activity\n\u00a7Individual risk factors \n\u00a7Diabetes mellitus\n\u00a7Nutritive -toxic compounds part. alcohol\n\u00a7Renal failure\n\u00a7Hypothyreosis\n\u00a7Collagenoses / vasculitis\n\u00a7Vitamine deficiency\n\u00a7HIV-Infection\n\u00a7CMT -Gen mutations\nUnclear :\n\u00a7Other genetic factors (SNPs, mutations)Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy -induced Peripheral Neuropathy\n\u2013Prevention \u2013\nOxford\nLoE GR AGO\nNon drug -based prevention\n\u00a7 Functional training (physical fitness, sensomotoric stimulation training etc.) 5 D +\n\u00a7 Compression treatment (tight surgical gloves, compression stockings) 2b B +\n\u00a7 Cooling gloves and stockings 2ba B +\n\u00a7 Elektro -acupuncture 1b B -\nDrug -based prevention\nThere is no drug -based prophylaxis available\n\u00a7 Venlafaxine 2a C +/-\n\u00a7 Palmitoylethanolamine (PEA) topically or PO 5 D +/-\n\u00a7 \u0391-lipoic -acid (thioctic acid) ,amifostine, amitriptyline, acetyl -L-car-nitine, carbamazepine, electrolyte \nsolutions, glutathione, Goshajinkigan (GJG), oxcarbazepine, vitamine B, vitamine E ,or other \ncompounds11b A -\n1For list of not recommended drugs, see Hershman et al. 2014Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy -induced Peripheral Neuropathy\n\u2013Therapy \u2013\n1For list of not recommended drugs, see Hershman et al. 2014Oxford\nLoE GR AGONon drug -based therapy\n\u00a7 Functional training (physical fitness , sensomotoric stimulation training etc.)2a C +\n\u00a7 Physiotherapy / physical treatment 5 D +\n\u00a7 acupuncture 2b B +Drug-based therapy\n\u00a7 Menthol locally (1%), capsaicin / lidocain locally 5 D +\n\u00a7 Baclofen / amitryptiline / ketamin -gel  2b B +\n\u00a7 Duloxetine for therapy of CIPN -induced pain 1b B +\n\u00a7 Opioids for therapy of CIPN -induced pain 5 D +\n\u00a7 Palmitoylethanolamine (PEA) topically orPO. 5 D +/-\n\u00a7 Venlafaxine 5 D +/-\n\u00a7 Gabapentin, pregabaline 1b B +/-\n\u00a7 Amitryptiline / nortripyline, imipramine / desipramine 1b B +/-\n\u00a7 Acetyl -L-carnitine , lamotrigine , orother compounds11b B -Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n7. Cardiac Disorders\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCardiotoxicity as Long -term Side Effect\nOxford\nLoE GR AGO\u00a7Equivalent cardiotoxicity of doxorubicin and epirubicin at recommended \ndose levels (450 \u2013500 and 900 \u20131000 mg/m\u00b2 cum. dose, resp.)2b B\u00a7Liposome encapsulated anthracyclines (doxorubicin) induce less \ncardiotoxicity1b B\u00a7Anthracycline -or trastuzumab -associated cardiotoxicity may occur \nearlier/more frequently:2b B\n\u00a7 Elderly patients, obesity, hypertension, hypercholesterinemia, \u00fcre -existing cardiac \ndisease (incl. borderline LVEF), diabetes mellitus\u00a7Monitoring of cardiac function: \n\u00a7 Standardized echocardiography (LVEF or SF in %) 3b C +\n\u00a7 ECG (QT -interval) 1a A +\n\u00a7 Troponin I as marker of cardiac toxicicty 2b B +/-\u00a7Betablocker -prohylaxis during anthracycline therapy 2a B +/-Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant Trastuzumab \nCardiac Monitoring for CHF\nOxford LoE: 5 GR: D AGO: ++\nBefore start of trastuzumab\n\u00a7History, physical examination (edema, \nhepatomegaly)\n\u00a7Echocardiography (alternative to MUGA)\nDuring trastuzumab\nRegular assessment of\n\u00a7Heart rate increase > 15% above individual base level\n\u00a7Body weight increase \u2265 2 kg/week\n\u00a7Cardiac signs and symptoms\n3 monthly assessment of LVEFAssessment\nof LVEF\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFeasibility of Treatment Combinations \nConsidering Toxicities \nOxfordLoEGRAGORegarding cardiac toxicity\u00a7Trastuzumab simultaneous to radiotherapy 2b B +\u00a7Trastuzumab simultaneous to epirubicin 2b B +/-\u00a7Trastuzumab simultaneous to doxorubicin 2b B -\u00a7Anthracycline simultaneous to radiotherapy 2c C -Regarding lung and breast fibrosis\u00a7Tamoxifen simultaneous to radiotherapy 3 C +/-\u00a7Chemotherapy simultaneous to radiotherapy 1b B -Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nSide Effects of Trastuzumab /Pertuzumab: \nAlgorithm in Case of Cardiac Toxicity \nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n8. Gastrointestinal Disorders\n\u00a7Nausea, Emesis\n\u00a7Mucositis\n\u00a7Stomatitis (Everolimus)\n\u00a7Diarrhea\n\u00a7ConstipationSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAntiemetic Therapy\nhttp://www.mascc.org/antiemetic -guidelines\nwww.onkosupport.de\nOxford\nLoE GR AGO\u00a7After assessment of emetic potential of chemotherapy protocol 5 D ++\u00a7Neurokinin -1-receptor -antagonists 1b A ++\u00a7Dexamethasone (also in chemotherapy combinations with ICPi) 1a A ++\u00a75-HT3-antagonists 1b A ++\u00a7Fixed antiemetic combination therapy 1b A ++\u00a7Rescue Medication\n\u00a7Olanzapine 1b A +\n\u00a7Levomepromazine, benzodiazepines 3b C +\n\u00a7Cannabinoids, ginger 3b C +/-\nICPi=Immune Checkpoint inhibitorSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAntiemetic Therapy\nhttps://www.mascc.org/antiemetic -guidelines\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAntiemetic Therapy\nhttps://www.mascc.org/antiemetic -guidelines\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSupportive Therapy\nAntiemetics\nWirkstoffgruppe Substanz Dosierung Nebenwirkungen Potenzial\nSerotonin -\nantagonistenOndansetron\nTropisetron\nGranisetron\nPalonosetron8 mg i.v., 2 x 4 -8 mg p.o\n5 mg i.v., 5 mg p.o.\n1-3 mg i.v.\n0, 25 mg i.v.Kopfschmerzen, Diarrhoe, \nFlushsymptomatik\nTransaminasenanstieg\nDarmatonie in hoher \nDosierungsehr hoch\nNK1-Antagonisten Aprepitant\nFosaprepitant\nRolapitant125 mg d1, \n80 mg d 2 -3 p.o.\n150 mg d1 i.v.\n180 mg  d1 p.o.Cytochrom -P-450-Aktivierung mit Dosis -reduktion von \nDexamethason (2 x 8 mg). \nKeine Kombination mit Astemizol, Terfenadin, Cisapridsehr hoch\nDopamin -\nantagonisten/ \nsubstituierte \nBenzamideMetoclopramid\nAlizapridbis zu 120 mg/24h als \nDauerinfusion od. als Tropfen\nbis zu 300 mg i.v. oder \np.o./24 h ( 6 Amp. od. 6 Tbl.)Dyskinesien\n(Antidot:Biperiden)\nAngstreaktion, Depressionen, \nDiarrhoehoch\nOxazapine Olanzepin 10mg/d for d1 -4\nGgf. 5mg/d for  d1 -4Sedation, weight gain hoch\nPhenothiazine/\nButyrophenoneHaloperidol 1-3 mg 4 x/d Sedation, Senkung der \nKrampfschwelle, transiente\nLeberwerterh\u00f6hungm\u00e4\u00dfig\nCorticosteroide Dexamethason\nPrednisolon8-20 mg i.v. 1 -3 x/d\n100-250 mg i.v. 1 -3 x/dBlutzuckerentgleisung, \npsychotische Reaktionen, \nFlush, Blutdruckanstiegm\u00e4\u00dfig\nBenzodiazepine Diazepam\nLorazepambis zu 20 mg/d\n0,5-1,0 mg/dSedation, \nAtemdepressiongering\nNEPA (Netupitant \nand Palonosetron)fixe Kombinations\npartner (oral)NE 300 mg PA 0,5 mg sehr hochSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nOxford\nLoE GR AGO\u00a7Standardized mouth hygiene for prophylaxis of oral mucositis \nshould be adhered to by all age groups and during all cancer -\nrelated therapies with any risk for oral mucositis. 2b ++\nThis entails:\n1. Patient:\n\u00a7Regular mouth washs (H2O, NaCl)\n\u00a7Soft toothbrushes\n\u00a7Interdental care: flossing or using interdental brush\n\u00a7Avoidance of alcohol, tobacco, hot food, sour food\n\u00a7Regular screening for lesions\n2. Risk adjusted prophylaxis by dentist\n3. Continuous clinical control\nThere is no evidence with regard to the use of one of the following compounds: allopurinol, capsaicin, glutamine, honey, \ncamomile, camomile oil or extract, chewing gum, kefir, methadone, nystatin, pentoxifylline , povidone -iodine , \nvitamine A/E/combinationesMucositis Prevention\nhttps://www.mascc.org/mascc -guidelines\nMultidisciplinary S3 guidelines of the AWMF (Reg. -Nr. 032 -054OL):  \u201eSupportive Therapie bei onkologischen Patientinnen \u2013\ninterdisziplin\u00e4re  Querschnittsleitlinie\u201c\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrevention of Everolimus -Induced Stomatitis \nUsing Corticosteroid -based Mouthwash\n\u00a7Study design: single arm phase II -trial (SWISH) \n\u00a7Cohort: 92 pts., treated with everolimus 10 mg and exemestane \n25 mg\n\u00a7Schedule: 10 mL of alcohol -free dexamethasone 15 mg per 5 mL \noral solution (swish for 2 min and spit) for at least 8 \u201312weeks*\n\u00a7Results: after 13 wks exposition all -grade incidence of stomatitis \n27% (BOLERO 67%), \u2265 grade 2 events 9% (BOLERO 27%)\nRugo et al., Lancet Oncol 2017, , Jones et al. Oncologist 2019*Alternatively Hydrocortison: Hydrocortisonacetat -Suspension 0,5% with Lidocainhydrochlorid and \nDexpanthenol (Germany: Arzneibuchrezeptur NRF 7.14.) Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7 Desinfecting / antiphlogistic measures: : \nMouth rinsing with infusions of chamomile or salvia, extracts of chamomile, etheric oils, polyvidon -iodine, \nhexetidine. Local therapy with crystal violet solution 0.5% or tinctura myrrhei, H. mometasonfuroate  + propylene \nglycol \n\u00a7 Mucosa protecting measures (during / after application of chemotherapy): \nSucking ice cubes (especially from pineapple juice) during 5 -fluorouracile -or HD -melphalane. Calcium folinate \n(Leucovorin -mouth gel\u00ae) every 4 \u20136 hrs for HD -methotrexate:\ndo not start earlier than 24 hours after end of MTX -Infusion (otherwise potential loss of efficacy of MTX!). \nDexpanthenole (Panthenol\u00ae -Solution. 5%) mouth rinsing. \n\u00a7 Local antimycotic treatment: \nAmphotericin B, nystatin, fluconazole \n\u00a7 Local antiviral treatment\nAminoquinuride / tetracaine -HCl , Aciclovir\u00ae \n\u00a7 Local anaesthesia: \nBenzocaine, Doxepin 0,5% p.o.\n\u00a7 Pain Therapy: Opioids if indicatedMucositis\nhttps://www.mascc.org/mascc -guidelines\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Adsorbent agents \n\u00a7Carbo medicinalis; caoline / pectine, Al -Mg-silicate hydrate\n\u00a7Analgetics, opioids \n\u00a7Loperamide; codeine, morphine IV, tinctura opii (tincture of opium), butylscopolamine\n\u00a7Off-label: Somatostatin -Analogon Octreotid s.c. (starting at grade 3)\n\u00a7Pseudomembranous colitis\n\u00a7Metronidazole or (if not effective) vancomycin\n\u00a7Initial dose escalation to reduce grade 3/4 diarrhea\n\u00a7CONTROL trial (dose escalation of neratinib: 120 mg/d day 1 -7, \n160 mg/d day 8 -14, 240 mg/d afterwards)Diarrhea\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Bulging agents\n\u00a7Psylium, flaxseed (shredded)\n\u00a7Osmotic laxatives\n\u00a7Macrogol > Lactulose (Cochrane review LoE 1a, AGO + )\n\u00a7Oral radio -opaque material: ultima ratio e.g. sodium amidotrizoate\n\u00a7Sorbitol\n\u00a7Motility stimulating laxatives\n\u00a7Senna, Ricinus (Castrol Oil), Bisacodyl, sodium -picosulfate\n\u00a7Emollients (Internal lubricants e.g. paraffin)\n\u00a7Opioid -receptor -antagonists (in opioid -related constipation)\n\u00a7MethylnaltrexoneConstipation\nImportant Side Effect of Opioid Treatment\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n9. Skin & Subcutaneous Tissue Disorders \n(Alopecia)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSkin Toxicities\nOxford\nLoE GR AGO\u00a7Avoidance of chemotherapy -induced alopecia by \ncooling the patient\u2018s scalp*1b +/-\u00a7Prophylaxis of hand -foot -syndrome using urea \ncontaining lotions (5 -10%)1b +\u00a7Prophylaxis of nail changes and hand -foot -\nsyndrome by cooling hands during application of \ndocetaxel2b +\n*Substance -and regimen specificSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAGO: +/ -LOE 2b B\n\u25aaNangia J, Wang T, Osborne C, et al. Effect of Scalp Cooling Device on Alopecia in \nWomen Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized \nClinical Trial JAMA. 2017 Feb 14;317(6):596 -605. \nPrimary Outcome: hair preservation\nCooling: 50.5% success vs. 49.5% failure\nNon -cooling: 0% success vs. 100% failure\nFisher\u2019s exact test p < 0.001\nTwo Meta -analyses: AGO: +/ -LOE 1b \n\u25aaScalp cooling reduced relative risk (RR) of alopecia by 43% (RR, 0.57; 95% CI, 0.45 -\n0.72; I2= 11%; p < .00001). ( Rugo & Voigt, Clinical Breast Cancer 2018; 18(1): 19 -28.)\n\u25aaIncidence rate of scalp metastasis (SC vs. no -SC)  0.61% vs. 0.41%; p =0.43. (Rugo & \nVoigt; BCRT 2017)Scalp Cooling: Scalp Cooling Alopecia \nPrevention Trial (SCALP) and Metaanalyses\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n10. Musculoskeletal & connective tissue \ndisorders\n(see Chapter Osteooncology)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n11. General Disorders & Administration Site \nConditions\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deExtravasation of Potentially Necrotizing Compounds\n(Anthracyclines, Taxanes, Vinorelbine)\nOxford\nLoE GR AGO\u00a7Dexrazoxane for treatment of anthracycline -\nextravasations\n(exception:  liposomal Anthracy clines )2b B ++\u00a7Hyaluronic acid for treatment of taxane /\nvinorelbine -extravasations (off -label use )3b B +\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deExtravasation of Chemotherapy\nRole of Dexrazoxane / Hyaluronic Acid\nDexrazoxane for treatment of anthracyclines paravasates\nDay 1: 1000 mg/m\u00b2 (max. 2000 mg), IV 1 \u20132 hrs\nDay 2: 1000 mg/m\u00b2 (max. 2000 mg), IV 1 \u20132 hrs\nDay 3:   500 mg/m\u00b2 (max. 1000 mg), IV 1 \u20132 hrs\nOtherwise or if treatment with dexrazoxane is not indicated, following measures are recommended:\n1. Local cooling: ice packs for 15 min every 6 hrs, for at least 3 days, alternatively: 24 h continuous ice cooling\n2. Local application (with swab) of dimethylsulfoxid 99% (DMSO) every 3 -4 hours for at least 3 days (better 14 \ndays),  allow it to air dry. The interval may be extended  to 6 hours from day 4 onward.\nHyaluronic Acid in case of Taxan/Vinorelbin Paravasates:\n\u00a71\u201310 Amp a 150 IU\n\u00a71 ml dissolvent (e.g. NaCl 0.9%)\n\u00a7Local anaesthesia\n\u00a7No thermotherapy after taxanes\n\u00a7Dry warmth 4 x daily 20 min during vincaalkaloidsSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n11. Lung\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDrug -induced Pneumonitis, \nInterstitial Lung Disease (ILD)\nOxford\nLoE GR AGO\u25aaDiagnostic work -up with chest CT 1a B ++Therapy according to grade and drug*\u25aaCorticosteroids (start with \u2265 0.5 mg/kg/d \nprednisolone -equivalent )1a B ++\u25aaDose hold ortherapy discontinuation * (accordingtorespective product information )++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nManagement ILD -Trastuzumab Deruxtecan\n\u2022Rugo HS et al. ESMO Open. 2022 Aug;7(4):100553\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFurther Supportive and Palliative Issues\n\u00a7Orphan symptome (from ESMO -guideline for orphan symptoms 2020):\n\u00a7Muscle cramps\n\u00a7Myoclonus\n\u00a7Taste alterations\n\u00a7Dry mouth (Xerostomia)\n\u00a7Cough, Hiccup\n\u00a7Rectal tenesmus\n\u00a7Restless legs -syndrom\n\u00a7Further issues\n\u00a7Nutrition \n\u00a7Pain management\n\u00a7Palliative CareSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Nutrient deficiency is a common medical problem affecting 15 -40% of \ncancer patients. It impairs their quality of life and can affect the success of \ntreatment. \n\u00a7Integration of nutritional advice into clinical management recommended.     \n\u00a7For nutrition see S3 guideline Palliative care and supportive therapy.Nutrition Deficiency\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Non -opioids; WHO Step 1 \nDiclofenac resinate, ibuprofen and / or metamizole,\nparacetamol (acetaminophen) \n\u00a7Mild opioids; WHO Step 2\nTramadol (preferentially \u201eretard\u201c -formulations) \nor tilidine / naloxone (also as \u201eretard\u201c -formulations) \n\u00a7Strong opioids; WHO Step 3 \nMorphine, buprenorphine (sublingual or transdermal), fentanyl \n(transdermal), hydromorphone, oxycodone, as a back -up levomethadone. \nThe dose of opioids should be titrated step by step according to the \nanalgetic effect.\n\u00a7Additional drugs \u2013\u201eadjuvants\u201c \nCanabinoide, Gabapentin, pregabalin, carbamazepine, amitriptyline, \nbisphosphonatesAnalgesia\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePalliative Care\n\u00a7All patients should be offered palliative care after the diagnosis of a non -\ncurable cancer, regardless of whether a tumour -specific therapy is carried\nout.\n\u00a7Specialized palliative care should be integrated into oncological decision -\nmaking processes, e.g. by participating in interdisciplinary tumor\nconferences.\n\u00a7Patients with incurable cancer who are cared for in structures of\nspecialized palliative care (palliative care ward, specialized outpatient care\nsuch as SAPV) should have access to oncological councelling.\nhttps://www.leitlinienprogramm -onkologie.de/leitlinien/palliativmedizin/ Supportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2021.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EBreast Cancer:\nSpecific Situations\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer:\nSpecific Situations\n\u00a7Versions 2005 \u20132022:\nDall / Ditsch / Fehm / Fersis / Friedrich / Gerber / Gluz / G\u00f6hring / \nHarbeck / Huober / Janni / Kolberg-Liedtke / Loibl / L\u00fcck / Lux / Maass / \nMundhenke / M\u00fcller / Oberhoff / Rody / Scharl / Schneeweiss / Sch\u00fctz / \nSinn / Solomayer / Stickeler / Thomssen\n\u00a7Version 2023\nMundhenke / Schmidt\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer:\nSpecific Situations\n\u00a7Young patients\n\u00a7Pregnancy -and breast -feeding -associated BC \n\u00a7Elderly patients\n\u00a7Male patients\n\u00a7Inflammatory BC\n\u00a7Occult Breast Cancer (Cancer of unknown primary \u2013axillary CUP)\n\u00a7Paget\u2018s disease \n\u00a7Malignant and Borderline Phyllodes Tumor\n\u00a7Angiosarcoma\n\u00a7Breast Implant -Associated Anaplastic Large -Cell Lymphoma (BIA -ALCL)\n\u00a7Metaplastic breast cancer Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer in\nYoung Women \u2264 40 Years\nOxford\nLoE GR AGO\u00a7Aggressive biological behavior with worse prognosis2a B\u00a7Local therapy independent of young age 2b B +\u00a7Guidelines adapted (neo -)adjuvant systemic                           treatment (see respective chapters)1b A ++\u00a7ET interruption (max. 2 years after at least 18 months of \nprevious therapy) in case of  desire to have children \nwithout short -term survival disadvantage 2b B +\u00a7GnRHa as ovarian protection                                                              (see chapter gynecological problems)1a B +\u00a7Genetic and fertility counseling 2b B ++\u00a7Contraception counseling 2b B ++Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer During Pregnancy*\nor Breast Feeding \u2013Diagnostics and Surgery\nOxford\nLoE GR AGO\u00a7Breast imaging and biopsy like as in non -pregnant \npatients (nogeneral indication forMRI)4 C ++\u00a7Staging if indicated (bone scan after delivery) 5 D +\u00a7Full body MRI (without contrast agent) 4 C +/-\u00a7Surgery like in non -pregnant patients 4 C ++\u00a7Sentinel node excision (technetium only) 2b B +\u00a7SLNE during 1sttrimester 5 D +/-\n\u00a7Sensitivity and specificity not established (during lactation); \nbreast feeding should be avoided for 24 hrs4 C ++\n\u00a7Blue dye (not tested in pregnant animals or humans) 4 C --\n*Participation in register study recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer During Pregnancy\n-(Neo -)adjuvant Therapy -\nOxford\nLoE GR AGO\u00a7Radiation therapy during pregnancy 4 C -\u00a7(Neo -)adjuvant chemotherapy only after first trimester \n(indication as in non -pregnant)++\n\u00a7 Anthracyclines : AC, EC 2b B ++\n\u00a7 Taxanes 2b B +\n\u00a7 Platinum salts (carboplatin , cisplatin ) 4 C +/-\n\u00a7 MTX (e.g. CMF) 4 D --\u00a7Endocrine treatment 4 D --\u00a7HER2 -targeted treatment 3a C --\u00a7Checkpoint inhibitors 4 D --\u00a7Bisphosphonates, denosumab 4 D --\nTreatment ( Chemotherapy , surgical procedure and radiotherapy ) ofpatients with breast cancer during pregnancy should be\nassimilar aspossible tostandard treatment ofyoung , not pregnant patients with breast cancer .  Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer During Pregnancy*\n\u2013Delivery and Breast -Feeding \u2013\nOxford\nLoE GR AGO\u00a7Delivery should be postponed until sufficient\nfetal maturation (avoid iatrogenic prematurity)2b C ++\u00a7Termination of pregnancy does not improve \nmaternal outcome 3b C\u00a7Delivery mode like in healthy women ; avoid \ndelivery during chemotherapy -induced leucocyte \nnadir4 C ++\u00a7If further systemic therapy is needed after delivery, breast feeding may be contra -indicated depending \non drug toxicities5 D ++\n*Participation in register study recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer and Pregnancy*\n\u2013Family Planning \u2013\nOxford\nLoE GR AGO\u00a7After breast cancer diagnosis ,reproductive\ntechniques can be used to induce pregnancy3b D\u00a7Success rates for getting pregnant and for\ndeliver inga child lowerin breast cancer patientscompared to non-cancer patients3b D\u00a7Breast cancer patients of reproductive ageshould be offered fertilitycounseling beforestarting any kind of treatment5D ++\u00a7Breast cancer patients should not be advisedagainst getting pregnant independent of their\ntumor\u2018s hormone receptor status and gBRCA status3a D\n*Participation in register study recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBreast Cancer During Pregnancy and Lactation* \n-Outcome -\nOxford\nLoE\u00a7BC during pregnancy\n\u00a7Prognosis isnot worse ifadequately treated 3a\u00a7BC during lactation and within the first year after pregnancy\n\u00a7Prognosis worse than in BCP and ifunrelated topregnancy 3a\u00a7Pregnancy / lactation after BC\n\u00a7Outcome not compromised 3a\n*Participation in register study recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7No specific algorithm is available\n\u00a7Ability to tolerate treatment varies greatly (\u201efunctional reserve\u201c)\n\u00a7Comprehensive geriatric assessment (CGA) describes a multidisciplinary evaluation \nof independent predictors of morbidity and mortality for older individuals\n\u00a7Physical, mental, and psycho -social health \n\u00a7Basic activities of daily living (dressing, bathing, meal preparation, medication management, etc.) \n\u00a7Living arrangements, social network, access to support services\n\u00a7Assessment tools:\n\u00a7Charlson Comorbidity Index (widely used; good predictor over a 10 -year period)\n\u00a712 prognostic indicators to estimate 4 -year mortality risk\n\u00a7Short screening tests (more qualitative evaluation)\n\u00a7IADL (IADL = The Lawton Instrumental Activities of Daily Living Scale with 8 domains of function, that \nare measured), G8 \n\u00a7Geriatric Prognostic Index (GPI), 3 parameters in oncological patients (psychological distress or acute \ndisease, >3 prescribed drugs, neuropsychological problems)Geriatric Assessment\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTreatment for Fit Elderly Patients \n(Life Expectancy > 5 yrs. and Acceptable Comorbidities) \nOxford\nLoE GR AGO\u00a7Clinical geriatric assessment 2b B ++\u00a7Treatment according toguidelines 2a C ++\n\u00a7Surgery similar to \u201eyounger\u201c age 2b B ++\n\u00a7Endocrine treatment (endocrine responsive ) 1a A ++\n\u00a7Chemotherapy (standard regimens )\n\u00a7 < 70 years 1a A +\n\u00a7 > 70 years  (especially N+, ER / PR -) 2a C +*\n\u00a7Radiotherapy 1a A +\n\u00a7Omit radiotherapy after BCS if low -risk, and if endocrine \ntreatment is administered1b B +\n\u00a7Anti -HER2 -therapy 2b C +\n*Study participation recommended Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTreatment for Frail Patients \n(Life Expectancy < 5 yrs., Substantial Comorbidities)\nOxford\nLoE GR AGO\u00a7Reduced standard treatment 2b C ++\u00a7Options extrapolated from trials in elderly:\n\u00a7No breast surgery (consider endocrine options) 2b C +\n\u00a7No axillary clearing (\u2265 60 y, cN0, HR -pos) 2b B +\n\u00a7No radiotherapy (Tumor size < 3 cm, pN0, HR -pos) 1b B ++\n\u00a7Hypofractionated radiotherapy 2b B +\n\u00a7No chemotherapy if > 70 yrs. and negative risk -benefit \nanalysis2b C +Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMale Breast Ca ncer*: Diagnostic \nWork -Up and Loco -Regional Therapy\nOxford\nLoE GR AGO\u00a7Diagnostic work -up as in women 4 C +\n\u00a7 Ultrasound 2b B ++\n\u00a7 Mammography 3b C +\u00a7Standard -surgery: Mastectomy 4 C ++**\n\u00a7 BCT is an option (tumor / breast relation) 4 C +**\n\u00a7 Sentinel -node excision (SLNE) 2b B +\u00a7Radiotherapy as in women \n(consider tumor / breast relation!) 4 C +\u00a7Genetic counseling if one additional relative affected \n(breast / ovarian cancer)2b B ++\u00a7Screening for 2ndmalignancies according to guidelines GCP ++\n* Treatment in certified breast cancer centers recommended ; **  Participation in register study recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMale Breast Cancer -Prognostic Factors\nOxford\nLoE GR AGO\u00a7Nodal status 2b A ++\u00a7Age 2b B +\u00a7Tumor size 2b A ++\u00a7ER / PR Expression 2b A ++\u00a7Ki-67 Expression 2b C +/-\u00a7Grade 2b C +/-\u00a7Genomic signatures (e.g. OncotypeDx) 2b B +Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMale Breast Cancer: \nSystemic Therapy\nOxford\nLoE GR AGO\u00a7(Neo -)adjuvant chemotherapy as in women 2a B ++\u00a7HER2 -targeted therapy (if HER2 -positive) 5 D ++\u00a7Endocrine therapy 4 D ++\n\u00a7Tamoxifen 2b B ++\n\u00a7GnRHa and AI 4 C +\n\u00a7Aromatase inhibitors without GnRHa 2b B -\n\u00a7Fulvestrant (metastatic BC) 4 C +/-\n\u00a7CDK4/6i (in combination) 2b B +\u00a7Palliative chemotherapy as in women 4 C ++Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deInflammatory Breast Cancer (IBC, cT4d)\nOxford\nLoE GR AGO\u00a7Invasive BC and clinical signs of  inflammation (e.g. \u2265 1/3 of the\nbreast affected) determine stage cT4d++\u00a7Staging 2c B ++\u00a7Skin punch biopsy (at least 2; detection rate < 75%) 2c B+\u00a7Treatment according to guidelines (neoadjuvant or adjuvant \u2013as\nin non -IBC)2c B ++\u00a7Mastectomy after chemotherapy 2c B+\n\u00a7Breast conserving therapy in case of pCR (individual) 2b C +/-\n\u00a7Delayed breast reconstruction 3b C+\n\u00a7Sentinel excision only 3b C-\u00a7Radiotherapy of the chest wall  including regional lymph nodes\nindependent of therapy response2c B ++Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Incidence: < 1% of metastatic axillary disease\n\u00a7In > 95% occult breast cancer, < 5% other primary\n\u00a7Immunhistology\nER-positive: 55%\nHER2 3+: 35%\nTriple -negative: 38%\n\u00a7Nodal status:\n\u00a71 -3 Ln-Met. in 48%\n> 3 Ln -Met in 52%\n\u00a7Outcome similar or better compared to breast cancer with similar tumor \nbiology and tumor stageAxillary Metastasis in Occult Breast Cancer\n(Cancer of Unknown Primary \u2013Axillary CUP)\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAxillary Metastasis in Occult Breast Cancer (Axillary \nCUP) Imaging Diagnostics\nOxford\nLoE GR AGO\u00a7Breast imaging incl. Breast -MRI 3 B ++\u00a7Exclude contralateral cancer 3 B ++\u00a7Exclude non -breast malignancy, especially\nin case of TNBC (e.g. skin, female genital tract,\nlung, thyroid gland, stomach)5 D ++\u00a7Staging (CT thorax / abdomen, pelvis, in certain \ncircumstances also thyroid sonography, HNT -exam)3 B ++\u00a7PET / PET -CT 3b B +Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAxillary Metastasis in Occult Breast Cancer (ex. CUP)\nPathology, Molecular Pathology\nOxford\nLoE GR AGO\u00a7ER, PR, HER2, GATA3 (in some casesCk5/6, Ck7, Ck20, SOX-10, PAX -8, TTF1, and others )5 D ++\u00a7Exclusion of other primary malignancies in case of \ntriple -negative phenotype or unusual histology, e.g. \nlung, female genital tract, HNT tumors, \nneuroendocrine ca.5 D ++\u00a7Gene expression profiling for determination \nor primary site \n(e.g. CUPprint, Pathwork, TOT, CancerType) 2c B +/-\u00a7NGS, epigenetics for determination of primary site \n(Panel -Sequencing, e.g. EPICup)2c B +/-\u00a7Prognostic gene expression tests 5 D --Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAxillary Metastasis in Occult Breast Cancer \n(Axillary CUP): Therapy\nOxford\nLoE GRAGO\u00a7Axillary dissection 3a C ++\n\u00a7Targeted axillary dissection after NACT (in caseof clinical complete remission3b C +/-\u00a7Mastectomy if breast MRI is negative 3a C --\u00a7(Neo -)adjuvant systemic therapy according \nto breast cancer guidelines (AGO)5 D ++\u00a7Breast irradiation if breast MRI is negative 2c B +\u00a7Irradiation of regional lymph nodes according to \nbreast cancer guidelines (AGO)3b B +Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Definition: Paget\u2018s disease of the breast is characterized by an intraepidermal tumor \nmanifestation originating in intraductal or invasive breast cancer. \n\u00a7Clinical presentation: skin eczema of the nipple, areola and surrounding skin; thickening, \npigmentation and scaly skinPaget\u2018s Disease of the BreastFeatureFrequencyPresentationPaget\u2018s disease with invasive Ca. (37-58%)Paget\u2018s disease mit DCIS (30-63%)Isolated Paget\u2018s disease (4-7%)Isolated Paget\u2018s disease with invasion (rare)IHCHER2-positive (83 -97%)ER-positive (10 -14%)AR-positive (71 -88%)Prognosis and tumor biologyBetter in isolated Paget\u2018s diseaseWorse if in combination with invasive breast cancer or DCIS compared to isolated Paget\u2018s diseaseBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePaget\u2018s Disease of the Breast Diagnosis\nOxford\nLoE GR AGO\u00a7Histological verification by skin biopsy ++\u00a7Mammography, sonography  4 D ++\u00a7MRI of the breast if other imaging negative 4 C +\u00a7Immun ohistochemistry (ER, PR, HER2, CK7 ) \nto detect benign and HER2 -negative cases5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePaget\u2018s Disease of the Breast -Therapy\nOxford\nLoE GR AGO\u00a7Paget\u2018 sdisease with underlying disease\n(invasive breast cancer, DCIS)\n\u00a7Therapy according to standard of underlying disease 5D ++\n\u00a7Surgery must achieve R0 1c B ++\u00a7Isolated Paget\u2018s disease of the NAC:\n\u00a7Surgery must achieve R0 1c B ++\n\u00a7Surgical resection only, no adjuvant radiotherapy 4D ++\n\u00a7Sentinel -node excision (SLNE) 2b B --Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Name derived from greek term of \u201cPhyllon\u201d (leaf) due to its lobulated histological \naspect\n\u00a7Differential diagnosis may be problematic on core biopsy\n\u00a7Resection margin is independent prognostic parameter\n\u00a7Comparable rates of recurrence in association with BCT or mastectomy\n\u00a7In-Breast recurrence relatively frequently seen (10 -30%)\n\u00a7Distant metastasis relatively rare (< 10%) and almost exclusively seen in malignant \nphyllodes tumor.\n\u00a7Adverse pathological criteria: marked stromal cellularity and overgrowth, \nincreased nuclear atypia, presence of large necrohemorrhagic areas, and high \nmitotic activity associated with increased risk of distant recurrenceBorderline and Malignant Phyllodes Tumor\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Frequency 0.3 \u20131% of all primary breast tumorsPhyllodes TumorparameterfrequenciesGrading   (3-STEP histological grading system)Benign (75%)Borderline (16%)Malignant (9%)Median age at time of diagnosisBenign PT: 39 yBorderline PT: 45 yMalignant PT: 47 yLocal recurrenceBenign PT: 4 \u201317%Borderline PT: 14 \u201325%Malignant PT: 23 \u201330%MetastasisBenign PT: < 1%Borderline: PT: 1.6%Malignant PT: 16-22%\n10 y OS: 86 \u201390% (range: 57 \u2013100%)  depending on subtype and unfavorable histological criteriaBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBorderline and Malignant Phyllodes Tumor \nDiagnosis\nOxford\nLoE GR AGO\u00a7Mammography, sonography 3 C ++\u00a7Diagnosis on core biopsy, grade determination on \nresection specimen3 C ++\u00a7Breast MRI 3 C +/-\u00a7Staging only malignant PT (CT thorax, skeletal \nsystem)5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBorderline and Malignant Phyllodes Tumor\nSurgery\nOxford\nLoE GR AGO\u00a7Borderline / malignant phyllodes tumor : Complete\nresection with adequate margins , min. > 1 mm 2b B ++\u00a7SLNE / Axillary dissection 4 C --\u00a7Treatment of local recurrence\n\u00a7R0 resection or simple mastectomy 4 C ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBorderline and Malignant Phyllodes Tumor\nAdjuvant Therapy\nOxford\nLoE GR AGO\u00a7Adjuvant radiotherapy (younger age, increased\ntumor volume > 5 cm, close resection margin )\n\u00a7Local control 2b B +\n\u00a7Effect on disease -free survival 2b B -\u00a7Systemic adjuvant therapy (chemo, endocrine) 4 C -\u00a7Adjuvant Treatment of local recurrence\n\u00a7Radiotherapy, chemotherapy after R1 resection 4 C +/-\u00a7Distant metastasis (very rare)\n\u00a7Treatment like soft tissue sarcomas 4 C ++Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Not infrequently associated with familial syndromes (Li -Fraumeni, familial \nadenomatous polyposis, neurofibromatosis type 1)\n\u00a7Primary sarcomas: angiosarcoma, undifferentiated sarcoma, leiomyosarcoma, \nliposarcoma, osteosarcoma\n\u00a7Secondary malignancies of the breast:\n\u00a7Radiotherapy -Associated Angiosarcoma\n\u00a7Breast Implant Associated Large -Cell Anaplastic Lymphoma (BI -ALCL)\n\u00a7Rare: intramammary sarcoma metastases\n\u00a7Staging: TNM (UICC) or AJCC scheme of the soft tissue sarcoma analogous to \nsarcoma of the breast\n\u00a7Grading: Analogous to the FNCLCC system for sarcoma or according to Rosen \n(1988) for angiosarcomasSarcomas of the Breast\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Most common primary sarcoma of the breast\n\u00a7Young age (median: 24 \u201346 years)\n\u00a7Indistinct tumor borders\n\u00a7Large tumor (median: 5 \u20137 cm)\n\u00a7Uncharacteristic findings on mammography and sonography\n\u00a7High local recurrence risk, even after mastectomy\n\u00a7More unfavorable prognosis than other primary sarcoma of the breast\n\u00a7Metastasize early, often to the lung and liverPrimary Angiosarcoma of the Breast\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrimary Angiosarcoma of the Breast*\nDiagnosis\nOxford\nLoE GR AGO\u00a7Mammography, sonography to determine extent ofdisease3a C --\u00a7Preoperative MRI to determine the extent of\ndisease3a C ++\u00a7Diagnosis by core biopsy 3a C ++\u00a7Diagnosis by FNB 3a C --\u00a7Staging (CT  thorax & abd.; angiosarcoma: MRI\nbrain)4D ++\u00a7Prognostic factors: size, grade, margins 3a C ++\n*Therapy in specialized centers recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePrimary Angiosarcoma of the Breast*\nTherapy\nOxford\nLoE GR AGO\u00a7Surgery with wide clear margins, mostly as \nmastectomy2b C ++\n\u00a7Breast -conserving therapy 3a C -\u00a7SLNE or axillary dissection if cN0 3a C --\u00a7Adjuvant chemotherapy \n(anthracycline / taxane -based)4 C +/-\u00a7Adjuvant radiotherapy if high risk (size > 5 cm, R1) 4 C +/-\n*Therapy in specialized centres recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSecondary Angiosarcoma \nof the Breast Therapy\nOxford\nLoE GR AGO\u00a7Tumor resection (BCT / mastectomy ) 3a C +\nRadical surgery ist not associated with better\noutcome\u00a7(Neo -)adjuvant chemotherapy 3a C +/-\u00a7Adjuvant radiotherapy if high risk \n(size > 5 cm, R1)2b B +/-\u00a7Regional hyperthermia (to improve local control) \nplus chemotherapy and / or radiotherapy2b B +/-\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSecondary (Radiotherapy -associated) \nAngiosarcoma of the Breast\n\u00a7Cumulative incidence of radiotherapy -associated sarcoma: 3.2 per 1,000 \nafter 15 years\n\u00a7Clinical presentation\n\u00a7> 5 years after BCT or mastectomy with irradiation\n\u00a7usually intracutaneously or subcutaneously in the irradiation area with livid \ndiscoloration\n\u00a7multiple foci\n\u00a7most often in advanced stages (II -III)\n\u00a7metastasis mostly pulmonary\n\u00a7lymph node metastasis possible\n\u00a7Prognosis is more unfavorable than in non -radiotherapy -associated \nsarcoma\n\u00a7Survival: after 5 yrs. up to 50.5%, after 10 yrs. up to 25.2%Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAngiosarcoma of the Breast \nTreatment of Local Recurrence and Metastases\nOxford\nLoE GR AGOTreatment ofLocal Recurrence :\u00a7R0 resection 4 C ++\u00a7Adjuvant radiotherapy for high -risk patients \n(tumor size > 5 cm, R1)4 C +/-DistantMetastases / Unresectable Tumors:\u00a7Treatment like as for soft tissue sarcomas (according to S3 \nguideline)4 C ++\u00a7Paclitaxel weekly / liposomal doxorubicin (as in angiosarcoma) 2b B +\u00a7Antiangiogenic treatment (e.g. in angiosarcoma) 4 C +/-Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\n\u00a7Aproximately 10.000.000 implant carrier\n\u00a7Rare disease, 3% of T -cell Non -Hodgkin Lymphomas, 0.04 -0.5% of all malignant breast \ndiseases\n\u00a71:3.000 \u201330.000 in women with textured implants (caveat: underreporting!)\n\u00a7Estimated incidence 0.6 -1.2/100.000 women with implants (median age: 54 y)\n\u00a7Mainly associated with textured implants (1:300 women)\n\u00a7Interval to diagnosis: 8 years (median)\n\u00a7Clinical symptoms\n\u00a7 Erythema, swelling and seroma. (60%)\n\u00a7 Solid tumor (17%)\n\u00a7 Seroma and solid tumor (20%)\n\u00a7 Axillary lymphadenopathia (20%)\n\u00a7Histology: CD30+ / ALK -T-Cell Lymphoma\n\u00a7Compulsory registration as SAE ( \u00a73 MPSV to BfArM) \n(https://www.bfarm.de/SharedDocs/Formulare/DE/Medizinprodukte/BIA -ALCL -Meldung.html)Breast Implant Associated Anaplastic Large Cell \nLymphoma (BIA -ALCL)\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBIA-ALCL \u2013Diagnosis \nOxford\nLoE GR AGO\u00a7Breast US (assessment of new seromas > 1 year after implant \ninsert, solid lesion (sensitivity: 84%, specificity: 75%))3a D ++\u00a7Mamma -MRT in confirmed cases 3a D ++\u00a7Staging (Imaging, e.g. CT, PET -CT) 3a D ++\u00a7Cytology of late seromas\n\u00a7-> 50 ml \n\u00a7-Complete assessment\n\u00a7-flow -cytology (T -cell clone)\n\u00a7-BIA-ALCL specific cytologic  diagnostic (e.g. CD 30+)3a D ++\u00a7Core needle biopsy in solid lesions\u00a7Lymphoma assessment of resected tissue and histologic staging3a D ++\u00a7Documentation of the implant and enter in registry 5 D ++Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBIA-ALCL \u2013Therapy\nOxford\nLoE GR AGO\u00a7Implant resection and complete capsulectomy including\ntumorectomy3a C ++\u00a7Contralateral implant resection including capsulectomy in case of\nbilateral implants (2 -4% BIA -ALCL bilateral)4D +/-\u00a7Resection of suspicious lymph nodes, no routine use of Sentinel -\nNode -Biopsy, no axillarx dissection4D ++\u00a7Systemic therapy in cases of extra capsular extension 4D +\u00a7Radiotherapy in unresectable tumors 5D +/-\u00a7Case discussion in an interdisciplinary tumor board in thepresenceofa specialist forlymphomas5D ++Breast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTNM Staging of BIA -ALCL (proposed)\nTNM -\nKategorieDefinition\nTumor extent\n(cT/pT)T1 Confined to seroma or a layer on \nluminal side of capsule\nT2 Early capsule infiltration\nT3 Cell aggregates or sheets infiltrating \nthe capsule\nT4 Lymphoma infiltrates beyond the \ncapsuleRegional lymph nodes (cN/pN)N0 No lymph node involvement\nN1 One regional lymph node positive\nN2 Multiple regional lymph nodes \npositive\nMetastasis\n(cM/pM)M0 No distant spread\nM1 Spread to other organs or distant \nsitesStage Definition\nIA T1 N0 M0\nTB T2 N0 M0\nTC T3 N0 M0\nIIA T4 N0 M0\nIIB T1-3 N1 M0\nIII T4 N1 -2 M0\nIV T any N any M1\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnostic Pathways and Assessment\nAdapted from the NCCN and UK guidelines\nLate Seroma\n>1 2  m o n t h s  s i n c e\n1stimplant\nUltrasound\nBreast + Axilla\nMass\nCore biopsy\n(any solid mass)\nHistology\nImmunohistology\nCapsule -related\nsolid tumor mass\n+/-\nMammogram\n(not useful if age < 40 yrs)\nEffusion\nFNA fluid\n(take > 50 ml)\nCytology\nimmune -cytology \nfor CD30\nPathological\nskin lesion\nPathological\nlymph nodesSuspicion Imaging\nSkin biopsy\nPET CT\n(r/o systemic disease)\nMRI Breast\n(if diagnosis is \nindeterminate)\nFindings Samples Assessment\nFlow -Cytometry\nClonality studies\n(for T -cell rearragenemnts)\nIndeterminate?\nSuspicious?\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBIA-ALCL Treatment Pathways\nAdapted from the NCCN and UK guidelines\nBIA-ALCL\nconfirmed\nReferral to\nexperienced\nbreast cancer \ncenter\nEn-bloc \ncapsulectomy and  \ncomplete excision \n(mass)\nStage I : No further \ntreatment\nClinical follow -up \n(ultrasound /CT \nscan) 3 \u20136 m for 2y, \nafterwards for 5y\nIndeterminate\nPET-CT & \nbreast MRI\n+/-other breast\n+/-axilla biopsy \n(SNB not recommended)\nStage II -IV:\nConsider adjuvant \ntreatment\nPET-CT if\nsymptomatic\nNegative for \nBIA-ALCLOutcome Workup\nClinical suspicion \nremains\nChemo -\nimmunotherapySurgery Adjuvant Therapy Follow -up\nTreatment of infection/ \nbenign seroma (serial \naspiration, implant \nexchange with \ncapsulectomy)Options: Further \nimaging US/MRI/Repeat \nFNAC , Tertiary referral\nRoutine bloods\n(+/-bone marrow bx)\nMTD Discussion\nConsider diagnostic \ncapsulectomy\nRadiotherapy for \npositive margins / \nirresectable  thoracic \nwall infiltration but \nN0/M0Histological Staging \n(Clemens et al. 2016)\nMTD Discussion\nReports to  BfArM, \nmanufacturer, DGPR\u00c4C, \nPROFILE database (FDA)\nTreatment as per \nsystemic ALCL regimes\n24-36 Gy in 15 \nfractionsBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Despite an increase of BIA -ALCL in association with texture implants \nthe use of textured implants is still permitted!\n\u201eFor the moment, textured implants can safely continue to be used with patient's fully informed \nconsent, and that women that have these type of implants already in place don't need to remove \nor substitute them, which would undoubtedly cause harm to many tens of thousands of women, \nto prevent an exceptionally rare, largely curable and currently poorly understood disease.\"BIA-ALCL \u2013EUSOMA -Recommendation\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetaplastisches Mammakarzinom\nDefinition: Metaplastische Transformation der glandul\u00e4ren Tumorzellen\n- Bei epithelialer Differenzierung: Plattenepithelkarzinom, Spindelzellkarzinom\n- Bei heterologer (mesenchymaler) Differenzierung: chondroides, oss\u00e4res oder rhabdoides metaplastisches \nMammakarzinom\nKlinisch -pathologische Charakteristika:\n- < 1 % der Malignome der Mamma\n- Gleiche Altersgruppe wie NST -Karzinome\n- Umschrieben, tastbar\n- Schnell wachsend, schlechtes Ansprechen auf Chemotherapie\n- > 90 % triple -negativ\nAggressivit\u00e4t:\n- Hoch maligne bei heterologer (mesenchymaler), plattenepithelialer oder high -grade spindelzelliger \nDifferenzierung\n- Unsicheres malignes Potential (low -grade) bei adenosquam\u00f6ser oder Fibromatose -\u00e4hnliche Differenzierung\nFrequent mutations:\n-TP53, EGFR , PIK3CA , PTENBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetaplastic breast carcinoma*\n-high -grade -\nOxford\nLoE GR AGO\u00a7Operative therapy surgery and axillary staging \naccording to standard4 C ++\u00a7Adjuvant chemotherapy (rather chemoresistant) 4 C +/-\u00a7Neoadjuvant chemotherapy (rather chemoresistant ) 4 C -\u00a7Adjuvant endocrine therapy ifHR-positive 4 C +\u00a7Adjuvant radiotherapy according to standard 4 C + +\n* Reference pathology recommendedBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetaplastic Breast Carcinoma with Uncertain Malignant \nPotential (Fibromatous and Adenosquamous Ca.)*\nOxford\nLoE GR AGO\u00a7Operative therapy and axillary staging according to\nstandard4C ++\u00a7Adjuvant chemotherapy 4C-\u00a7Neoadjuvant chemotherapy 4C - -\u00a7Adjuvant endocrine therapy (not applicable, since\ntriple -negative tumors)4C-\u00a7Adjuvant radiotherapy according to standard 4C +\n*R e f e r e n c e  p a t h o l o g y  r e c o m m e n d e dBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer \nFollow -Up\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer \nFollow -Up\n\u25aaVersions 2002 \u20132022: \nBauerfeind / Bischoff / Blohmer / B\u00f6hme / Costa / Diel / Friedrich / \nGerber / Gluz / Hanf / Heinrich / Huober / Janni / Kaufmann / Kolberg -\nLiedtke / K\u00fcmmel / L\u00fcftner / Lux / Maass / M\u00f6bus / M\u00fcller -Schimpfle / \nMundhenke / Oberhoff / Rody / Scharl / Solbach / Solomayer /  \nStickeler / Thomssen / W\u00f6ckel\n\u25aaVersion 2023 : \nFriedrich / K\u00fcmmel\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer Follow -Up\nObjectives\nOxford\nLoE GR AGOEarly detection of curable events\u00a7In-breast recurrence 1a B ++\u00a7Loco -regional recurrence* 1a B ++Early detection of contralateral cancers1a B ++Early detection of metastasis\u00a7Early detection of symptomatic metastases 3b C +\u00a7Early detection of asymptomatic metastases1a A -\n*loco -regional recurrence is associated with a higher risk of mortality in node -positive, PR -negative, \nyounger patients and in patients with a short time between primary diagnosis and recurrenceBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer Follow -Up\nObjectives \nOxford\nLoE GR AGO\n\u00a7Improve quality of life 2b B +\n\u00a7Improve physical performance 2a B +\n\u00a7Reduction and / or early detection of therapy -related \nside effects (such as osteoporosis, cardiac failure, fatigue, \nneurotoxicity, lymphedema, web axillary pain syndrome (abacterial \nlymphangitis), sexual disorders, cognitive impairment, sterility, and \nsecondary tumors ) and start of necessary therapies2b B +\n\u00a7Participation in interventional programs during follow -\nup for breast cancer survivors in order to maximize \ntherapy adherence, assess life -style interventions, and \nimprove quality of life3b B +\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EMonitoring after Cardiotoxic Therapy \n(Anthracycliens, anti -HER2)\nAfter anthracyclines / Trastuzumab:\n\u00a7ECG and echocardiography: \n\u00a76, 12, 24 months and yearly up to 5 years after therapy. \n\u00a7After 5th year, every 5 years and if patient is symptomatic.\n\u00a7If cardiovascular risk factors: \n\u00a7blood pressure at least yearly\n\u00a7lipids and HbA1c in serum yearly\n\u00a7Modify risk factors if possible: \n\u00a7nicotine, body weight, bmi. \n\u00a7Education about individual risk profile and lifestyle\nRisk factors: \nradiotherapy of left breast, nicotine, hypertonus, diabetes mell., dyslipidaemia, \nadiposity, age > 60, cardiac diseases: reduced ejection fraction, post -\nmyocardial infarction status , \u2265 moderate heart defectsBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer Follow -Up\nObjectives\nOxford\nLoE GR AGO\u25aaEvaluation of current adjuvant therapy2b B ++\n\u25aa incl. monitoring of adherence to endocrine therapies\n\u25aa Control of menopausal status, e.g. in case of CT -induced amenorrhea \n(FSH/2 or bleeding history) and addition of GnRH analogs (up to 2 years \nafter CT) if premenopausal status in women < 45 years old,  or switch to \naromatase inhibitors (if postmenopausal) \u25aaPro-active improvement of therapy adherence 5 D ++\n\u25aa Patient information about efficacy data for 5 -10 years \nendocrine therapy\n\u25aa Early therapy of side effects (sports, NSAIDs, \nvitamin D / calcium)Breast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer Follow -Up\nObjectives\nOxford\nLoE GR AGO\u00a7Psycho -social aspects of support and counseling 4 C +\n\u00a7Pregnancy, contraception, sexuality, quality of life, \nmenopausal symptoms, fear of recurrence\n\u00a7Inclusion of related persons (partner, family, friends, caregivers)\u00a7Second opinion regarding primary therapy 2c B ++\u00a7General counseling ( e.g.changes in family history of breast, ovarian, prostate, pancreas carcinoma with \nnew indication for genetic counseling, HRT, \nprophylactic surgery, breast reconstruction)2c C +\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer Follow -Up\nRecommended Interventions\nOxford\nLoE GR AGO\u25aaTreatment of type II -diabetes  \n(> 25% undetected DM in postmenopausal BC patients, endocrine therapy improves \nrisk for DM)2a B ++\u25aaWeight/lifestyle intervention (if BMI < 18.5 and > 30) 2a B +\u25aaNightly fastening > 13 h 2b B +\u25aaReduction of dietary intake (at least 15 % calories from fat) \nin HR -negative BC is associated with improved overall survival2b B +\u25aaStop smoking (smoking causes 2 -fold increase in BC -specific and 4 -fold increase in \nnot directly BC -associated mortality)2b B ++\u25aaAlcohol consumption reduction (below 6g/d) 2b B +\u25aaModerate sport (in patients with reduced physical activity prior to diagnosis) (at \nleast 150 minutes/w, 2x/w)1b A ++\u25aaDistress reduction 3b B +Interventions regarding lifestyle risks and comorbidity in order to\nreduce an unfavorable impact on disease outcome\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EProlonged nightly fasting improves prognosis in breast cancer patients\nretrospective cohort study: \n2413 BC -pat. (no diabetes), nightly fasting more or less than 13 hrs\nFasting < 13 hrs: HR 1.36, 36% increase of risk for recurrence\nHR 1.21, n.s. increase of risk for mortality\nevery 2 -hrs-prolonged fasting was correlated with a 20% increase\nof sleeping durationNightly Fasting\nMarinac CR, Nelson SH, Breen CI et al. JAMA Oncol 2016: 2:1049 -1055Breast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ERoutine Follow -Up Examinations in \nAsymptomatic Patients\nOxfordTests:LoE GR AGO\u25aaHistory (specific symptoms) 1a A ++\u25aaPhysical examination 1a B ++\u25aaBreast self -examination  5 D +\u25aaMammography 1a A ++\u25aaSonography of the breast 2a B ++\u25aaRoutine MRI of the breast* 3a B +/-\u25aaBreast MRI if conventional imaging is inconclusive 3b B +\u25aaPelvic examination 5 D ++\u25aaDXA -scan at baseline and repeat scan according to individual risk in women with premature menopause or women taking an AI5 D +\n*Consider in case of increased risk (age < 50 y, HR -neg., diagnostic assessability C/D in mammography + ultrasound)Breast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1ERoutine Follow -Up Examinations in \nAsymptomatic Patients\nOxford\nLoE GR AGO\u25aaRoutine biochemistry (incl. tumor markers) 1a A -\u25aaBlood tests for monitoring of acute and late toxicities 5 D +\u25aaUltrasound of the liver 1a A -\u25aaBone scan 1a A -\u25aaChest X -ray  1a A -\u25aaCT of chest, abdomen, and pelvis 2a D -\u25aaDetection of isolated / circulating tumor cells 2a D -\u25aaPET 2b B -\u25aaWhole body MRI  2b B -Breast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBackground for Toxicity ManagementTamoxifen:Cholesterol, Triglycerides, Bilirubin, ALAT, ASAT, gamma-GT, GlucoseAromatase inhibitors:Cholesterol, Triglycerides, Bilirubin, ALAT, ASAT, gamma-GTAnthracyclines:pro-BNP, possibly TroponinTrastuzumab:pro-BNP, possibly Troponin              Checkpoint inhibitors:Bilirubin, ALAT, ASAT, gamma-GT, Creatinine, TSH, fT3/T4, Myoglobin\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EEarly Detection of Potentially Curable Events\nOxford\nLoE GR AGOLocoregional recurrence (chest wall, in-breast):\n\u25aaIncidence 7 \u201320% (depending on time of F/U)\u25aaBreast self -examination 5 D +\u25aaPhysical examination, mammography & US 1a A ++\u25aaMagnetic resonance imaging (MRI)* 3a B +/-\n*Consider in case of increased risk (age < 50 y, HR -neg., diagnostic assessability C/D in mammography + ultrasound)Breast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EEarly Detection of Potentially Curable Events\nOxford\nLoE GR AGOContralateral breast cancer:\u25aa Relative risk: 2.5 \u20135 \n\u25aa Incidence: 0.5 \u20131.0 %/year \u25aaBreast self -examination 5 D +\u25aaPhysical examination, mammography & US 1a A ++\u25aaRoutine breast MRI* 3b B +/-Male breast cancer: analogous to BC in women**5 D +\n*    Consider in case of increased risk: age < 50 y, HR -neg., diagnostic assessability C/D in mammography + ultrasound.\n**  See chapter \u201cBreast Cancer Specific Situations\u201dBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EEarly Detection of Potentially Curable Events\nOxford\nLoE GR AGOUnrelated site carcinoma:\u25aaMDS (RR 10.9), AML (RR 2.6 \u20135.3), Colon RR 3.0; \nendometrium RR 1.6; ovary RR 1.5; lymphoma RR \u25aaScreening for secondary malignancies according to current guidelines 5 D ++\u25aaPelvic examination and PAP smear 5 D ++\u25aaRoutine endometrial ultrasound / biopsy 1b B -Breast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EFollow -Up Care\nfor invasive / non -invasive Breast Cancer Clinical follow-up Follow -up* Screening/\nFollow -upYears after primary therapy1        2        3 4        5 > 5History, physical examination, counselingevery 3 months\nDCIS every 6 monthsevery 6 months inv.: every 12 monthsSelf-examination monthlyImaging modalities and biochemistryindicated only if complaints, clinical findings, or suspicion of recurrenceMonitoring of side effects of therapyMammo-graphy and additional sonographyBCT**both sides: every 12 monthsMastectomycontralateral every 12 monthsEchocardiography6,12,24 months and yearly up to 5 years after completion of cardiotoxic \ntherapy, after 5th year, every 5 years and if patient is symptomatic.Recommendations for asymptomatic pts. \n(mod. according to ASCO -ACS recommendations 2016, NCCN 2021, ESMO 2019 and S3 -guidelines 2017 )\n*Continued follow -up visits if still on adjuvant treatment\n**In pts after breast -conserving therapy (BCT):  First mammography 1 year after initial mammography or at least 6 months \nafter completion of radiotherapyBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EBreast Cancer Follow -up\nDuration and Breast Nurses\nOxford\nLoE GR AGO\u25aaDuration of follow -up\n\u25aaup to 5 years1c A ++\n\u25aaup to 10 years1c A +\u25aaSurveillance by specialized breast nurses 2b B +/-*\n*Studies recommendedBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\u00a7Intrinsic typing of breast cancer leads to subgroups with different course \nof disease. Thus, postoperative surveillance should be adapted to specific \ntime -dependent hazards of recurrence.\n\u00a7ER-positive patients have stable risk over many years requiring long term \nsurveillance.\n\u00a7However, patients with HER2 -positive disease and TNBC have more risk \nin the early phase of follow -up and should therefore receive more intense \nsurveillance in the first years of follow -up.Luminal -like, HER2 -positive and \nTriple -negative Breast Cancer Patients\nRibelles et al. BCR 2013Breast Cancer Follow-Upwww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nLoco -Regional Recurrence\nLoco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELoco -regional Recurrence\n\u00a7Versions 2002 \u20132022:\nAudretsch / Bauerfeind / Blohmer / Brunnert / Budach / \nCosta / Dall / Ditsch / Fehm / Fersis / Friedrich / Harbeck / Heil /\nGerber / Gluz / G\u00f6hring / Hanf / K\u00fchn/ Lisboa / Lux / Maass / \nMundhenke / Rezai / Simon / Solbach / Solomayer / \nSouchon / Thomssen / Wenz / W\u00f6ckel\n\u00a7Version 2023 :\nRody / W\u00f6ckel\nLoco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELoco -regional Recurrence\nIncidence and PrognosisLocalization10-y. incidence (%)5-y. Overall Survival (%)Ipsilateral recurrence1 (post BEO + irradiation)10 (2\u201320)65  (45\u201379)Chest wall1\n(post mastectomy)4 (2\u201320)50  (24\u201378)As above plus supraclavicular fossa2Axilla:3449 (3-y. OS) After ALND11 (0.1\u20138)55  (31\u201377)After SLNE4 193Multiple localizations216 (8\u201319)21  (18\u201323)\n1Haffty et al. Int J Radiat Oncol Biol Phys 21(2):293 -298, 1991;\n2Reddy JP . Int J Radiat Oncol Biol Phys 80(5):1453 -7, 201;\n3Karabali -Dalamaga S et al. Br Med J 2(6139):730 -733,1978;\n4Andersson Y , et al. Br J Surg 99(2):226 -31,2012Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELoco -regional \nRecurrence Staging\nOxford\nLoE GR AGOExaminations before treatment\u00a7Tissue biopsy 3b B ++\u00a7Re-assessment of ER, PR, HER2 3b B ++\u00a7Complete re -staging (slice imaging*) 2b B ++\u00a7\u201eLiquid biopsy\u201c 5D -\n*S t a n d a r d :  C T  t h o r a x  /  a b d o m e n  a n d  b o n e  s c a n ,  i n  c e r t a i n  c a s e s  w h o l e  b o d y  M R I  o r  18F FDG PET-CT\nmay be usedLoco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ERisk Factors for another Relapse*\nOxford\nLoE GR AGO\n\u00a7 Tumor size 2a B\n\u00a7 Multifocality 2a B\n\u00a7 Localisation 2b B\n\u00a7 Negative progesterone receptor 3b B\n\u00a7 High grade 3b C\n\u00a7 Omitted radiotherapy at first recurrence 3b C\n\u00a7 Omitted chemotherapy at first recurrence 3b C\nParameters of the locally recurrent tumor to define the risk for distant metastasis / survival\n\u00a7 Early (< 2 -3 yrs.) vs. late recurrence 2b B\n\u00a7 LVSI / Grade / ER -neg / positive margins (if \u2265 2 factors positive) 3b B\nPredictive factors for treatment considerations \n\u00a7 HER2 2b B ++\n\u00a7 ER and PR\n* Risk factors for local relapse see chapter \u201cprognostic factors\u201d2b B ++Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EIpsilateral Locoregional Recurrence \nSurgical Treatment\nOxford\nLoE GR AGO\n\u00a7 After mastectomy: wide exzision (aim R0) 3b B ++\n\u00a7 After BCS: \n\u00a7 Mastectomy (aim: R0) 3b B ++\n\u00a7 Re-BCS with tumor -free margins (R0) +partial breast irradiation* 2b B +\n\u00a7 Re-BCS with tumor -free margins (R0) 2b B +/-\n\u00a7 rcN0:\n\u00a7 Axillary intervention after prior AxDiss 4 C -\n\u00a7 Re-SLNE after prior SLNE 2a B -\n\u00a7 rfnN+: (Re -)Axillary dissection (R0) 5 C +\n\u00a7 Palliative surgery in M1 -situation or R0 not achievable\n(e.g. pain, ulceration, psychosocial indication)5 D +\n* After consideration of risk factors for repeated relapse (time from primary diagnosis, tumor size)Loco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMastectomy vs. BCS + Partial Breast Irradiation\nHannoun -Levi et al. Int J Radiat Oncol Biol Phys. 2020\u00a71327 pts. from 7 European countries with first local recurrence 01/1995 -06/2017\n\u00a7ME vs. BCS + Brachytherapy\n\u00a7Propensity Score matched control (1:1): clinical and histopathological  factors\n\u00a7Primary endpoint:  5 -y OS; secondary endpoints: e.g. 5 -y-DFS, complications\n\u00a7Median follow -up 75.4 months\n\u00a7No differences in 5 -y OS and sec. Endpoints: 5 -y -OS: 88 vs. 87%\n\u00a7cumulative incidence 2. recurrence: 2.3 vs. 2.8%\n\u00a75-y incidence of mastectomy after 1. recurrence 3.1%Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELoco -regional Recurrence after\nR0-Resection Systemic Treatment\nOxford\nLoE GR AGOAccording to pathohistological re-evaluation of the recurrent tumor (ER, PR, HER2) and in consideration of time from primary diagnosis, pre-treatment, co -morbidities and patient\u2019s preference\u00a7Endocrine therapy in endocrine responsive  tumors 2b B ++\u00a7Chemotherapy (consider preoperative) in particular in case of first HR -negative relapse2b B +\u00a7In case of HER2 -positive disease, chemotherapy \n+ HER2 -targeted therapy5 D +Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\u00a7CALOR Trial update\n\u2022n = 163 (2003 \u20132010), median follow -up of 4.9 years, all R0 resection\n\u20225-y DFS: 69% (95% CI 56 \u201379) with chemotherapy \nvs. 57% (44 \u201367) without chemotherapy (hazard ratio 0.59 \n[95% CI 0.35 \u20130.99]; p = 0.046): 24 (28%) patients vs. 34 (44%). \n\u2022Adjuvant chemotherapy was significantly more effective in \nER negative disease (pinteraction = 0.046).\n\u2022Multivariate analysis: predictors of survival\n\u2022chemotherapy for primary cancer (HR 3.55, p = 0.03)\n\u2022interval from primary surgery (HR 0.87, p = 0.05)Locoregional Recurrence\nChemotherapy \nWapnir IL et al.  Annals of Surgical Oncology, February 2017, Volume 24, Issue 2,  pp 398 \u2013406Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\u00a7CALOR Trial updateLoco -regional Recurrence\nChemotherapy\nWapnir IL et al.  Annals of Surgical Oncology, February 2017, Volume 24, Issue 2,  pp 398 \u2013406ER-positive ER-negative\nEndpoint CT No-CT HR (95% CI) CT No-CT HR (95% CI)\n10-yr DFS 50% 59% 1.07 (0.57 \u20132.00) 70% 34% 0.29 (0.13 \u20130.67)\nInteraction P -Value =0.013\n10-yr OS 76% 66% 0.70 (0.32 \u20131.55) 73% 53% 0.48 (0.19 \u20131.20)\nInteraction P -value =0.53\n10-yr BCFI 58% 62% 0.94 (0.47 \u20130.85) 70% 34% 0.29 (0.13 \u20130.67)\nInteraction P -value = 0.034Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELocoregional Recurrence in Case of \nR1-Resection / Inoperability \u2013Systemic Treatment\nOxford\nLoE GR AGOAccording to pathohistological re-evaluation of the recurrent tumor (ER, PR, HER2)\u00a7Endocrine based therapy in endocrine responsive \ntumors corresponding to metastatic disease 2b B ++\u00a7Chemotherapy and targeted therapy (pre -or \npostoperative) corresponding to metastatic disease2b B ++Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EIpsilateral breast tumor recurrence \nafter BCT \u2013Radiotherapy \nOxford\nLoE GR AGO\nAfter Re -BCS\n\u00a7 Whole breast irradiation\n(in case of no prior adjuvant radiotherapy)3b C ++\n\u00a7 Repeated (2.) -breast irradiation (Partial breast irradiation, brachytherapy/\nexternal beam RT, in case of prior adjuvant radiotherapy) *2b B+\nAfter mastectomy\n\u00a7 Radiation of chest wall +/ -regional lymph nodes (in case of no prior adjuvant\nradiotherapy, according to risk factors)2b B+\n\u00a7 Radiation dose escalation 3b C-\n\u00a7 Repeated (2.) irradiation\n\u00a7 in case of R0 resection (according to risk factors) 3b B +/-\n\u00a7 in case of R1/R2 resection (e.g. as brachytherapy) 3b B+\n\u00a7 Additional regional hyperthermia (especially for R1/2 -resections) 1a B +/-\n*Preoperative consultation with Radiation Oncology todetermine ifre-irradiation is possible.Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1EThoraxic wall recurrence after mastectomy and \naxillary recurrence \u2013Radiotherapy\nOxford\nLoE GR AGOThoracic wall recurrence after mastectomy\u00a7Noprior radiotherapy\n\u00a7 Curative situation : Radiotherapy tothethoracic wall +/ -regional nodal\nirradiation2b B +\u00a7Re-irradiation ofthethoracic wall 3b B +/-\n\u00a7 R0-resection 3b B +/-\n\u00a7 R1/2 -resection (e.g. brachytherapy ) 3b B +\n\u00a7 Additional regional hyperthermia (especially forR1/2 -resections) 1a B +Axillaryrecurrence\u00a7Radiotherapy totheaxilla (R0-resection)\n\u00a7 Noprior radiotherapy totheaxilla 3b C +\n\u00a7 Prior radiotherapy totheaxilla 5 D +/-Loco-Regional Recurrencewww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1ELoco -Regional Recurrence\nTreatment Options in Non -Curative Cases\nOxford\nLoE GR AGO\u00a7Concomitant radio -chemotherapy 3b C +\u00a7Hyperthermia (in centers listed on DKG website)\n\u00a7In combination with radiotherapy 1b B +\n\u00a7In combination with chemotherapy 4 C +/-\u00a7Intra -arterial chemotherapy 4 C +/-\u00a7Photodynamic therapy 4 C +/-\u00a7Electrochemotherapy 3b C +/-Loco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nEndocrine based and targeted \nTherapy of Metastatic Breast \nCancer\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine- based and targeted Therapy of \nMetastatic Breast Cancer\n\u25aaVersions 2002 \u20132022:\nAlbert / Bischoff / Dall / Fasching / Fersis / Friedrich / Gerber / Huober / \nJanni / Jonat / Kaufmann / Kolberg -Liedtke / Loibl / L\u00fcftner / L\u00fcck / von \nMinckwitz / M\u00f6bus / M\u00fcller / Mundhenke / Nitz / Schmidt / Schneewei\u00df\n/ Sch\u00fctz / Stickeler / Thill / Untch / Witzel / W\u00f6ckel\n\u25aaVersion 2023 :\nBanys -Paluchowski / Lux / Untch\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine -based and targeted Therapy of \nMetastatic Breast Cancer\nEndocrine -based therapy is the first treatment option in patients with \nhormone receptor (HR) positive / HER2 -negative metastatic breast cancer.\nImpending organ failure and/or symptomatic visceral metastases do not \nnecessarily represent an indication for chemotherapy, and endocrine -based \ntherapy can be used individually for endocrine -sensitive disease.\nCaveat: Receptor status may change during the course of disease. \nHistology of recurrent site should be obtained whenever possible.Oxford LoE: 1a GR: A AGO: ++Indication\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nMeta -analysis based on 39 (mostly retrospective) analyses, exclusively comparing \nprimary tumor and metastasis (no lymph nodes):\nPooled discordance proportions were:\n\u00a7 19,3% (95 % CI 1\u20444 15.8% to 23.4%) for ER\n\u00a7 30,9% (95% CI1\u20444 26.6% to 35.6%) for PR\n\u00a7 10,3% (95% CI 1\u20444 7.8% to 13.6%) for HER2\nPooled proportions of tumors shifting from positive to negative \n\u00a7 22.5% (95% CI = 16.4% to 30.0%) for ER\n\u00a7 49.4% (95% CI\u2009=\u200940.5% to 58.2%) for PR\n\u00a7 21.3% (95% CI\u2009=\u200914.3% to 30.5%)) for HER2\nPooled proportions of tumors shifting from negative to positive \n\u00a7 21.5% (95% CI\u2009=\u200918.1% to 25.5%) for ER\n\u00a7 15.9% (95% CI\u2009=\u200911.3% to 22.0%) for PR\n\u00a7 9.5% (95% CI\u2009=\u20097.4% to 12.1%) for HER2Comparison ER / PR and HER2\nMetastasis vs. Primary Tumor (n = 5.521)\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine Therapy \nGeneral Considerations\n\u00a7Within all lines of treatment, treatment options should consider prior \nendocrine therapies, age and comorbidities as well as the respective \napproval status.\n\u00a7Premenopausal patients treated with GnRH analogues or after \novarectomy can be treated like postmenopausal patients.\n\u00a7In this chapter, the recommendations refer to pre -and postmenopausal \nwomen, unless menopausal status is explicitly mentioned (in \npremenopausal patients, the combination with GnRH analogues is usually \ncarried out).Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine Resistance in\nMetastatic Breast Cancer\nPrimary endocrine resistance:\n\u00a7Relapse within 2 years of adjuvant endocrine treatment (ETx)\n\u00a7Progressive disease within first 6 months of first -line ETx for MBC\nSecondary (required) endocrine resistance:\n\u00a7Relapse while on adjuvant ETx but after the first 2 years or a relapse \nwithin  12 months after completing adjuvant ETx\n\u00a7PD \u2265 6 months after initiation of ET for MBC\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine Therapy in Premenopausal Patients \nwith HER2 -Negative Metastatic Breast Cancer\nOxford\nLoE GR AGO\u00a7GnRHa + Fulvestrant + CDK4/6i 2b B ++\u00a7GnRHa + AI + Ribociclib 1b B ++\u00a7GnRHa + AI + Palbociclib / Abemaciclib 3b/5 C +\u00a7GnRHa + Tamoxifen + Palbociclib / Abemaciclib 2b B +/-\u00a7GnRHa + Tamoxifen 1a A +\u00a7Tamoxifen 2b B +/-\u00a7GnRHa + AI (first + second line) 2b B +\u00a7GnRHa + Fulvestrant 1b B +\u00a7Aromataseinhibitors without OFS 3 D --Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine -Based Therapy with CDK4/ -Inhibitor for \nPostmenopausal Patients with HER2 -Negative Metastatic \nBreast Cancer\nOxford\nLoE GR AGO\u00a7Ribociclib\n\u00a7+ non -steroidal AI 1b A ++\n\u00a7+ Fulvestrant 1b A ++\u00a7Abemaciclib\n\u00a7+ non -steroidal AI 1b A +\n\u00a7+ Fulvestrant 1b A ++\u00a7Palbociclib\n\u00a7+ non -steroidal AI 1b A +\n\u00a7+ Fulvestrant 1b A +Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine -Based Therapy with CDK4/ -Inhibitor for Patients \nwith HER2 -Negative Metastatic Breast Cancer\nOxford\nLoE GR AGO\u00a7Abemaciclib monotherapy 3 C +/-\u00a7CDK4/6 -Inhibitor beyond progression (with\nchange oftheendocrine therapy partner )2b- C +/-\u00a7CDK4/6 -Inhibitor switch based on toxicity 5 D +/-\nCombination with GnRH agonists recommended in the premenopause . Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1E\nwww.ago -online.de\nCDK4/6 Inhibitors in First -line Studies\nStudy\nnamePaloma -2 Monarch -3 Monaleesa -2 Monaleesa -7\nTreatment \narmsPalbociclib / placebo with letrozole Abemaciclib / placebo with nonsteroidal AIRibociclib / placebo \nwith letrozoleRibociclib / placebo with \ntamoxifen or non -steroidal aromatase inhibitor, all with goserelin\nPatients 666 493 668 672\nMenopausal \nstatuspostmenopausal postmenopausal postmenopausal premenopausal\nProgression -\nfree survival\n(months, m)27.6 vs. 14.5 m \n(+13.1 m) \n(HR 0.563 )29.0 vs. 14.8 m \n(+14.2 m)\n(HR 0.518)25.3 vs. 16.0 m \n(+9.3 m)\n(HR 0.568)23.8 vs. 13.0 m\n(+10.8 m) \n(HR 0.55)\nOverall \nsurvival\n(months, m)53.9 vs. 51.2 m \n(+ 2.7 m)\n(HR 0.956, n.s.)67.1 vs. 54.5 m \n(+ 12.6 m)\n(HR 0.754, n.s.)63.9 vs. 51.4 m\n(+12.5 m)\n(HR 0.76)58.7 vs. 48.0 m \n(+10.7 m) \n(HR 0.76)Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFurther Endocrine -Based Treatment Options for Patients with \nHER2 -Negative Metastatic Breast Cancer\nOxford\nLoE GR AGO\u00a7Alpelisib + Fulvestrant (PIK3CA mutated ) 1b B +\u00a7Everolimus\n\u00a7+ Exemestane 1b A +\n\u00a7+ Tamoxifen 2b B +\n\u00a7+ Letrozole 2b B +/-\n\u00a7+ Fulvestrant 2b B +\nCombination with GnRH agonists recommended in the premenopause . Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine Monotherapy in Patients with HER2 -\nNegative Metastatic Breast Cancer\n*There is no evidence for superiority of a single aromatase inhibitor. As everolimus plus \nexemestane is indicated after AI treatment, a non -steroidal AI should be used in first line.\n#   Cave: noEMA approval yet\nCombination with GnRH agonists recommended in the premenopause . Oxford\nLoE GR AGO\n\u00a7 Fulvestrant 500 mg 1b B +\n\u00a7 Aromatase inhibitor* 1a A +\n\u00a7 Tamoxifen 1a A +\n\u00a7 Fulvestrant 250 mg + Anastrozole 1b B +/-\n\u00a7 Endocrine monotherapy (AI / Fulvestrant ) after prior CDK4/6i therapy 1b B +/-\n\u00a7 Elacestrant after prior CDK4/6i therapy (especially in case of prolonged \nresponse to CDK4/6i )#\n\u00a7 ESR1mut 1b B +\n\u00a7 ESR1wt 2b B +/-\n\u00a7 Repeat prior treatments 5 D +/-Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine Therapy in Patients with HER2 -Negative Metastatic \nBreast Cancer in Combination with Bevacizumab\nOxford\nLoE GR AGO\u00a7Maintenance bevacizumab  plus endocrine \ntherapy after remission with chemotherapy and \nbevacizumab1b B +/-\u00a7Bevacizumab plus endocrine treatment as first \nline therapy for advanced disease1b B +/-\nCombination with GnRH agonists recommended in the premenopause . Endocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePARP Inhibitors in Patients with HER2 -negative, \ngBRCA -Mutant, Metastatic Breast Cancer\nOxford\nLoE GR AGO\u00a7Olaparib 1b A ++\nOxford\nLoE GR AGO\u00a7Talazoparib 1b A ++\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nHR-positive and HER2 -positive \nMetastatic Breast Cancer\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deEndocrine -based Therapy in HER2 -Positive \nMetastatic Breast Cancer Patients\nPoor efficacy of endocrine therapy alone. \nConsider induction chemotherapy + anti -HER2 -therapy (followed by endocrine + anti -HER2 -\ntherapy as maintenance therapy)!\nCombination with GnRH agonists recommended in the premenopause . Oxford\nLoE GRAGO\u00a7Abemaciclib + Fulvestrant + Trastuzumab (\u22653rd line, after T -DM1) 2b B +\u00a7Aromatase inhibitor + Trastuzumab + Pertuzumab 2b B +\u00a7Aromatase inhibitor + Trastuzumab 1b B +/-\u00a7Aromatase inhibitor + Lapatinib 1b B +/-\u00a7Fulvestrant + Lapatinib 1b B +/-\nEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deConcomitant or Sequential \nEndocrine- Cytostatic Treatment\nOxfordLoEGRAGO\u00a7Concomitant endocrine-cytotoxic treatment 1b A-\n\u00a7May increase response rate and progression\nfree interval but not overall survival\n\u00a7May increase toxicity\u00a7Endocrine maintena nce therapy after\nchemotherapy +/- anti-HER2 therapy-inducedresponse  +/- anti HER2 therapy2b B+\n\u00a7Increases progression free intervalEndocrine based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2021.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E Chemotherapy With or Without\nTargeted Drugs* in Metastatic \nBreast Cancer\n*Substances without published evidence based on at least one phase III/II b trial were omittedChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy \u00b1Targeted Drugs in \nMetastatic Breast Cancer\n\u00a7Versions 2002 \u20132022: \nAlbert / Bischoff / Dall / Fehm / Fersis / Friedrichs / Harbeck / \nJackisch / Janni / Kolberg -Liedtke / L\u00fcftner / Lux / von Minckwitz / \nM\u00f6bus / M\u00fcller / Rody / Schaller / Scharl / Schmidt / Schmutzler / \nSchneeweiss / Sch\u00fctz / Stickeler / Thill / Thomssen / Untch\n\u00a7Version 2023:\nLoibl / Untch \nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetastatic Breast Cancer (mBC)\nDisease -Free and Overall Survival \nOxford\nLoE\u00a7In MBC, an increase in survival over time has been shown in \nclinical trials1b\u00a7Multiple lines of sequential  therapy are beneficial\n(at least same efficacy, less toxicity)1b\u00a7Targeted drugs in combination with chemotherapy can induce substantial survival benefits1b\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetastatic Breast Cancer\nEndocrine Resistance\nPrimary endocrine resistance:\n\u00a7Relapse within 2 years of adjuvant endocrine treatment (ET)\n\u00a7Progressive disease within first 6 months of first -line ET for MBC\nSecondary (required) endocrine resistance:\n\u00a7Relapse while on adjuvant ET but after the first 2 years or a relapse within  \n12 months after completing adjuvant ET\n\u00a7PD \u2265 6 months after initiation of ET for MBC\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTreatment of Metastatic Breast Cancer\nPredictive Factors for response\nOxford\nTherapy Factor LoE GR AGO\n\u00a7 Endocrine therapy ER / PR (prim. tumor , better : metastasis ) 1a A ++\nResponse toprior therapy 2b B ++\nAutocrine receptor mutation (ESR1 ) 2b B+\n\u00a7 Alpelisib PIK3CA mutation (prim. tumor , metastases , \nplasma )1b A ++\n\u00a7 Trastuzumab Deruxtecan HER2 -low orHER2 -positive 1b A ++\n\u00a7 Chemotherapy Response to prior therapy 1b A ++\n\u00a7 Anti -HER2 -therapy HER2 (prim. tumor, better: metastasis) 1a A ++\n\u00a7 Checkpoint -Inhibitors PD-L1 positivity#(PD-L1ic, CPS) in TNBC \n(primary tumor or metastasis)1b B ++\n\u00a7 PARP -Inhibitors gBRCA1/2 -mutation 1a A ++\n\u00a7 Bone modifying drugs Bone metastasis 1a A ++\n# seechapter \u201epathology \u201cChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Mono -Chemotherapy: \n\u00a7Favorable therapeutic index*\n\u00a7Indicated in case of\n\u00a7Slow, not life -threatening progression\n\u00a7Insensitivity to or progression during endocrine therapy\n\u00a7Poly -Chemotherapy:\n\u00a7Unfavorable therapeutic index \n\u00a7Indicated to achieve rapid remission in the case of\n\u00a7Extensive symptoms\n\u00a7Visceral crisis (ABC -5 definition)\n\u00a7Survival benefit in comparison to sequential single -agent therapies with the same \ncompounds not proven Oxford LoE: 1bGR: AAGO: ++\n*Therapeutic index evaluates overall efficacy, toxicity, and impact on quality of lifeMetastatic Breast Cancer\nTreatment Rationale\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nDefinition of Visceral Crisis (ABC 5)\n\u00a7Visceral crisis is defined as severe organ dysfunction, as assessed by signs \nand symptoms, laboratory studies and rapid progression of disease. Visceral \ncrisis is not the mere presence of visceral metastases but implies important \norgan compromise leading to a clinical indication for the most rapidly \nefficacious therapy.\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u00a7Evaluate compliance before and during therapy (especially in patients of \nolder age, with reduced performance status, or significant co -morbidities \nand secondary primaries)\n\u00a7Assess subjective and objective toxicities, symptoms, and performance as \nwell as quality of life (QoL) status repeatedly\n\u00a7Use dosages according to published protocols\n\u00a7Assess tumor burden at baseline and approx. every 2 months, i.e.every 2 -4 \ncycles. In slowly growing disease, longer intervals are acceptable. GR: AAGO: ++Metastatic Breast Cancer\nSystemic Therapy\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7As long as therapeutic index* remains positive 1a A ++\n\u00a7Treatment until progression 2b B+\n\u00a7Treatment until best response 2b B +/-\n\u00a7Change to alternative regimen before progression 2b B +/-\u00a7Stop therapy in case of 1c A ++\n\u00a7Progression\n\u00a7Non tolerable toxicityMetastatic Breast Cancer\nDuration of Cytotoxic Therapy\n*Therapeutic index evaluates overall efficacy, toxicity, and impact on quality of lifeChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deChemotherapy in mBC\nGeneral Considerations -Drug Selection\n\u00a7Participation in clinical trials is recommended\n\u00a7The choice of systemic therapy depends on:\n\u00a7ER/PR, HER2, PD -L1-Status, gBRCA -Status (evtl.  sBRCA -Status, evtl. PALB2), PIK3CA , AKT, \nPTEN , evtl. MSI, NTRK, ggf. m ESR1 , other (NGS Panel preferred )\n\u00a7Prior therapies (and their toxicities)\n\u00a7Disease -free interval after end of adjuvant treatment\n\u00a7Progression -free interval achieved by the previous line of therapy\n\u00a7Disease aggressiveness and localization of metastases\n\u00a7Estimated lifeexpectancy\n\u00a7Co-morbidities (including organ dysfunction )\n\u00a7Patient preferences and expectationsAGO: ++\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.demBC HER2- negative / HR -positive\n1st-Line Chemotherapy (if indicated)\nLoE GR AGO\u00a7Monotherapy:\n\u00a7Paclitaxel (q1w), Docetaxel (q3w) 1a A ++\n\u00a7Doxorubicin, epirubicin, Peg -liposomal doxorubicin (Alip) 1b A ++\n\u00a7Vinorelbine 3b B+\n\u00a7Capecitabine 2b B+\n\u00a7Nab-paclitaxel 2b B+\u00a7Polychemotherapy:\n\u00a7A + T 1b A ++\n\u00a7Paclitaxel + capecitabine 2b B+\n\u00a7Docetaxel + capecitabine after adj. A 1b A+\n\u00a7T + gemcitabine after adj. A 2b B ++\n\u00a7A + C or Alip+ C 1b B ++Oxford\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.demBC HER2 -negative / HR -positive:\nChemotherapy after Anthracycline Treatment*\nOxford\nLoE GR AGO\u00a7Paclitaxel q1w 1a A ++\u00a7Docetaxel q3w 1a A ++\u00a7Capecitabine 2b B ++\u00a7Nab-paclitaxel 2b B ++\u00a7Peg-liposomal doxorubicin 2b B+\u00a7Eribulin 1b B+\u00a7Vinorelbine 2b B+\u00a7Docetaxel + Peg -liposomal doxorubicin 1b B +/-\n*Independent whether anthracyclines were used in adjuvant or 1stline metastatic situationChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.demBC HER2 -negative / HR -positive: \nChemotherapy after Pretreatment *\nOxford\nLoE GR AGO\u00a7Trastuzumab -Deruxtecan (if HER2 -low) 1b A ++\u00a7Sacituzumab Govitecan 1b A+\u00a7Capecitabin 2b B+\u00a7Eribulin 1b B+\u00a7Vinorelbine 2b B+\u00a7(Peg) -liposomal Doxorubicin 2b B+\u00a7Taxane re-challenge ** 2b B+\u00a7Anthracycline re-challenge ** 3b C+\u00a7Metronomic therapy (e.g. cyclophos . + MTX) 2b B+\n* See approval details forprevious therapy\n** at least 1 year recurrence free after adjuvant therapyChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nmBC HER2 -negative / HR -positive*\nTrastuzumab Deruxtecan\nHR pos, Her 2 low\n(331 Patients )HazardRatio comparedtothecontrol arm \nChemotherapySacituzumab Govitecan\nHR pos/ Her 2 neg\n(272 Patients )Hazard Ratio compared to\nthecontrol arm \nChemotherapyPrevioustherapyChemotherapyforMetastastaticdiseaseAll Patients All Patients1 Line61% 0,54 forPFS 0 %2 Lines37% 0,47 forPFS 44% 0,85 forOS3-4 Lines 3 % 0,47 forPFS 60 % 0,75 forOSEndocrineTherapy forMetastaticdiseaseAll Patients (> 6 Months ,86 % of patients )\nNone or< 6 Months0,79 forOS\n0,88 forOS1 Line32% NE NE2 Lines33% NE 40 %3 Linesandmore 27 % NE NEwithoutCDK 4/6 plus endocrine therapywithCDK 4/6 plus endocrine therapy30 %\n70%0,42 forPFS\n0,55 f\u00fcr PFS\u2264 12 Months 59%\n> 12 Monate 39%0,68 forOS\n0,98 forOSPFS (Months ) 10.1 0,51 5.5 0,66OS (Months ) 23.9 0,64 14.4 0,79\n*Data from two different prospective phase 3 studies withdifferent patient cohorts\nNE Not evaluated, PFS Progression freesurvival, OS Overall survival , HR Hazard ratioChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTriple negative mBC PD -L1+ \nIndependent of germline mutation in BRCA 1/2 \nOxford\nLoEGRAGO\u00a7Pembrolizumab + Chemotherapy* first -line PD -L1 CPS \n\u226510# (if TFI \u2265 6 months)1b B ++\u00a7Atezolizumab + Nab -Paclitaxel first -line PD -L1 IC \u2265 1# (if TFI \u2265 12 months)1b B+\u00a7Atezolizumab + Paclitaxel first -line PD -L1 IC \u2265 1# 1ba B-\u00a7Pembrolizumab monotherapy (after chemotherapy w/o previous immune oncology based therapy) in case of CPS \u2265 20#1ba B +/-\n#(see chapter \u201ePathology\u201c)\n*nab-Paclitaxel or Paclitaxel or Carboplatin / Gemcitabine \nTFI = therapy -free intervalChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTriple negative mBC independent ofPD-L1 Status and\nGermline Mutations in BRCA \u00bd orPALB2 *\nOxford\nLoE GR AGO\u00a7Sacituzumab Govitecan 1b A ++\u00a7Bevacizumab 1st line in combination with\n\u00a7Paclitaxel (weekly) 1b B+\n\u00a7Capecitabine 1b B+\n\u00a7nab-Paclitaxel 2b B +/-\u00a7Carboplatin (vs. Docetaxel) 1b B +/-\u00a7Gemcitabin / Cisplatin (vs. Gem / Pac) 1b A+\u00a7Nab-Paclitaxel / Carboplatin (vs. Carbo / Gem ) 2b B+\u00a7Trastuzumab Deruxtecan (in HER2 low) 2b C +/-\n* According tolabelChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTreatment Options in mBC \nwith BRCA 1/2 or gPALB2 Mutation\nOxford\nLoE GR AGO\u00a7Carboplatin (vs. docetaxel) (if Platinum -naive) 1b B+\u00a7PARP -Inhibitors (HER2 -negative mBC)\n\u00a7HER2 -negative, g BRCA 1/2 mutation\n\u00a7Olaparib 1b A ++\n\u00a7Talazoparib 1b A ++\n\u00a7sBRCA 1/2 mutation\n\u00a7Olaparib 2b B +/-\n\u00a7gPALB2 mutation\n\u00a7Olaparib 2b B +/-Chemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHER2 -pos. mBC\n1st line without Pretreatment or after Trastuzumab\nOxford\nLoE GR AGOPrimary metastatic \u00a7 Docetaxel + Trastuzumab + Pertuzumab 1b A ++\n\u00a7 Paclitaxel (weekly) + Trastuzumab + Pertuzumab 2b B ++\n\u00a7 nab-Paclitaxel + Trastuzumab + Pertuzumab 2b C+After Trastuzumab in the adjuvant setting (TFI > 6 months)\u00a7 Docetaxel + Trastuzumab + Pertuzumab 1b A ++\n\u00a7 Paclitaxel (weekly) + Trastuzumab + Pertuzumab 2b B ++\n\u00a7 nab-Paclitaxel + Trastuzumab + Pertuzumab 2b C+\n\u00a7 Vinorelbin + Trastuzumab + Pertuzumab 3b B+After pretreatment with only Trastuzumab in the adjuvant setting (TFI < 6 months)\u00a7 Trastuzumab Deruxtecan (T -DXd) 4D +/-\n\u00a7 T-DM1 2b B +/-\n\u00a7 Chemotherapy + Trastuzumab + Pertuzumab 4D +/-Chemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHER2 -pos. mBC\n1st line after Trastuzumab / Pertuzumab +/ -TDM -1\nOxford\nLoE GR AGOAfter Trastuzumab / Pertuzumab in the (neo-)adjuvant setting\u00a7Re-induction CTx + Trastuzumab + Pertuzumab (TFI > 6 -12 months) 4D ++\u00a7Trastuzumab Deruxtecan (T-DXd ) 4D +\u00a7T-DM1 (TFI < 6 -12 months) 5D +/-\u00a7Capecitabine + Lapatinib 1b B +/-After Trastuzumab / Pertuzumab in the (neo-)adjuvant setting andT-DM1 in the post -neoadjuvant setting\u00a7Re-induction CTx + Trastuzumab + Pertuzumab (TFI > 6 -12 months) 4D +\u00a7T-DXd 5D +\u00a7Tucatinib + Capecitabine + Trastuzumab 5D +\u00a7Capecitabine + Lapatinib 5D +/-Chemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7Trastuzumab Deruxtecan (T -DXd) 1b B ++\u00a7Tucatinib + Trastuzumab + Capecitabine (after \npretreatment with T -DM1)1b B ++\u00a7T-DM 1 1b A+\u00a7Capecitabine + Lapatinib / Trastuzumab 1b B +/-\u00a7TBP: 2ndline Chemotherapy* + Trastuzumab / Pertuzumab 2b B +/-\u00a7Trastuzumab + Pertuzumab 2b B +/-\u00a7Trastuzumab + Lapatinib (HR neg.) 2b B +/-\n* e.g. Taxane; Vinorelbin; Taxane / Carboplatin; Capecitabine; Capecitabin / Docetaxel (Toxizit\u00e4t!)HER2 -pos. mBC\n2nd line\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxfordDepending on the previous therapy (substance) LoE GR AGO\u00a7Tucatinib + Trastuzumab + Capecitabine 1b B ++\u00a7Trastuzumab Deruxtecan 1b B+\u00a7T-DM 1 1b A+\u00a7Capecitabine +  Trastuzumab / Lapatinib 1b B+\u00a7Capecitabine + Neratinib 1b B+\u00a7Margetuximab + Chemotherapy 1b B +/-HER2 -pos. mBC\n\u2265 third -line\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7Trastuzumab + Aromatase inhibitor (HR+) 2b B +/-\u00a7Lapatinib + Aromatase inhibitor (HR+) 2b B +/-\u00a7Aromatase inhibitor + Trastuzumab + Pertuzumab (HR+) 2b B+\u00a7Abemaciclib + Trastuzumab + Fulvestrant 2b B+\u00a7Trastuzumab + Pertuzumab 2b B +/-\u00a7Trastuzumab + Lapatinib (HR neg.) 2b B+\u00a7Trastuzumab mono 2b B +/-HER2 -pos. mBC \nNo Chemotherapy Possible or Desired\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nOsteooncology and \nBone Health\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOsteooncology and \nBone Health\n\u00a7Versionen 2002 \u20132022: \nBanys -Paluchowski / Bischoff / B\u00f6hme / Brunnert / Dall / Diel / Fehm\n/ Fersis / Friedrich/ Friedrichs / Hanf / Huober / Jackisch / Janni / \nKolberg -Liedtke / Lux / Maas / Nitz / Oberhoff / Reimer / Schaller / \nScharl / Sch\u00fctz / Seegenschmiedt / Solbach / Solomayer / Souchon\n\u00a7Version 2023:\nHarbeck / Huober\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBisphosphonates in Metastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Therapy of hypercalcemia 1a A ++\n\u00a7Reduction of skeletal events / complications 1a A ++\n\u00a7Reduction of bone pain 1a A ++\n\u00a7Increasing bone pain -free survival 1a A ++\n\u00a7Treatment beyond osseous progression 5D ++\n\u00a7Use of bone resorption marker for therapymonitoring5D -\n\u00a7Bisphosphonates alone for pain control 5D -Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDenosumab in \nMetastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Therapy of hypercalcemia 1a A ++\n\u00a7Reduction of skeletal events / complications 1a A ++\n\u00a7Reduction of bone pain 1a A ++\n\u00a7Increasing bone pain -free survival 1b A ++\n\u00a7Treatment beyond progression 5 D +\n\u00a7Progression while on bisphosphonates 4 C +/-\n\u00a7Use of bone resorption markers for therapy monitoring5 D -\n\u00a7Denosumab alone for pain control 5 D -Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nLonger -Interval vs. Standard Dosing of\nBone -Targeted Agents\n\u00a7 CALGB 70604 trial : n = 1822 patients with metastatic breast cancer, metastatic prostate cancer, or multiple \nmyeloma, 795 completed the study\nSRE after 2 years: 29.5% zoledronic acid every 4 weeks\n28.6% zoledronic acid every 12 weeks\n\u00a7 OPTIMIZE -2 trial : n = 416 women with metastatic breast cancer, prior exposure to zoledronate or pamidronate \nfor approx. 1 year or more\nSRE after 1 year: 22.0% zoledronic acid every 4 weeks\n23.2% zoledronic acid every 12 weeks\n\u00a7 REaCT -BTA trial : n = 263 metastatic cancer (160 breast, 103 prostate)\nDenosumab (n = 148), zoledronate (n = 63) or pamidronate (n = 52) q4w vs. q12w\nPrimary endpoint (non -inferiority of q12w vs. q4w in HRQoL) reached\nCumulative SSE after 1 year: 7.6% bone -targeted agent every 4 weeks\n16.6% bone -targeted agent every 12 weeks (p = 0.27)Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBone Modifying Agents for the \nTherapy of Bone Metastases\nOxford\nLoE GR AGO\n\u00a7Clodronate PO 1600 mg daily 1a A ++\n\u00a7Clodronate IV 1500 mg q3w / q4w 1a A ++\n\u00a7Pamidronate IV 90 mg\n\u00a7q3w / q4w 1a A ++\n\u00a7q12w 2b B +/-\n\u00a7Ibandronate  IV 6 mg q3w / q4w 1a A ++\n\u00a7Ibandronate PO 50 mg daily 1a A ++\n\u00a7Zoledronate IV 4 mg \n\u00a7q4w 1a A +\n\u00a7q12w 1a A ++\n\u00a7Denosumab 120 mg SC\n\u00a7q4w 1a A ++\n\u00a7q12w 2b B +/-\n\u00a7Other dosing or schedules, e.g. from adjuvant trials or therapy of \nosteoporosis5 D --\n\u00a7Planned sequential therapy with multiple agents 2b B +/-Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSkeletal Metastases\nTreatment with Radionuclids\nOxford\nLoE GR AGO\n\u00a7Tumor progression after standard treatment of \nmultiple / disseminated metastases and intolerable \nbone pain1b B +\n\u00a7186Rhenium -hydroxyethyliden -diphosphonat 2b B +\n\u00a7153Samarium 1b B +\n\u00a789Strontium 1b B +\n\u00a7223Radium 2b C +\n\u00a7177Lu-EDTMP 2b C +\n\u00a7188Rhenium -HEDP 1b B +\nCave: the potential benefits should be weighed against the risk of \nmyelosuppression and pancytopeniaOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetastatic Bone Disease of the Spine\nIndications for surgery\n\u00a7Spinal cord compression\n\u00a7With progressive neurological symptoms\n\u00a7With pathological fractures\n\u00a7Instability of the spine\n\u00a7Lesions in pre -irradiated parts of the spineOxford LoE: 2b GR: C AGO: ++\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBone Metastases Acute Spinal\nCord Compression / Paraplegia\nOxford\nLoE GR AGO\n\u00a7Decompression surgery, reduction of tumor volume, \nstabilization surgery (< 24 h) and irradiation of the \nspine2b C ++\n\u00a7Irradiation of the spine (< 24 h)\n\u00a7Radiatiotherapy regimen (1 x 8 -10 Gy vs. multiple fractions) \ndepending on prognosis, performance status and patient\u2018s \npreference3b C ++\n\u00a7Immediate start of treatment  1c D ++\n\u00a7Steroids (start at first symptoms) 2a C +\nClinical trials have included patients with different tumor entities!Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSurgery for Bone Metastases\nTechnical Aspects\nSpine and limbs\n\u00a7Marrow splints\n\u00a7Plate osteosynthesis\n\u00a7Compound osteosynthesis (replacement by PMMA and osteosynthesis)\n\u00a7Vertebral replacement bytitanspacer\n\u00a7Tumor -Endoprothesis\n\u00a7Vertebroplasty / Kyphoplasty +/ -thermoablation of the tumor\n\u00a7Kypho -IORT (in studies only )\n\u00a7Resection of involved bone in oligometastatic disease  \n(sternum, ribs, vertebrae )Oxford LoE: 3b GR: C AGO: +\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetastatic Bone Disease: \nRadiotherapy (RT)\nOxford\nLoE GR AGO\nBone metastases\n\u00a7With fracture risk 1a B ++\n\u00a7With functional impairment 1a B ++\n\u00a7With bone pain 1a B ++\nSingle dose RT = fractionated RT 2a B ++\n\u00a7With neuropathic bone pain 1b B ++\n\u00a7Asymptomatic isolated bone metastasis 5D +/-\n\u00a7Reduction of radiation -induced pain flare -up by\ndexamethasone1b B+\n\u00a7Radiotherapy in combination with hyperthermia 2b B +/-\nLimited studies included breast cancer patients!Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMetastatic Bone Disease \nRecurrent Bone Pain after RT\nOxford\nLoE GR AGO\nRecurrent bone pain in pre -irradiated parts of the \nskeleton\n\u00a7Single dose RT * 3b C ++\n\u00a7Fractionated RT * 3b C ++\n\u00a7Radionuclide therapy 2b B +\n\u00a7Magnetic resonance -guided focused ultrasound 1b B +\n\u00a7Radiofrequency ablation 4 C +\n\u00a7Cryoablation 4 C +\n*Dose and fractionation depending on location, interval from first radiotherapy (RT), \nand dose and fractionation of first RTOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSide -Effects and Toxicity: Bisphosphonates \n(BP) and Denosumab (Dmab)\nLoE\n\u00a7Renal function deterioration due to IV -aminobisphosphonates 1b\n\u00a7Osteonecrosis of the jaw (ONJ) mostly under IV -BP and \nDmab therapy (1.4 \u20132.8% / 1.3 \u20133.2%)1b\n\u00a7Association with (simultaneous) anti -angiogenetic therapies 3b\n\u00a7Severe hypocalcemia (Dmab > BPs) 1b\n\u00a7Acute Phase Reaction (IV Amino -BPs, Dmab ) 10\u201330% 1b\n\u00a7Gastrointestinal side effects (oral BPs) 2 \u201310% 1b\n\u00a7Atypical femur fractures\n(absolute risk of 11 per 10,000 person years of BP use)2b\n\u00a7Extremely rare: Uveitis / Scleritis under BP treatment 4Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nFrequent side effects under treatment with \nBPs / Denosumab \nCave: Hypocalcemia under antiresorptive therapy in pts with bone metastases!DrugAcute\nphase -\nreactionKidney\nTox.Upper \nGIDiarrhea ONJ\nClodronate 1500 IV 0 + 0 0 0 Non -Amino.\nClodronate 1600 PO 0 0 + + 0 Non -Amino.\nIbandronate 50 mg PO 0 0 + 0 0 Aminobisph.\nIbandronate 6 mg IV + 0 0 0 + Aminobisph.\nZoledronate 4 mg IV (q4w orq12w) + + 0 0 + Aminobisph.\nPamidronate 90 mg IV + + 0 0 + Aminobisph.\nZoledronate 4 mg IV q6m + 0 0 0 0 Aminobisph.\nDenosumab 120 mg SC q4w + 0 0 + +Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deRecommendations for Prevention of \nOsteonecrosis of the Jaw (ONJ)\n\u00a7During bisphosphonate ordenosumab treatment , avoid any elective dental \nprocedures involving jaw bone manipulations during treatment with\nbisphosphonates ordenosumab (LoE2a, recommendation grade A )\n\u00a7Optimize dental status before start of bisphosphonate or denosumab treatment \n(LoE2a, recommendation grade A )\n\u00a7Inform patients about ONJ risk and educate about early symptom reporting\n\u00a7In case of high risk for ONJ, use oral bisphosphonate\n\u00a7Recommend good oral hygiene, limiting alcohol intake and quit smoking\n\u00a7Under adjuvant bisphosphonate therapy, ONJ is rare (< 1%)Oxford LoE: 2a GR: A AGO: ++\nASORS Evaluation\nhttps://www.onkosupport.de/asors/content/e4126/e1743/e1861/e1862/e4628/LaufzettelAGSMOFarbefinal.pdfOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdjuvant Bone Targeted Therapy for \nImprovement of Prognosis\nOxford\nLoE GR AGO\n\u00a7Clodronate (oral)\n\u00a7Postmenopausal patients 1a A +\n\u00a7Premenopausal patients 1a B +/-\n\u00a7Aminobisphosphonate (IV or oral)\n\u00a7Postmenopausal patients  1a A +\n\u00a7Premenopausal patients 1a B +/-\n\u00a7Denosumab (6 x 120 mg/3 \u20134w + 14 x 120 mg/3m)\n\u00a7Stage II and III postmenopausal patients 1b B -\n\u00a7Denosumab (60 mg SC q6m)\n\u00a7Postmenopausal patients undergoing AI therapy 1b B +/-Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDosage of Adjuvant Bisphosphonates \nfor Improvement of Survival\n\u00a7Non -Aminobisphosphonates:\n\u00a7Clodronate PO 1600 mg/d (Bonefos / Clodronic acid)\n\u00a7Clodronate PO 1040 mg/d (Ostac / Clodronic acid)\n\u00a7Aminobisphosphonates:\n\u00a7Zoledronate IV 4 mg/6 m (Zometa / Zoledronic acid)\n\u00a7Ibandronate PO 50 mg/d (Bondronat / Ibandronic acid)\n\u00a7Pamidronate PO ( orally not available in most countries )\n\u00a7Risedronate PO 35 mg/w*(Actonel / Risedronic acid)\n\u00a7Alendronate PO 70 mg/w (Fosamax / Alendronic acid)\n\u00a7Optimal duration yet to be defined; in adjuvant studies duration of BP treatment varied \nfrom 2 \u20135 years \nAminobisphosphonates include:\nZoledronic acid (65%), oral ibandronate (24%), oral pamidronate (8%), \noral risedronate (2%), oral alendronate (1%) (data from EBCTCG meta -analysis)Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nReduction in Bone Density ofIndividual Agents\n0,51377,6\n012345678Normal Postmenopausal womenAI in postmenopausalAI + GnRHa in premenopausalOvarian ablation after Chemo\nBone mineral density (%) \nreduction within 1 year\n(1)Kanis JA Osteoporosis 22, 1997, (2) Gnant M SABCS 2004, (3) Shapiro CL, JCO 19:3305, 2001Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nKyvernitakis et al Osteoporosis Int 2018\npremenopausal postmenopausalRisk ofOsteoporosis and Tamoxifen\n(Fracture Risk)\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTherapy and Prevention of Tumor \nTherapy -Induced Bone Loss / Osteoporosis\nOxford\nLoE GR AGO\n\u00a7Bisphosphonates\n\u00a7Therapy 1b B ++\n\u00a7Prevention (2 \u20135 yrs) 1b A +\n\u00a7after discontinuation ofDenosumab (1-2 years ) 3c C +\n\u00a7Denosumab\n\u00a7Therapy 1b B ++\n\u00a7Prevention (up to max. 3 yrs) 1b A +/-\n\u00a7Hormone replacement therapy 5 D -\n\u00a7Clinical risk assessment for osteoporosis at baseline \naccording to DVO S3 -guidelines++\n\u00a7DXA -scan at baseline in ptswith endocrine therapy and / or\npremature menopause5 D +\n\u00a7Antiresorptive therapy according toDVO S3 -guidelines ++\n\u00a7Repeat DXA -scan based on risk 5 D +Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deTherapy and Prevention of Tumor Therapy -\nInduced Bone Loss / Osteoporosis\nOxford\nLoE GR AGO\n\u00a7Physical activity 4 C ++\n\u00a7Avoiding immobilisation 4 C ++\n\u00a7Calcium (1000 \u20131500 mg/d)** 4 C ++\n\u00a7Vitamine D3 suppl. (800 \u20132000 U/d or 20,000 U/w) 4 C ++\n\u00a7Quit smoking, reduction of alcohol 2b B ++\n\u00a7Avoid BMI < 20 kg/m23b C ++\n\u00a7Bisphosphonates after discontinuation ofDenosumab (1-2 \nyears ) 3c C +\n\u00a7Drugs approved for osteoporosis treatment\nin adults (see next slide)Further recommendations (based on DVO -guidelines for \ntreatment, diagnosis and prevention of osteoporosis)*\n*http://www.dv -osteologie.or g/osteoporose -leitlinien\n**if nutritional supply is insufficient (in combination with Vit D3 only)Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nEffect of Denosumab Discontinuation\nFREEDOM / FREEDOM Extension Trial\nn= 1001, \u2265 2 dose ofDenosumab orplacebo , follow up\u2264 7 months after \ndiscontinuation treatment\nVertebral fracture rate per 100 participant year :\n1.2 during denosumab therapy\n7.1 after denosumab therapy\n8.5 placebo\nNon vertebral fracture rate per 100 participant year :\n2.8 after denosumab vs. 3.8 placebo (n.s.)\nMultiple vertebral fracture (% ofall vertebral fractures ): \n60.7% after denosumab therapy vs. 38.7% placebo ; p = 0.049\nCummings SR  et al. J Bone Miner Res  2017Osteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMedical Treatment ofOsteoporosis\n*Drugs tested in clinical studies with breast cancer patients and tumor therapy -induced osteoporosis\n**Elevated risk of myocardial infarction (MI); only for to postmenopausal pts. with severe osteoporosis + high fracture risk\n*** Elevated risk of MI and CVI; only for postmenopausal. pts with severe osteoporosis + high fracture riskLoE GR AGO\n\u00a7Alendronate 70 mg PO/ w* 1b B ++\n\u00a7Zoledronate 5 mg IV/12m* 1b B ++\n\u00a7Ibandronate 150 mg PO/m* 1b B ++\n\u00a7Ibandronate 3 mg IV/3 m 1b B ++\n\u00a7Risedronate 35 mg PO/ w* 1b B ++\n\u00a7Denosumab 60 mg SC/6m* 1b B ++\n\u00a7Raloxifene 60 mg PO/d ( improves spine only ) 1b B +/-\n\u00a7Parathyroid hormone (1-84) 100 \u00b5g SC/d 1b B +\n\u00a7Strontium ranelate 2 g PO/d** 1b B +\n\u00a7Teriparatide (1-34) 20 \u00b5g SC/d 1b B +\n\u00a7Romosozumab 210mg s.c./m for12m*** 1b B +Oxford\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dehttps://www.dv -\nosteologie.org/uploads/Leitlinie%202017/DVO%20Leitlinie_\nKitteltaschenversion_16012020.pdf\nDiagram courtesy of the DVO\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nSites of Metastases\nSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSites Of Metastases\nSpecific Approaches to Metastatic Disease\n\u00a7Versionen 2002 \u20132022: \nAlbert / Bauerfeind / Bischoff / B\u00f6hme / Brunnert / Dall / Diel / Fehm / \nFersis / Friedrich / Friedrichs / Gerber / Hanf / Janni / Kolberg -Liedtke / \nKreipe / Loibl / L\u00fcck / Lux / Maass / Mundhenke / Oberhoff / Park -Simon \n/ Rezai / Rody / Schaller / Sch\u00fctz / Seegenschmiedt / Solbach / Solomayer\n/ Souchon / Thomssen\n\u00a7Version 202 3:\nL\u00fcftner / Solomayer\nSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSites of Metastases\n\u00a7Liver and lung metastases\n\u00a7Malignant pleural and pericardial effusions\n\u00a7Ascites\n\u00a7Bone marrow involvement\n\u00a7Soft tissue metastases\n\u00a7Contralateral axillary metastasis\nSee also chapters \u201eCNS Metastases \u201c and \u201eLocoregional Recurrence (Loco -Regional Recurrence Treatment Options \nin Non Curative Cases)\u201cSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGeneral Treatment Aspects ofMetastases\nOxford\nLoE GR AGO\u00a7Histological verification 3 B ++\u00a7Cytological verification , ifhistology not possible 3 B +\u00a7Systemic therapy preferred 2a B ++*\u00a7Consider surgery of metastases in case of good response to \npalliative treatment, oligometastases2b C +/-\u00a7Stereotatic Radiotherapy for patients with oligometastases 2b B +/-\u00a7Local -interventional ablative procedure 3b C +/-\u00a7Local treatment in the case of pain, \nexulceration , persistence after systemic \ntreatment, bowel obstruction, hydrocephalus occlusus , spinal \ncord compression 5 D +/-\u00a7Systemic treatment after surgery 2c B ++\n*See chapters with systemic treatment recommendationsSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deLocal Therapy \nin Primary Metastatic Disease\nOxford\nLoE GR AGO\u00a7Surgery (R0) of the primary tumor (individualized \nprocedure in case of oligometastatic disease)\n\u00a7In case of bone metastases only 1b B +/-\n\u00a7In case of visceral metastases 1b B -\u00a7Axillary surgery for cN1 3b B +/-\u00a7Sentinel biopsy if cN0 5 D -\u00a7Radiotherapy of the primary tumor\n\u00a7Alone (without surgery) 3a C +/-\n\u00a7After local surgical treatment with BCS or mastectomy \n(according to adjuvant indication)2c B +/-Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nRandomized Phase III Trials \nST +/ -Surgery of the Primary Tumor\nTrial n Therapy prior torandomizationLocal ControlImproved OS Primary EndpointQoL\nECOG 2108 *1,2\n(USA/Kanada)2001 -2016256 4-8 months systemic therapyyes no nsTata Memorial Hospital *3\n(India) \n2005 -2012350 chemotherapy yes no -\nMF07 -01 *4,5,6,7\n(Turkey)\n2008 -2012278 no systemic therapy no\n10 y LRP: LRT 1% vs \n14% ST, s10 y fu OS: LRT 19% vs. ST 5%, s\n(HR+, Her2 -, < 55 y, solitary bone \nonly metastasis)ns\nABCSG -28#*8.9\n(Austria)2010 -201990 no systemic therapy yes no ns\nJCOG 1017\n(Japan)2011 -2018410 primary ST Completed , results not reported so far\nns not significant, s: significant  #trial terminated due to poor recruitment\nST = systemic therapy, LRT= locoregional therapy, LRP = locoregional progressionSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nProspective Registry Study (Bone only)\nTrial n Randomization Local ControlImproved OS Primary EndpointQoLBOMET MF 14-01#\n2014 -505 ST vs LRT (LRT+ST vs. \nST+LRT)yes3 y fu: improved OS in the LRT group (HR 0.40)HR+, Her2 -; Her2+ subgroups, no \nbenefit in triple neg. patients-\nST = systemic therapy, LRT = locoregional therapy, Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deLiver Metastases \nLocal Therapy\nOxford\nLoE GR AGO\u00a7Resection of liver metastases (R0) 3a B +/-\n\u2022 HR-positive: chemotherapy -sensitive, long disease -free interval, \nabsence of extrahepatic disease, \u2264 3 metastases \n\u2022 HER2 -positive: age < 50 y, metastases < 5 cm, no further \nmetastases\u00a7Interventional regional chemotherapy (TACE)* 3b C +/-\u00a7Interventional regional radiotherapy (SIRT/TARE)* 3b C +/-\u00a7Stereotactic Radiotherapy with VMAT (SRS -VMAT), other modalities* 2a B +/-\u00a7Regional ablative procedures (RFA, MWA) 3b C +/-\n\u00a7IRE, LITT, HIFU 5 D -\n\u00a7Cryoablation 3b C -\n* interdisciplinary decisionSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.dePulmonary Metastases\nLocal Therapy\nOxford\nLoE GR AGO\u00a7Before any local therapy: staging and biopsy, histology for exclusion of second tumor3a B +\u00a7Resection of pulmonary metastases by VATS or \nconventional resection \n\u00a7In case of multi -locular metastatic disease 3a B -\n\u00a7In case of single / few unilateral metastasis 3a B +/-\u00a7Thermoablation (CT -guided RFA, LITT) 3b C +/-\u00a7Regional radiotherapy 2a B +/-(stereotactic radiotherapy with volumetric intensity modulated arc therapy (SRS -VMAT))\n*VATS = video -assisted thoracic surgerySites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMalignant Pleural Effusion (MPE)\nLocal Therapy\nOxford\nLoE GR AGO\u00a7If short life expectancy, less invasive procedures should beconsidered4C ++\u00a7VATS and Talcum -pleurodesis* 1b B ++\u00a7Continuous pleural drainage 2a B ++\u00a7Chemical pleurodesis*\n\u00a7 Talcum powder 1a B+\n\u00a7 Bleomycin, Doxycycline, Mitoxantrone 2b C +/-\n\u00a7 Povidone -iodine (20 ml of 10% solution) 1b B+\u00a7Serial thoracocentesis 4C +/-\n*Adequate pain -relief\nVATS: video -assisted thoracoscopic surgerySites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMalignant Ascites\nLocal Therapy\nOxford\nLoE GR AGOAscites:\u00a7Puncture, drainage in symptomatic patiens 4 D ++\u00a7Continous drainage of ascites 3b D +\u00a7Systemic therapy 3b D ++\u00a7Local chemotherapy 3b D -\nSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMalignant Pericardial Effusion \nLocal Therapy\nOxfordSymptomatic pericardial effusion:LoE GR AGO\u00a7Drainage, fenestration 3b B ++\u00a7Combination with optimized systemic therapy 4 C ++\u00a7VATS (video -assisted thoracic surgery) 4 C +\u00a7Ultrasound -guided puncture and instillation of \ncytotoxic / targeted compounds\n\u00a7Bleomycin, cisplatinum, mitomycin C, mitoxantrone etc., \nBevacizumab4 C +/-\nSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deBone Marrow Infiltration\nAssociated with Pancytopenia\nOxford\nLoE GR AGO\u00a7Weekly chemotherapy with*:\n\u00a7Epirubicin, Doxorubicin, Paclitaxel 4 D ++\n\u00a7Capecitabine 4 D ++\u00a7HER2 -positive:\n\u00a7anti-HER2 -treatment 5 D ++\u00a7Hormone receptor -positive:\n\u00a7Endocrine -based therapy 3b C +\n*Consider pre -treatmentSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSoft Tissue Metastasis\nLocal Therapy\nOxford\nLoE GR AGO\u00a7Surgery of limited locoregional metastasis \n(e.g. skin, muscular, nodal) with complete resection (R0) after exclusion of further metastases 4 C +/-\u00a7Radiotherapy in*:\n\u00a7Soft tissue metastases 3b C +/-\n\u00a7Paresis, spinal cord compression 2b C ++\n\u00a7Plexus infiltration 3b C ++\n* Ecception : acute indication forsurgerySites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\u201cOLIGO -METASTATIC DISEASE in CONTRALATERAL AXILLA Contralateral axillary nodal metastasis \n(in the absence of contralateral primary) as initial diagnosis of recurrent disease is considered \nstage 4 metastatic breast cancer.\nHowever, after prior local therapy to ipsilateral axilla for early breast cancer, subsequent \nmetachronous contralateral axillary nodal metastasis, either alone or concurrent with an in -breast \nipsilateral recurrence, could be considered and treated as a regional metastasis (due to altered \nlymphatic drainage), and has the potential for long survival or cure with a multidisciplinary \napproach\u201dOligo -Metastases\nContralateral Axillary Metastasis\nABC6 2021: LoE: Expert opinion/NA (85%) \nSites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nCNS Metastases \nin Breast Cancer\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCNS  Metastases in Breast Cancer\n\u00a7Versions 2003 -2022:\nBauerfeind / Bischoff / Diel / Ditsch / Fehm / Friedrich / Gerber / Huober / \nLoibl / L\u00fcck / L\u00fcftner / Maass / M\u00fcller / Nitz / Park-Simon / Jackisch / Jonat / \nJunkermann / Rody / Sch\u00fctz / Solbach / Stickeler / Witzel\n\u00a7Version 2023:\nFehm / Krug\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCNS  Metastases \nin Breast Cancer\n\u00a7Breast cancer is the 2ndmost common cause of CNS metastases.\n\u00a7At autopsy:\n\u00a7Parenchymal CNS metastases: ~ 30 \u201340% \n\u00a7Leptomeningeal CNS metastases: ~  5\u201316%\n\u00a7Increasing incidence (10% \u21e840%)\n\u00a7Increasing incidence due to \n\u00a7More effective treatment of extra -cerebral sites with improved prognosis \n\u00a7Increasing use of MRI for diagnostic evaluation\n\u00a7Lack of  specific knowledge about treatment of brain metastases in breast \ncancer since most studies are not breast cancer specific. Therefore, \nparticipation in the German registry study is recommended \n(www.gbg.de).CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nIncidence of Brain Metastases among Patients with Metastatic Breast \nCancer \u2013 Meta -Analysis of 25 Trials between 2010- 2020\nSubtype No \npatientsIncidence per \npatient -yearPooled cumulative \nincidenceMedian \nfollow -up\n(months)\nHER2 positive (all) 5971 13%95% CI: 0.22 \u20130.38 31% 31\nHR-/ HER2 positive 2092 13% 95% CI: 0.08 \u20130.20 - -\nHR+ / HER2 positive 3480 8%95% CI: 0.05 \u20130.13 - -\nHR-/ HER2 negative 4102 13%95% CI: 0.09 \u20130.20 32%95% CI: 0.19 \u20130.49 33HR+ / HER2 negative14656 5%95% CI: 0.03 \u20130.08 15%95% CI: 0.078 \u20130.27 33\nKuksis M, Gao Y, Tran W et al. Neuro Oncol. 2021 Jun 1;23(6):894 -904CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCNS Metastases in Breast Cancer\nTumour biology\n\u00a7Primary Tumor:\n\u00a7Negative hormone receptor status (basal -like cell type / triple -negative)\n\u00a7High grade, high Ki -67 index\n\u00a7HER2 and / or EGFR (HER1) overexpression\n\u00a7Molecular subtype (Luminal B, HER2 positive, triple -negative)\n\u00a7Inflammatory breast cancer\n\u00a7Brain metastases are more likely estrogen receptor negative and\noverexpress HER2 and / or EGFR.\n\u00a7Discordance of molecular subtype between primary tumor and\nbrain metastases: for ER = 16.7%, for PR = 25.2% and HER2 =\n10.4%\n\u00a7There is no evidence for a survival benefit of BM-screening in\nasymptomatic BC -patients.CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nUpdated Breast -GPA (Graded Prognostic Assessment ) \nWorksheet to Estimate Survival from Brain Metastases (BM)\nPrognostic Factor 0 0.5 1 1.5 Score\nKPS  \u2264 60 70-80 90 \u2013100  n/a \nSubtype Basal LumA n/a HER2 or LumB \nAge, years \u2265 60 < 60 n/a n/a \nECMpresentabsent n/a n/a \nNo of BM \u2265 2 1 n/a n/a Sum total Median survival byBreast -GPA: \nBreast -GPA 0\u20131.0    =   6 months\nBreast -GPA 1.5\u20132.0 =  10 months\nBreast -GPA 2.5\u20133.0 = 13 months\nSubtype : Basal: triple negative; LumA : ER / PR positive, HER2 negative; LumB : triple positive; HER2: ER / PR \nnegative, HER2 positive. ECM: extracranial metastases BM: brain metastases\nSperduto PW et al, JCO 2020CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSingle / Solitary Brain Metastasis and \nOligo -Brain Metastases*\nOxford\nLoE GR AGO\nLocal therapy alone: SRS (\u2264 4 cm) o. SRT 1b B ++\nSingle / Solitary Metastasis: 1b B ++\nResection (if indicated) + irradiation of the tumor bed (without WBRT)\nOligo -Brain Metastases: 1b B ++\nResection (if indicated) + irradiation of the tumor bed and SRS or SRT of \nunresected metastases (without WBRT)\nWBRT + Boost (SRS, SRT) or resection + WBRT 2a B+\nWBRT alone 2b B+\nPatients with reduced general condition and limited life expectancy\nHippocampal -sparing** (if prognosis is favourable) 1b B+\nSRS = stereotactic radiosurgery (single session ), SRT = stereotactic RT(fractionated); WBRT = whole brain radiotherapy *Oligometastases orlimited tumour volume refers to\u2264 4 brain metastases orcumulative tumour volume < 15 ml in 5 -\n10 brain metastases\n**  Metastases in hippocampus excludedCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nSingle / Solitary Brain Metastasis and \nOligo -Brain Metastases*\n\u00a7Local therapy (surgery , SRS, SRT) depends on localization, size, number of metastases, previous\ntherapy, Karnofsky -Performance -Scale, prognosis.\n\u00a7WBRT in addition to SRS/SRT improves intracranial control, but does not improve duration of\nfunctional independence and overall survival.\n\u00a7WBRT impairs neurocognitive function.\n\u00a7In case oflimited* number ofbrain metastases , SRS / SRT arepreferred .\n\u00a7Postoperative radiotherapy :\nSingle/ solitary brain metastasis (resection cavity < 5 cm): SRS v. WBRT no difference in\noverall survival .\nOligo -brain metastases : SRS ofsurgical cavity and SRS ofunresected metastases v. WBRT\nno difference in overall survival .\nSRS = stereotactic radiosurgery (single session), SRT = stereotactic RT(fractionated); WBRT = whole brain radiotherapy *O l i g o m e t a s t a s e s  o r  l i m i t e d  t u m o u r  v o l u m e  r e f e r s  t o  \u2264  4  b r a i n  m e t a s t a s e s  o r  c u m u l a t i v e  t u m o u r  v o l u m e  <  1 5  m l  i n  5 -\n10 b rain metastases\n**Metastases in Hippocampus excludedCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nStudy design:\nPatients with 1 -3 brain metastases, each < 3 cm by contrast MRI, were randomized to \nSRS alone or SRS + WBRT and underwent cognitive testing before and after treatment. \nThe primary endpoint was cognitive progression (CP) defined as decline > 1 SD from \nbaseline in any of the 6 cognitive tests at 3 months. Time to CP was estimated using \ncumulative incidence adjusting for survival as a competing risk.* \nConclusion:\nDecline in cognitive function, specifically immediate recall, memory and verbal fluency, \nwas more frequent with the addition of WBRT to SRS. Adjuvant WBRT did not improve \nOS despite better brain control. Initial treatment with SRS and close monitoring is \nrecommended to better preserve cognitive function in patients with newly diagnosed \nbrain metastases that are amenable to SRS.NCCTG N0574 (Alliance): A Phase III Randomized Trial of \nWhole Brain Radiation Therapy (WBRT) in Addition to \nRadiosurgery (SRS) in Patients with 1 to 3 Brain Metastases\n*Remark: No hippocampus -sparing was applied\nBrown PD, Jaeckle K, Ballman KV et al.: Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation \nTherapy on Cognitive Function in Patients With 1 to 3 Brain Metastases JAMA 2016 Jul 26;316(4): 401 -409. CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nFactors in favor of neurosurgery:\n\u00a7Histological verification e.g. after a long recurrence -free interval\n\u00a7Need for immediate decompression, life -threatening symptoms\n\u00a7Tumor size not allowing stereotactic radiotherapy\nFactors in favor of primary radiotherapy*:\n\u00a7Tumor location poorly amenable to surgery\n\u00a7More than four lesions\n\u00a7Comparable local control for SRS/SRT vs. surgery + postoperative RTPossible Factors for Decision Making Neurosurgery \nversus Stereotactic Radiosurgery\n* stereotactic radiotherapy should be preferred if possibleCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deMultiple Brain Metastases\nifStereotactic Radiotherapy isnot indicated\nOxford\nLoE GR AGO\u00a7WBRT (supportive steroids1) 1a A ++\u00a7Hippocampal -sparing radiotherapy2(if prognosis is\nfavourable)1b B+\u00a7Corticosteroids alone13a B +/-\u00a7Systemic therapy alone 3a D +/-\n\u00a7For newly diagnosed or progressive asymptomatic brain\nmetastases (only for HER2 breast cancer)32b C+\u00a7Radiochemotherapy for intracerebral control 3b C-\u00a7WBRT in case ofrecurrence44C +/-\n1adapted tosymptoms ; 2metastases in hippocampus excluded ; 3only if regimens with proven clinical activity in \nactive brain metastases are used ; 4can be discussed depending on time -interval from first radiation, prior dose, \nand localization if local therapy (surgery, SRS, FSRT) is not indicated and / or possible\nSRS = stereotactic radiosurgery ; SRT = stereotactic radiotherapy (fractionated) ; WBRT = whole brain radiotherapyCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSymptomatic Therapy \nof Brain Metastases\nOxford\nLoE GR AGO\u00a7Anticonvulsants only if symptoms of seizures 3a C +\u00a7Glucocorticoids only if symptoms and /\nor mass effect (Dexamethasone with best evidence)3a C ++\u00a7For patients with bad prognosis and reduced physical common conditions best supportive care is an option5 D +\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deClinical Classification of Brain Metastases\nStable brain metastases (definition: RECIST / RANO): \nstabilization after treatment of brain metastases.\nStable brain metastases (definition: DESTINY -BREAST03): \nstable brain metastases \u2265 2 weeks after whole brain radiotherapy, asymptomatic, \nno requirement of  corticosteroid or anticonvulsant therapy\nActive brain metastases (definition: HER2Climb): \nlocally pretreated brain metastases with progressive disease or newly diagnosed \nbrain metastases not needing immediate local therapy\nor\nuntreated brain metastases not needing immediate local therapy CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSystemic Therapy of Brain Metastases\nOxford\nLoEGRAGO\u00a7Interdisciplinary treatment planning (tumor board)5       D++\u00a7Systemic therapy alone as primary treatment 3aD+/-\n\u00a7For newly diagnosed or progressive asymptomatic brain metastases (only for HER2 -positive breast cancer)*2b C +\u00a7Continuation of the current systemic therapy if first \ndiagnosis of brain metastasis and stable extracranial \ndisease**2c C +\n*only ifregimens with proven clinical activity in active brain metastases areused\n** only in case ofadequate local treatment ofbrain metastasesCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSystemic Therapy of Brain Metastases:\nHER2 positive\nOxford\nLoEGRAGO\u00a7Tucatinib + Trastuzumab + Capecitabine * 2b B +\u00a7Trastuzumab -Deruxtecan ** 2b B +\u00a7Trastuzumab -Deruxtecan* 2b C +/-\u00a7T-DM1 ** 2b B +/-\u00a7Lapatinib + Capecitabine * 2b B +/-\u00a7Neratinib + Capecitabine* 2b B +/-\u00a7Neratinib + Paclitaxel** 2b B +/-\u00a7High -dose Trastuzumab + Pertuzumab * 2b C -\n* efficacy demonstrated in active and stable brain metastases based on trial inclusion criteria\n** efficacy demonstrated in stable asymptomatic brain metastases based on trial inclusion criteriaCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nPertuzumab Plus High -Dose Trastuzumab in Patients With Progressive \nBrain Metastases and HER2 -Positive Metastatic Breast Cancer \n-PATRICIA trial (Phase II) NCT02536339 -\nN=39 patients with HER2 positive MBC \n-with CNS metastases and CNS progression despite prior RT\n-stable extracranial disease\nTreatment:\nPertuzumab (840 mg loading dose, 420 mg every 3 weeks thereafter)\nTrastuzumab (6mg/kg weekly )\nTreatment until CNS orsystemic progression orunacceptable toxicities\nResults :\nCNS ORR: 11% with 4 partial remissions\nCBR at 4 mths : 68%; CBR at 6 mths : 51%\n2 ptswith stable disease > 2 years\nConclusion :\nHigh -dose trastuzumab for HER2 -positive CNS metastases may warrant further study.CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nClinical trials including HER2 positive patients with\nbrain metastases\n*reference list Adapted from O\u2018Brian B et al. SABCS 2022TrialPhaseN**Brain metastasesCombinationIC-ORR\nHER2Climb1*II 291 Stable + active Tucatinib+Trastuzumab+\nCapecitabine47%\nDESTINY 032III 36 Stable Trastuzumab -Deruxtecan 64%\nTUXEDO -13II 15 Active Trastuzumab -Deruxtecan 73%\nKAMILLA4III 398 Stable T-DM1 21%\nLANDSCAPE5II 45 Active Lapatinib + Capecitabin 66%\nNALA6III 161 Stable Neratinib + Capecitabine 23%\nTBCRC -0227II 49 Active Neratinib + Capecitabine 49% (Lapatinib -naive)\n33%  (prior Lapatinib)\nPATRICIA8II 39 Active Pertuzumab + high dose \nTrastuzumab11%\nNEfERT -T9II 29 Asymptomatic Paclitaxel + Neratinib Not reported ; \nCNS incidence \u00f2CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deLeptomeningeal Carcinomatosis:\nTherapy\nOxford\nLoE GR AGOIntrathecal or  ventricular therapy\u00a7 MTX 10 \u201315 mg 2 \u20133 x/ week (+/ -folinic acid rescue) 2b B +/-\n\u00a7 Steroids 4D +/-\n\u00a7 Trastuzumab (HER2 pos. disease) 3a C +/-Systemic therapy 3b B+Radiotherapy\u00a7 Focal (bulky disease) 4D +\n\u00a7 WBRT 4D +\n\u00a7 Neuroaxis Craniospinal irradiation (disseminated spinal lesions) 2b B +/-CNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nIntrathecal administration ofTrastuzumab\n1Kumthekar PU  et al. Neuro Oncol . 2022, 2Oberkampf F et al. Neuro Oncol . 2022Kumthekar PU et al.1Oberkampf F et al.2Type of studyMulticenter, Phase Ib/IIMulticenter, Phase Ib/IIN3419Trastuzumab delivery80 mg intrathecally twice weekly150 mg intrathecally weeklyCBR69.2%(PR: 19.2%, SD 50%)Median PFS-5.9 monthsMedian OS8.3 months7.9 months\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nComplementary Therapy \nSurvivorship\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Therapy \u2013Hormonal Treatment and \nAlternatives in Breast Cancer Survivors \u2013Survivorship\n\u00a7Versions 2002 \u20132022: \nAlbert / Bauerfeind / Blohmer / Dall/ Fersis / Friedrich / Gerber / \nG\u00f6hring / Hanf / Janni / K\u00fcmmel / L\u00fcck / von Minckwitz / Nitz / \nOberhoff / Rhiem / Scharl / Schmidt /  Sch\u00fctz / Solomayer / \nThomssen\n\u00a7Version 2023:\nHeil / Solomayer\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deUCT\nUnconventional Tx\nComplementary\nIn addition to \nscientifically \nbased medicineAlternative\nInstead of\nscientifically \nbased medicineCAM\nComplementary + alternative medicine\nUnconventional\nUnproven outsider \nmethods\u201eIntegrative Oncology\u201c \u201eUnconventional \nmethods\u201cCAM \nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGood Clinical Practice\nAll patients should be consulted as early as \npossible and in the course of the process \nrepeatedly on the interest in information \ncomplementary medical measures and, if \ninterested, reliable sources of information \nshould be referred.\nS3 LL \u201c Komplement \u00e4rmedizin in der Behandlung von onkologischen Pa=entInnen\u201cComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGeneral Considerations\nOxford\nLoE GR AGO\u00a7CAM instead of loco -regional interventions 2b B --\u00a7CAM instead of systemic treatment 2b B --\u00a7Patients should be asked and advised about their use of CAM modalities\u00a7Diagnostic procedures in connection with complementary and alternative therapy concepts without evidence (e.g. iris diagnostics, bioresonance) should not be \nrecommended.\u00a7During anti -cancer treatment: Beware of drug interactionsComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Therapy\nPre-and Postoperative\nOxford\nLoE GR AGOPreoperative:\u00a7 Hypnosis (reduces anxiety, pain, nausea) 1b B +Postoperative:\u00a7 Acupuncture ( pain relief, anxiety) 1b B +/-\n\u00a7 Acupuncture ( nausea, vomiting ) 2b B +\n\u00a7 Massage therapy (pain relief) 2b C +/-\n\u00a7 Early postoperative exercise reduces upper -limb dysfunction \n(beware: increased wound drainage)     1a A +\n\u00a7 Physical exercise \n\u00a7 to reduce breast cancer related secondary lymphedema 1a A +\n\u00a7 as a prophylaxis of lymphedema 1b B +/-\n\u00a7 Prophylactic lymphatic drainage 1b B --\n\u00a7 Yoga (arm and shoulder pain) 2b C +\n\u00a7 Music therapy (reduces pain after mastectomy) 2b C +/-Complementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Treatment\nWhile on Cancer Treatment \u2013Impact on Toxicity IDuring anti-cancer treatment: Beware of drug interactionsOxford\nLoE GR AGO\u00a7Mistletoe (Viscum album) in order to reduce side effects 1a B +/-\u00a7Thymic peptides lower risk of severe infections 2a B +/-\u00a7Ginseng reduces fatigue; note: interacts with cytochrome P enzymes e.g. CYP \n3A42b C -\u00a7Ganoderma Lucidumreduces fatigue, note: inhibits cytochrome P enzymes (e.g. CYP 3A4)2b C -\u00a7L-Carnitine\n\u00a7peripheral  neuropathy\n\u00a7treatment of fatigue1b\n1bB\nB--\n-\u00a7Melatonin (reduces fatigue, improve sleep, depressive symptoms, cognition) 2b B +/-\u00a7Curcumin adjunct to reduce radiation -induced dermatitis 1b B +/-\u00a7Ginger adjunct to guideline -oriented medication to treat chemotherapy induced nausea & vomiting \u2013beware of drug interactions1b C +/-Complementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Treatment\nWhile on Cancer Treatment \u2013Impact on Toxicity II\nOxford\nLoE GR AGO\u00a7Antioxidant supplements 1b B -\n\u2022 various antioxidative extracts (to reduce anthracyclin -induced \ncardiotoxicity)2b B +/-\u00a7High dose vitamin C 1b C -\u00a7Vitamine E 2b D -\u00a7Selenium (for alleviating therapy side effects) 1b B -\u00a7Co-Enzyme Q 10 (fatique, QoL) 1b B -\u00a7Proteolytic enzymes (for reduction of chemotherapy -induced toxicity) 3b B -\u00a7Chinese herbal medicine improves wound healing 1b B -*inf\u00a7Oxygen and ozone therapy 5 D --\u00a7Short -term fasting (Qol, Fatigue) 2b B+/-***inf: i.v.-infusion (in Germany not approved) \n**treatment in clinical trials recommendedComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdditional Complementary Therapy \nof Side Effects Related to Cancer Treatments \nOxford\nLoE GR AGO\u00a7Chinese medicinal herbs (to treat the side effects \nof chemotherapy)1b B -\u00a7Homoeopathic medicine (against therapy side effects / \nPlaceboeffect)1b B +/-\u00a7Topical Silymarin ( to prevent acute dermatitis during radiotherapy) 3a B +/-\u00a7Massage (to improve on fatigue, pain, anxiety, nausea) 1b C +/-\u00a7Transcutaneous Electrical Nerve stimulation (TENS) (against cancer pain)2b D +/-\u00a7Hydrotherapy (for supportive skin care) 3b C +/-Complementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAdditional Complementary Therapy \nof Side Effects Related to Cancer Treatments\nAcupuncture in order to improve onOxford\nLoE GR AGO\n\u00a7Chemotherapy -induced  nausea and vomiting\n\u00a7 (Electro) -Acupuncture as adjunct to entiemetic treatment 1b B +\n\u00a7 Acupressure as adjunct to entiemetic treatment 1b B +\n\u00a7 Pain\n\u00a7 Cancer pain 1b B +\n\u00a7 Aromatase -inhibitor \u2013induced athralgia 1a B +\n\u00a7 Fatigue 1a B +\n\u00a7 Acupressure 1b B +\n\u00a7 Anxiety and depression 2b B +\n\u00a7 Cognitive dysfunction 5 D +/-\n\u00a7 Menopause syndrome in Breast Cancer Patients 1b B +\n\u00a7 to improve on frequency and severity of hot flashes 1b B +/-\n\u00a7 Electro -Acupuncture to improve on sleep and hot flashes 2a B +\n\u00a7 Leucopenia (Moxibustion) 2b B +/-\n\u00a7 Treatment of chemotherapy induced polyneuropathy\n\u00a7 prophylactically 1b B -\n\u00a7 therapeutically 2b B +/-\n\u00a7 Chronic lymph edema after Breast Cancer Treatment 2b B +/-Complementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Treatment \nMind -Body Medicine I\nOxford\nLoE GR AGOMBSR(Mindfulness -Based Stress Reduction) 1a A +Program improves quality of life, coping strategies, attentiveness, and lowers stress, anxiety, depression, fatigue, and sleep disturbancesPhysical exercise / sportmin. 3x/week moderate endurance training in combination with workout exercises (2x per week)improve quality of life, cardio-respiratory fitness, physical performance, sleep, pain, depression, lymphedema, and fatigue1a A ++\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Treatment \nMind -Body Medicine II\nLoE GR AGORelaxation techniquesReduction of anxiety and nausea, improvement of quality of life, reduction of psychological stress2b C +/-YogaImproves sleep, quality of life, stress, anxiety, depression, fatigue, and sleep1b A +Qi GongMay improve quality of life, fatigue, and mood2a B +/-Tai ChiImproves quality of life, muscular strength, sleep2a B +/-Hypnosis (in combination with cognitive training)Improves fatigue and muscle weakness under radiotherapy; also reduces distress 1b A +Oxford\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCAM\nPrevention of Recurrence / Improvement of Overall Survival I\nModifiable Lifestyle Factors\nOxford\nLoE GR AGO\u00a7Physical exercise 2a A ++\n(equivalent to 3 \u20135 hrs moderate walking per week) \nimproves DFS and OS, cardio -respiratory fitness, \nphysical functioning\u00a7Reduce smoking 2b A +\u00a7Reduce alcohol consumption (< 6 g/day) 2b A +\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deModifiable Lifestyle Factors\nNutrition after Breast Cancer Diagnosis \nPrevention of Recurrence / Improvement of Overall Survival  II\nOxford\nLoE GR AGO\u00a7Adherence to normal BMI / weight loss\nif overweight, irrespective of HR -status1a A ++\u00a7Low fat diet\ndietary counseling recommended1a B +\u00a7Increased fiber intake (e.g. Flaxseed) 2a B +\u00a7Adherence to general nutrition guidelines \n(e.g. DGE, WCRF) similar to a Mediterranean Diet2a B ++\u00a7Dietary extremes 2a B --\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Treatment\nPrevention of Recurrence / Improvement of Overall Survival III.1\nDietary Supplements \u2013Herbal Therapies\nDuring anti -cancer treatment: Beware of drug interactions Oxford\nLoE GR AGO\nPost treatment vitamine / antioxidant supplements does not appear to be \nassociated with increased risk of recurrence (beware of drug / treatment \ninteractions)2b B\nSmokers on antioxidant supplements are at higher risk for lung cancer  1b A\nFor Prevention of BC Recurrence:\n\u00a7 Antioxidants 2a B +/-\n\u00a7 Vitamine supplementation in patients on a balanced diet (esp. Vitamine C, E) 2a B +/-\n\u00a7 Vitamine D (after Vit D level) 2b B +/-\n\u00a7 Soy-food (natural source of phytoestrogenes) 2a B +/-\n-food or concentrates containing \u2265 100 mg) isoflavones per day 2a B -\n\u00a7 Black Cohosh (Cimicifuga racemosa) 3b C +/-\n\u00a7 Antioxidant supplements (after completion of radiotherapy) 2b B +/-\n\u00a7 Green tea 3a C +/-\n\u00a7 Selenium 2b B +/-Complementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deComplementary Treatment\nPrevention of Recurrence / Improvement of Overall Survival III.2\nDietary Supplements \u2013Herbal TherapiesDuring anti-cancer treatment: Beware of drug interactionsOxford\nLoE GR AGO\u00a7Other orthomolecular substances (Zinc...) 5 D -\u00a7Artificial carotenoids appear to be associated with worse outcome 2b B -\u00a7Proteolytic enzymes (Papain, Trypsin, Chymotrypsin) 3b B -\u00a7Mistletoe (Viscum album) 1b C -\u00a7Thymic peptides (impact on OS) 2a B -\u00a7Oxygen -and ozone therapy  5 D --\u00a7Laetrile ( Amygdalin, \u201eVitamine B17\u201c) 1c D --\u00a7Methadone 5 D --\u00a7Cancer bush (Sutherlandia frutescens), Devil's claw \n(Harpagophytum procumbens), Rooibos tea (Aspalathus linearis),\nBambara groundnut (Vignea subterranean)  4 C -\u00a7Incense 5 D -\u00a7Curcuma, curcumine 5 D -Complementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nGynecological Issues in \nBreast Cancer Patients\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGynecologic Issues in \nBreast Cancer Patients\n\u00a7Versions 2015 \u20132022: \nAlbert / Bauerfeind / Blohmer / Fersis / Gerber / Hanf / Huober / \nLoibl  / Maas / Mundhenke/ Reimer / Rody / Scharl / Thill / \nThomssen / Witzel \n\u00a7Version 2023:\nFehm / Stickeler\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHormone (Replacement) Therapy (HT) of Estrogen \nDeficiency after Diagnosis of Breast Cancer\nOxford\nLoE GR AGOSystemichormone (replacement -) therapy\u00a7Endocrine responsive disease (ER pos.) 1a B -\n\u00a7Combined treatment TAM plus low dose HT 2b B +/-\u00a7Endocrine non-responsive disease (ER neg.) 1a B +/-\u00a7Tibolone 1b A --Topicalvaginal application of\u00a7Estriol (E3 0.03 mg as treatment course*) 2b B +/-\u00a7DHEA locally 2b B -\u00a7Testosterone locally 2b B -\u00a7Estradiol (E2) during AI therapy 4 C -\n*4 weeks daily 1 x 1, followed by8 weeks 3 x 1 per week \u2013Note:. Elevated E3-blood levels only with start oftherapy ; \noncological endpoints were not studied . Non -hormonal alternatives should bepreferred , seeslide \u201eSexual Health \u201cGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deFurther Medical Approaches to Reduce \nMenopausal Symptoms I\nMedical approaches* (reduction of hot flushes) Oxford\nLoE GR AGO\n\u00a7 Selective serotonin reuptake inhibitors and serotonin -(noradrenalin) reuptake \ninhibitors (SSRI -SNRI): reduce hot flashes in BC patients\n\u00a7 Venlafaxine 1a A +\n\u00a7 Desvenlafaxine, Sertraline, Escitalopram 1b A +/-\n\u00a7 Gabapentin (patients using TAM) 1a A +\n\u00a7 Oxybutynine (2.5 mg / 5 mg) 1b A +/-\n\u00a7 Pregabalin 1b A +/-\n\u00a7 Clonidine 0.05 -0.15 mg/die (patients uasing TAM) 2a B +/-\n\u00a7 MPA (i.m. 500 mg single shot) (most potent, but endocrine agent!) 1b A +/-\n\u00a7 Vitamin E 1b A -\n\u00a7 Omega -3 fatty acids 1b A +/-\nMedical approaches (other treatment goals)\n\u00a7 Melatonin (improvement in sleep quality) 2b C +\n\u00a7 Duloxetine (treating arthralgias while on AI) 1b B +\n*Note: Substantial placebo -effect hasbeen proven (23-57%) LoE1b A +Gynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deCAM* -Approaches to \nReduce Menopausal Symptoms II\n* Complementary and Alternative Medicine\nDuring anti -cancer treatment: Beware of drug interactions! Oxford\nLoE GR AGO\n\u00a7 Soy-derived phytoestrogens \u2013isoflavonoids * \nHot flushes\nSleep disturbance\nTopical vaginal application1b\n1b\n1bB\nB\nB-\n+/-\n+/-\n\u00a7 Red Clover isoflavonoids *\nHot flushes, sleep disturbance 1b B +/-\n\u00a7 Flaxseed -supplementation (40 g/d)  (in HR+ \u2264 10 g/d)\n(reduces relapses, no effect on hot flashes)2b B +/-\n\u00a7 Black Cohosh for hot flushes\n\u00a7 Black cohosh + St. John's Wort (fixed combination )1b\n1bB\nB+/-\n+/-\n\u00a7 St. John\u2018s Wort\n(pharmacokinetic interference with endocrine therapy, cyctotoxic drugs, \nand tyrosin kinase inhibitors) 1b B +/-\n\u00a7 Ginseng root (Panax ginseng or P. quinquefolius) 1b B -\n\u00a7 Bromelain + Papain + Selenium + Lectin (for AI induced joint symptoms) 3b B +\n\u00a7 Homeopathic medicine to reduce hot flushes (consider placebo -effect) 1b B +/-\n* might stimulate BC, especially in endocrine responsive disease Gynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deGeneral Approaches  to Reduce Menopausal \nSymptoms III -Integrative Oncology AspectsGeneral approaches:Oxford\nLoE GR AGO\u00a7Physical exercise 1a A ++\u00a7Cognitive behavioral therapy (CBT), hypnosis 1a A ++\u00a7Mind body -medicine\n(yoga, education, counselling, mindfulness training)1b B +\u00a7Short interruption of endocrine therapy in case of \nunacceptable side effects5 D +(Electro) Acupuncture\u00a7Aromatase -inhibitor treatment induced arthralgia 1a B +\u00a7Hot flushes 2a B +\u00a7Anxiety, Depression 2b B +\u00a7Sleep 2a C +*   asin SOLE TrialGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOvarian Protection with GnRHa and Fertility Preservation in \nPremenopausal Patients Receiving (Neo) -Adjuvant Chemotherapy (CT) \nOxford\nLoE GR AGO\u00a7CTx + GnRHa\n(preservation of ovarian function)\n(GnRHa application > 2 weeks prior to chemo -therapy, \nindependent of hormone receptor status )1a A +\u00a7CTx+ GnRHa\n(preservation of fertility)2a B +/-\u00a7Fertility preservation counselling including \nreferral ofall potential patients to appropriate \nreproductive specialists (further information        \nhttps:// fertiprotekt.com /english ; S2K Guideline Fertility\npreservation in oncology )++\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoE GR AGO\u00a7Pretreatment approaches topreserve fertility\nGnRHa 1a A ++\nCryopreservation ofovarian tissue with\nsubsequent transplantation24 D +\nCryopreservation ofoocytes (unfertilized / \nfertilized ) after ovarian stimulation2a C +\u00a7ART after (neo -)adjuvant systemic treatment 4 C +\n1Evidence islimited due tostudies with poor quality e.g. ( prospective randomized trials arenot feasible )\n2Risk ofrelapse caused bytransplantation ofovarian tissue containing tumor cells from theoriginal malignancy ; Removal oftransplanted\novarian tissue isnecessary in patients with BRCA1/2 mutations due toincreased riskofovarian cancerFertility preservation and assisted reproductive therapy (ART)\n-Oncological safety1-\nGynecological Issues in Breast Cancer Patientswww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EOncological Safety ofcontrolled ovarian stimulation\n(COS) orassisted reproductive therapy (ART)\nN=15 studies including 4643 patients undgoing COS orART ( assisted\nreproductive therapy )\nCOS before starting treatment (n=11 studies ):\nReduced riskofrecurrence RR 0.58, 95% CI 0,46 -0,73\nReduced riskofmortality RR 0.54, 95% CI 0,38 -0,76\nNodetrimental effect on EFS 0,76, 95% CI 0,55 -1,06\n-Subgroup ofHR positive pts. HR 0.36, 95% CI 0.20 \u20130.65\nART after treatment (n=4 studies):\nReduced risk of recurrence (RR 0.34, 95% CI 0.17 -0.70) \nNo detrimental effect EFS (HR 0.43, 95% CI 0.17 -1.11).\nConclusion: COS at diagnosis or ART following breast cancer treatment completion \ndoes not appear to be associated with any detrimental prognostic effect in young \nwomen Arecco et al. Human Reprod 2022Gynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.de\nOvarian Protection \u2013\nSynopsis of Randomized TrialsZOROPROMISEMunster et al. -USPOEMSOptionPatient number60 (60 HR-)281 (50 HR-)49 (13 HR-) of 124218 (218 HR-)227 (126 HR-)Age median38 years39 years39 yearsPremenop. < 50 yearspremenopausalTreatmentgoserelintriptorelintriptorelingoserelingoserelinStart of treatment> 2 weeks prior to cht> 1 week prior to cht> 1 week prior to cht> 1 week prior to cht> 1 week prior to chtPrimary Endpointmenstruation at month 6 after chemotherapyrate of early menopause at month 12 after chtmenstruation rate within 2 years after chtOvarian failure at 2 yrs after chtAmenorrhea with elevated FSH levels between 12 and 24 monthsPrimary objectiveto detect 30% absolute increase of menstruation rateto detect at least 20% absolute reduction in early menopauseto detect 20% difference in amenorrhea  rate \u2013from 10% to 30%To detect 20%-25% absolute reduction in early menopauseMultivar. analysisage as only independent predictive factortreatment as only independent predictive factorn.d.Treatment as only Independent predictive factorAge, total cyclophosphamide dose and baseline AMHResumption of menses at month 1283% with LHRH vs. 80% w/o93% with LHRHa vs. 74% w/o74% with LHRH vs. 68% w/o78% with LHRH vs. 75% w/o; at 2 years; 22% with LHRH vs. 8%78% with LHRHa vs. 62% amnorrhea rate between month 12 and 24Median time to restoration of menses (months)6.1 with LHRHa vs. 6.8 w/o; p = 0.30not reached with LHRH vs. 6.7 w/o; p = 0.075.8 with LHRH vs. 5.0 w/o; p = 0.58n.d.n.d.Cyclophosph. dose4600 vs. 4700 mg4080 vs. 4008 mgn.r.n.a.5940 vs. 5940 mgGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deAssessment of Ovarian Reserve \nOxford\nLoE GR AGOTests forfertility assessment\u00a7Anti -Mullerian Hormone 1b B +\u00a7Antral follicle count 3b B +\u00a7FSH 2ba B +\u00a7Combined test procedures for assessment of \novarian reserve*5 C +\n*Tests are suggested for women > 35 y and infertility for 6 -12 months; the tests do not predict failure to conceive. \nThey should be used in counselling patients and to provide a rough estimate of the fertility window. Results may \ndecrease patient referral time to infertility centers.Gynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deContraceptive Options for Women \nafter Diagnosis of  Breast Cancer\nOxford\nLoE GR AGO\u00a7Barrier methods 5 D +\u00a7Sterilization (tubal ligation / salpingectomy / vasectomy) 5 D +\u00a7Non -hormonal intrauterine devices (IUDs) 3b D +\u00a7Levonorgestrel -releasing IUDs 2b C -\n\u00a7 Removal in newly diagnosed patients 4 D +/-\u00a7Timing methods 5 D -\u00a7Injectable progestin -only contraceptives 5 D -\u00a7Progestin -only oral contraceptives 5 D -\u00a7Combined oral contraceptives 5 D -\u00a7Options of emergency contraception\n\u00a7 Copper intrauterine device (Copper -IUD) 5 D +\n\u00a7 Levonorgestrel , Ulipristal orally 5 D +Gynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deSexual Health / Vaginal Dryness\nOxford\nLoE GR AGO\u00a7Assessment of sexual dysfunction 5 D +\u00a7Use of patient -reported questionnaires 4 C +Therapy of dyspareunia and vaginal dryness\u00a7Psychoeducational support, group therapy, sexual counselling, \nmarital counselling, psychotherapy1b B +\u00a7Topical vaginal treatment\n\u00a7Non -hormonal lubricants / moisturizers (also with physiotherapy) 1b B +\n\u00a7Estriol (E3 0.03 mg as treatment course*) 2b B +/-\n\u00a7DHEA local application 2b B -\n\u00a7Testosterone local application 2b B -\n\u00a7Estradiol (E2) during AI therapy 4 C -\n\u00a7Fractionated microablative CO2 -Laser / Vaginal Erbium:YAG -Laser 2a B +/-\n*4 weeks daily 1 x 1, followed by8 weeks 3 x 1 per week \u2013Note:. Elevated E3-blood levels only with start oftherapy ; \noncological endpoints were not studied . Non -hormonal alternatives should bepreferred .Evaluation\nGynecological Issues in Breast Cancer Patientswww.ago -online.de\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2023 .1EEinsch\u00e4tzung der sexuellen Gesundheit1\n\u00a7Kurze Checkliste Sexueller Symptome f\u00fcr Frauen (BSSC -W)2\n\u00a7Screening -Fragebogen zur Sexualfunktion insgesamt\n1. Sind Sie zufrieden mit Ihrem Sexualleben? Ja \u2013Nein\nWenn nein, dann beantworten Sie bitte die n\u00e4chsten Fragen:\n2. Seit wann/wie lange sind Sie mit Ihrem Sexualleben unzufrieden?  .......\n3a. Ihr Problem im Sexualleben ist: (eins oder mehrere markieren)\n1. Problem mit weniger oder gar kein Interesse bzw. Lust 0\n2. Problem mit reduzierter Empfindlichkeit / Sensibilit\u00e4t im Genitalbereich (Gef\u00fchl) 0\n3. Problem mit verringerter vaginaler Lubrikation (Trockenheit der Scheide) 0\n4. Problem, einen Orgasmus zu erreichen 0\n5. Probleme mit Schmerzen beim Geschlechtsverkehr 0\n6. Andere Probleme oder Sorgen \u2026\u2026\u2026\n3b. Welche Probleme st\u00f6ren Sie am meisten?  Bitte ankreuzen: 1 \u20132 \u20133 \u20134 \u20135 \u20136 \n4. Wollen Sie \u00fcber diese Probleme mit Ihrem Arzt/Ihrer \u00c4rztin reden? Ja \u2013Nein\n\u00a7Sexual Complaints Screener For Women (SCS -W)3,4\n\u00a7FSFI-19, FSFI -65,6Gynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nHealth Literacy and Communication\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\n\u00a7Versions 2020 -2022:\nBauerfeind / Maass / Rhiem / Schmidt / Sch\u00fctz\n\u00a7Version 2023: \nBauerfeind / Rhiem\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nDefinition\n\u201cHealth literacy is linked to literacy and entails people\u2019s \nknowledge, motivation and competences to access, \nunderstand, appraise, and apply health information\nin order to make judgments and take decisions in everyday \nlife concerning healthcare, disease prevention and health \npromotion to maintain or improve quality of life during the \nlife course.\u201d\nS\u00d8rensen etal.,(2012 )\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy Model\n(according to S\u00f6rensen)\nS\u00f8rensen K, Van den Broucke S, Fullam J, Doyle G, Pelikan J, Slonska Z, Brand H. Health \nliteracy and public health: A systematic review and integration of definitions and models. \nBMC Public Health. 2012, 12:80\nCompetencies\nAccess: seek, find, obtain \nhealth information.\nUnderstand: \nUnderstanding the health \ninformation received\nAppraise: Interpret, select, \nassess, review health \ninformation\nApply: Use health \ninformation to make \ndecisions that support and \nimprove health\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\n\u00a7The more developed health literacy is, the better a person can inform himself or \nherself about health (e.g. prevention, therapy) in everyday life, form an opinion \nand make self -determined decisions that maintain or improve the quality of life \nand health throughout the self -determined course of life.\n\u00a7However, the extent of health literacy of a person depends not only on his or her \nindividual prerequisites and acquired competencies, but especially on the \nprofessional quality, appropriateness, comprehensibility, form of \ncommunication and availability of the information provided. \nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nUser Participation\nReasons cited foroveruse , underuse and misuse in thehealth care system\ninclude theweak position ofpatients (SVR 2001).\nIn thecontext ofhealth literacy , thepatient is\n\u00a7more autonomous actor and co-designer \n\u00a7theone who takes responsibility and an active role in medical decisions\n\u00a7theperson who extracts theindividually relevant meaning from\nprofessionally offered information and behaves in accordance with\nindividual ideas about certain health situations\n\u00a7theone whose digital health literacy (e.g. media literacy , critical judgement ) \n\u2013aswell asthat ofhealth professionals \u2013should besupported .\nSVR -Council of Experts for the Assessment of Developments in the Health Care SystemHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nCommunication\nOxford\nLoE AGO\n3a +Aim of a physician -patient communication: enable a self -\ndetermined decision based on sufficient health competence \n(Shared Decision Making)\nDoctor -patient communication iskeyforacquiring health competence . Itis\nthebasis forsuccessful oncological treatment and support. Core elements\nare, forexample :\n\u00a7Non -directive communication -i.e. those seeking advice have the right to choose \ntheir own goals in life, even if they contradict generally accepted, even evidence -\nbased, recommendations after well -founded consideration.\n\u00a7Comprehensible communication -i.e. geared to the level of knowledge, reception \nhabits, competence requirements and preferences of the different patientsHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nBasic Principles of Communication\n\u00a7Communicate information truthfully and empathetically\n\u00a7Impart medical evidence -based knowledge\n\u00a7Critical debate of pseude -scientific recommendations\n\u00a7Active listening\n\u00a7Showing empathy\n\u00a7actively listening and expressing empathy\n\u00a7Find out if and how the patient wants to be informed about his / her situation\n\u00a7use understandable language avoiding or explaining technical terms\n\u00a7Continuously improve understanding through e.g. repetitions, breaks, summary, \ncomprehensible information material\n\u00a7Encourage asking questions and expressing feelings\n\u00a7Identifying individual stresses, problems and needs\n\u00a7Motivating self -determination and personal activities (\"empowerment\")\n\u00a7Giving hope for healing and relief\n\u00a7Offer further assistance (e.g. psycho -oncology, self -help)Health Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nEvidence -based Information\nEvidence -based information in health care should be used to answer patients' questions in \nan understandable way. They are based on the current state of knowledge and are free from \ninfluence:\nrequirement for evidence -based health information as a discremination against pseude -scientific \nrecommendations:\n\u00a7The information on services or products may not be used directly or indirectly for marketing purposes.\n\u00a7The systematic search corresponds to the questions relevant to the target group.\n\u00a7The selection of evidence suitable for the research question is justified.\n\u00a7An undistorted presentation of the results relevant to the patients (e.g. mortality, complaints, complications, health -\nrelated QoL) is available.\n\u00a7The presentation of uncertainties is appropriate in terms of content and language.\n\u00a7The presentation of results is clearly separated from the derivation of recommendations.\n\u00a7Consideration of current evidence to communicate figures, risk information and probabilities. \n\u00a7there must be sufficient time for the decision.\n\u00a7The possibility that the measure may be refused must not be a reason for withholding information. Health Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxfordLoE\u00a7Reduction of fear 2b\u00a7Trust in treating oncologists is increased 2b\u00a7Treatment satisfaction is increased 2a\u00a7Therapy adherence is increased 2a\u00a7Decision making is improved 2a\u00a7Mental complaints are improved 2aHealth Literacy\nCommunication\nNon -directive and evidence -based doctor -patient communication geared to \nthe current needs, values, problems, resources and preferences of patients \nhas beneficial effects.\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deOxford\nLoEAGOQualified training measures can help to promote communicative skills.+communication training for doctors  can e.g.\u00a7Enhance empathy 2a\u00a7Extend and enrich communication skills 2a\u00a7Increase patient satisfaction (information,\nsupport, consideration of concerns)2b\u00a7Improve transmission of information 2bHealth Literacy\nCommunication Training\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nShared Decision Making -Participatory Decision\nOxford\nLoE GR AGO\u00a7Patients want to be integrated actively into\ndecision making and open discussions about\nprognosis, treatment options, and quality of life1b A\u00a7Doctors should motivate patients to ask\nquestions, demand clarification, express\nemotions, opinions, and preferences3b C+\nHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nDecision Aids forPatients\nOxford\nLoE AGOThe use of decision support in the physician-patient communication +\n\u00a7 improves knowledge about treatment options 1a\n\u00a7 reduces the decision conflict 1a\n\u00a7 improves the level of information 1a\n\u00a7 increases the feeling about the clarity of personal values 1a\n\u00a7 encourages a more active role in decision -making 2b\n\u00a7 improves risk perception 2b\n\u00a7 improves the match between the chosen option and the patient's \nvalues3aHealth Literacy and Communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2023.1E\nwww.ago -online.deHealth Literacy\nDecision coaching\nOxford\nLoE GR AGOThe use of decision coaching by health professionals based on evidence-based patient information can improve the decision -making process of patients.Decision coaching is able to improve+\u00a7the knowledge of patients 2a B\u00a7the active role of patients in the process of decision making 2b BHealth Literacy and Communication\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0005\u0016\u000e\u0014\u001a\u001b\u001e\u0016\u001e\u0001\u000e\u001a\u0011\u0001\r\u001d\u0012\u000e\u001f\u0019\u0012\u001a\u001f\u0001\u001b\u0013\u0001\n\u000e\u001f\u0016\u0012\u001a\u001f\u001e\u0001\n\"\u0016\u001f\u0015\u0001\u0006\u000e\u001d\u0018$\u0001\u000e\u001a\u0011\u0001\u0002\u0011!\u000e\u001a\u0010\u0012\u0011\u0001\u0003\u001d\u0012\u000e\u001e\u001f\u0001\u0004\u000e\u001a\u0010\u0012\u001d\n\r\u0015\u0012\u001d\u000e\u001c$\u0001\u0002\u0018\u0014\u001b\u001d\u0016\u001f\u0015\u0019\u001e\n\u0001\u0007\u0004\u0002\u0006\u0003\u0005\u0004\b\n\u000e\u0017\u0014!\u0010 (\u0001\u001e #\u0018\u001e\u001d\"\u0001\"\u0017\u001e'\u001d\u0001\u0018\u001d\u0001#\u0017\u0014\u0001\u0010\u001b\u0016\u001e!\u0018#\u0017\u001c\"\u0001\u0010!\u0014\u0001\u0011\u0010\"\u0014\u0013\u0001\u001e\u001d\u0001#\u0017\u0014\u0001\u0012$!!\u0014\u001d #\u0001\u0002\u0006\u000b\u0001\n!\u0014\u0012\u001e\u001c\u001c\u0014\u001d\u0013\u0010#\u0018\u001e\u001d\"+\u0001\u0011$#\u0001\u0012\u0010\u001d\u001d\u001e#\u0001!\u0014 !\u0014\"\u0014\u001d#\u0001\u0010\u001b\u001b\u0001\u0014&\u0018\u0013\u0014\u001d\u0012\u0014.\u0011\u0010\"\u0014\u0013\u0001#!\u0014\u0010#\u001c \u0014\u001d#\u0001\u001e #\u0018\u001e\u001d\"+\u0001\"\u0018\u001d\u0012\u0014\u0001\n !\u0018\u001e!\u0001#\u0017\u0014!\u0010 \u0018\u0014\"+\u0001 \u0014!\u0015\u001e!\u001c\u0010\u001d\u0012\u0014\u0001\"#\u0010#$\"+\u0001\u0012\u001e\u001c\u001e!\u0011\u0018\u0013\u0018#\u0018\u0014\"+\u0001 \u0010#\u0018\u0014\u001d#\u0001 !\u0014 \u0015\u0014!\u0014\u001d\u0012\u0014+\u0001\" \u0014\u0012\u0018\u0010\u001b\u0001#$\u001c\u001e!\u0001\n\u0011\u0018\u001e\u001b\u001e\u0016(\u0001\u0014#\u0012,\u0001\u001c$\"#\u0001\u0011\u0014\u0001#\u0010\u001a\u0014\u001d\u0001\u0018\u001d#\u001e\u0001\u0010\u0012\u0012\u001e$\u001d#\u0015\u001e!\u0001#\u0017\u0014\u0001\u0010\u0012#$\u0010\u001b\u0001#!\u0014\u0010#\u001c\u0014\u001d# \u0001\u0012\u0017\u001e\u0018\u0012\u0014,\u0001\n\u001e!\u001c\u0010\u001b\u001b(\u0001\n\u001e\u001d\u001b(\u0001!\u0014\u0012\u001e\u001c\u001c\u0014\u001d\u0013\u0010#\u0018\u001e\u001d\"\u0001'\u0018#\u0017\u0001#\u0017\u0014\u0001!\u0014\u0012\u001e\u001c\u001c\u0014\u001d\u0013\u0010#\u0018\u001e\u001d\u0001\u0016!\u0010\u0013\u0014\"\u0001\u0002\u0006\u000b1\u0001\u0010\u001d\u0013\u0001\u0002\u0006 \u000b11\u0001\u0010!\u0014\u0001#\u0010\u001a\u0014\u001d\u0001\n\u0018\u001d#\u001e\u0001\u0010\u0012\u0012\u001e$\u001d#,\n\u0007\u001d\u0001\u0018\u001d\u0013\u0018&\u0018\u0013$\u0010\u001b\u0001\u0012\u0010\"\u0014\"+\u0001\u001e#\u0017\u0014!\u0001\u0014&\u0018\u0013\u0014\u001d\u0012\u0014.\u0011\u0010\"\u0014\u0013\u0001#!\u0014\u0010#\u001c\u0014\u001d#\u0001\u001e #\u0018\u001e\u001d\"\u0001/\u001d\u001e #\u0001\u001b\u0018\"#\u0014\u0013\u0001\u0017\u0014!\u00140\u0001\u001c\u0010(\u0001\u0010\u001b\"\u001e\u0001\n\u0011\u0014\u0001\u0010  !\u001e !\u0018\u0010#\u0014\u0001\u0010\u001d\u0013\u0001\u0019$\"#\u0018\u0015\u0018\u0014\u0013,\n\f\u0014\u0016\u0010!\u0013\u001b\u0014\"\"\u0001\u001e\u0015\u0001\u0010  !\u001e&\u0010\u001b\u0001\" #\u0010#$\"+\u0001#\u0017\u0014\u0001\u0010\u001b\u0016\u001e!\u0018#\u0017\u001c\"\u0001\u001e\u001d\u001b(\u0001#\u0010\u001a\u0014\u0001\u0018\u001d#\u001e\u0001\u0010\u0012 \u0012\u001e$\u001d#\u0013!$\u0016\"\u0001#\u0017\u0010#\u0001'\u0014!\u0014\u0001\n\u0010&\u0010\u0018\u001b\u0010\u0011\u001b\u0014\u0001\u0018\u001d\u0001\u0006\u0014!\u001c\u0010\u001d(\u0001\u0010#\u0001#\u0017\u0014\u0001#\u0018\u001c\u0014\u0001#\u0017\u0014\u0001\u0010\u001b\u0016\u001e!\u0018#\u0017\u001c\u0001'\u0010\"\u0001\u001b\u0010\"#\u0001$ \u0013\u0010#\u0014\u0013 ,\u0001Therapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\r\u0015\u0012\u001d\u000e\u001c$\u0002\u0018\u0014\u001b\u001d\u0016\u001f\u0015\u0019\u001e\n\u0001\u0002\u0003\u0007\b\u0004\u0006\u0005\u0001\r\u000b\r\f\n\r\u000b\r\r\t\u0001\n\r\u0012\u0017\u001d\u0014\u0014'\u0014\u0018\"\"\u0001-\u0001\u0003\u0010$\u0014!\u0015\u0014\u0018\u001d\u0013\u0001-\u0001\u0005\u0014\u0017\u001c\u0001-\u0001\t%\u001b\u001b\u0014!\u0001-\u0001\u000e\u0017\u0018\u001b\u001b\u0001-\u0001\u000e\u0017\u001e\u001c\"\"\u0014\u001d\u0001-\u0001\u000f \u0018#)\u0014\u001b\u0001-\u0001\u000f\u001f\u0012\u001a\u0014\u001b\u0001-\u0001\n\b\u0010\u001d\u001d\u0018\n\u0001\u0002\u0003\u0007\b\u0004\u0006\u0005\u0001\r\u000b\r\u000e\t\n\r\u0012\u0017\u001d\u0014\u0014'\u0014\u0018\"\"-\u0001\t%\u001b\u001b\u0014!\u0001'\u0018#\u0017\u0001#\u0017\u0014 \u0001\u0003!\u0014\u0010\"#\u0001\u0004\u001e\u001c\u001c\u0018##\u0014\u0014\u0001\u001e\u0015\u0001#\u0017\u0014\u0001\u0002\u0006\u000b\n\u0001\u0004\f\r\n\u0005\u000e\u0001\t\u0007\b\u0007\u000b\u0006\u000f\n\u0001 \u0004\u0011\u0012\u0015\u0019\u0015\u001e\u0015\u001a\u0019\u001d$\u0001\u0012\u0011\r\u001e\u001f\u001c\u0011\u001d$\u0001\u001b\r\u001c\r\u0018\u0011\u001e\u0011\u001c\u001d\n\u0001 \f\u0014\u0011\u001c\r\u001b#\u0001!\u0015\u001e\u0014\u0001\u0013\u001c\r\u0010\u0011\u0001\u001a\u0012\u0001\u001c\u0011 \u000f\u001a\u0018\u0018\u0011\u0019\u0010\r\u001e\u0015\u001a\u0019\u0001\u0002\u0006\t-\u0001\u001a\u001c\u0001\u0002\u0006\t--\n\u0001 \f\u0014\u0011\u001c\r\u001b#\u0001!\u0015\u001e\u0014\u0001\u0013\u001c\r\u0010\u0011\u0001\u001a\u0012\u0001\u001c\u0011\u000f\u001a\u0018\u0018\u0011\u0019\u0010\r\u001e\u0015 \u001a\u0019\u0001\u0002\u0006\t-&'(\u000f\r\u001d\u0011\u0001\u000e#\u0001\u000f\r\u001d\u0011\u0001\u0010\u0011\u000f\u0015\u001d\u0015 \u001a\u0019)\n\u0001 \u000b\u0011\u000f\u001a\u0018\u0018\u0011\u0019\u0010\u0011\u0010\u0001\u001b\r\u001e\u0014\u0001!\u0015\u001e\u0014\u0001\u0013\u001c\r\u0010\u0011\u0001\u001a\u0012\u0001\u001c \u0011\u000f\u001a\u0018\u0018\u0011\u0019\u0010\r\u001e\u0015\u001a\u0019\u0001\u0002\u0006\t-\u0001\u001a\u0010\u0011\u001c\u0001\u0002\u0006\t--\n\u0001 \u0003\u001c\u001a\u001d\u001d\u0015\u0019\u0013\u0001!\u0015\u001e\u0014\u001a\u001f\u001e\u0001\u001e\u001c\r\u0019\u001d\u0015\u001e\u0015\u001a\u0019\u0001\n\u0001 \n\r\u001e\u0014\u0001\u001a\u0012\u0001\u000f\r\u001d\u0011\u0001\u000e#\u0001\u000f\r\u001d\u0011\u0001\u0010\u0011\u000f\u0015\u001d\u0015\u001a\u0019\u0001 (\u0013\u001c\r\u0010\u0011\u0001\u001a\u0012\u0001\u001c\u0011\u000f\u001a\u0018\u0018\u0011\u0019\u0010\r\u001e\u0015\u001a\u0019\u0001\u0002\u0006\t-&')\n\u0001 \u0002\u001c\u001c\u001a!\u0001\u001b\u001a\u0015\u0019\u001e\u001d\u0001\u001e\u001a\u0001\u001e\u0014\u0011\u0001\u0019\u0011\"\u001e\u0001\u001e\u0014\u0011\u001c\r\u001b#\u0001\u001a\u001b\u001e\u0015\u001a\u0019\n\u0001 \u0002\u0006\t\u0001\u0013\u001c\r\u0010\u0011\u0001\u001a\u0012\u0001\u001c\u0011\u000f\u001a\u0018\u0018\u0011\u0019\u0010\r\u001e\u0015\u001a\u0019\u001a\u0012\u0001\u001e\u0014\u0015\u001d\u001b\r\u001e\u0014\n\u0001\u0002\u0003\u0006\u0006\u0005\t\u0015\u0011\n\u0005\t\u0015\u0011\n\u0005\t\u0015\u0011\nTherapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0004\u001b\u001a\u001f\u0012\u001a\u001f\n\u0001\u0007\u0002\u0003\n\u0001(\b\u0011\u001a)\r\u0010\u0016\u001f \r\u0019\u001e\u0001\u001e\u0014\u0011\u001c\r\u001b#\u001a\u0012\u0001\u0007\u0005\u000b+'\u001b\u001a\u001d\u0015\u001e\u0015 \u0011\u0001\u000e\u001c\u0011\r\u001d\u001e\u000f\r\u0019\u000f\u0011\u001c\u0001(\b\u0011\u001a)\r\u0010\u0016\u001f \r\u0019\u001e\u0001\u001e\u0014\u0011\u001c\r\u001b#\u0001\u001a\u0012\u0001\u001e\u001c\u0015 \u001b\u0017\u0011'\u0019\u0011\u0013\r\u001e\u0015 \u0011\u0001\u000e\u001c\u0011\r\u001d\u001e\u0001\u000f\r\u0019\u000f\u0011\u001c\u0001\u0002\"\u0015\u0017\u0017\r\u001c#\u0001\u001d\u001f\u001c\u0013\u0011\u001c#\u0001\r\u0019\u0010\u0001\u0019\u0011\u001a\r\u0010\u0016\u001f \r\u0019\u001e\u0001\u000f\u0014\u0011\u0018\u001a\u001e\u0014\u0011\u001c\r\u001b#\u0001(\b\u0002\u0003\f)\u0001\u0002\u0010\u0016\u001f \r\u0019\u001e\u0001\u0011\u0019\u0010\u001a\u000f\u001c\u0015\u0019\u0011\u0001\u001e\u0014\u0011\u001c\r\u001b#\u0001\u0015\u0019 \u0001\u001b\u001c\u0011\u0018\u0011\u0019\u001a\u001b\r\u001f\u001d\r\u0017\u0001\u001b\r\u001e\u0015\u0011\u0019\u001e\u001d\u0001\u0002\u0010\u0016\u001f \r\u0019\u001e\u0001\u0011\u0019\u0010\u001a\u000f\u001c\u0015\u0019\u0011\u0001\u001e\u0014\u0011\u001c\r\u001b#\u0001\u0015\u0019 \u0001\u001b\u001a\u001d\u001e\u0018\u0011\u0019\u001a\u001b\r\u001f\u001d\r\u0017\u0001\u001b\r\u001e\u0015\u0011\u0019\u001e\u001d\n\u0001\n\u0002\u0003\n\u0001\u0007\u000b'\u001b\u001a\u001d\u0015\u001e\u0015 \u0011\u0001&\u0001\u0007\u0005\u000b+'\u0019\u0011\u0013\r\u001e\u0015 \u0011\u0001\u0018\u0011\u001e\r\u001d\u001e\r\u001e\u0015\u000f\u0001\u000e\u001c\u0011\r\u001d\u001e\u0001\u000f\r\u0019\u000f\u0011\u001c%\u0001\u001d\u001e\u001c\r\u001e\u0011\u0013\u0015\u0011 \u001d\u0001\u0007\u000b'\u001b\u001a\u001d\u0015\u001e\u0015 \u0011\u0001&\u0001\u0007\u0005\u000b+'\u0019\u0011\u0013\r\u001e\u0015 \u0011\u0001\u0018\u0011\u001e\r\u001d\u001e\r\u001e\u0015\u000f\u0001\u000e\u001c\u0011\r\u001d\u001e\u0001\u000f\r\u0019\u000f\u0011\u001c%\u0001\u0011\u0019\u0010\u001a\u000f\u001c\u0015\u0019\u0011 '\u000e\r\u001d\u0011\u0010\u0001\u0012\u0015\u001c\u001d\u001e\u0001\u0017\u0015\u0019\u0011\u0001\u001e\u001c\u0011\r\u001e\u0018\u0011\u0019\u001e\u0001\u0007\u0005\u000b+'\u001b\u001a\u001d\u0015\u001e\u0015 \u0011\u0001\u0018\u0011\u001e\r\u001d\u001e\r\u001e\u0015\u000f\u0001\u0001\u000e\u001c\u0011\r\u001d\u001e\u0001\u000f\r\u0019\u000f\u0011\u001c%\u0001*\u001d\u001e',\u001c\u0010'\u0017\u0015\u0019\u0011\u0001\f\u001c\u0015\u001b\u0017\u0011'\u0019\u0011\u0013\r\u001e\u0015 \u0011\u0001\u0018\u0011\u001e\r\u001d\u001e\r\u001e\u0015\u000f\u0001\u000e\u001c\u0011\r\u001d\u001e\u0001\u000f\r\u0019\u000f\u0011\u001c\nTherapy Algorithms\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2023.1E\nwww.ago-online.de(Neo)adjuvant Therapy of HER2-positive Breast Cancer\nCNB, core needle biopsy; HR, hormone receptor; Ner, Neratinib; pCR, pathological complete response; Pz, Pertuzumab; q3w, every 3 weeks; T-DM1, Trastuzumab emtansine; Tz, Trastuzumab; y, year; if HR+ adjuvant endocrine therapycT1 andcN0SurgerypT1 andpN0pT\u2265 2 orpN+Tz  + paclitaxel(Tz for 1y)2Tz-basedregimen(Tz for 1y)3,4PzTz-basedregimen(PzTzfor 1y)6,7pN0pN+cT\u2265 2 orpNCNB+PzTz-basedregimen(6-8 cycles)1,10pCR(ypT0/isandypN0)Tz to complete1y814 x T-DM1 q3w9SurgerypCR andcN0pCR andpNCNB+PzTztocomplete1ynon-pCR\nNer1y(onlyHR+, Stage II-III)5Tz + paclitaxel\nAGO+AGO++AGO++\nAGO+\nAGO++AGO+/-AGO+\nAGO++AGO+AGO+\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n'\t\u0012\u001b(\u000e\u0011\u0017 !\u000e\u001a\u001f\u0001\r\u0015\u0012\u001d\u000e\u001c$\u0001\u001b\u0013\u0001\r\u001d\u0016\u001c\u0018\u0012&\u001a\u0012\u0014\u000e\u001f\u0016!\u0012\u0001\n\u0003\u001d\u0012\u000e\u001e\u001f\u0001\u0004\u000e\u001a\u0010\u0012\u001d\n&\"\b$\u0001\n&\u001d\u0007!85*(5<3\"\b$\u00013\u001d\u0007\n&&\u0015\u0013\u0001\u2192\u001d 3\u0013 \n!85*(5<\n121\u00053\u0013 *\u0012 \u0013\u0011\b\u0006\t)&\n*\u0012 \u0013\u0011\b\u0006\t '&\u0013$3(&,7$%,1(\u000e\n\u001e/$3$5,%\u0001\b<\u000f\n\u001d'/$31\u0004\u0001\u0001\n\u001d\u0013$\u2192\u0015\u0013!85*(5<\n\u0001\u0002\u0003\u0006\u0001\u0002\u0003\u0006\u0006\u0010\u00013\"\b$\u00013\u001d\u0007\n\u0011'-89$17\u0001\u0013\";6,0,/$572\n1(2$'-89$176,78$7,21\u0007\n\u001d\u00020\u001d\u0003\u0013$\u2192\n&&\u0015\u0002\u0011\u0003\u0013\t\u0006\f\n\u0002+\u0001\u0014\u001f(\u001f\"%\u0012\u0019\u0013\u0019\u001e,\u0001\u0004+\u0001\u0013)\u0013\u001c\u001f \u0018\u001f# \u0018\u0011\u001d\u0019 \u0014\u0015,\u0001\u0004\u0012+\u0001\u0013\u0011\"\u0012\u001f \u001c\u0011$\u0019\u001e,\u0001\u0004\u0010(+\u0001\u0013\u0018\u0015\u001d \u001f$\u0018\u0015\"\u0011 ),\u0001\u0014\u0014+\u0001\u0014\u001f#\u0015\u0001\u0014\u0015\u001e#\u0015.\u0015&\u0015\")2\u0001'\u0015\u0015\u001b#/,\u0001\u0006+\u0001\u0015 \u0019\"%\u0012\u0019\u0013\u0019\u001e,\u0001\u001d%$+\u0001\n\u001d%$\u0011$\u0015\u0014,\u0001\u001e\r+\u0001\u001e\u0011\u0012- \u0011\u0013\u001c\u0019$\u0011(\u0015\u001c,\u0001\r\u0015\u001d\u0012\"\u001f+\u0001 \u0015\u001d\u0012\"\u001f\u001c\u0019*%\u001d\u0011\u0012,\u0001\r+\u0001 \u0011\u0013\u001c\u0019$\u0011( \u0015\u001c,\u0001'$+\u0001'\u0019\u001c\u0014\u0001$) \u0015,\u0001)+\u0001)\u0015\u0011\",\u0001\u000e\u0019\u0016\r\u0015\u001d\u0012\"\u001f\u001c\u0019*%\u001d\u0011\u0012'\u0011#\u0001#$\u0011\"$\u0015\u0014\u0012\u0015\u0016\u001f\"\u0015\n#%\"\u0017\u0015\"),\u0001!\u0001\u0007\f\u0016\u000b\u0015\u0001\u0005\u0003\u0006\u0002\t\u0013\u0012\u0016\u0007\u000f\u0012\u000f\u0012\r \t\u000e\u000b\u0011\u0013\u0016\u000e\u000b\u0015\u0007\u0014\u0019\u0004\u0001\"\u0001\u0007\f\u0016\u000b\u0015\u0001\t\u000e\u000b\u0011\u0013\u0016\u000e\u000b\u0015\u0007\u0014\u0019 \u0018\u000f\u0016\u000e \u0014\u0010\u0007\u0016\u000f\u0012\u0017\u0011 \u0007\u0012\n\u0003\u0013\u0015 \u0014\u000b\u0011\b\u0015\u0013\u0010\u000f\u001a\u0017\u0011\u0007\b\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\u0001\u0002\u0003\u0006\u0006\n #8#0'\u0001\u0004\u0001\u0013$\r\u0005\u000e\n&\"\b%\u0001\n&\u001d\u0007\u0001\u0002\u0003\u0006\u0004\u0005\n&&\n\u0001\u0002\u0003\u0006\u0004\u0005\n\u001f(0%5272\u0001&203/(7(\b<\u0015\u0004\u0007\u0006\u0004\u0007\u0007\n\u0001\u0002\u0003\u0006\u0006\u0001\u0002\u0003\u0006\u0004\u0005\n\u0001\u0002\u0003\n\u0001\u0002\u0003\u0006\u0004\u0005 ?\u0001&\"\t\n25\n3\u001d\u0004&\"\b&\u0001\n&\u001d\u0007\u0001\u0002\u0003\u0006\u0006\u0001\n\u0001\u0002\u0003\u0006\u0004\u0005\u0002\nTherapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\n\u0002#\u0016\u0018\u0018\u000e\u001d$\u0001\f \u001d\u0014\u0012\u001d$\u0001\u000e\u001a\u0011\u0001\t\u0012\u001b\u000e\u0011\u0017 !\u000e\u001a\u001f\u0001\n\u0004\u0015\u0012\u0019\u001b\u001f\u0015\u0012\u001d\u000e\u001c$\u0001'\t\u0002\u0004\r(\u0001\n\u0002\u0007\b\u0005$\u0001\u000e\"\u0016\u0018\u0018\u000e\u001d#\u0018#\u0019\u001c\u0015\u001a\u001b\u0011\u0012\u0011\u0016\u001e\u001e\u0012\u0010\u001f\u0016\u001b\u001a%\u0001\u0004\b\u0003$\u0001\u0001\u0010\u001b\u001d\u0012\u001a\u0012\u0012\u0011\u0018\u0012\u000f\u0016\u001b\u001c\u001e#%\u0001\b\u0002\u0004\u000b $\u0001\u001a\u0012\u001b\u000e\u0011\u0017 !\u000e\u001a\u001f\u0001\u0010\u0015\u0012\u0019\u001b\u001f\u0015\u0012\u001d\u000e\u001c#%\u0001\u001e\u001a$\u0001\u001e\u0012\u001a\u001f\u0016\u001a\u0012\u0018\u001a\u001b\u0011\u0012%\u0001\n\u0007\b\u0006$\u0001\u001e\u0012\u001a\u001f\u0016\u001a\u0012\u0018\u0018#\u0019 \u001c\u0015\u001a\u001b\u0011\u0012\u0012\"\u0010\u0016\u001e\u0016\u001b\u001a%\u0001\u000b\u0002\u0005\u0001$\u0001\u001f\u000e\u001d\u0014\u0012\u001f\u0012\u0011\u000e\"\u0016\u0018\u0018\u000e\u001d#\u0011\u0016\u001e\u001e\u0012\u0010\u001f\u0016\u001b\u001a)\n\u0007\b\u0006\u00015\u0001\u000b\u0007\b\u0006*%\u0001\u000b\u0007\b\u0006$\u0001\n\u001f\u000e\u001d\u0014\u0012\u001f\u0012\u0011\u0018#\u0019\u001c\u0015\u001a\u001b\u0011\u0012\u0012\"\u0010\u0016\u001e\u0016\u001b\u001a%\u0001\u0002\u001c\u000e\u001d\u001f\u0016\u0010\u0016\u001c\u000e\u001f\u0016\u001b\u001a\u0016\u001a\u0001\u0006\f\u0003\t\u0006\u0002\n\u000b(-.\u0001\u001e\u001f \u0011#\u0001\u001d\u0012\u0010\u001b\u0019\u0019\u0012\u001a\u0011\u0012\u0011%\u0001\u0006- .0(\"(- 0(,+ (+\u0001 \u0002\r\n\u0002\b\u0002\u0001/01#5\u0001.$\",**$+#$#\u0011\u0001\u0007\u0001\u000b\u0002\u0005\u0001\u0016\u001a\u0001\u0010\u000e\u001e\u0012\u001b\u0013\u0001.(0\u0001\u001e \u001e\u001c\u0016\u0010\u0016\u001b \u001e\u0018#\u0019\u001c\u0015\u001a\u001b\u0011\u0012\u001e\u000f\u0012\u0013\u001b\u001d\u0012\b\u0002\u0004\u000b&\u00015$\u0001\u0016\u001a\u0001\u0010\u000e\u001e\u0012\u001b\u0013\u0001 6\u00011\u0001\n\u001e \u001e\u001c\u0016\u0010\u0016\u001b \u001e\u0018#\u0019\u001c\u0015\u001a\u001b\u0011\u0012\u001e\u000f\u0012\u0013\u001b\u001d\u0012\b\u0002\u0004\u000b&\u00015'(%\u0001\u0003\u0001\u0013\u001b\u001d\u0001\u001d\u000e\u0011\u0016\u001b\u001f\u0015\u0012\u001d\u000e\u001c#\u001c\u001d\u001b\u0010\u0012\u0011 \u001d\u0012\u001e\u001e\u0012\u0012\u001d\u0012\u0010\u001b\u0019\u0019\u0012\u001a\u0011\u000e\u001f\u0016\u001b\u001a\u001e\u0013\u001b\u001d\u0001\u001d\u000e\u0011\u0016\u001b\u001f\u0015\u0012\u001d\u000e\u001c#-\u001b\u0003\u0004\u0002\u0004\n\u0004\u00010 &&(+&\u00010'$\u0001\n!(,/-/($#\n+,#$\u0002/\u0003\u0001\u0002\u0003\u0006\u0006 \u0001\u0002\u0003\u0006\u0004\u0005\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0006\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u001d\u0011\u0013\"\n\u0001\u0002\u0003\u0006\u0004\u0005\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0004\u0005\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u001d\u0011\u0013\"!\u001b\u001d\u0015\u0001\u0006\n\"\u001b\u001d\u0015\n\"\u0011\u0014\u001792\u001c\u0004\u0001+0-.\u0007\u000192\u001c\n/+92\u001c\t\u0001\u0002+\u0004\u000392\u001c\t\n92\u001c\t\u0001\n92\u001c\t\u0001\u0002+\u0004\u0003\u0001\n92\u001c\u0004\u0001+0-.\u0007\u000192\u001c\n/+92\u001c\n/+\u0001\u000240\u0003\u000192\u001c\t\u0002+\u0004\u0003\u0001\u000240\u000392\u001c\t\u0001\u000240\u0003\n92\u001c\n\u0001\u000240\u0003\u0001\n\u0001\u0002\u0003\u0006\u0004\u0005\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0004\u0005\n\u0001\u0002\u0003\u0006<&\u001d\u0007\u0001\n<&\u001d\u0004\u0001\u0001\u0007 \u0003\n\b\t\u0004\u0002\b\n\u0005\u0006\t\u0002\b\u000b\u0002\u0006\t\u0005\u0007\u0006\n\u0011\u001b\u001d\u0014\n\u0011\u001b\u001d\u0014\n\u0011\u001b\u001d\u0014\n\u0001\u0007 \u0003\n\b\t\u0004\u0002\b\n\u0005\u0006\t\u0002\b\u000b\u0002\u0006\t\u0005\u0007\u0006\u0001\n\u0011\u001b\u001d\u0014\n\u0011\u001b\u001d\u0014\n\u0011\u001b\u001d\u0014\u0011\u001b\u001d\u0014\n\u0011\u001b\u001d\u0014%\u001c\u0004!%\u001c\t !\u001b\u001d\u0015\n\u0001\u0007 \u0003\n\b\t\u0004\u0002\b\n\u0005\u0006\t\u0002\b\u000b\u0002\u0006\t\u0005\u0007\u0006\u0001\n\u0001\u0007 \u0003\n\b\t\u0004\u0002\b\n\u0005\u0006\t\u0002\b\u000b\u0002\u0006\t\u0005\u0007\u0006\u0001Therapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0002\u0011\u0017 !\u000e\u001a\u001f\u0001\u0006\u001a\u0011\u001b\u0010\u001d\u0016\u001a\u0012&\u000f\u000e\u001e\u0012\u0011\u0001\r\u0015\u0012\u001d\u000e\u001c$\u0001\u0016\u001a\u0001\n\n\u001d\u0012\u0019\u0012\u001a\u001b\u001c\u000e \u001e\u000e\u0018\u0001\n\u000e\u001f\u0016\u0012\u001a\u001f\u001e\u001f5(\u0005253(5,0(123$86$/\n\u0002\t&\u0001\u0010\u001f\u001d\u001b\u0010!\u0010 \u0014\u0001\u0018\u001c\u0017\u0018\u0011\u0018!\u001d\u001f'\u0001\u0004\r\u000f)\u0005\u0007&\u0001\u0012\u001a\u0018\u001c\u0018\u0012\u0010\u001a\u0001\u001e\u0010!\u0017\u001d\u001a\u001d\u0016\u0018\u0012\u0010\u001a\u0001 !\u0010\u0016\u0014\u0001-\u0001 \u0014 !\u001f\u001d\u0016\u0014\u001c\u0001\u001f\u0014\u0012\u0014\u001e!\u001d\u001f\u0001 !\u0010!\" \u0001\u0010\u001c\u0013\u0001\u0016\u001f\u0010\u0013\u0014\u0001 \u0012\u001d\u001f\u0014'\u0001\u0016\u0003\u000e\u0004\u0002*(+\f\u0012\u0011&\u0001\u0016\u0014\u001f\u001b\u0001\n\u001a\u0018\u001c\u0014\u0001\u0003\u000e\u0004\u0002*(+\u0001\u001b\"!\u0010!\u0018\u001d\u001c'\u0001\n\u000b&\u0001\u001a%\u001b\u001e\u0017\u0001\u001c\u001d\u0013\u0014'\u0001\f\u0006\u000f&\u0001\u001d#\u0010\u001f\u0018\u0010\u001c\u0001\u0015\"\u001c\u0012!\u0018\u001d\u001c\u0001 \" \u001e\u001e\u001f\u0014  \u0018\u001d\u001c'\u0001\u001e\u0004\u000e&\u0001\u001e\u0010!\u0017\u001d\u001a\u001d\u0016\u0018\u0012\u0001\u0012\u001d\u001b\u001e\u001a\u0014!\u0014\u0001\u001f\u0014 \u001e\u001d\u001c \u0014'\u0001%&\u0001%\u0014\u0010\u001f '\u0001\n\u0015\u0001\u0002\u0013\u001b\u0018\u001c\u0018 !\u001f\u0010!\u0018\u001d\u001c\u0001\u001d\u0015\u0001\u0012\u0017\u0014\u001b\u001d!\u0017\u0014\u001f\u0010\u001e%\u0001$\u0010 \u0001\u0010\u0001 \"\u001f\u001f\u001d\u0016\u0010!\u0014\u0001\u001b\u0010\u001f\u0019\u0014\u001f\u0001\u0015\u001d\u001f\u0001\u0017\u0018\u0016\u0017\u0014 \u001f\u0001\u001f\u0018 \u0019\u0001\u001d\u0015\u0001\u001f\u0014\u0012\"\u001f\u001f\u0014\u001c\u0012\u0014\u0001\u0018\u001c\u0001\u0012\u001a\u0018\u001c\u0018\u0012\u0010\u001a\u0001!\u001f\u0018\u0010\u001a '\u0001\u0007\f\u0006\u000f\u0001\u0010\u001a \u001d\u0001\u0018\u001c\u0001\u0012\u0010 \u0014\u0001\u001d\u0015\u0001\n\u001f\u0014\u001b\u0010\u0018\u001c\u0018\u001c\u0016\u0001\u001d\u001f\u0001\u001f\u0014\u0012\"\u001f\u001f\u0018\u001c\u0016\u0001\u001d#\u0010\u001f\u0018\u0010\u001c\u0001\u0015\"\u001c\u0012!\u0018\u001d\u001c\u0001$\u0018!\u0017\u0018\u001c\u0001+,\u0001\u001b\u001d\u001c!\u0017 \u0001\u0010\u0015!\u0014\u001f\u0001 \u0012\u0017\u0014\u001b\u001d!\u0017\u0014\u001f\u0010\u001e%\u0001\u0018\u001c\u0013\"\u0012\u0014\u0013\u0001\u0010\u001b\u0014\u001c\u001d\u001f\u001f\u0017\u0014\u0010'\u0001\b\u001d\u001c\u001a%\u0001\b\u0005\u000e+)\u001c\u0014\u0016\u0010!\u0018#\u0014\u0001\u00191&5($6('\n5,6.)25\u0001\n5(&855(1&(\u0015\u001d2 \"$02;,)(1\u0001)25\u0001\f<\u0007\n#(6\n\u0001\u0002\u0003\u0006\u0006\n\"$02;,)(1\u00013/86\u0001\u001e\u0016!\u0016)25\u0001\t\u0005\f<\t\u0004\f\u0001\u0002\u0003\u0006\u0006 \u0001\u0002\u0003\u0006\n\u0011\u00193/86\u0001\u001e\u0016!\u0016)25\u0001\f<\t\u0005\f\u0013217,18(\n7$02;,)(1)25\u0001\n\f<\t\n\u0001\u0002\u0003\u0006\u0006 \u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n3/86\u0001\u001e/$3$5,%\u0001)25\u0001\b<\u0017\u0004\u0001\u000e\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n3/86\u0001\u0011%(0$&,&/,%)25\u0001\t<\u0017\u0004\u0001\r\n\u0006\f\u0001\u001a\u001c\u0004\u0001#0&\u0001\u0002 \f\u000113\u0017\f\u0003\n\u0005\u0006<\u0001\r\u0001\u001a\u001c\u0004\n)\u0012\u001e\u0013\u0011\n\b\u000b*10#0&\u0001\n010\u00062\u0013\u001e\u0001\u0004\u0001\u0013\u001d\u001f\u0006\u0015\u0017\u0001<\u0001\f\u0010\u0005\b\u0007\n\u0005\u0006<\u0001\r\u0001\u001a\u001c\u0004\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\n\u0001\n\u0001\u0002\u0003\u0006\u0006\nTherapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0002\u0011\u0017 !\u000e\u001a\u001f\u0001\u0006\u001a\u0011\u001b\u0010\u001d\u0016\u001a\u0012&\u000f\u000e\u001e\u0012\u0011\u0001\r\u0015\u0012\u001d\u000e\u001c$\u0001\u0016\u001a\u0001\n\n\u001b\u001e\u001f\u0019\u0012\u001a\u001b\u001c\u000e \u001e\u000e\u0018\u0001\n\u000e\u001f\u0016\u0012\u001a\u001f\u001e\u001f2670(123$86$/\u0001%()25(7+(67$57\n2)\u0001$'-89$17\u00017+(5$3<\n\u0002\t)\u0001\u0011!\u001f\u001d\u0011#\u0011\"\u0015\u0001\u0019\u001e\u0018\u0019\u0012\u0019#\u001f!*\u0001\u0004\r\u000f-\u0006\u0007)\u0001\u0013\u001c\u0019\u001e\u0019\u0013\u0011\u001c\u0001 \u0011#\u0018\u001f\u001c\u001f\u0017\u0019\u0013\u0011\u001c\u0001\"#\u0011\u0017\u0015\u00017\u0001 \u0015\"#!\u001f\u0017\u0015\u001e\u0001!\u0015\u0013\u0015 #\u001f!\u0001\"#\u0011#$\"\u0001\u0011\u001e\u0014\u0001\u0017!\u0011\u0014\u0015\u0001\"\u0013\u001f!\u0015*\u0001\u0006\u0002\u0010)\u0001\u0015&#\u0015\u001e\u0014\u0015\u0014\u0001\u0011\u0014\u001a$%\u0011\u001e #\u0001#\u0018\u0015!\u0011 '*\u0001\u0001\u0017\u0003\u000e\u0004\u00021,2\u0019 \u001f)\u0001\u0017\u0015!\u001d\u0001\u001c\u0019\u001e\u0015\u0001\n\u0003\u000e\u0004\u00021,2\u0001\u001d$#\u0011#\u0019\u001f\u001e*\u0001\u000b\f)\u0001\u001c'\u001d \u0018\u0001\u001e\u001f\u0014\u0015*\u0001\u0010\u0011\u001d)\u0001#\u0011\u001d\u001f&\u0019\u0016\u0015\u001e*\u0001')\u0001'\u0015\u0011!\"*\u0001\u000f\u0014\u0015\u0013\u0019\"\u0019\u001f\u001e\u0001\u0013!\u0019#\u0015!\u0019\u0011\u0001\u001d\u0011'\u0001\u0019\u001e\u0013\u001c$\u0014\u0015+\u0001\u0013\u001f\u001e\u0014\u0019#\u0019\u001f\u001e\u0001\u0011\u0016#\u0015!\u0001\u001e\u0015\u001f.\u0011\u0014\u001a$%\u0011\u001e#/\u0001\u0013\u0018 \u0015\u001d\u001f#\u0018\u0015!\u0011 '\u0001\u0001.\u0019\u001e\u0014\u0019\u0013\u0011#\u0019\u001e\u0017\u0001\u0018\u0019\u0017\u0018\u0001!\u0019\"\u001b/)\u0001\n \u001f\"\u0019#\u0019%\u0015\u0001\u001c'\u001d \u0018\u001e\u001f\u0014\u0015\"#\u0011#$\")\u0001\u00102,\u00103\u0001#$\u001d\u001f!\")\u0001\u0015\u001c\u0015%\u0011#\u0015\u0014\u0001!\u0019\"\u001b\u0001\u001f\u0016\u0001!\u0015\u0013$!! \u0015\u001e\u0013\u0015\u0001\u0001\u0012\u0011\"\u0015\u0014\u0001\u001f\u001e\u0001\u0019\u001d\u001d$\u001e\u001f-\u0018\u0019\"#\u001f\u0013\u0018\u0015\u001d\u0019\u0013\u0011\u001c\u0001\u0013!\u0019#\u0015!\u0019\u0011\u0001\u001f!\u0001\u0012\u0011\"\u0015\u0014\u0001\u001f\u001e\u0001\u001d$\u001c#\u0019- \u0017\u0015\u001e\u0015\u0001\u0015& !\u0015\"\"\u0019\u001f\u001e\u0001\u0011\"\"\u0011'\")\u0018\u0019\u0017\u0018\u0001\n\u0004\u0010\u000f5-\u000f\u0013\u001f!\u0015*\u0001\u0010$ \u0001#\u001f\u0001\u0014\u0011#\u0015\u0001\u001e\u001f\u0001\u0019\u001d \u0011\u0013#\u0001\u001f\u001e\u0001\u001f%\u0015!\u0011\u001c\u001c\u0001\"$!%\u0019%\u0011\u001c*\u0001\u0011\u001f\u001e\u001c'\u0001\b\u0006\u000e2-\u001e\u0015\u0017\u0011#\u0019%\u0015\u0001 (&200(1'\n\u0015\u0011\"\u0001)25\u000183\u000172\u0001$\u0001\n727$/\u0001'85$7,212)\u0001\n7+(5$3<2)\u0001\u000e\u0005\u000f<\u0016\u0004\n\"$0\u0001)25\u0001\f<\u0007\n\u0002(\u0019$*\"\u001f\u0018\u0004\u0001(\u0019$*\u001f\")\u0001$\u001d%\u001e\"\u001a\u0001$\u0019\u0017'$$\u0019!\u0017\u0019\"$\u001d\u001a\u0017\"!&$\u0015\u001d!\u0018\u001d\u0017\u0015&\u001d\"!%\u001a\"$\u0001\u0010\u0013\u0001 \u0015$\u0019#$\u0019%\u0019!&\u0003\u0014,6&866\u0015\u0011\"\t\n\"$0\u0001)25\u0001\t\u0005\n<\u0001)2//2:('%<\u0011\u0019\u0001\u0002&203/(7(\f<\u0003\t\n\u0002\u0003\n\u0011\u0019\u0001)25\u0001\t\u0005\n<\u0001)2//2:('%<\"$0\u0001\u0002&203/(7(\f<\u0003\t\n\u0002\u0001\n\u0011\u0019\u0001)25\u0001\f<\t\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0018,*+\u00015,6.2)\u0001\n5(&855(1&(\u0015\n\u001d21\u000567(52,'$/\u0001\u0011\u0019\u0001)25\u0001\f<\t\n\u0002\u001d!(\u0015%\u001d(\u0019\u0001\u001f\"\u0016'\u001f\u0015$\u001c\u001d%&\"\u001f\"\u001b*\u0003\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n3/86\u0001\u001e/$3$5,%\u0001)25\u0001\b<\u0017\u0004\u0001\f\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n3/86\u0001\u0011%(0$&,&/,%)25\u0001\t<\u0017\u0004\u0001\u000b\n\u0006\f\u0001\u001a\u001c\u0004\u0001#0&\u0001\u0002 \f\u000113\u0017\f\u0003\n\u0005\u0006<\u0001\r\u0001\u001a-\u0004\n)\u0012\u001e\u0013\u0011\n\b\u000b*10#0&\u0001\n010\u00062\u0013\u001e\u0001\u0004\u0001\u0013\u001d\u001f\u0006\u0015\u0017\u0001<\u0001\f\u000e\u0005\u000f\u0005\u0006\n<\u0001\r\u0001\u001a\u001c\u0004\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0006\u0006\n\u0001\n\u0001\u0001\u0001\u0001\u0001\n\u0001\u0002\u0003\u0006\nTherapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0005\u0007\u0017\u0010\u000f\u0012\r\u0013\r\u0014\u000b\u0016\u0005\u0004\u0007\u0018\u0017\u000e\u000b\f\t\u0013\r\u0014\u000b\u0001\u0006\u000b\u0013\t\u0012\u0013\t\u0013\r\n\u0001\u0002\u0011\u000b\t\u0012\u0013\u0001\n\u0003\t\u000e\n\u000b\u0011\u0015\u0001\b\u0013\u0011\t\u0013\u000b\f\r\u000b\u0012\n\u001900,1(17\u000125*$1)$,/85(\n$1'\u0001/$&.\u00012)\u0001(1'2&5,1(\n6(16,7,9,7<\n\u0013\";&20%,1$7,21\u0007\u0005\n\u0006\u0007\n6,1*/($*(17\u0013\";\n!7$1'$5'\u00017+(5$3<\n\u0002$/62\u0001,1\u0001&$6(2) \u0001,00,1(17\u0001\n25*$1)$,/85(\u0003\n\u0013\u0014\u001a\u000b\u0006\r, \u0002\u0001\u0011\u0019\u0001\u0006\u0007\u0013\u0014\u001a\u000b\u0006\r,\u0015\n\u0004\u0001)8/9(675$17\f\u0005\r\n\u0001\u0002\u0003\u0006\u0006\u0001\u0002\u0003\u0006\u0006\n\u0002\t)\u0001\u0011!\u001f\u001d\u0011#\u0011\"\u0015\u0001\u0019\u001e\u0018\u0019\u0012\u0019#\u001f!*\u0001\u0004\u0005\n4,6\u0019)\u0001\u0004\u0005\n4,6\u0001\u0019\u001e\u0018\u0019\u0012\u0019#\u001f!*\u0001\u0004\u0010&)\u0001\u0013\u0018\u0015\u001d\u001f# \u0018\u0015!\u0011 '*\u0001\u0006\u0010&)\u0001\u0015\u001e\u0014\u001f\u0013!\u0019\u001e\u0015\u0001#\u0018\u0015!\u0011 '*\u0001\u0017\u0003\u000e\u0004\u00021,2)\u0001\u0017\u0015!\u001d\u0001\u001c\u0019\u001e\u0015\u0001\u0003\u000e\u0004\u00021,2*\u0001\b\u000e )\u0001\u0018\u001f!\u001d\u001f\u001e\u0015\u0001!\u0015\u0013\u0015 #\u001f!*\u0001\u001d\u0003\u0004)\u0001\n\u001d\u0015#\u0011\"#\u0011#\u0019\u0013\u0001\u0012!\u0015\u0011\"#\u0001\u0013\u0011\u001e\u0013\u0015!*\u0001\u001d\u001f)\u0001\u001d\u001f\u001e#\u0018\"*\u0001\"\r\t\n3\u0004\u0002)\u0001\"\u001f\u001d\u0011#\u0019\u0013\u0001\r\t\n3\u0004\u0002\u0001\u001d $#\u0011#\u0019\u001f\u001e*\u0001\u0001\u000f !\u0015\u001d\u0015\u001e\u001f \u0011$\"\u0011\u001c\u0001\u0011\u0014\u0014\u0001\u001f%\u0011!\u0019\u0011\u001e\u0001\u0016$\u001e\u0013#\u0019\u001f\u001e\u0001\"$  !\u0015\"\"\u0019\u001f\u001e*\u0001\u0010\u0001\u0012\u0015%\u0011\u0013\u0019($\u001d\u0011\u0012\u00017\u0001 \u0011\u0013\u001c\u0019#\u0011&\u0015\u001c\u0001\u001f!\u00017\u0001\n\u0013\u0011 \u0015\u0013\u0019#\u0011\u0012\u0019\u001e\u0015\u0013\";\u0004\u0001%(9$&,=80$%\u0016\u0001\u0002\u0003\u0006\u0018 \u0004\u0001\u0006\u0001\n\u0018\u0015 \t\u0005\n0\u0012\u0013\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\u0015\";\n\u0001\u0002\u0003\u0006*\u0012 \u0013\u0011\b\u0006\t\u0001087$7,21\n (63216(\u0001>\u0001\r\u000102\u001f\u0011 \u001f\u0001,1+,%,725\r\u0005\u0007\t\n\u0013\";\u0007\n\u0001\u0004\u0006\u0005%(9$&,=80$%\u0016\u0004\u0007\n (63216(\u0001\u0010\u0001\r\u000102\n\u0015\";\u0004\u0001(9(52/,086\u0007\u000b\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n6\u001f\u0019\u001a\n\u0013\u0011\u0001087$7,21\n\u0015\";\u0004\u0001$/3(/,6,%\u0007\f (63216(\u0001\u0010\u0001\r\u0005\b\t\u000102$1'\u0001\u0015! \b\u0001087$7,21\n\u0015/$&(675$17\u0007\r\u0001\u0002\u0003\u0006\n\"5$678=80$%\u0001\u0014(58;7(&$1\n\u0002\u0018\u0015 \t\u0005/2:\u0003\u0007\u000e\n!$&,78=80$%\u001729,7(&$1\u0007\u000f\u00151'2&5,1(5(6,67(17\u0001$1'\u000135(75($7('\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0001\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\n($7('\n($7('\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006Therapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0006\t\u001c\u0015\u0014\u0017\u0011\u0018\u0011\u0019\u000f\u0001\u001b\u0001\u0006\u0004\t\u001d\u001c\u0013\u000f\u0010\u000b\u0018\u0011\u0019\u000f\u0001 \b\u000f\u0018\u000b\u0017\u0018\u000b\u0018\u0011\r\u0001\u0002\u0016\u000f\u000b\u0017\u0018\u0001\u0003\u000b\u0013\r\u000f\u0016\u001a\u0001\n\u0004\u0013\u000e\u0014\r\u0016\u0011\u0013\u000f\u001c\f\u000b\u0017\u000f\u000e\u0001\u0005\u0011\u0016\u0017\u0018\u0001\u0007\u0011\u0013\u000f\u0001\n\u0016\u000f\u000b\u0018\u0012\u000f\u0013\u0018\n\u0018 \u0004\u0001\u0006\u0001\u0018\u0015 \t\u0005\n0\u0012\u0013\u001f5(0(123$86$/\n67$1'$5'7+(5$3<\n\u0002\t\u001f\u0001\r\u001b\u0019\u0017\r\u001d\r\u001c\u0011\u0001\u0015\u0018\u0014\u0015\u000e\u0015\u001d\u0019\u001b \u0001\u0004\u0005\n$!%\u0015 \u001f\u0001\u0004\u0005\n$!%\u0001\u0015\u0018\u0014\u0015\u000e\u0015\u001d\u0019\u001b \u0001\u0007\u0018\u000b\b\r\u001f\u0001\u0007\u0018\u000b\b \u0001\r\u0013\u0019\u0018\u0015\u001c\u001d \u0001\b\u000b\u001f\u0001\u0014\u0019\u001b\u0017\u0019\u0018\u0011\u0001\u001b\u0011\u000f\u0011\u001a\u001d\u0019\u001b \u0001 \u0018\u001c\u001f\u0001\u0018\u0019\u0018\"\u001c\u001d\u0011\u001b\u0019\u0015\u0010\r\u0016 \u0001\u0017\u0003\u0004\u001f\u0001\u0017\u0011\u001d\r\u001c\u001d\r \u001d\u0015\u000f\u0001\u000e\u001b\u0011\r\u001c\u001d\u0001\u000f\r\u0018\u000f\u0011\u001b \u0001\n\u0017\u0019\u001f\u0001\u0017\u0019\u0018\u001d\u0014\u001c \u0001\f\u0006\t\u001f\u0001\u001d\u001b\u0011\r\u001d\u0017\u0011\u0018\u001d\"\u0012\u001b\u0011\u0011\u0001\u0015\u0018\u001d\u0011\u001b\u001e\r\u0016\u00171 \u0018$\u0004\u0001)8/9(675$17\u0004\u0001\u0013\u0014\u001a\u000b\u0006\r,\u0007\u0004\b\u0004\f\n\u00171 \u0018$\u0004\u0001\u0011\u0019\u0001\u0004\u00015,%2&,&/,%\n\u0004\u000b\n\u00171 \u0018$\u0004\u00017$02;,)(1\r\u0004\u000e\n\u00171 \u0018$\u0004\u0001\u0011\u0019\u0001 \u0006\u0007\u00171 \u0018$\u0004)8/9(675$17\u000f\u0005\u0007\b\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u00171 \u0018$\u0004\u0001\u0011\u0019\u0001\u0004\u00013$/%2&,&/,%25$%(0$&,&/,%\t\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u001f$/%2&,&/,%\u0001\u0004\u000116\u0011\u0019\u0007\f\u0005\u0007\u000e25\u00168/9(675$17\t\u0006\u0004\t\u0007\u0011%(0$&,&/,%\u0001\u0004\u0001)8/9(675$17\t\n\u0004\t\u000b ,%2&,&/,%\u0004\u000116\u0011\u0019\b\u0006\u0004\b\u000725)8/9(675$17\t\b\u0004\t\t\n\u001f2670(123$86$/\n67$1'$5'7+(5$3< \u0011%(0$&,&/,%\u0001\u0004\u000116\u0011\u0019\b\b\u0004\b\t\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006Therapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\u0007\u0006\u000b*&\u001c\u001b\u001e\u0016\u001f\u0016!\u0012\u0001\b\u0012\u001f\u000e\u001e\u001f\u000e\u001f\u0016\u0010\u0001\u0003\u001d\u0012\u000e\u001e\u001f\u0001\u0004\u000e\u001a\u0010\u0012\u001d%\u0001\n)\u0003\u0004&+\u0002\u0001&\u0018\u0016\u001a\u0012\n\u0012!$\u0005\u0001\u0012!$* \"(\")(!\u0011\u0001\u0012\u0018\u0005\u0001 .,* 0  /$\u0001(+'(!(0,.\u0011\u0001\u0013 -\u0005\u0001\" -$\"(0 !(+$\u0011\u0001\u0013\u001e4\u0005\u0001\"'$*,0'$. -5\u0011\u0001\u0015\u001e4\u0005\u0001$+#,\" .(+$\u00010'$. -5\u0011\u0001\u00161)\u0005\u0001\u00161)2$/0. +0\u0011\u0001\u0017\u001d\u0005\u0001',.*,+$\u0001.$\"$-0,.\u0011\u0001\u0019 -\u0005\u0001) - 0(+(!\u0011\u0001*,\u0005\u0001*,+0'/\u0011\u0001\u001b$.\u0005\u0001\n+$. 0(+(!\u0011\u0001\u001c6\u0005\u0001-$.0161* !\u0011\u0001\u001e\u0006\u0014\u001a\b\u0005\u00010. /0161* !\u0001$*0 +/(+$\u0011\u0001\u001e\u0006\u0014\u001f#\u0005 \u00010. /0161* !\u0001#$.140 $\" +\u0011\u0001\u001e\u0016\u0018\u0005\u00010.$ 0*$+0\u0006%.$$\u0001(+0$.2 )\u0011\u0001\u001e1\"\u0005\u000101\"  0(+(!\u0011\u0001\u001e6\u0005\u00010. /0161* !\u0011\u0001\u0005+,\u0001,2$. ))\u0001/1.2(2 )\u0001!$+$%(0\u0005\u0001\n\",+/(#$.\u0001(+#1\"0(,+\u0001\"'$*,0'$. -5\u0011\u0001\u0006\u0001#,\"$0 4$)\u0001\u0002\u0004\u0004\u0003\u0005\u0001- \")(0 4$)\u0001\u0002\u0004\u0004\u0003\u0001,.\u0001+ !\u0006- \")(0 4$)\u0001\u0002\u0004\u0003\u0011\u0001\u0007,+)5\u0001 %0$.\u0001\u001e\u0006\u0014\u001a\b\u0011\u0001\b,+)5\u0001(%\u0001\u0017\u001d\u0001-,/\u0011\u0001\t,+)5\u0001(%\u0001\u0017\u001d\u0001+$&\u0001\u0014'\u00010171/'5#45#5+%\n \u0006\u0014\"&\b\u000e\u0005\b\u000f\u0013#2\u0001\u0004\u0001 :\u0001\u0004\u0001 6%\f\u0005\r\n\u0013#2\u0001\u0004\u0001 3#4\b\b\n \u0006\u0014\u001b\n\n\u0005\u000b\n\u0013#2\u0001\u0004\u0001\u001c'3\u0010\u0013#2\u0001\u0004\u0001\u001a#2\u000e\u0005\u000f!046+5#$.'(13\u0001\u0013 8\b\u0001\n2#5+'05=423'('3'0%' \u0015 8\u0004\u0001 :\u0001\u0004\u0001\u001d:#\u0005\b\f\n :\u0001\u0004\u0001\u001a#2$\u0005\b\n\u0015\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\u0013 8!\u0004\n :\u0001\u0004\u0001\u001d:\b\u0005\t\n :\u0001\u0004\u0001\u001a#2$\u0005\u0001\b\n\u0005\b\u000b\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\u0011(5'3\u0001 :\u0001\u00020'1\u0003#&,67#05\n \u0016\u0019\u0001\u0010\u0001\u000e\u0001/1\b\r\n\u0011(5'3\u0001 :\u0001\u00020'1\u0003#&,67#05\n \u0016\u0019\u0001;\u0001\u000e\u0001/1\b\r\n\u0011(5'3\u0001 :\u0001\u0004\u0001\u001d:\u0001\u00020'1\u0003#&,67#05\n \u0016\u0019\u0001\u0010\u0001\u000e\u0006\n\u000b\u0001/1\n\u0011(5'3\u0001 :\u0001\u0004\u0001\u001d:\u0001\u00020'1\u0003#&,67#05\n \u0016\u0019\u0001\u000f\u0001\u000e\u0006\n\u000b\u0001/1\n\u0011(5'3\u0001 :\u0005\u0001\u001d:\u0001\u0004\u0001 \u0006\u0014\u001b\n\u0001\n\u00020'1\u0003#&,\u0007\u0001 \u0016\u0019\u0001\u0010\u0001\u000e\u0006\n\u000b\u0001/1\n\u0011(5'3\u0001 :\u0005\u0001\u001d:\u0001\u0004\u0001 \u0006\u0014\u001b\n\u00020'1\u0003#&,\u0007 \u0016\u0019\u0001\u000f\u0001\u000e\u0006\n\u000b\u0001/1\n \u0006\u0014\"&\b\u000e\u0005\b\u000f\n\u0013#2\u0001\u0004\u0001 :\u0001\u0004\u0001\n 6%\"\u0005\f\u0005\r\n\u0013#2\u0004 :\n\u0011\u0019\u0001\u0004\u0001 :\u0001\u0004\u0001\u001d:#\u0005\b\t\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\u0004\u0014'2'0&+0)\u000110\u00015*'\u000123'7+164\u00015*'3#29\u0001\u0002&36)\u0003 \u0013#2\u0001\u0004\u0001 :\u0001\u0004\u0001\n 6%\f\u0005\r\n \n\u0014\"&\n\b\u000e\n\u0001\u0002\u0003\u0004\u0004\n\u0001\u0002\u0003\u0004\u0004\n\u0001\u0002\u0003\u0004 \u0001\u0002\u0003\u0004\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\u0001\u0002\u0003\u0004\u0004\u0001\u0002\u0003\u0004\u0004\n\u0001\u0002\u0003\u0004\u0004\n\u0001\u0002\u0003\u0004 \u0006\u0014\"&\b\u000e\u0005\b\u000f\n\u0001\u0002\u0003\u0004\n\u0001\u0002\u0003\u0004\n\u0011$'\u0001\u0004\u0001 :\u0001\u0004\u0001\u00166.\b\u0010Therapy Algorithms\u0002\u0001\u0003\u0004\u0005\u0001\u0007\u0002\u0001\u0006\u0002\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\n\n\n\u0001\u000f\u0002\f\u0002\u0001\n\u0015\u0013\u0018\u0010\u000f\u0001\n\u0010\u0012\u0001\u000e\u000f\u0014\u0001\b\u000b\n\u0001\u000f\u0002\f\u0002\n\n\u0017\u0010\u000e\u000f\u0011\u0010\u0012\u000f\u0015\u0001\u0007\u0014\u000f\r\u0015\u0016\n\f\u000f\u0014\u0015\u0010\u0013\u0012\u0001\u0005\u0003\u0005\u0006\u0002\u0004\t\n\u000b\u000b\u000b\u0002\u0003\u0006\n\u0001\n\t\b\u0007\t\u0005\u0002\u0004\u0005\r\u001d\u0016\u001c\u0018\u0012&\u001a\u0012\u0014\u000e\u001f\u0016!\u0012\u0001\b\u0012\u001f\u000e\u001e\u001f\u000e\u001f\u0016\u0010\u0001\u0003\u001d\u0012\u000e\u001e\u001f\u0001\u0004\u000e\u001a\u0010\u0012\u001d\n\u0002&\u0001\u000f\u001a\u001f\u0016\u001d\u000f\u0011$\u0011\u0018\u0017\u001a\u0013'\u0001\u0002\u001f\u0013%\u001b&\u0001\u000f\u001f\u0013%\u001b\u0018\u0017% \u0019\u000f\u0010'\u0001\u0003\u0013!&\u0001\u0010\u0013!\u000f\u0011\u0017% \u0019\u000f\u0010'\u0001\u0004\u000e#&\u0001\u0011 \u0016\u0013\u0019\u001b\u001f\u0016\u0013\u001d\u000f\u001c$'\u0001\u0001\u0015\u0003\f\u0004\u0002&\u0001\u0015\u0013\u001d\u0019\u0001\u0018\u0017\u001a\u0013\u0001\u0003\f\u0004\u0002\u001e\u001f\u000f\u001f \u001e'\u0001\t\b\u0004&\u0001\u0017\u0019\u0019 \u001a\u001b\u0016\u0017\u001e\u001f\u001b\u0011\u0016\u0013\u0019 \u0017\u001e\u001f\u001d$'\u0001\u0019\u001f\u0016\u001e&\u0001\u0019\u001b\u001a\u001f\u0016\u001e'\u0001\u0019 \u001f&\u0001\u0019 \u001f\u000f\u001f\u0013\u0012'\u0001\u001a\u0013\u0015&\u0001\u001a\u0013\u0015\u000f\u001f\u0017!\u0013'\u0001'\u0001\u0001\u001a\u000b\u000f\u0011&\u0001\u001a\u000f\u0010) \u001c\u000f\u0011\u0018\u0017\u001f\u000f#\u0013\u0018'\u0001\u000b\u0013\u0019\u0010\u001d\u001b&\u0001\u001c\u0013\u0019\u0010\u001d\u001b\u0018\u0017% \u0019\u000f\u0010'\u0001\u000b\u0005)\n-&\u0001\n\u001c\u001d\u001b\u0015\u001d\u000f\u0019\u0019\u0013\u0012\u0001\u0011\u0013\u0018\u0018\u0001\u0012\u0013\u000f\u001f\u0016\u0001\u0018\u0017\u0015\u000f\u001a\u0012\u0001-'\u0001\u001c\u001b\u001e&\u0001\u001c\u001b\u001e\u0017\u001f\u0017!\u0013'\u0001\u000e&\u0001\u001f\u000f#\u000f\u001a\u0013'\u0001\u000e\u0006\t&\u0001 \u001f\u001d\u0013\u000f\u001f\u0019\u0013\u001a\u001f)\u0014\u001d\u0013\u0013\u0001\u0017\u001a\u001f\u0013\u001d!\u000f\u0018'\u0001\"\u001f&\u0001\"\u0017\u0018\u0012\u0001\u001f$\u001c\u0013'\u0001\u0002\u0001\u000b\u0013\u0019\u0010\u001d\u001b(\u0001\u0004\u000b\r\u00012\u0001-,\u0001*\u001a\u0013\u0015+\u0001\u001b\u0012\u0013\u001d\u0001\u0004\u000b\r\u00013 \u0001-,\u0001*\u001c\u001b\u001e+&\u0001\u0002\u001f\u0013%\u001b(\u0001\t\u0004\u00012\u0001-0\u0001*\u001a\u0013\u0015 +&\u0001\u0001\t\u0004\u00013\u0001-0\u0001*\u001c\u001b\u001e+'\u0001\u0003 \u001e\u0013\u0001\u001b\u0014\u0001\u001a\u001b\u001f\u0001\u001c\u001d\u0013!\u0017\u001b \u001e\u0018$\u0001 \u001e\u0013\u0012\u0001\u0011\u001b\u0019\u001c\u001b \u001a\u0012\u001e\u0001\u001b\u001d\u0001\u001d\u0013\u0015\u0017\u0019\u0013\u001a'\u0001\u0004\u001a\u000b\u000f\u0011&\u0001\u000b\u000f\u0011\u0001\u001b\u001d\u0001\n\u0004\u000f\u001d\u0010\u001b\u001c\u0018\u000f\u001f\u0017\u001a1\u0007\u0013\u0019\u0011\u0017\u001f\u000f\u0010\u0017\u001a\n\u001d\u0014\u0006\u001a\n\u00010') \n\u0002\u0004\u0003\n)\u0012\u001e\u0013\u001130\n\u001d\u0014\u0006\u001a\n\u0001214 \n\u0002\u0004\u0003\u0001\u0001\n)\u0012\u001e\u0013\u001130\n\u001d\u0014\u0006\u001a\n\u00010') \n\u0002\u0004\u0003\u0001\n)\u0012\u001e\u0013\u0011*10\n\u001d\u0014\u0006\u001a\n\u0001214 \n\u0002\u0004\u0003\u0001\n)\u0012\u001e\u0013\u0011*10\r\u0015\u001d\u0012\"\u001f5\u0001\u0004\u0010(\u0010$...\u0010\u0007\n\u00016\u00014\u0001\u001d$\u0018#/\u0002\u001c$\u0015\"\u001e\u0011$\u0019&\u0015\u0001\u0004\u0010(\u000f$\u0001.(0$./(.1\n\r\u0002\u000e\r\u0001\u0019\u001e\u0018\u0019\u0012\u0019$\u001f\"1$3$4\u0004\u0010(\u0001\u0003\u0015&\u0004\u0002\u0006\u0001\b\u0001\n\u0001\u0004\u0005\u0001\u0004\u0007\u0001\u0004\b\n\u0001\u0002\u0003\u0006\u0006\u0001\u0002\u0003\u0006\u0006\n\r\u0002\u000e\r\u0001\u0019\u001e\u0018\u0019\u0012\u0019$\u001f\"1$3$4\r\u0002\u000e\r\u0001\u0019\u001e\u0018\u0019\u0012\u0019$\u001f\"1$3$4\n\r\u0002\u000e\r\u0001\u0019\u001e\u0018\u0019\u0012\u0019$\u001f\"1$2\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0004\u0010(\u0001\u0003\u0015&\n\u0004\u0002\u0006\u0001\b\u0001\n\u0001\u0004\u0005\u0001\u0004\u0007\u0001\u0004\b\n\u0004\u0011\"\u0012\u001f \u001c\u0011$\u0019\u001e./\u0003\r\u0001\u000e\u000f\t\u0013\u000b\r\u0012\u0010\u0001\n\u0011\n\t\u000f\u0006\u000e\u0016\u0001\u0014\u000b\u0011\n\u0001\n\u0002\u0017\u0005\n\u0004\u000f\t\u0013\u000b\r\u0012\u0010\u0001\n\u0011\n\t\u000f\u0006\u000e\u0016\u0001\u0014\u000b\u0011\n\u0001\n\u0002\u0017\u0005\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\u0014'5'3/+0#5+10\u0001\n1(\u0004\u0002\u0005\u0001\u0007\u0001\t\u0002\n\u0001\u001d\u0014\u0006\u001a\n\u0001\u0019\u0018\u0013\n\u0001)\u0012\u001e\u0013\u0011\u0001\u0002\u0003\u0006\u0006\n\u0002$\u0015*\u001f5\u0001\u001e\r\u0011\u0013.-.\u0010\u0007\n\u00016\u000112\u0001\u001d$\u0018#/\n\u0002\n\r\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n\r\u0015\u001d\u0012\"\u001f5\u0001\u0004\u0010(\u0010$...\u0010\u0007\n\u00016\u00014\u0001\u001d$\u0018#/\n\u0002$\u0015*\u001f5\u0001\u001e\r\u0011\u0013.\u0010\u0007\n\u00016\u000112\u0001\u001d$\u0018#/\u0001\n\r\n\r\u0015\u001d\u0012\"\u001f5\u0001\u0004\u0010(\u0010$...\u0010\u0007\n\u00016\u00014\u0001\u001d$\u0018#/\n\u0002$\u0015*\u001f5\u0001\u001e\r\u0011\u0013.-.\u0010\u0007\n\u00016\u000112\u0001\u001d$\u0018#/\n\r\n\u0002\n\r\n\r\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\u000f\u0011\u0013\u0019$%*%\u001d\u0011\u0012 \b\u001f&\u0019$\u0015\u0013\u0011\u001e.2(.3\u0001.\u0011\u0016$\u0015\"\u00016\u00012\u0001\u001c\u0019\u001e\u0015#/\u0001\n\u0018#\n/\n#\n/\u0001\n/\u0001\n\u0001\u0002\u0003\u0006\u0006\n\u000f\n\u0002\n\u0001\u0002\u0003\u0006\n\u0001\u0002\u0003\u0006\u0006\n\u0001\u0002\u0003\u0006\n1\n\u0011\u001e\n.2\n(\n.3\n.\u0011\u0016$\u0015\"\nTherapy Algorithms", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}